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Abstract 
Despite reducing rates of cardiovascular disease in high income countries, individuals who are 
the most socioeconomically deprived remain at the highest risk of disease. The mechanisms 
by which the inequalities arise are still unknown. In this thesis I use causal inference methods, 
including Mendelian randomisation (MR), mediation analysis and polygenic scores, to 
understand the aetiology of educational inequalities in cardiovascular disease, using UK 
Biobank. 
 
Establishing causality in epidemiology can be challenging, due to unmeasured (or mis-
measured) confounding, measurement error and reverse causality. One method to overcome 
these sources of bias is MR. In this thesis I demonstrate using simulations and applied 
examples how MR can be applied to mediation analysis, identifying sources of bias and 
methodological limitations. 
 
Using MR mediation methods and non-genetic (phenotypic) mediation methods I 
demonstrate that body mass index, systolic blood pressure and lifetime smoking behaviour 
mediate up to 40% of the association between education and cardiovascular disease. 
Intervening on these intermediate risk factors would likely reduce cases of cardiovascular 
disease attributable to low educational attainment. 
 
I then investigate inequalities in prescribing of statins as a primary cardiovascular preventative 
medication. I identified clear inequalities, where for a given level of underlying cardiovascular 
risk (assessed via QRISK3 score) individuals with lower educational attainment were less likely 
to receive statins. 
 
Finally, explore the role of education as an effect modifier of genetic suscepbility to 
cardiovascular disease.I demonstrate that on the additive scale, higher education protects 
against genetic susceptibility to body mass index and smoking but accentuates genetic 
susceptibility to low-density lipoprotein cholesterol and systolic blood pressure. On the 
multiplicative scale, higher education accentuates genetic susceptibility to atrial fibrillation 
and coronary heart disease. 
 
This thesis demonstrates that body mass index, systolic blood pressure, smoking and statin 
use all likely contribute to educational inequalities in cardiovascular disease, whilst 
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Chapter 1. Introduction  
This introductory chapter outlines the aims and objectives of my thesis and provides a brief 
description of the main topics and work covered. 
1.1 Socioeconomic inequalities in cardiovascular disease 
Cardiovascular disease (CVD) is the leading cause of mortality worldwide. The 2017 Global 
Burden of Disease study estimated that CVD accounted for one third of all deaths globally (1). 
Insights into aetiological mechanisms have improved prevention through the modification of 
risk factors and age-standardised rates for prevalent cases of CVD in high-income countries 
are declining; however, CVD mortality has plateaued in these same countries (1, 2).  
Socioeconomic position (SEP) has long been associated with increased morbidity and 
mortality from CVD in high income countries. The Whitehall study of British civil servants, 
which began in 1967, provided much of the early data on this; although socioeconomic 
differences in CVD were observed for many years prior to this (3, 4). Despite overall 
reductions in morbidity and mortality since the Whitehall studies, these social class 
differences have persisted in the population (5, 6). Additionally, there is evidence to show that 
the effect of SEP accumulates across the life course (7). The causal effect of education on CVD 
has recently been demonstrated using non-genetic instrumental variable (IV) methods and 
genetic IV methods (Mendelian randomisation [MR]) (8, 9). 
SEP can be measured in a number of ways both at the population level, such as a postcode 
deprivation index or at the individual level typically from occupation, income or educational 
attainment (10). In this thesis I proxy SEP by measuring educational attainment, where self-
reported education is mapped to the International Standard Classification for Education 
(ISCED) years of schooling measure United Nations Educational, Scientific and Cultural 
Organization (UNESCO (11).  
Education may prevent CVD, in part, through its effects on modifiable risk factors for CVD, 
including body mass index, smoking and systolic blood pressure  (12-14). Intervening on 
education is difficult to achieve without social and political reform. Targeting intermediate 
risk factors for CVD could therefore help to reduce educational inequalities in CVD risk. In 
this thesis I hope to identify where interventions may be possible to reduce inequalities in 
CVD. 
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1.2 Data used in this thesis 
The main data used throughout this thesis is the UK Biobank study (Chapter 3-Chapter 6). 
The UK Biobank is a population-based cohort study which recruited 503,317 UK adults 
between 2006 and 2010. Participants attended baseline assessment centres involving 
questionnaires, interviews, anthropometric, physical and genetic measurements (15, 16) and 
have been periodically followed up following baseline both in clinics and online 
questionnaires. Additionally, the UK Biobank has data linked with hospital episode statistics 
(in England and Wales), Sottish morbidity records and death registers, meaning clinical 
outcomes are routinely updated. Full details of the UK Biobank and the data and 
measurements used are described in detail in each results chapter (Chapters 3-6). 
1.3 Statistical methods used in this thesis 
UK Biobank is an incredibly rich data source, with large amounts of both phenotypic and 
genetic data available. A number of methods are used in this PhD which allow for the 
incorporation of genetic data with phenotypic data for robust causal inference. In Chapter 3 
and Chapter 4, the main method used is MR; an IV approach using genetic variants to 
instrument modifiable phenotypic exposures. Given the random allocation of genetic variants 
at meiosis, genetic variants provide suitable instruments for many exposures of interest in 
epidemiology; including educational attainment (17).  
Where these assumptions hold, MR can be used to obtain estimates of causal effects that are 
robust to non-differential measurement error and confounding of the exposure-outcome 
relationship (18). Methods have been developed, including two-step (network) MR and 
multivariable MR (19-22), which allow us to estimate the mediating effects of risk factors and 
begin to disentangle the causal pathways. These methods, and the assumptions of them, are 
described in detail in Chapter 3 and applications of these methods are described in Chapter 3 
and Chapter 4. 
In Chapter 5, I derive a cardiovascular risk score, QRISK3 (23), used in general practices in 
England to determine 10-year cardiovascular risk and statin prescriptions as primary 
cardiovascular prevention (24-26). Using self-reported educational attainment, I consider how 
interactions may arise between education and QRISK3 score to lead to inequalities in access to 
statins. 
In Chapter 6 I consider whether and how educational inequalities may exist in genetic risk for 
cardiovascular disease. Using a number of polygenic scores (PGS) for cardiovascular risk 
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factors and cardiovascular outcomes, I investigate effect modification by educational 
attainment. 
1.4 Thesis outline 
This PhD thesis begins with an introductory chapter, briefly introducing the rationale for 
studying socioeconomic inequalities in CVD, as well as the data and statistical methods used. 
Additionally, the primary aim and objectives are outlined. Chapter 2 is a literature review of 
what we currently understand about the association between education and CVD. It explores 
in detail the risk factors currently understood to be implicated in this association and the 
methods that have typically been used to explore the topic. It ends with a review of causal 
inference methods that have recently been developed to strengthen our causal understanding 
about the effect of education on CVD. A detailed description of UK Biobank is presented in 
each results chapter (Chapter 3-Chapter 6) including how variables were selected and assessed 
for use in this thesis as well as the statistical methods used in each chapter. Chapter 3, is the 
first of my analysis chapters. This chapter explores the use of mediation analysis in MR. Using 
the motivating example of the effect of education on systolic blood pressure, with mediation 
by body mass index, I present results comparing different analytical methods for mediation 
analysis, including in an MR framework. I explore a range of research scenarios and show 
which methods introduce bias, given the variables included in the analysis, and which 
methods are robust to bias in the examples. These methods are then used in the subsequent 
analysis chapter. In Chapter 4, I present and discuss results showing the mediating role of 
body mass index (BMI), systolic blood pressure and smoking in the association between 
education and CVD. In Chapter 5, I show how there are educational inequalities in access to 
statin treatment in the primary care setting, investigating interactions between 10-year risk of 
cardiovascular disease and educational attainment on statins. In Chapter 6, I then consider 
whether education acts as an effect modifier of genetic risk scores for cardiovascular risk 
factors, which might contribute to the accumulation of excess cardiovascular risk in people 
with low educational attainment. There is also a brief discussion of the results in all of these 
chapters. Finally, in Chapter 7, I discuss the findings of each analysis chapter in the context of 
the wider research aim and their implications. I discuss the overall strengths and limitations of 
my research, along with opportunities for future research. I discuss how the methods used 
here allow us to make causal inference about the objectives studied and how this could be 
used to reduce socioeconomic inequalities in CVD and improve prevention mechanisms.  
 29 
1.5 Thesis aims and objectives  
The overarching aim of my thesis is to understand what factors are driving socioeconomic 
inequalities in CVD, triangulating across causal inference methods. 
This aim will be achieved by addressing the following objectives: 
1) Compare and contrast methods for mediation analysis, with and without the use of 
genetic IVs, applied to the motivating example of the roles of BMI and low-density 
lipoprotein cholesterol in mediating the association between education and 
cardiovascular outcomes  
2) Investigate the causal effects of education on cardiovascular disease subtypes and the 
role of BMI, systolic blood pressure and smoking in mediating the association  
3) Identify whether there is an interaction between education and a clinical risk score for 
cardiovascular disease with respect to statin prescribing  
4) Investigate whether education modifies genetic susceptibility to cardiovascular disease 




Chapter 2. Literature review 
In this chapter I will introduce the epidemiology of cardiovascular disease (CVD), including 
how mortality from CVD is declining and current known risk factors for disease. I will review 
socioeconomic position (SEP) as a risk factor for cardiovascular disease, specifically 
considering education as a measure of SEP. Following this, I will explore what factors may 
help explain the effects of education, and SEP more widely, on cardiovascular outcomes, 
including potential mediators or explanatory mechanisms of the association. I will introduce 
the methods used in this thesis, beginning with epidemiological methods and principles, with 
a focus on causal inference using mediation analysis and genetic epidemiology; two of the 
main approaches used in this thesis. Finally, I will explore how predictive risk scores are used 
in clinical practice and opportunities for integrating genetic risk into these scores.  
2.1 Epidemiology of cardiovascular disease 
Globally, CVD remains the leading cause of death, accounting for over 17.5 million deaths 
annually (27). In the United Kingdom (UK), there is clear evidence from a number of studies 
that mortality from CVD and subtypes of CVD, such as coronary heart disease (CHD), stroke 
and myocardial infarction (MI) are decreasing (28-31). Bhatnagar and colleagues estimate that 
age-standardised absolute CVD mortality has declined by 70% from 1979 to 2013 (28). 
However, evidence that the incidence and prevalence of CVD is decreasing is less clear, where 
some studies estimate the prevalence is decreasing (32, 33) and others estimate the prevalence 
of CVD is stable (28, 34). For subtype specific cardiovascular mortality, the Global Burden of 
Disease (GBD) study estimates that CHD mortality has declined by 60% between 1990 and 
2013, and for the same time period mortality from stroke has declined by 46% (29). Similar to 
all-cause CVD, the evidence for subtype specific incidence and prevalence decreasing is mixed. 
For example, Lampe et al estimate that between 1978 and 1996 angina symptoms decreased by 
1.8%, but the prevalence of CHD diagnosis remained unchanged (34). One potential 
contributor to the reduction in cardiovascular mortality is the widespread prescribing of 
medications for the primary, and often secondary, prevention of cardiovascular disease, such 
as statins and antihypertensive medications (35-38). 
Cardiovascular disease is a complex, multi-factorial disease (39). A number of modifiable 
behavioural, biological and environmental (including societal) risk factors have been 
identified for CVD. Behavioural risk factors include among others, alcohol consumption (40, 
41), smoking (42) (43-45) and physical inactivity (46-48). Biological risk factors include 




triglycerides (50), lipoprotein(a) (51) and elevated blood pressure (52, 53). Both individual SEP 
(such as income and educational attainment) and neighbourhood level SEP are risk factors for 
CVD (54). More recently environmental exposures such as air pollution and chemical exposure 
have emerged as risk factors (55). Indeed a number of risk factors will be multifactorial 
themselves, such as body mass index (BMI) (56-59), which can be increased by among other 
factors, diet and activity levels, the obesogenic environment (60) or genetics (61). Additionally, 
non-modifiable factors such as age and sex are risk factors for disease. Although there are 
distinct cardiovascular subtypes with different clinical pathologies, these typically share many 
of the same risk factors.  
Although CVD events typically occur later in adult life, the aetiology of CVD emerges early in 
the life course, with precursors of disease or associations between known CVD risk factors and 
intermediate processes evident from infancy onwards (62-68). Additionally, risk factors for 
CVD, such as elevated BMI, blood pressure, or adverse lipid profiles are often present from 
early in life and track throughout the life course (69, 70). Therefore, early interventions to 
reduce harmful levels of these risk factors are crucial to reduce the burden of disease later in 
life. 
2.2 Socioeconomic position and socioeconomic inequalities 
Socioeconomic position is used to describe one of, or a combination of, resource-based 
measures (such as income and wealth) and prestige-based measures (evaluated by the 
consumption of good and services as linked to income and education) that influence 
populations and society (71, 72). In line with the recommendations made by Krieger, I do not 
refer to this as socioeconomic status or social class, which implies status as determined by 
societal norms, rather than material resources, such as income and wealth (72). 
Socioeconomic position can be measured both at the individual level, such as educational 
attainment, or the population level, such as index of neighbourhood deprivation; where 
different measures of SEP can have different effects on later life health (73).  
Social inequalities have been defined by Krieger to state that these are “health disparities, 
within and between countries, that are judged to be unfair, unjust, avoidable, and unnecessary 
(meaning: are neither inevitable nor irremediable) and that systematically burden populations 
rendered vulnerable by underlying social structures and political, economic, and legal 
institutions”(72). Importantly, this definition states that these inequalities are modifiable and 




which can simply mean any difference in health between groups, without specifically 
referencing SEP (72, 74). 
2.3 Role of socioeconomic position in cardiovascular disease  
The concept of socioeconomic inequalities in health is not new, where mortality differences 
across neighbourhoods were reported as early as the 1820s (75). Although mortality from CVD 
is decreasing in high income countries, the most socioeconomically deprived individuals 
remain at the greatest risk (3, 76). The wider determinants of health (including living and 
working conditions, health care services, housing) are suggested to be the most important 
drivers of health (77). Indeed, low SEP is one of the strongest indicators of morbidity and 
mortality (78-80). A number of indicators of SEP have consistently been implicated as risk 
factors for CVD, or cardiovascular risk factors, in high income countries. These include 
occupation and employment status (4, 81), education (8, 9, 82-84), income (85-87) and 
neighbourhood SEP (54, 88, 89). Although inequalities in CVD, and morbidity and mortality 
more widely, are evident in low- and middle-income countries (90-92), this PhD focuses on 
the United Kingdom (UK), therefore, this review of the literature will focus on the context of 
socioeconomic inequalities in high-income countries. 
Much of the evidence base identifying these inequalities came from the occupational cohort 
study, the Whitehall I study of civil servants set up in 1967 (93). A number of key findings 
came from this study, including identifying the social gradient between occupational social 
class and CHD (94), and occupational social class grade and all-cause and cause-specific 
mortality (95, 96). These studies demonstrated that men in the lowest employment grade 
working as messengers had 3.6 times the mortality from CHD compared with those in the 
highest employment grade, working as administrators. This was similar considering all-cause 
mortality and mortality due to other causes.  
At a similar time to the Whitehall I study, the Black report identified the worsening of 
inequalities in health, following the advent of the National Health Service in 1948 (97, 98). 
This report considered outcomes including mortality, but also wider factors such as access to 
health services (97). Prior to the Whitehall studies, social factors were often thought of as a 
potential confounder, usually adjusted for, rather than considered an exposure in their own 
right (99). 
In recent years, the Marmot reviews (Fair Society, Health Lives and Health equity in England) 
have sought to characterise the extent to which health inequalities exist in England, and what 




review published in 2010 aimed to identify evidence of health inequalities in England and how 
evidence could be translated into practice to reduce inequalities. This review found that if 
mortality rates were equal between the least deprived individuals and most disadvantaged 
individuals, between 1.3 and 2.5 million extra years of life could have been lived. It was 
proposed that to reduce health inequalities action is required to address all of the social 
determinants of health, through a method termed proportionate universalism (“with a scale 
and intensity that is proportionate to the level of disadvantage”) so as to benefit the whole of 
society equally (100). In 2020, the Marmot review was reviewed, with the goal of assessing how 
population health and health inequalities have changed during the decade. It was reported 
that rather than any marked improvements in health, health has deteriorated and inequalities 
widened in England (101). Although life expectancy has slowed down for all groups, those who 
live in the most deprived areas of the country have seen the greatest reductions. It was 
reported that the life expectancy for males born in the most deprived areas in England during 
2016-2018 was 73.9 years, compared with 83.4 years for males born in the least deprived areas 
(difference in mortality of 9.5 years). The life expectancy for females born in the most deprived 
area was 78.6 years compared with 86.3 years in the least deprived area (difference in in 
mortality of 7.7 years) (101). These mortality differences are widening, where the equivalent 
difference in mortality in males in 2010-2012 was 9.1 years and the equivalent difference in 
females was 6.9 years (102). 
Public Health England (PHE) posit that much of these differences in life expectancy are due to 
higher mortality from lung cancer, chronic lower respiratory diseases and CVD in more 
deprived areas (103). This report estimated that individuals living in the most deprived areas 
are four-times more likely to die prematurely (below the age of 75) from CVD compared with 
individuals in the least deprived areas (103, 104). 
A number of studies have sought to estimate the contribution of low educational attainment 
to all-cause mortality and cause-specific mortality. In a 2005 analysis, Huisman and colleagues 
estimated in an analysis of Western European countries that the absolute rate difference for 
total mortality between the lowest educated and highest educated participants was 796 deaths 
per 100 000 person years in males and 442 deaths per 100 000 person years in females. Of these 
total mortality differences, it was estimated that CVD accounted for 39% of the total mortality 
difference in males and 60% in females. In England and Wales, the rate difference in total 
mortality was 1052 deaths per 100 000 person years in males and 435 deaths per 100 000 person 




However, the methods by which socioeconomic factors cause disease are not well understood. 
In the years following The Black report and the Whitehall I study findings, epidemiologists 
have sought to characterise how these inequalities emerge and persist through the life course 
(105-107), what explanatory (intermediate) factors might help explain the associations (12-14), 
and whether the effects of SEP on cardiovascular outcomes are causal (8, 9, 108-110).  
2.3.1 Mediators of the association between education and cardiovascular 
disease 
An intermediate variable, or mediator, is one that can either wholly, or partly explain the 
association between an exposure and an outcome (111). These downstream factors offer an 
opportunity to intervene after an exposure has occurred. Where an exposure is difficult to 
intervene on, such as educational attainment, identifying these mediators offers an 
opportunity to mitigate the impact of the exposure on later outcomes. A number of modifiable 
risk factors, such as BMI, diet, exercise, smoking and risky drinking have been identified as 
mediators of low SEP and CVD (12-14, 112-117).  
Lower levels of education have been shown to lead to an increase in BMI, using traditional 
epidemiological analyses and instrumental variable analyses (118-121). Increased education has 
also been shown to improve diet (122, 123) and increase physical activity (124), likely to 
contribute to this reduction in BMI. Similarly, increased SEP has been shown to decrease 
systolic blood pressure (125-128). 
Lower levels of education have also been shown to increase both smoking uptake and decrease 
smoking cessation in those who initiate smoking (129, 130). Smoking is one of the leading 
causes of CVD (131). Smoking rates are declining in high income countries , including the UK 
(132); between 2011 and 2018, smoking prevalence has decreased from 20% to 14% (133). 
However, education inequalities persist between smokers and non-smokers. According to the 
Office of National Statistics 2018 report on adult smoking habits in the UK, 29.8% of 
individuals with no formal qualification were smokers, compared with 7.5% of individuals 
with a degree (133). In turn, BMI, smoking and systolic blood pressure have all been shown to 
increase the risk of CVD (45, 59, 134-136).  
Méjean and colleagues identified that smoking explained 26% of the variation in CHD 
according to strata of educational attainment, whilst alcohol consumption explained 23% of 
the variance, physical activity explained 9% of the variation and dietary factors explained 48% 




In phenotypic mediation analyses, Kershaw and colleagues identified that smoking behaviour 
explained almost 27% of the effect of education on coronary heart disease, 10% of the effect 
was explained by BMI and 5% of the effect explained by hypertension (114). However, these 
estimates may be biased by confounding, reverse causality or measurement error (see 2.7.1). 
Therefore, in this thesis, I use Mendelian Randomisation (MR) (see 2.7.3) to estimate the 
causal effect of the mediating role of BMI, systolic blood pressure and smoking in Chapter 4. 
Additionally, putative biological mediators, such as low-density lipoprotein cholesterol (LDL-
C) (115) and hypertension (14) have been identified as potential mediators, or as downstream 
effects of education (137). These intermediate variables are already targeted by clinical 
interventions where statins and antihypertensives are prescribed respectively. 
Later life measures of SEP have been implicated as mediators of early life SEP and CVD risk, 
for example occupation, housing, financial stress are downstream of early life SEP and 
themselves, independent risk factors for CVD (112, 116, 138). In mediation analyses, Hossin and 
colleagues found up to 39% of the effect of childhood SEP on CVD mortality could be 
explained by own occupation; this increased to 59% of the effect when behavioural 
intermediates (such as BMI and smoking) were included. Mental health and emotional states 
have also been implicated as mediators (113). 
2.3.2 Association between socioeconomic position and preventative 
medication for cardiovascular disease 
Biological intermediate risk factors, such as elevated cholesterol levels and elevated blood 
pressure (hypertension) are already targets of cardiovascular preventative medication, where 
statins and antihypertensives are prescribed respectively. Inequalities in access to, or 
prescribing of, these preventative medications may also contribute to inequalities in CVD. 
Many of the factors described in section 2.3.1 are individual level factors which may explain 
inequalities in CVD. However, access to medication begins to allude to a wider societal 
contributor to inequalities in CVD. 
Statins are a group of cholesterol-lowering drugs, widely prescribed for both primary (before 
an adverse event) or secondary (following an adverse event) prevention of CVD (139). They are 
one of the most commonly prescribed drugs in the UK (140). Current guidance in England 
states that individuals should be prescribed statins if they have a 10% of greater risk of 
experiencing an adverse cardiovascular event in 10 years (24-26). Typically, this is examined 
using a QRISK score in general practice (currently the QRISK3 version). This score 




ethnicity, systolic blood pressure, area level deprivation, BMI, smoking and family history of 
CVD (23). In the case of some adverse cardiac events, statins will be prescribed as secondary 
prevention, without estimating 10-year risk of disease. 
To date, there is limited evidence for the role of medication prescribing in contributing to 
inequalities. Although, it was described as early as The Black Report (1980), that access to 
healthcare was not equitable (98). 
Considering access to statins, the literature is mixed in the direction to which inequalities in 
exist. Some studies suggest that there are no socioeconomic differences in prescribing (141), 
others suggest that those with lower socioeconomic position are more likely to be prescribed 
statins (36, 142-144), whereas some studies suggest individuals of lower socioeconomic 
position are less likely to be prescribed statins (87, 145-147). These inequalities have 
predominantly been explored in the secondary prevention setting, where they are prescribed 
following an adverse cardiac event to prevent further events. This is in contrast to the primary 
prevention setting, where prescribing aims to prevent an adverse cardiac event happening 
initially. 
One potential reason for this mixed evidence is that individuals of a lower SEP are more likely 
to have a greater underlying clinical need for medication. For example, as discussed in 
section2.3.1, lower SEP leads to, among other factors, higher BMI, increased smoking 
prevalence and elevated cholesterol levels. These factors are all considered in clinical decision 
making, for example, these three factors all contribute to the QRISK3 model of CVD risk used 
to inform statin prescribing (23).  
In Chapter 5 of this thesis, I explore the potential role of access to statins, as a primary 
prevention mechanism, contributing to socioeconomic inequalities of CVD, after controlling 
for measures of clinical need.  
2.4 Defining socioeconomic position in this thesis 
In this thesis, I focus on educational attainment to measure SEP for a number of reasons. 
Firstly, educational attainment is largely determined early in life. When considering mediators 
of SEP and CVD, it is important to consider the temporal relationship between all of the 
exposures, the mediators and the outcomes (111). Therefore, using an early measure of SEP, 
such as education, compared with a later life measure such as occupation or income, means 
that temporality between exposures and outcomes can be better accounted for. For example, a 




affect income in adulthood. Additionally, education is a strong predictor, and highly 
correlated with, future employment and income, both later life measures of SEP (71). 
Therefore, considering education as an exposure, in an adult population, is also likely to be 
capturing part of the effect of later life SEP. Secondly, this thesis uses MR and the integration 
of genetic data with epidemiological analyses. In recent years, a number of genome wide 
association studies (GWAS) have been carried out for education, and up to 11% of the variance 
in education can now be detected via these genetic variants (17, 148, 149). Thirdly, education 
can be easily and widely measured. Typically, an individual knows when they left school, 
either by being asked the age in which they left or what their highest qualification is. 
Education is also relatively stable during an individual’s life course. Conversely, a measure 
such as occupation or income for example, often changes across a life course and can be 
difficult to measure when participants may have retired prior to study entry (71, 73).  
As UK Biobank data are used in this thesis, and participants were aged 40-69 at recruitment, 
SEP measures such as income, employment or occupation could introduce bias to analyses 
(16). Given their age, it is common in UK Biobank for participants to have retired from work. 
Although both current and historical employment is recorded in UK Biobank, it is not straight 
forward how to determine their SEP from employment in this context. Similarly, participants 
were asked to report current average annual, monthly and weekly household income. This 
measure is unlikely to truly capture SEP in individuals who have retired and does not account 
for individual life-time income. 
2.5 Intermediate variables considered in this thesis 
In this thesis I focus on four main intermediate pathways between education and CVD; BMI, 
systolic blood pressure, smoking and medication prescribing (see section 2.3.2). These are all 
modifiable major public health targets, either through lifestyle interventions (150), clinical 
interventions (151) or, major public health campaigns (152). The total years of education 
completed are largely determined in early life, prior to adulthood. Although CVD is largely 
considered a disease of ageing (153), socioeconomic patterns of BMI, systolic blood pressure 
and smoking all emerge during early life and adolescence (129, 154). The incubation period 
between major cardiovascular risk factors and CVD is long (155), providing ample opportunity 
to intervene following the establishment of educational attainment and prior to developing 
disease. 
There is likely to be significant overlap in how these mediators work together to increase the 




smoking (156). The INTERSALT study also found that BMI and smoking behaviours were 
mediators of the association between education and systolic blood pressure (127). 
Additionally, many other measures of SEP and potential mediators are likely to overlap with 
the variables considered in this thesis, and therefore will be captured to some extent by these 
factors. For example, a higher income may result in a more cardioprotective diet (i.e. more 
fruits, vegetables and wholegrains, and less processed foods) (157) and thus lower BMI and 
SBP. By looking at the modifiable intermediate factors chosen here, in a causal inference 
framework, I hope to identify intermediates that could be used as interventional targets to 
reduce the burden of CVD attributable to educational inequalities. 
2.6 Genetic determinants of cardiovascular disease 
Cardiovascular disease is a complex multifactorial condition, encompassing a wide range of 
conditions, where environmental and genetic factors both contribute to the aetiology of 
disease (158). As previously outlined, a number of behavioural, lifestyle, societal and 
environmental risk factors exist for CVD. However, there is also a strong genetic component of 
disease. It has been estimated that the heritability of CHD lies between 40% to 60% (159), 
whilst for atrial fibrillation heritability is estimated at 22% (160) and heritability of ischaemic 
stroke lies between 34% to 42% (161). Despite the presence of distinct cardiovascular subtypes, 
much like shared environmental risk factors for disease subtypes (162-164), there is evidence of 
shared genetic contributions for subtypes of CVD (165, 166). 
2.6.1 Genetic Epidemiology 
Genetic epidemiology considers the contribution of genetics in disease aetiology, including 
understanding heritable aspects of disease and individual susceptibility (18). One of the 
primary aims of genetic epidemiology is to identify, isolate and understand, the genetic 
component of disease risk from complex, multifactorial disease states (167). The advent of 
genetic epidemiology was in part driven by the human genome project and wide scale genome 
sequencing and genotyping. More recently, the advent of large-scale human biobanks (often 
as part of cohort studies) have enabled genetics to be widely incorporated to epidemiology (15, 
168, 169). Genetics can be used in epidemiology to answer a host of research questions, 
including understanding disease aetiology (how much a genetic variant can explain disease 
risk, and the non-genetic risk factors that affect risk of disease) and in health services research 
(such as the impact of using genetic tests in health services) (18, 170).  
Genetic epidemiology methods provide opportunities for improving causal inference in 




for disease pathogenesis (171) and help prioritize targets for intervention (172). One common 
method in genetic epidemiology is that of Mendelian randomisation; the use of genetic 
variants as an instrumental variable for a phenotype (see section 2.7.3) (18). 
2.6.2 Polygenic prediction of disease 
Since the rapid increase in genetic data, and the explosion of GWAS summary statistics, 
polygenic scores (PGS) (or genetic risk scores, polygenic risk scores or weighted allele scores), 
have been increasingly used in epidemiology to understand how genetics contribute to the 
aetiology of polygenic (i.e. multiple genetic causes) phenotypes (173, 174). A PGS incorporates 
information from across the genome to understand the genetic component of a phenotype, 
where there may not be one single gene responsible for the acquisition of the trait. For 
example, height or BMI are examples of polygenic traits, where a number of genetic variants 
contribute to the trait (61), as well as interactions with the environment (175-177). Conversely, 
a monogenetic trait is determined by a mutation in a single genetic variant (or few genes), 
such as cystic fibrosis, which is caused by a mutation in the CTFR gene (178). Indeed, most 
common diseases are polygenic (170). 
Typically, in polygenic traits, each genetic variant explains very little of the phenotype, but the 
cumulative risk across many genetic variants can begin to explain a substantial fraction of the 
variation in a phenotype (173, 179). As the samples size of GWAS increase, the power and 
predictive accuracy of PGS have been improving (180). This leads to an increase in the number 
of genetic variants identified to be associated with the phenotype, and an increase in the total 
variance in the phenotype explained by known genetic variants. For example, in the 2015 
Locke et al GWAS of BMI, the 97 independent genetic variants identified for BMI at the 
genome-wide significance level explained about 2.7% of the variation in BMI (181). The 
updated 2018 Yengo et al GWAS of BMI, identified 941 near-independent genetic variants 
related to BMI at the genome-wide significance level explaining around 6% of the variation 
(61). The latter GWAS had a sample size of around 700 000 individuals, compared with almost 
340,000 in the 2015 GWAS. 
A PGS is usually derived by weighting the sum of the genetic variants with their relative effect 
sizes (182, 183). This upweights the genetic variants with the greatest effect on the phenotype, 
improving the explanatory power of the score, although unweighted scores can also be 
generated. When a PGS is derived for the purpose of disease prediction, genetic variants 
included may be broad, including variants in linkage disequilibrium (i.e. highly correlated 




be used as an instrument in MR, for example, genetic variants may be limited to those that, 
are not in linkage disequilibrium to other variants, or those that meet a stringent GWAS 
significance threshold of P<5×10-8. 
Importantly, although not their sole use, PGS are used in disease prediction modelling; 
meaning that across the population a PGS can be used to estimate the probability of 
developing a phenotype, but they are not deterministic (184). Behaviour modification, or 
treatments, can therefore be used to modify the risk of disease. A strong association between a 
PGS and a trait does not necessarily mean there is a causal effect of the PGS on the trait; 
associations could be induced due to population structure or assortative mating, or dynastic 
effects (185, 186). The causal aetiology of the PGS and subsequently of the trait, can be 
interrogated via different study designs. 
2.6.3 Applications of polygenic scores in disease prediction 
Genetic information is already used in clinical practice to aid decision making. For example, in 
the cases of familial breast cancer, genetic testing can be offered to identify whether high-risk 
genetic variants, BRCA1, BRCA2 or TP53 are present (187). The identification of these genes 
will then feed into clinical decision making. Similarly, in the case of familial 
hypercholesterolaemia genetic testing may be offered to identify the presence of disease 
causing mutations (188). As PGS become more powerful, explaining a greater amount of the 
variation in a trait, there is a growing body of research that could potentially be incorporated 
into clinical practice. 
Khera and colleagues generated PGS for a host of disease outcomes and compared the 
predictive ability of them with known monogenic disease-causing mutations (170). It is 
estimated that the mutation for familial hypercholesterolaemia causes a three-fold increase in 
the risk of CHD (189). In this sample, the authors identified that using the PGS for CHD 8% of 
the population were at the equivalent 3-fold risk of disease. Comparatively, the mutation for 
familial hypercholesterolaemia is found in approximately 0.4% of the population (189). Khera 
et al concluded that “it is time to contemplate the inclusion of polygenic risk prediction in 
clinical care”. In addition to CHD, these conclusions could be made for atrial fibrillation, type 
2 diabetes, inflammatory bowel disease and breast cancer. 
Similarly, Inouye and colleagues concluded that a PGS for CHD had a greater predictive power 
for incident CHD than individual conventional CVD risk factors, smoking, diabetes, 
hypertension, BMI, cholesterol or family CVD history (190). This finding was replicated for 




information on genetic risk to participants led to greater reductions in low density lipoprotein 
cholesterol than information based on conventional risk factors alone (192). 
As genetic testing becomes more widespread and financially feasible, more consideration is 
being given to how they could be used in clinical practice (193). However, this isn’t without 
ethical considerations; especially in societies with no national health service (194). However, a 
number of recent studies have compared the additional predictive power of polygenic risk 
over and above phenotypic risk. Typically, these studies have found little improvement in 
predictive power when including genetic risk (195-197).  
2.6.4  Gene*environment interactions in cardiovascular disease 
As discussed throughout this chapter, CVD has many risk factors, both environmental and 
genetic. It has been widely noted that consideration needs to be given as to how genetics and 
the environment work together to contribute to disease risk, rather than considering either in 
isolation (198, 199). Whilst socioeconomic inequalities in health have been widely studied, the 
extent to which the interplay with genetic factors contributes to these inequalities been 
sparsely studied (200). An interaction analysis assesses the joint effect of two risk factors (the 
environment and genetics), where a joint effect greater than the sum of the individual effects 
indicates positive interaction (201). 
Understanding gene*environment interactions are important for a number of reasons, 
including estimating the population attributable risk for genetic and environmental risk 
factors and their shared effects, helping to identify biologically plausible mechanisms for 
disease aetiology, identify potential therapeutic targets and tailor preventative treatments to 
those most at risk or identify who would benefit the most from treatment (198, 202).  
Often, these interactions have typically been assessed in a candidate gene approach. For 
example, Hamrefors and colleagues carried out analyses to identify whether the rs4977574 
allele, an allele in the chromosome 9p21 region which is suggested to increase susceptibility to 
CHD, interacted with smoking, education and physical activity to increase cardiovascular risk 
(203). Here, it was found smoking, but not education or physical activity, interact with the risk 
allele to increase cardiovascular risk. However, these approaches have been criticised for 
failing to replicate, likely due to statistical power, publication bias and low prior probabilities 
of hypotheses being true (204).  
Therefore, more recently, gene*environment interactions have been assessed using polygenic 




more informative to consider the whole of the polygenic risk susceptibility, rather than 
focussing on interactions with single genetic variants each with small effects on disease risk. 
In Chapter 6 I explore whether polygenic susceptibility to cardiovascular risk is modified by 
strata of educational attainment. 
2.7 Causal inference in epidemiology 
Epidemiology is defined as “the study of the occurrence and distribution of health-related 
events, states and processes in specified populations and the application of this knowledge to 
control health problems” (205). Being able to make causal inference is central to epidemiology; 
practitioners, policy makers, clinicians and scientists want to know whether intervening on a 
risk factor will lead to a reduction in disease, or other outcomes. Causality has been a key aim 
of decades of research following Bradford and Hill’s research on the causal criteria in the 1960s 
(206). This work suggested for a risk factor to be causal the strength of the evidence should be 
evaluated by 9 factors. These are i) strength of the association ii) consistency of the association 
iii) specificity of the association iv) temporality of the relationship v) biological gradient vi) 
biologically plausible vii) coherence of the effect interpretation viii) experimental evidence to 
support the observed effects and ix) useful analogy. Since this seminal work, the field of causal 
inference has worked to improve methods and knowledge to enable the study to make claims 
of causality (207, 208).  
In this thesis, I use a number of causal inference approaches to understand educational 
inequalities in cardiovascular disease. In Chapter 3 I demonstrate how mediation analyses 
(section 2.7.2) can be carried out using MR (section 2.7.3). In Chapter 4 I use MR methods for 
mediation analysis to identify the role of BMI, systolic blood pressure and smoking in 
mediating the association between education and CVD, triangulating across data sources and 
methods. In Chapter 5 I triangulate across different data sources with different sources of bias 
to identify educational inequalities in statin treatment to prevent cardiovascular disease. In 
Chapter 6 I use different PGS’ to identify whether there is evidence of education as an effect 
modifier of polygenic susceptibility to CVD.  
2.7.1 Sources of bias in epidemiological research  
Epidemiology aims to determine the causal effect of an exposure (cause) on an outcome, 
however, spurious associations can be observed for many reasons. These spurious associations 





One of the main sources of bias comes from confounding, where both the exposure and 
outcome share a common cause, which can wholly, or more likely partly, explain some of the 
association between the exposure and confounder. Where all confounders are perfectly 
measured, and adjusted for, effect estimates will be unbiased due to confounding. Although 
confounding can be addressed in epidemiological analyses , such as multivariable adjusted or 
propensity score designs, for most study designs it is vital that information on a sufficient set 
of confounders are available (209). In a causal diagram approach, confounders are said to be 
sufficiently controlled for when all backdoor paths are blocked between the exposure and 
outcome and no spurious associations can exist (210). When multiple confounders are 
correlated, not all confounders are required to be adjusted for in the minimally sufficient 
model to block all backdoor pathways (see Figure 2.1) (211). If a minimally sufficient set of 
confounders is not available, or confounders are measured with error, residual confounding 
will bias estimates. Confounding can be addressed during the study design stage, for example 
by restriction or matching. Here, the study population are selected on key variables which 
may be confounders, for example selecting participants all of a similar age range or of the 
same sex (209, 210). Alternatively, analyses can be carried out stratified by certain key 
confounders, such as carrying out sex-stratified analyses (210, 212). However, where data are 
sparse, this can lead to inefficient analyses, or introduce additional biases (213). 
 
Figure 2.1: : Directed acyclic graph demonstrating the hypothetical association between education (X) and cardiovascular 
disease (CVD) (Y)  controlling for the measured confounder (C), maternal education. Maternal income and paternal education 
are unmeasured confounders (U). Unmeasured paternal education biases the effect estimate (demonstrated in purple). 




Estimates from multivariable adjusted regression can be biased by information bias or 
measurement error; either because information is not reported accurately, study equipment 
may not be calibrated accurately, the information being collected doesn’t actually reflect the 
true causal variable of interest, or due to random chance (214). These biases can occur in an 
exposure, outcome, confounder or mediator (where included) (see Figure 2.2). Information 
bias and measurement error are often used similarly to describe errors in data. Measurement 
error occurs when the quality of measurement is poor (215). Measurement error can either be 
systematic, e.g. a mis-calibrated blood pressure monitor adds 5 mmHg to all readings, or 
random, e.g. a mis-calibrated blood pressure monitor can add or subtract up to 5 mmHg from 
some readings. Recall bias is an example of a systematic bias, when participants do not 
accurately remember past experiences, or omit specific details (205). Information bias, or 
misclassification bias, occurs when information is measured or recorded inaccurately (215). 
Information bias can either be non-differential or differential. Non-differential bias does not 
relate to the outcome, meaning the chance of being misclassified, is equal across all study 
groups and outcomes (205). For example, in a study exploring the association between 
hypertension and incident CHD, all participants, regardless of outcome could be incorrectly 
classified as being hypertensive. Conversely, where misclassification is differential, the bias 
varies according to the outcome of interest (216, 217). In the same hypothetical example, this 
may mean only those diagnosed with incident CHD can incorrectly be classified as 
hypertensive. Where error is non-differential, or random, in the exposure, effect estimates are 
typically attenuated  towards the null, also known as regression dilution bias (217, 218). If error 
is non-differential or systematic in the exposure or outcome, bias can be present in either 
direction (e.g. over- or underestimate the true association). Where a confounder is measured 
with error, this will result in residual confounding; it is not possible to predict which direction 





Reverse causality can introduce bias, when the temporality of the exposure and outcome is 
mis-specified and the outcome itself affects the exposure (see Figure 2.3) (220). This type of 
bias can frequently occur in case-control studies which often collect data on the outcome 
prior to the exposure, or cross-sectional studies where the exposure and outcome are 
measured at the same time. However, in an incorrectly specified model, this can occur in 
other study types. One method to minimise this bias is to collect data prospectively or 
maintain temporality between an exposure and outcome e.g. recall of early life exposure and 
later life outcome measured at the same time (cross-sectional). 
 
Further bias can be introduced by selection into the study, where individuals in the study 
population are not reflective of the wider population of interest. If selection involves 
conditioning on a factor that is a cause or effect of both the exposure and the outcome collider 
bias can be introduced (221). This bias is demonstrated in Figure 2.4. In this hypothetical 
Figure 2.2: Directed acyclic graph demonstrating measurement error, where the effect of education (X) on cardiovascular 
disease (CVD) (Y) is mediated by the true value of body mass index (BMI). Where BMI is measured (observed) with error 
(BMI*) this direct effect association is no longer observed. 
Figure 2.3: Directed acyclic graph depicting reverse causality, where the model is mis-specified and the outcome (Y), 




example, to be recruited into the study, a participant must be alive at recruitment, where all 
participants eligible have to be at least 60 years old. Both the hypothetical exposure, Lower 
education, and the hypothetical outcome, CVD are associated with higher mortality at 
younger ages. Therefore, selection into the study is conditional on being alive at age 60, which 
could induce a spurious association between education and CVD.  
Well conducted randomised controlled trials (RCTs) provide the strongest evidence of 
causality, and often described as the ‘gold standard’ (222). Here, participants are randomised 
to either the exposure of interest, or a control condition and followed up to determine their 
outcomes. This study design examines the cause and effect relationship between two factors, 
controlling for temporality and allocating actual exposure (223). However, RCTs are very 
costly, not always ethical or practical, or timely. Particularly in the case of social epidemiology, 
it would be highly impractical, potentially unethical, to randomise access to education, and 
take a lifetime to discover the effects on health outcomes later in life. Additionally, the 
generalisability of RCTs is often criticised. Often the external validity of a trial (i.e. how well 
the trial results relate to the population of interest for the intervention) is given less 
consideration than the internal validity of the RCT (designing and carrying out the study with 
minial opportunites for bias) (224). 
2.7.2 Mediation analysis 
Mediation analysis has been widely used by a number of disciplines to identify intermediate 
variables between an exposure and an outcome, including behavioural or biological variables, 
which provide opportunities for interventions, or gain a wider understanding of how an 
exposure may be causing a disease outcome.  
Sewall Wright first proposed early methods for path tracing, an early form of mediation 
analysis (225), which were extended to allow for decomposition of total effects in to direct and 
Figure 2.4: Directed acyclic graph depicting selection bias. In this hypothetical example, study entry is conditional on being 
alive at aged 60 or above, which is caused by both education (X), the exposure, and cardiovascular disease (CVD (Y)), the 





indirect effects (226). These early methods provided the first statistical decompositions of 
mediated effects. Baron and Kenny formalised mediation analysis in the 1980s by proposing 
four steps that were required to establish mediation in a hypothesised model (227) (Figure 
2.5). 
1. Regress the dependent variable (Y) on the independent variable (X) and show that X is 
associated with Y to establish a total effect which can be mediated (path c). 
2. Regress the mediator (M) on the independent variable and show that X affects M (path 
a). 
3. Regress the dependent variable (Y) on the mediator (M) controlling for X to show that 
the mediator affects the dependent variable, independent of X (path b). 
4. Establish that M completely mediates the X-Y, where there is no effect of X on Y once 
M is controlled for (path c’). If this condition is not met but the regression coefficient 
is smaller in step 3 than step 1, there is evidence for partial mediation. 
A number of assumptions are required for these estimators to be unbiased. Firstly, there 
should be no unmeasured confounding between the exposure, the mediator and outcome 
(228-230). A second, strong assumption required, is that of no exposure-mediator interaction. 
A third assumption is that confounders of the mediator and outcome are not themselves 
Figure 2.5: Schematic of total and mediated effects. Path c represents the total effect of the exposure on the outcome. Path c’ is 
the direct effect; that is the effect of X on Y not mediated by M. The indirect effect can be estimated by i) a*b known as the 




caused by the exposure, which if present can induce collider bias  (231-233). Causal inference 
methods, including G-computation (234) and inverse probability weighting (235) can be used 
to estimate the unbiased direct effect, whilst also controlling for the confounder.  
In order to relax some of these assumptions, a focus of methods development in mediation 
analysis is to identify methods that can account for some of these strong assumptions and 
clearly specify how causal interpretations are made (207, 228, 236). Robins and Greenland 
proposed that counterfactual conditional statements were fundamental to causal models. In 
this situation, each individual is observed under a given circumstance, but analyses consider 
what would happen to the same individual if they were observed under the counterfactual 
circumstance, that is the effect that is counter-to-fact (did not occur) (237). Counterfactual 
(counter to fact) theory prescribes that an event (effect) has only occurred because of a prior 
fact (cause); for example, “If I had not gone to sleep, I would not have woken up”. In order for 
one to wake up, one must first go to sleep. Whereby, for the effect to happen, there must have 
been a cause (and in turn an intermediate cause, the mediator cause). Similarly, if that cause 
was not present, the effect would also not be present (207). 
The parameters estimated in counterfactual mediation methods differ somewhat from 
traditional methods, where these assumptions are explicitly stated. These parameters are, the 
total causal effect (either as the individual causal effect or the population causal effect) the 
controlled direct effect (CDE), the natural direct effect (NDE) and  the natural indirect effect 
(NIE) (208). Where interactions exist between an exposure and mediator the natural indirect 
effect reflects the portion of the total effect attributable to mediation only, as opposed to 
interaction only or mediation and interaction combined (mediated-interaction) (238-240). 
However, counterfactual methods for mediation analysis still require strong, unverifiable, 
assumptions to be made around unmeasured confounding; these are that there are i) no 
unmeasured confounders of the exposure and outcome ii) no unmeasured confounders of the 
mediator and outcome and iii) no measured, or unmeasured, confounders of the mediator and 
outcome that are themselves affected by the exposure (intermediate confounders) (233, 241). 
In addition to these confounding assumptions, all mediation models also assume appropriate 
temporal ordering of the exposure, mediator and outcome and can be biased by measurement 
error in either the exposure or the mediator (238, 241). 
In this thesis (Chapter 3 and Chapter 4), these methods are described as phenotypic mediation 




2.7.3 Mendelian randomisation 
Mendelian randomisation is an application of instrumental variable (IV) analysis, which uses 
genetic variants as an instrument for an exposure of interest and often described as natures’ 
RCT (18, 242). MR relies on the principle that offspring randomly inherit their DNA from their 
parents during meiosis and at conception and that germline DNA is not modified by lifestyle 
factors later in life. For this reason, effect estimates from an MR analysis can be more robust to 
confounding and are not affected by reverse causality, two of the major pitfalls of traditional 
phenotypic epidemiology. MR can therefore offer a more robust form of causal inference in 
analyses (18).  
There are three core assumptions that need to be satisfied for MR results to be valid (Figure 
2.6): 
1. The instrument (genotype) is associated with the exposure of interest (relevance 
assumption) 
2. There are no common cause of the instrument and the outcome (the independence 
assumption) 
3. The instrument only affects the outcome via the exposure of interest – i.e. no 
pleiotropic pathways (the exclusion restriction criteria)  
Two types of data can be used for an MR analysis. This first is individual level data where 
information is available for the instrument (genotype), exposure and outcome for every 
individual the analysis is to be carried out on (243). This is also known as one-sample, single 
Figure 2.6:Schematic of Mendelian Randomisation and the assumptions that must be satisfied for the results to be valid 




sample or individual level MR. This can involve either individual single nucleotide 
polymorphisms (SNPs) or a PGS for each individual where the SNPs which are included in the 
score are identified from a GWAS of the exposure of interest.  
The second approach is known as two-sample MR or summary MR (244-247). In this 
approach, the estimates of the instrument to exposure association and the instrument to 
outcome association come from two separate GWAS. The Wald ratio can then be estimated by 
dividing the summary statistics for the instrument-outcome association by the instrument-
exposure association summary statistics. This method does not require access to individual 
level data.  
Methods for MR have rapidly expanded in recent years (248) including the development of 
methods to extend the applications of MR to understand more complex causal mechanisms. 
For example, factorial MR can be used to investigate the joint effects of two risk factors on a 
single outcome (249-252). 
Recently developed MR methods can be used in mediation analyses. These are two-step, or 
network, MR and multivariable MR (MVMR) (19, 20, 253). These methods are discussed in 
detail in Chapter 3 and Chapter 4. 
Sources of bias in Mendelian randomisation 
Bias can arise when any one of the three instrumental variable assumptions are violated. Of 
particular concern, and indeed one of the most common sources of bias in MR, is that of 
assumption (3), where the genetic variant is associated with the outcome via an alternative 
path to the exposure of interest. Where a genetic variant influences more than one trait this is 
termed ‘pleiotropy’ (18). Pleiotropy can take two forms; vertical pleiotropy and horizontal 
pleiotropy. Vertical pleiotropy occurs when the genetic variant influences a trait downstream 
of the exposure i.e. a mediator of the exposure of interest, but any effect of the genetic variant 
on this mediator is via the exposure of interest. This does not violate the instrumental variable 
assumption (3) (248, 254). Conversely, horizontal pleiotropy occurs when the effect of the 
genetic variant independently affects a second phenotype, here the instrumental variable 
assumption (3) is violated  (248, 254). A number of methods have been developed in recent 
years to test for, and minimise bias due to horizontal pleiotropy, such as MR-Egger (255) and 




Due to the often limited explanatory power of the genetic instrumental variables used in MR, 
sample size for MR are typically required to be much larger than conventional phenotypic 
epidemiology methods to achieve appropriate statistical power (257, 258).  
2.7.4 Triangulation 
Triangulation has long been described and used in many research fields, but the use of 
triangulation in epidemiology is emerging. Triangulation aims to obtain more reliable research 
answers by integrating results from several different approaches, such as the methods or data 
used, which have different key sources of bias (259). This is distinct from replication or 
validation analyses, which aim to use the same method or data to compare results from the 
same study design. Where these different approaches are carried out, and provide consistent 
effect estimates or directions of effect, the evidence of causality can be strengthened. 
Importantly for this causal inference, the key sources of bias should be explicitly 
acknowledged, as well as the expected direction of effect that these biases would result in 
(260).  
In this thesis, triangulation is carried out, where possible, by comparing results from different 
methods (Chapter 3 and Chapter 4), such as phenotypic and MR methods for mediation 
analysis. In Chapter 4 results from individual level and summary MR are compared, and in 
Chapter 5 analyses carried out using data from UK Biobank baseline assessment centres to 
derive QRISK3 cardiovascular risk scores are compared with analyses using QRISK3 
cardiovascular risk scores recorded in primary care data. 
2.8 Applying genetic epidemiology to social epidemiology  
This thesis integrates genetic epidemiology methods, such as MR and PGS analysis to 
understand the social causes and consequences of CVD. In recent years, social epidemiology 
has expanded to consider the biological interplay with social exposures, acknowledging that 
omitting either biology or sociology would likely lead to incomplete conclusions (261-263). In 
some instances, the biological state is the outcome. For example in a study by Fraga et al, the 
authors look to explore the effect of socioeconomic position on the inflammatory markers C-
reactive protein, Interleukin-6 and tumour necrosis factor-α (264).  
In other examples, the biological measure may be used in the context of an exposure, such as 
the MR analyses by Tyrell and colleagues demonstrating potential causal effects of genetically 
instrumented BMI and height on socioeconomic outcomes, including education and income 




identify genetic contributions to phenotypes, the opportunities for identifying genetic variants 
for social exposures increase (149, 266).  
2.8.1 Genome wide association study of educational attainment 
The first GWAS for educational attainment was carried out in 2013 and included 101 069 
individuals. Three independent genetic variants were identified to associate with education 
(148). The effect size of these three variants was small, equating to approximately one 
additional month of schooling per risk allele or about 2% of the variance in educational 
attainment. There have since been a further two GWAS of educational attainment since, each 
increasing in sample size (N = 293 723 and 1.1 million respectively), number of genetic variants 
identified (74 SNPs and 1271 SNPs respectively) and variance explained (3.2% and 11% 
respectively) (17, 149). Importantly for this thesis, these GWAS allow for opportunities to 
triangulate results with different analytical methods and types of data to infer causality (259). 
A number of epidemiological analyses have now been carried out using the results from these 
GWAS, including investigating the causal effects of educational attainment on CVD and 
cardiovascular risk factors. 
Davies and colleagues compared instrumental variables estimates from the Raising of School 
Leaving age (RoSLA), a natural experiment, and MR estimates from the Okbay educational 
attainment GWAS (17). Both methods rely on the same instrumental variable assumptions as 
discussed in section 2.7.3, but the different data sources may be biased by different 
mechanisms through violations of these assumptions. Here, it was demonstrated that the 
effect of a 1-year increase in educational attainment, instrumented either via the RoSLA or the 
polygenic score, associated similarly with adverse effects on health (267). This work 
demonstrates the validity of the PGS in an MR approach, compared with a widely accepted 
natural experiment instrument. Although it should be acknowledged that the MR estimates 
may be biased by family level confounding (dynastic effects), which would not bias RoSLA 
estimates. 
Tillmann and colleagues demonstrated how genetic variants for educational attainment could 
be used to instrument the effect of educational attainment on cardiovascular outcomes. Here, 
it was found that each 3.6 years of genetically instrumented higher educational attainment 
was associated with a 33% reduction in CHD (9). Additionally, it was demonstrated that this 
may be partially mediated by health-related behaviours such as smoking and BMI. Further MR 




lower BMI (118), lower rates of smoking initiation, heaviness and cessation (268) and reduced 
binge drinking but increased alcohol intake frequency (269).  
Given that education and intelligence are highly correlated, it is difficult to know whether 
genetically predicted educational attainment is capturing phenotypic education, phenotypic 
intelligence or both (270). Using MVMR the causal effect of educational attainment 
independent of intelligence, on a number of outcomes have been demonstrated, including 
independent effects on smoking (271, 272), BMI (272), sedentary behaviour (272) and CHD 
(273). 
2.9 Chapter summary 
In this chapter I have explored the historical context of social causes of CVD, and how SEP can 
be considered and defined in epidemiology. I then considered causal inference in 
Epidemiology, including the sources of bias hindering causality and methods aimed at 
improving causality which are used throughout this thesis. As part of this, I introduced 
existing methods typically used in mediation analyses, genetic epidemiology, MR methods and 
the concept of triangulation. I then went on to explore potential mediators downstream of 
educational attainment, an early life measure of SEP, in the aetiology of CVD. I considered 
how phenotypic and genetic risk scores can be used in disease prediction. Finally, I considered 
the role that genetic epidemiology can play in interrogating social epidemiological research 




Chapter 3. Mendelian randomisation for mediation 
analysis: current methods and challenges for 
implementation 
3.1 Author list and contributions 
Alice R Carter 1,2, Eleanor Sanderson 1,2, Gemma Hammerton 1,2,3, Rebecca C Richmond 1,2, 
George Davey Smith 1,2,4, Jon Heron 1,2,3, Amy E Taylor 1,2,4, Neil M Davies 1,2,5, Laura D Howe 1,2 
All affiliations are presented in Appendix 1 
ARC devised the project, analysed and cleaned the data, interpreted results, wrote and revised 
the manuscript. ES devised the project, generated and analysed simulated data, interpreted 
results and critically revised the manuscript. GH, RCR, GDS, KT, JH AET, NMD and LDH 
devised the project, interpreted the results, and critically revised the manuscript. All authors 
had full access to the data in the study and can take responsibility for the integrity of the data 
and the accuracy of the data analysis. ARC and LDH are the guarantors. The corresponding 
author attests that all listed authors meet authorship criteria and that no others meeting the 
criteria have been omitted. 
3.2 Summary of personal contributions 
This chapter uses simulations and applied examples to demonstrate how Mendelian 
randomisation mediation methods, multivariable Mendelian randomisation and two-step 
Mendelian randomisation, can be used to minimize bias in mediation analysis. I applied 
methods previously developed to decompose mediation effects. Prior to this work, 
multivariable Mendelian randomisation had largely been used to estimate direct effects, either 
in the presence of pleiotropy or potential mediation.  Two-step, or network Mendelian 
randomisation had predominantly been used to infer causal mediation pathways, but had not 
decomposed the direct effect, indirect effect or proportion mediated. 
These analyses were primarily carried out with support from Dr. Eleanor Sanderson who 
advised on and carried out simulation analyses. A version of this work has been posted to the 
preprint server BioRxiv (doi: https://doi.org/10.1101/835819) and is currently under peer review.  
My role in this work was to assist in developing simulations to include, such as deciding which 
sources of bias to include, which methods to simulate and which simulations would 
contribute most to the existing literature. Additionally, I was responsible for carrying out 




for collating all results and creating publication quality tables and figures. I drafted the 
manuscript, which was advised and informed by comments from all co-authors. 
Due to journal word limits it was agreed by all co-authors to focus the manuscript on the main 
conclusions from the simulation scenarios, with the full results available as supplementary 
material. The applied examples were presented as a standalone supplementary material. In 
this thesis chapter, the applied example has been integrated with the manuscript. Some 
simulation results are presented within the chapter, however due to the volume of tables and 
results, some are included in the appendix and referenced to throughout the chapter. To 
enhance readability, this chapter does not follow a standard IMRAD structure.   
Full contributions from myself include devising the project, writing and circulating the 
analysis plan, cleaning the UK Biobank data, analysis and interpreting the results, writing and 
drafting the manuscript, submitting the manuscript, responding to and revising according to 





3.3 Abstract  
Background 
Mendelian randomisation uses genetic variants randomly allocated at conception as 
instrumental variables for a modifiable exposure of interest. Recent methodological advances 
allow for mediation analysis to be carried out using Mendelian randomisation. When genetic 
instruments are available for both an exposure and mediator, both multivariable and two-step 
Mendelian randomisation may be applied.  
Methods 
I use simulations and an applied example to demonstrate when multivariable Mendelian 
randomisation and two-step Mendelian randomisation methods are valid and how they relate 
to traditional phenotypic regression-based approaches to mediation. I demonstrate how 
Mendelian randomisation methods can relax assumptions required for causal inference in 
phenotypic mediation, as well as which Mendelian randomisation specific assumptions are 
required. I illustrate these methods in data from UK Biobank, estimating the role of body mass 
index and low-density lipoprotein cholesterol mediating the association between education 
and cardiovascular outcomes. 
Results 
Both multivariable Mendelian randomisation and two-step Mendelian randomisation are 
unbiased when estimating the total effect, direct effect, indirect effect and proportion 
mediated when both confounding, and measurement error are present. Where both the 
exposure and mediator are continuous, in the presence of a rare or common binary outcome, 
we found little evidence of bias from non-collapsibility of the odds ratio. 
Conclusion 
Phenotypic mediation methods require strong, often untestable, assumptions. Mendelian 
randomisation provides an opportunity for improving causal inference in mediation analysis. 
Although Mendelian randomisation specific assumptions apply, such as no weak instrument 
bias and no pleiotropic pathways, strong assumptions of no confounding and no measurement 






Mediation analysis can improve aetiological understanding and identify intermediate variables 
as potential intervention targets when intervening on an exposure is not feasible. However, in 
order to make causal inferences, phenotypic mediation analysis requires strong assumptions. 
Mendelian randomisation (MR) is an alternative causal inference approach using genetic 
variants as instrumental variables (IV) for a phenotype (245). In this chapter phenotypic 
regression-based methods for mediation analysis are compared with MR methods for 
mediation analysis, and the assumptions required for MR mediation methods to make valid 
causal inferences are described.  
3.4.1 Mediation analysis 
Methods for mediation analysis emerged in the early twentieth-century, although often not 
described as such at the time, with formal methods developed by Baron and Kenny in the 
1980s (225, 227). More recently, a large amount of research has built on and improved 
mediation methods for better causal inference (241).  
Three parameters are typically estimated in traditional mediation analysis i) the total effect 
(the effect of the exposure on the outcome through all potential pathways) ii) the direct effect 
(the remaining effect of the exposure on the outcome that acts through pathways other than 
the specified mediator or set of mediators) and iii) the indirect effect (the path from exposure 
to outcome that acts through the mediator(s)). In situations where the total effect, direct 
effect and indirect effect all act in the same direction, an estimate of the “proportion 
mediated” (i.e. proportion of the total effect explained by the mediator) can be calculated. 
Two common approaches to estimate the indirect effect are; the product of coefficients 





Traditional mediation methods, such as Baron and Kenny methods, rely on several strong, 
untestable assumptions  including, among others i) a causal effect of the exposure on the 
outcome, exposure on the mediator and mediator on the outcome ii) no unmeasured 
confounding between the exposure, mediator and outcome iii) no exposure-caused 
confounders of the mediator and outcome (intermediate confounders, see Figure 3.2 A) and 
iv) no exposure-mediator interaction (111, 229, 241). Furthermore, measurement error in either 
the exposure or mediator can introduce bias (275).  
 
Figure 3.1: The decomposed effects in A) phenotypic regression-based mediation analysis where C represents the total effect, 
C' represents the direct effect and the indirect effect can be calculated by subtracting C’ from C (difference method) or 
multiplying A times B (product of coefficients method) B) multivariable MR, using a combined genetic instrument for both 
the exposure and mediator of interest, to estimate the direct effect (C') of the exposure and C) two-step Mendelian 
randomisation, where the effect of the exposure on the mediator (A) and mediator on the outcome (B) are estimated 
separately, using separate genetic instrumental variables for both the exposure and mediator. These estimates are then 




Baron and Kenny methods were introduced to estimate mediation with a continuous 
exposure, outcome and mediator, although they are also now often applied to binary 
variables. In the presence of a continuous or rare binary outcome the estimates from the 
difference in coefficients and the product of coefficients method should coincide (228, 241). 
Where effects are estimated on the odds ratio scale, the causal effects are only approximated 
Figure 3.2: Schematic diagram illustrating the causal assumptions (dashed lines) in A) phenotypic regression-based mediation 
methods and B) Mendelian randomisation mediation analysis with the measured associations in solid black lines. 
Additional assumption for phenotypic mediation is that of no measurement error in the exposure or mediator 
In Mendelian randomisation, the exclusion restriction criteria mean there are no alternative pathways from the instrument to 












due to non-collapsibility of odds ratios, where the association between an exposure and 
outcome would not be constant by strata of categorical covariate. This is a major limitation as 
binary disease status is often of interest as an outcome. 
Counterfactual reasoning has been used to develop methods that can address some of the 
previously described strong assumptions (228, 238, 240, 276, 277). These methods can estimate 
mediation in the presence of exposure-mediator interactions and account for measured 
intermediate confounders. Additionally, these more flexible counterfactual methods can allow 
for binary mediators and outcomes. However, these methods remain biased in the presence of 
unmeasured confounding, measurement error in the exposure or mediator, or in a mis-
specified model with reverse causality (241, 278). In counterfactual methods, the estimated 
direct effect is described as being a “controlled direct effect” (CDE) if the value of the mediator 
is controlled at a certain value for all individuals in the population, or a “natural direct effect” 
(NDE), when the value of the mediator is allowed to take the value for each person that it 
would have taken naturally had they been unexposed, in a counterfactual scenario. The 
“natural indirect effect” (NIE) represents the average change in an outcome if the value of the 
exposure was fixed, but the value of the mediator changes from its natural value when exposed 
to its natural value when unexposed. If there is no interaction between the exposure and 
mediator, the estimate of the natural direct effect is equivalent to the controlled direct effect, 
and indeed would align with estimates from Baron and Kenny approaches to mediation (228, 
237, 241).  
3.4.2 Mendelian randomisation 
In MR, randomly allocated genetic variants are used as IVs for a phenotype (18, 245, 279). 
Given the random allocation of genetic variants at meiosis and conception, MR estimates are 
robust to bias from confounding, reverse causation and non-differential measurement error 
(279). Three core assumptions are required for a genetic variant to be a valid instrumental 
variable, these are i) the genetic variants are robustly associated with the exposure (the 
relevance assumption) ii) the genetic instruments are exchangeable with the outcome (the 
independence assumption) and iii) the genetic variants do not affect the outcome via any 





3.4.3 Rationale for using Mendelian randomisation in mediation analysis 
Mendelian randomisation can be used to overcome some of the previously described strong 
assumptions required for causal inference in mediation analysis. For example, estimates can 
be robust to bias from specific forms of unmeasured confounding, including that of 
intermediate confounding, and estimates cannot be biased by reverse causality.  
In mediation terms, a univariable MR estimates the total effect of the exposure on the 
outcome. Two differing MR approaches can then be used which broadly mirror traditional 
phenotypic regression-based approaches to mediation to decompose the direct and indirect 
effects: multivariable MR (MVMR) (253, 280) and two-step MR (19, 20, 281).  
In MVMR the controlled direct effect of the exposure on the outcome, controlling for the 
mediator, is estimated (20, 253). The genetic instruments for both the primary exposure and 
the second exposure (mediator) are included as instruments in the analysis (Figure 3.1 A) (282, 
283). The indirect effect can then be estimated by subtracting the direct effect from the total 
effect (akin to the difference in coefficients method). MVMR assumes no interaction between 
the exposure and the mediator; therefore, the CDE estimated is equivalent to the NDE where 
this assumption holds true. As such, this is referred to as the direct effect, without further 
distinction, throughout this chapter. 
Two-step Mendelian randomisation (also known as network MR) is akin to the product of 
coefficient methods. Two MR estimates are calculated i) the causal effect of the exposure on 
the mediator and ii) the causal effect of the mediator on the outcome (Figure 3.1 B) (19, 20, 
Figure 3.3: Directed acyclic graph illustrating Mendelian randomisation and the instrumental variable assumptions 




248). These two estimates can then be multiplied together to estimate the indirect effect. Two-
step MR also assumes no interaction between the exposure and the mediator.  
These MR methods are increasingly being used in mediation analysis (253, 284-287). In this 
chapter, I demonstrate how MVMR and two-step MR can be used to estimate the direct effect, 
indirect effect and the proportion mediated, and which assumptions are required for the 
resulting estimates to be unbiased (20, 282, 283). I provide guidance about how to carry out 
each method, with code provided, and illustrate each method using both simulated and real 
data, applied to an individual level MR analysis.  
3.5 Methods 
3.5.1 Simulation study 
Data were simulated under the model illustrated in Figure 3.1 with continuous, rare binary (5% 
prevalence) and common binary (25% prevalence) outcomes. The size of the total effect of the 
exposure, direct effect of the exposure and proportion mediated were varied. Additionally, 
results were simulated where the total effect of the exposure on the outcome is small, and 
where each of the exposure and mediator were subject to non-differential measurement error. 
Finally, simulations were used to show how MR methods can estimate mediation in the 
presence of multiple mediators, these simulations are illustrated in Figure 3.4. The full range 
of scenarios simulated are presented in Table 3.1. Simulation analyses were carried out using R 










Figure 3.4: Directed acyclic graphs depicting simulation scenarios considering the role of multiple mediators where in A) all three 






Table 3.1: Simulation scenarios  
In all simulations the effect of the mediator on the outcome is set to 0.2. All simulations undergo 1000 replications. 
Confounding is simulated as residual covariance between the exposure, mediator and outcome in all scenarios except 
* 







No Mediation 0.5 0     5000   
Inconsistent 
mediation 




0 0.05 0.25 0.75   5000   
0.2 0.05 0.25 0.75   5000   
0.5 0.05 0.25 0.75   5000   




0.01 0.05 0.25 0.75   5000   
0.05 0.05 0.25 0.75   5000   








0.5 0.25     5000 Exposure  





0.5 0.25     5000  Exposure 












5000   
0.45 
0.56 0.11 0.18 0.12 0    
0.56 0.11 0.18 0.27 0.06    
3.5.2 Applied example 
Using data from UK Biobank (N = 184 778) (see Figure 3.5: Flow chart for exclusions made in 
UK Biobank for resultant sample for mediation analysis), I investigated the role of body mass 
index (BMI) and low-density lipoprotein cholesterol (LDL-C) in mediating the associations of 
education with systolic blood pressure, cardiovascular disease (CVD) and hypertension 
(continuous, rare binary and common binary outcomes, respectively). The effects on binary 
outcomes (hypertension and incident CVD) were estimated on risk difference, log odds ratio, 
and odds ratio scales. Applied analyses were performed using Stata version 15 (StataCorp LP, 






Figure 3.5: Flow chart for exclusions made in UK Biobank for resultant sample for mediation analysis 
Note: At each stage the same participant could have missing data for multiple variables, therefore overlap is present 
between the variables. The total excluded may be less than the sum of individuals at each stage. 
UK Biobank full sample 
N = 503,317 
With complete genetic 
data 
N = 336 807 
Full genetic and phenotypic 
data with no prevalent CVD 
N = 242 047 
Missing exposure, mediator or outcome 
data 
Education N = 2 394 
BMI N = 783 
LDL-C N = 12 788 
Systolic blood pressure N = 24 788 
CVD at baseline 
All cause CVD N = 35 889 
Missing covariable data 
Age N = 0 
Sex N = 0 
Place of birth N = 5 820 
Townsend at birth N = 57 269 
 
With complete data 
included in analysis 
N = 184 778 
Withdrawn N = 790 
Pregnant N = 371 
Missing genetic data N = 14 358 
Highly related N = 9 
Non-white British N = 78 674 
Recommended withdrawals N = 1 812 




3.5.2.1 UK Biobank 
At baseline, UK Biobank participants (N = 503 317) took part in questionnaires, interviews, 
anthropometric, physical and genetic measurements (15, 16). A total of 184 778 individuals of 
White British ancestry, with complete data on genotypes, age, sex, educational attainment, 
cardiovascular outcomes, BMI, LDL-C, blood pressure (including hypertension), 
socioeconomic position (as measured by Townsend Deprivation Index at birth [TDI]) and 
place of birth. Individuals of White British descent were defined using both self-reported 
questionnaire data and having similar genetic ancestry (principal components [PCs]) to the 
European reference panel (from 10,000 genomes panel derived by UK Biobank) (288).  
Data from the baseline assessment centre on highest qualifications completed, BMI, LDL-C, 
systolic blood pressure, hypertension, and all covariate measures (age, sex, place of birth and 
Townsend deprivation index at birth) were used for the analyses.  
3.5.2.2 Genetic exclusion criteria 
Individuals were excluded if their genetic sex differed to their gender reported at the 
assessment centre or for having aneuploidy of their sex chromosomes. Further individuals 
were excluded for being outliers for their heterozygosity and any missing genetic data. Related 
individuals were also excluded from analyses, and the remaining subset was a maximal set of 
unrelated individuals. This exclusion list was derived in-house using an algorithm applied to 
the list of all the related pairs provided by UK Biobank (3rd degree or closer) (Figure 3.5). It 
preferentially removes the individuals related to the greatest number of other individuals until 
no related pairs remain (288).  
3.5.2.3 Education 
Participants reported their highest qualification at the baseline assessment centre ranging 
from no qualifications (equivalent to leaving school after 7 years) up to degree level 
(equivalent to 20 years of schooling). These were converted to the International Standard 




Table 3.2 International Standard for Classification of Education codes mapped to UK Biobank self-report highest 
qualification to estimate years of education 
Qualification (as reported in UK Biobank) ISCED Years of education N 
College or University degree 5 20 61 037 
NVQ or HND or HNC or equivalent 5 19 11 775 
Other prof. qual. e.g.: nursing, teaching 4 15 9 154 
A levels/AS levels or equivalent 3 13 22 190 
O levels/GCSEs or equivalent 2 10 42 194 
CSEs or equivalent 2 10 10 662 
None of the above 1 7 27 806 
Prefer not to answer Excluded 
 
Mendelian randomisation studies require independent samples for the genetic variant-
exposure discovery genome-wide association study (GWAS) and analysis sample. If samples 
overlap MR estimates can be overestimated (289). Therefore, in this analysis, genetic variants 
were selected from GWAS that did not include UK Biobank, and as such, are not always the 
most recent GWAS (244, 289).  
To estimate the education polygenic score (PGS), 72 independent single-nucleotide 
polymorphisms (SNPs) that attained genome-wide significance (P<5x10-8) for education 
reported in main results from an earlier 2016 SSGAC GWAS meta-analysis of 293,723 
individuals and were available in the UK Biobank genotyping platform, to create a weighted 
allele score (17). Alleles were harmonised to all reflect education increasing single nucleotide 
polymorphisms (SNPs) and individual variants were recoded as 0, 1 or 2 according to the 
number of education increasing alleles. A genetic score for education was created by 
weighting each SNP by its relative effect size in the GWAS and summing all variants together 
in an additive model. Five instruments for education were not available in UK Biobank and 
proxy SNPs in perfect LD (r2=1) were used (Table 3.3). 
Table 3.3: Proxy SNPs for education instrument used in one-sample MR analysis 









For phenotypic sensitivity analyses to further test the non-collapsibility of odds ratios, a binary 
measure of low and high education was created. Individuals who left school with 10 years or 
less of education (equivalent to a highest qualification of GCSE, or equivalent) were classed as 
low education. Individuals who completed further education after GCSEs were classed as 
having high education. 
3.5.2.4 Body mass index 
Clinic nurses at baseline assessment centres measured participants’ height (m) and weight 
(kg), which was used to calculate BMI (kg/m2). 
To estimate the BMI PGS, 69 independent SNPs, available on the UK Biobank genotyping 
platform, which had attained genome-wide significance (P<5´10-8) for BMI in both males and 
females of European ancestry in the Genetic Investigation of ANthropometric Traits (GIANT) 
Consortium GWAS, which did not include UK Biobank participants (290). Alleles were 
harmonised to all reflect BMI increasing SNPs and individual variants were recoded as 0, 1 or 2 
according to the number of BMI increasing alleles. A genetic score for BMI was created by 
weighting each SNP by its relative effect size in the GWAS and summing all variants together 
in an additive model.  
In phenotypic sensitivity analyses a binary measure of BMI was created. Individuals with a 
BMI of less than 25kg/m2 were grouped together as normal or underweight individuals. Those 
with a BMI of 25kg/m2 or higher were grouped together as overweight or obese individuals.  
3.5.2.5 Low density lipoprotein cholesterol  
Direct low-density lipoprotein cholesterol (LDL-C) was measured from serum samples 
collected at baseline, using the Enzymatic Selective Protection Method.  
To estimate the LDL-C PGS, 9 independent SNPs (Table 3.4) which had attained genome-wide 
significance (P<5x10-8) for LDL-C in both males and females of predominantly European 
ancestry from the Global Lipids Genetics consortium (291). Genetic variants for LDL-C are 
often also associated with high density lipoprotein cholesterol and triglycerides. To avoid bias 
from pleiotropy, any SNP that was associated with LDL-C and at least one other lipid trait (as 
reported by Willer et al) was excluded from MR analysis (NSNP=51). Alleles were harmonised to 
all reflect LDL-C increasing SNPs and individual variants were recoded as 0, 1 or 2 according to 
the number of LDL-C increasing alleles. The PGS was weighted by each SNP by its relative 




Table 3.4: Independent SNPs used as instruments for LDL-C 






Beta P value 
rs267733 G A 1 150.96 -0.0331 5.29x10-09 
rs2710642 A G 2 63.15 0.0239 6.09x10-09 
rs1250229 C T 2 216.3 0.0243 3.13x10-08 
rs4942486 C T 13 32.95 -0.0243 2.26x10-11 
rs8017377 A G 14 24.88 0.0303 2.52x10-15 
rs1801689 C A 17 64.21 0.1028 9.81x10-12 
rs364585 G A 20 12.96 0.0249 4.28x10-10 
rs2328223 C A 20 17.85 0.0299 5.63x10-09 
rs5763662 T C 22 30.38 0.0767 1.19x10-08 
 
3.5.2.6 Blood pressure 
Systolic and diastolic blood pressure were both recorded automatically and manually at the 
baseline assessment centre. All participants had an automatic reading, but manual readings 
were only taken for a subset. Each reading was taken twice, two minutes apart. This analysis 
uses the second reading of the automated blood pressure, where missing data were replaced 
with the first measure.  
A binary measure of hypertension was created according to the World Health Organization’s 
standard classification for hypertension (SBP ≥ 140 mm Hg and DBP ≥ 90 mm Hg) or if an 
individual was taking antihypertensive medication as recorded at the nurse’s interviews.  
3.5.2.7 Cardiovascular disease 
Cardiovascular disease diagnoses were ascertained through linkage mortality data and hospital 
episode statistics (HES) and Scottish morbidity records (SMR) (referred to jointly as hospital 
inpatient records), with cases (all subtypes) defined according to ICD-9 (390-459) and ICD-10 
codes (all I codes and G45) (292). Individuals who had experienced a CVD event prior to the 
baseline assessment (prevalent cases) were excluded and only first event, incident cases 
following the assessment centre were considered. Date of diagnoses are provided by hospital 
inpatient records, which was linked with the date of assessment centre provided by UK 
Biobank to identify incident and prevalent cases. All UK Biobank participants are linked to 
either HES data or SMRs, with data available from 1997 in England, 1998 in Wales and 1981 in 





Variables considered as confounders were measured at the baseline assessment centres 
through interviews. Covariates considered were age, sex, place of birth (northing and easting 
co-ordinates), birth distance from London, and TDI at birth. Sex and ethnicity were confirmed 
according to genetic data. Place of Birth was adjusted for by the northing and easting birth 
location coordinates. Although the TDI of historic birth location is not recorded in UK 
Biobank, this has been estimated from the index of multiple deprivation indices using the 
current TDI of birth location as a proxy for historic birthplace TDI. Mendelian randomisation 
models were also adjusted for the same confounders. Although a core assumption of MR is 
that the genetic variants are unrelated to confounders, there is some evidence of associations 
with place of birth for the educational attainment variants in UK Biobank (8).  
3.5.3 Statistical analysis 
The following approaches were applied to both applied analyses and simulated data.  
Using the notation X = exposure, M = mediator, M1 = mediator 1, M2 = mediator 2, M3 = 
mediator 3, Y = outcome, G = genetic instruments, C = measured confounders, V = 
uncorrelated error term, µ = uncorrelated error term, four methods are compared (figure 1). 
Notation and equations for the difference method and product of coefficients method are 
adapted from Vanderweele, 2015, where full details of the equations and notations are 
available (294). Variables and parameters given in bold indicate the main coefficient(s) of 
interest in each case.  
All phenotypic analyses were adjusted for potential confounders; age, sex, place of birth, birth 
distance from London, and Townsend deprivation index at birth. Mendelian Randomisation 
analyses were adjusted for the same confounders, in addition to the 40 genetic principal 
components (derived by UK Biobank) to account for population structure. 
3.5.3.1 Difference in coefficients method 
Each outcome was regressed on the exposure adjusting for the mediator to estimate the direct 
effect of the exposure. The direct effect was subtracted from the total effect, estimated using 
multivariable regression adjusting for potential confounders, to estimate the indirect effect. In 
all simulation scenarios the standard deviation of the regression coefficients was calculated 






Total:    Y = θ+0 + θ+1X + θ+3C 
Direct:   Y = θ0 + θ1X + θ2M + θ4C 
Indirect:   θ+1 - θ1 
3.5.3.2 Product of coefficients method 
Two regression models were estimated. Firstly, the mediator was regressed on the exposure. 
Secondly, the outcome was regressed on the mediator, adjusting for the exposure. These two 
estimates were multiplied together to estimate the indirect effect. In applied analyses, 
confidence intervals for the indirect effect were derived from bootstrapping with 100 
replications. 
Exposure-Mediator:  M = β0 + β1X + β3C 
Direct:   Y= θ0 + θ1X + θ2M + θ4C 
Indirect:   β1θ2 
3.5.3.3 Multivariable Mendelian randomisation 
Using MVMR to estimate the direct effect, in the first stage regression, the weighted allele 
score for the exposure and the weighted allele score for the mediator are used to predict each 
exposure respectively, conditional on each other. In the second stage regression, the outcome 
was regressed on the predicted values of each exposure. The direct effect was then subtracted 
from the total effect, estimated using two-stage least squares regression, to estimate the 
indirect effect.  
Total: 
X = π0 + π1Gx + v1 
Y = β0 + βXTX + µ1 
 Direct: 
 X = π0 + π1xGx + π2xGM + v1 
M = π0 + π1zGx + π2zGM + v2 
Y = β0 + βXX + βMM + µ2 
Indirect: 
 βXT- βX 
3.5.3.4 Two-step Mendelian randomisation 
A univariable MR model was carried out to estimate the effect of the exposure on the 




out using MVMR. Both the genetic variants for the mediator and the exposure were included 
in the first and second stage regressions in MVMR. Previous approaches in the literature have 
not used MVMR for this second step (19, 20) and propose carrying out a univariable MR of the 
effect of the mediator on the outcome. However, using MVMR ensures any effect of the 
mediator on the outcome is independent of the exposure. Additionally, this method provides 
an estimate of the direct effect of the exposure on the outcome. The two regression estimates 
from the second stage regression are multiplied together to estimate the indirect effect. In 
applied analyses, confidence intervals for the indirect effect were derived from bootstrapping 
with 100 replications. 
Exposure-Mediator: 
X = π0 + π1Gx + v1 
 M = β0 + βXMX + µ1 
Direct: 
X = π0 + π1xGx + π2xGM + v1 
M = π0 + π1zGx + π2zGM + v2 
Y = β0 + βXX + βMM + µ2 
Indirect: 
βXM βM 
3.5.4 Multiple mediators 
In phenotypic analyses, to estimate the direct effect attributable to multiple mediators, the 
outcome was regressed on the exposure, controlling for all mediators, using multivariable 
regression. Here, the coefficient for the exposure reflects the direct effect (295). This direct 
effect was then subtracted from the total effect to estimate the indirect effect. Secondly, the 
product of coefficients method was used to estimate the indirect effect of each mediator 
individually. The combined effect of all three mediators was then estimated by summing 
together each individual effect.  
In MR analyses, the direct effect attributable to multiple mediators was assessed using MVMR, 
controlling for all mediators. This direct effect was then subtracted from the total effect to 
estimate the combined indirect effect. Secondly two-step MR was used, as previously 
described, considering each mediator individually and summing the effects together to obtain 
the indirect effect of all mediators combined.  




3.5.5 Proportion mediated 
The proportion mediated is calculated by dividing the indirect effect by the total effect. In 
individual-level MR, the confidence intervals were estimated via bootstrapping with 100 
replications.  
3.5.6 Applied sensitivity analyses 
In the applied phenotypic analysis, sensitivity analyses were carried out dichotomising 
education and/or BMI to a binary variable to further test non-collapsibility, where analyses 
were carried out on the log odds ratio scale. See supplementary methods for details.   
Bidirectional univariable MR analysis was carried out to test whether mediator-mediator 
associations exist between BMI and LDL-C. 
Instrument strength was assessed by calculating F-statistics for univariable MR and 
conditional F-statistics for MVMR (296). Sensitivity analyses for MR methods included using 
MR-Egger and MVMR-Egger to test for pleiotropy in the applied example (255, 297).  
3.6 Applied analysis results 
3.6.1 Participant characteristics 
Descriptive characteristics of UK Biobank participants included in the real data example are 
shown in Table 3.5. To summarise, participants were more likely to be more highly educated, 
with 32% of participants leaving school after 20 years of education compared with 16% leaving 
with 7 years of education. Participants eligible for analyses were comparable to the full UK 
Biobank sample, although in the analysis sample hypertension was less prevalent. The 





Table 3.5: UK Biobank cohort descriptive statistics 
Variable 
Eligible Sample 
N = 184 778 
 
All UK Biobank (excluding 
withdrawals) 
N = 502 527 
Mean (SD) or N (%) N 
Mean (SD) or N 
(%) 
Sex Female 101 757 (55%) 502 527 273 396 (54%) 
Age (at baseline)  56.21 (8.04) 502 527 56.53 (8.10) 
Educational attainment (years) 
7 27 806 (15%) 
492 393 
85 275 (17%) 
10 52 816 (29%) 132 087 (11%) 
13 22 190 (12%) 55 325 (11%) 
15 9 154 (5%) 25 805 (5%) 
19 11 775 (6%) 32 730 (7%) 
20 61 037 (33%) 161 171 (33%) 
Body mass index  27.07 (4.55) 499 422 27.43 (4.80) 
Low-density lipoprotein cholesterol  3.63 (0.85) 468 727 3.56 (0.87) 
Systolic blood pressure  137.89 (18.53) 456 985 137.78 (18.63) 
Incident cardiovascular disease 
Control 141 909 (77%) 
418 781 
321 633 (77%) 
Case 42 869 (23%) 97 148 (23%) 
Hypertension 
Control 124 119 (67%) 
467 429 
282 816 (61%) 
Case 60 659 (33%) 184 613 (40%) 
 
3.6.2 Effect of education on systolic blood pressure, CVD and hypertension 
Both multivariable regression and univariable MR provided evidence to support a causal effect 
of education on systolic blood pressure, as well as for a role of BMI mediating this effect on the 
risk difference scale. Phenotypically, the difference method estimated the indirect effect for a 
one standard deviation increase in education on systolic blood pressure mediated via a one 
standard deviation increase in BMI to be -0.33 mmHg (95% CI: -0.35 to -0.32) and the 
proportion mediated to be 27.7% (95% CI: 25.6% to 29.9%) (Table 3.6). Using MVMR the 
indirect effect estimated was -0.55 mmHg (95% CI: -0.83 to -0.28). Despite the MVMR indirect 
effect and total effect being larger than the phenotypic difference estimate, this corresponded 
to a smaller proportion mediated of 16.9% (95% CI: 8.6% to 25.2%).  
Using the phenotypic product of coefficients method, the indirect effect of a one standard 
deviation increase in education via a one standard deviation (SD) increase in BMI on systolic 
blood pressure was -0.33 mmHg (95% CI: -0.35, -0.32) with a proportion mediated of 27.7% 
(95% CI: 25.7% to 29.8%) (Table 3.6). Comparatively, using two-step MR, the indirect effect 
was estimated to be -0.55 mmHg (95% CI: -0.85 to -0.26) corresponding to a proportion 




Both multivariable regression and univariable MR provided evidence to support a causal effect 
of education on CVD, including for a mediating role of BMI. For example, the indirect effect 
via a one SD increase in BMI on the effect of a standard deviation increase in education on 
incident CVD, was estimated to be reduce the risk of CVD by -0.02 (95% CI for MVMR and 
two-step MR: -0.02 to -0.01). The estimate of the proportion mediated via both MVMR and 
two-step MR was 21.0% (95% CI for MVMR: 11.0% to 30.9%; 95% CI for two-step MR: 10.3% to 
31.6%). The estimates of the decomposed mediated effects were similar when analysed using 
the log odds ratio scale, however estimates had wider confidence intervals (Table 3.6). 
Mendelian randomisation suggested more education reduced risk of hypertension; however, 
estimates were imprecise and confidence intervals were consistent with an increased risk. This 
led to large confidence intervals around the estimate of the proportion mediated by BMI. On 
the risk difference scale, the proportion mediated that was estimated by MVMR was 21.0% 
(95% CI: 3.7% to 38.2%) and by two-step MR was 22.7% (95% CI: 1.7% to 43.7%). Similar values 
were obtained using the log odds ratio scales (Table 3.6). 
For both CVD and hypertension, the decomposed mediated effects estimated on the odds 





Table 3.6: Real-data example estimating the mediating role of BMI independently between education and systolic blood pressure, cardiovascular disease and hypertension, using multivariable 
observational methods and mendelian randomisation methods 
Outcome Scale Method 
Total Effect (95% 
CI) 
Direct effect (95% 
CI) 













Phenotypic -1.20 (-1.28, -1.12) -0.87 (-0.95, -0.79) -0.33 (-0.35, -0.32) 27.73 (25.62, 29.85) -0.33 (-0.35, -0.32) 27.73 (25.70, 29.76) 





Phenotypic -0.03 (-0.03, -0.03) -0.02 (-0.02, -0.02) -0.01 (-0.01, -0.01) 22.24 (20.19, 24.28) -0.01 (-0.01, -0.01) 22.24 (20.29, 24.19) 
MR -0.08 (-0.11, -0.06) -0.07 (-0.09, -0.04) -0.02 (-0.02, -0.01) 20.97 (11.03, 30.91) -0.02 (-0.02, -0.01) 20.97 (10.3, 31.63) 
Log odds 
ratio 
Phenotypic -0.16 (-0.17, -0.15) -0.13 (-0.14, -0.11) -0.03 (-0.03, -0.03) 20.49 (18.47, 22.51) 
-0.04 (-0.04, -
0.03) 
22.84 (20.87, 24.82) 
MR -0.50 (-0.63, -0.37) -0.4 (-0.53, -0.26) -0.11 (-0.14, -0.07) 21.11 (10.54, 31.68) -0.11 (-0.14, -0.07) 21.15 (11.56, 30.75) 
Odds 
ratio 
Phenotypic 0.85 (0.84, 0.86) -0.13 (0.87, 0.89) -0.03 (-0.03, -0.03) -3.31 (-3.5, -3.11) -0.15 (-0.15, -0.14) -17.22 (-18.01, -16.44) 
MR 0.61 (0.53, 0.69) 0.67 (0.59, 0.77) 
-0.07 (-0.09, -
0.05) 




Phenotypic -0.02 (-0.03, -0.02) -0.02 (-0.02, -0.02) -0.01 (-0.01, 0.01) 22.73 (20.54, 24.93) -0.01 (-0.01, 0.01) 22.73 (20.14, 25.32) 
MR -0.05 (-0.07, -0.02) -0.04 (-0.06, -0.01) -0.01 (-0.02, 0.01) 20.97 (3.73, 38.20) -0.01 (-0.02, 0.01) 22.71 (1.69, 43.74) 
Log odds 
ratio 
Phenotypic -0.11 (-0.12, -0.10) -0.09 (-0.1, -0.08) -0.03 (-0.03, -0.02) 22.64 (20.37, 24.91) -0.03 (-0.03, -0.03) 24.61 (22.16, 27.06) 
MR -0.24 (-0.35, -0.12) -0.18 (-0.31, -0.06) 
-0.05 (-0.09, -
0.02) 
22.82 (-4.81, 50.45) 
-0.05 (-0.08, -
0.02) 
22.87 (1.48, 44.26) 
Odds 
ratio 
Phenotypic 0.89 (0.88, 0.90) -0.09 (0.91, 0.93) 
-0.02 (-0.02, -
0.02) 
-2.56 (-2.72, -2.40) -0.13 (-0.14, -0.13) -15.09 (-15.82, -14.37) 
MR 0.79 (0.7, 0.89) 0.83 (0.74, 0.95) 
-0.04 (-0.07, -
0.02) 
-5.53 (-9.13, -1.93) -0.43 (-0.5, -0.35) -54.18 (-64.94, -43.42) 





There was little evidence that LDL-C mediates the effect of education on systolic blood 
pressure, hypertension and CVD (Table 3.7). Phenotypically, both the difference in coefficients 
method and product of coefficients method estimated 0.9% (95% CI (product method): 0.3% 
to 1.6%) of the effect of education on systolic blood pressure was mediated by LDL-C. In MR, 
both MVMR and two-step MR estimated the proportion mediated to be -1.8% (95% CI (two-
step MR): -6.6 to 2.4). In both phenotypic and MR analyses, there was limited evidence that 




Table 3.7: Real-data example estimating the mediating role of low-density lipoprotein cholesterol independently between education and systolic blood pressure, cardiovascular disease and hypertension, 
using multivariable observational methods and mendelian randomisation methods 





Difference method or MVMR Product method or two-step MR 
Indirect effect (95% 
CI) 
Proportion 
mediated (95% CI) 








Phenotypic -1.20 (-1.28, -1.12) -1.18 (-1.26, -1.10) -0.02 (-0.03, -0.01) 1.78 (1.14, 2.42) -0.02 (-0.03, -0.01) 1.78 (1.09, 2.47) 





Phenotypic -0.03 (-0.03, -0.03) -0.03 (-0.03, -0.03) 
2.86x10-4 (1.78x10-4, 
3.93x10-4) 
-1.04 (-1.49, -0.58) 
2.86x10-4 (1.81x10-4, 
3.90x10-4) 
-1.04 (-1.47, -0.61) 
MR -0.08 (-0.11, -0.06) -0.09 (-0.11, -0.06) 
6.43x10-4 (-2.76x10-3, 
4.04x10-3) 
-0.76 (-4.57, 3.05) 
6.43x10-4 (-2.49x10-3, 
3.77x10-3) 
-0.76 (-4.58, 3.06) 
Log odds 
ratio 
Phenotypic -0.16 (-0.17, -0.15) -0.16 (-0.17, -0.15) 
9.88x10-4 (4.15x10-4, 
1.56x10-3) 
-0.62 (-1.03, -0.22) 
1.48x10-3 (8.68x10-4, 
2.08x10-3) 
-0.93 (-1.25, -0.61) 
MR -0.50 (-0.63, -0.37) -0.51 (-0.63, -0.38) 3.94x10-3 (-0.01, 0.02) -0.78 (-3.88, 2.31) 3.93x10-3 (-0.02, 0.02) -0.78 (-4.9, 3.33) 
Odds 
ratio 
Phenotypic 0.85 (0.84, 0.86) -0.16 (0.84, 0.86) 
8.43x10-4 (3.72x10-4, 
1.31x10-3) 
0.10 (0.04, 0.15) -0.01 (-0.01, -0.01) -1.26 (-1.80, -0.72) 




Phenotypic -0.02 (-0.03, -0.02) -0.02 (-0.03, -0.02) 
4.78x10-4 (3.14x10-4, 
6.42x10-4) 
-2.06 (-2.93, -1.19) 
4.78x10-4 (2.91x10-4, 
6.65x10-4) 
-2.06 (-2.85, -1.27) 
MR -0.05 (-0.07, -0.02) -0.05 (-0.07, -0.03) 
1.82x10-3 (-2.27x10-3, 
0.01) 
-3.91 (-14.18, 6.36) 
1.82x10-3 (-2.21x10-3, 
0.01) 
-3.91 (-16.79, 8.97) 
Log odds 
ratio 
Phenotypic -0.11 (-0.12, -0.10) -0.11 (-0.12, -0.10) 
1.87x10-3 (1.00x10-3, 
2.74x10-3) 
-1.67 (-2.44, -0.91) 
2.24x10-3 (1.50x10-3, 
2.98x10-3) 
-2.00 (-2.76, -1.25) 
MR -0.24 (-0.35, -0.12) -0.25 (-0.36, -0.13) 0.01 (0.01, 0.02) -4.01 (-11.86, 3.84) -0.01 (-0.01, 0.03) -4.01 (-14.69, 6.68) 
Odds 
ratio 
Phenotypic 0.89 (0.88, 0.90) -0.09 (0.91, 0.93) -0.02 (-0.02, -0.02) -2.56 (-2.72, -2.40) -0.13 (-0.14, -0.13) -15.09 (-15.82, -14.37) 
MR 0.79 (0.70, 0.89) 0.78 (0.69, 0.88) -0.04 (-0.08, 0.01) 0.94 (-0.60, 2.48) -0.04 (-0.08, 0.01) -5.11 (-9.41, -0.81) 




Table 3.8: Effect of a one standard deviation increase of body mass index (BMI) on low-density lipoprotein cholesterol 




3.6.3 Joint mediation by BMI and LDL-C  
Considering BMI and LDL-C jointly, in phenotypic mediation using the difference method on 
the risk difference scale 28.4% (95% CI: 26.3% to 30.5%) of the association between education 
and systolic blood pressure was explained (Table 3.9), compared with 27.7% (95% CI: 25.62% to 
29.9%) by BMI individually and 1.8% (95% CI: 1.1% to 2.4%) (Table 3.6) by LDL-C individually 
(Table 3.7). When considering CVD as the outcome 21.7% (95% CI: -20.1% to 23.4%) was 
explained by BMI and LDL-C jointly (Table 3.9), similar to the amount explained by BMI 
individually (22.2% [95% CI: 20.2 to 24.3%]) (Table 3.6). BMI and LDL-C jointly explained 21.8% 
(95% CI: 19.7% to 23.9%) of the association between education and hypertension (Table 3.9), 
again, this was similar to the amount explained by BMI individually (22.7% [95% CI: 20.5% to 
24.9%]) (Table 3.6). 
In MR analyses, using MVMR to estimate the combined proportion mediated on the risk 
difference scale, 12.6% (95% CI: 1.95% to 23.1%) was explained by BMI and LDL-C on the 
association between education and SBP (Table 3.9). This was less than the amount explained 
by BMI individually (16.9% [95% CI:8.6% to 25.2%]) (Table 3.6). BMI and LDL-C jointly explained 
20.3% (95% CI: 18.5% to 22.0%) of the association between education and CVD (Table 3.9), 
similar to the amount explained by BMI individual (21.0% [95% CI:11.0% to 30.95]) (Table 
3.6).Considering hypertension as the outcome, BMI and LDL-C jointly explained 21.9% (95% CI: 
19.1% to 24.6%) of the association (Table 3.9). Again, this was similar to the amount explained 
by BMI individually (21.0% [95% CI: 3.7% to 38.2%]) (Table 3.6). 
 
 
Exposure Outcome Beta (95% CI) 
BMI LDL-C 0.51 (0.48, 0.55) 
 




Table 3.9: Real-data example estimating the joint mediating role of BMI and LDL-C between education and systolic blood pressure (SBP), hypertension and cardiovascular disease 
(CVD) using multivariable observational methods and mendelian randomisation methods, where the joint direct effect was estimated using the difference in coefficients method, or 
multivariable mendelian randomisation method 
Outcome Scale Method Total Effect (95% CI) 
Direct effect 
(95% CI) 
Difference method or MVMR 





Phenotypic -1.20 (-1.28, -1.12) -0.86 (-0.94, -0.78) -0.34 (-0.36, -0.32) 28.39 (26.29, 30.48) 





Phenotypic -0.03 (-0.03, -0.03) -0.02 (-0.02, -0.02) -0.01 (-0.01, -0.01) 21.73 (20.05, 23.42) 
MR -0.16 (-0.17, -0.15) -0.13 (-0.14, -0.12) -0.03 (-0.03, -0.03) 20.25 (18.46, 22.03) 
Log odds 
ratio 
Phenotypic -0.08 (-0.11, -0.06) -0.07 (-0.09, -0.05) -0.02 (-0.02, -0.01) 19.50 (8.70, 30.29) 




Phenotypic -0.02 (-0.03, -0.02) -0.02 (-0.02, -0.02) -0.01 (-0.01, 0.01) 21.8 (19.70, 23.91) 
MR -0.11 (-0.12, -0.10) -0.09 (-0.10, -0.08) -0.02 (-0.03, -0.02) 21.88 (19.13, 24.62) 
Log odds 
ratio 
Phenotypic -0.05 (-0.07, -0.02) -0.04 (-0.06, -0.01) -0.01 (-0.02, 0.01) 19.50 (-5.2, 44.19) 
MR -0.24 (-0.35, -0.12) -0.20 (-0.32, -0.07) 0.17 (-0.05, 0.39) -71.08 (-223.18, 81.03) 





3.6.4 Sensitivity analyses  
Applied examples using phenotypic mediation methods were extended to examine the role of 
binary exposures or mediators on non-collapsibility. In both rare and common binary 
outcomes, where the education exposure was dichotomized to low (10 years of education or 
less) compared with high education (greater than 10 years of education) the difference in 
coefficients method and product of coefficients method estimated similar mediating roles by a 
continuous standard deviation increase in BMI. For example, the proportion mediated by BMI 
on the association between education (high vs low) and CVD was 19.6% (95% CI: 17.7% to 
21.4%) for the difference method and 22.0% (95% CI: 20.0% to 24.1%) for the product of 
coefficients method. Where the mediator was binary (normal and underweight vs overweight 
and obese) the two methods diverged. For example, the proportion mediated by high versus 
low BMI on the association between a one SD increase in education and incident CVD was 
11.7% (95% CI: 10.5% to 12.8%) for the difference in coefficients method and 62.7% (95 % CI: 
57.2% to 68.1%) for the product of coefficients method. This was similar when both the 
exposure and outcome were considered as binary. Similar results were also seen when 
considering common hypertension as the outcome (Table 3.10). Where both the mediator and 
outcome are binary, counterfactual methods for mediation analysis should be considered. 
All instruments had strong F statistics (215 to 3094) and conditional F statistics (214 to 2457) 
(Table 3.11).  
Both MR-Egger and MVMR-Egger provide little evidence to support pleiotropic effects of the 




Table 3.10:  Evaluating non-collapsibility in real-data example with binary exposures and/or binary mediators with a rare binary and common binary outcome on the log odds ratio 
scale using phenotypic mediation methods 
Outcome Exposure (education) Mediator (BMI) 
Total effect (95% 
CI) 












Education low vs 






-0.16 (-0.17,-0.15) -0.02 (-0.02, -0.02) 11.68 (10.53, 12.83) -0.10 (-0.11, -0.09) 62.66 (57.21, 68.11) 





-0.29 (-0.31,-0.26) -0.03 (-0.04,-0.03) 11.45 (10.03, 12.87) -0.17 (-0.19,-0.16) 61.20 (54.78, 67.61) 
Hypertension 
(common) 
Education low vs 






-0.13 (-0.14,-0.12) -0.02 (-0.02,-0.01) 13.77 (12.00, 15.54) -0.08 (-0.08,-0.07) 70.05 (62.02, 78.08) 





-0.19 (-0.21,-0.17) -0.03 (-0.03,-0.02) 14.01 (12.10, 15.91) -0.14 (-0.15,-0.12) 70.91 (61.58, 80.22) 
Low education defined as 10 years or less years of education, equivalent to a highest qualification of GCSE/CSE or equivalent. High education defined as more than 10 years of 
education equivalent to post-secondary qualifications. Low education had a prevalence of 34% 
BMI = body mass index ; CI = confidence interval 




Table 3.11: F statistics to test instrument strength in real-data Mendelian randomisation 
 Education BMI LDL-C 
Conditional 
variable  
Education 1452.99 2456.54 216.92 
BMI 1296.39 3093.68 213.46 
LDL-C 1406.35 1866.21 214.63 
Education, BMI and 
LDL-C 1189.71 1697.33 216.92 
 
F statistics for univariable MR analyses are in bold, all other estimates are conditional F statistics 





Table 3.12: MR-Egger and MVMR-Egger results for the applied example examining the mediating role of body mass index (BMI) and low-density lipoprotein cholesterol (LDL-C) on the 
association between education and systolic blood pressure, cardiovascular disease and hypertension, estimated on the mean or risk difference scale 
 Systolic blood pressure Cardiovascular disease Hypertension 
 Univariable MR-Egger Multivariable MR-Egger* Univariable MR-Egger 
Multivariable MR-








-2.67x10-5 to 2.21x10-5  -2.58x10-7to 2.93x10-7  -4.08x10-7 to 4.12x10-7  
P Value 0.853  0.901  0.992  
Body mass index 




-2.75x10-5 to 2.40x10-5 -1.97x10-5 to 1.64x10-5 -2.73x10-7 to 3.30x10-7 -1.76x10
-7 to -
2.32x10-7 -4.67x10
-7 to 4.95x10-7 -3.02x10
-7 to 3.28x10-
7 
P Value 0.895 0.857 0.851 0.784 0.953 0.934 
Low-density lipoprotein cholesterol 




-4.30x10-5 to 3.84x10-5 -2.56x10-5 to 2.11x10-5 -3.38x10-7 to 3.79x10-7 -2.08x10
-7 to -
2.51x10-7 -4.89x10
-7 to 5.06x10-7 -3.09x10
-7 to 3.27x10-
7 
P Value 0.909 0.850 0.908 0.855 0.972 0.955 
 
Education adjusted for either body mass index or low-density lipoprotein cholesterol 





3.7 Testing the assumptions of mediation analysis 
In this analysis, a number simulations were carried out to demonstrate scenarios where 
phenotypic or MR methods for mediation analysis may provide biased answers. In this section 
I outline these results and any implications for analyses. 
3.7.1 Unmeasured confounding 
Many of the key assumptions in phenotypic mediation analysis relate to assumptions of no 
unmeasured confounding between all of the exposure, mediator and outcome, including 
where confounders of the mediator and outcome are descendants of the exposure 
(intermediate confounding). Multivariable regression analyses often suffer from residual 
confounding because it is generally impossible to measure a sufficient set of confounders, and 
frequently those that are measured are measured with error. 
Indeed, in simulations where residual covariance was simulated to reflect confounding, both 
the phenotypic difference method and phenotypic product of coefficients method were 
equally biased (Figure 3.6 and Appendix 1 Table 1). Where no confounding was simulated in 
the case of no true total effect, estimates from phenotypic approaches were free from bias 
(Appendix 1 Table 2). In simulations both with and without residual covariance to reflect 
confounding, MVMR and two-step MR estimated the direct effect, indirect effect and 
proportion mediated with no bias (Figure 3.6 and Appendix 1 Table 3-Appendix 1 Table 4). 
Collider bias can be introduced by adjusting for the mediator in the presence of un- or mis-
measured mediator-outcome confounders, where a backdoor path opens up between the 
exposure and the confounder (Figure 3.7) (229, 231, 232). Given that MR estimates are 
unbiased by unmeasured confounding of the exposure-outcome and mediator-outcome 
relationships (245, 279), this means that within MR analyses, adjusting for the mediator does 




Figure 3.6: Size of absolute bias for the indirect effect of an exposure on range of outcomes through a continuous mediator, for a range of fixed true total 
effect sizes (0.2, 0.5 and 1.0) and range of true indirect effect sizes using phenotypic mediation methods or Mendelian randomisation, on the risk 






Figure 3.7: Directed acyclic graphs depicting how collider bias can be introduced in phenotypic mediation analysis 




3.7.2 Analysis of binary outcomes 
Mediation analysis of binary outcome is challenging because of the non-collapsibility of odds 
ratios.  This means the association between an exposure and outcome would not be constant 
on the odds-ratio scale by strata of categorical covariate (298, 299). In mediation analysis, 
including the mediator in the model estimating the direct effect, means the model is no longer 
comparable with that for the total effect.  
The mediation literature indicates that to estimate the direct and indirect effects of a binary 
outcome, the outcome must be rare (less than 10% prevalence), so the odds ratio approximates 
the risk ratio, and the product of coefficients method should be used for phenotypic data 
(228). In the presence of a common binary outcome, estimates from the product of 
coefficients method and difference method are unlikely to align (and indeed the literature 
suggests both are likely biased) (241).  
In simulations, both the difference in coefficients and the product of coefficients phenotypic 
methods, with common and rare binary outcomes on a linear relative scale were biased as 
expected (Figure 3.6 and Appendix 1 Table 5 to Appendix 1 Table 8). In simulated MR scenarios 
with common and rare binary outcomes on a linear relative scale, estimated effects were 
concordant between MVMR and two-step MR, with little to no bias (Figure 3.6 and Appendix 1 
Table 9 to Appendix 1 Table 12). 
In the scenarios simulated, there was some bias when analysing binary outcomes on the log 
odds ratio scale using both MVMR and two-step MR, for both common and rare binary 
outcomes (Appendix 1 Table 13 and Appendix 1 Table 14). This bias was small and typically 
would not alter conclusions made, although typically the size of absolute bias increased as the 
size of the true proportion mediated increased. However, the exact bias from non-
collapsibility will be unique to each scenario, including depending on the strength of the 
mediators. Analyses in individual level MR can be conducted on the risk difference scale, 
which reduced bias due to non-collapsibility. 
In simulation scenarios explored, neither MVMR nor two-step MR were able to estimate the 
mediated effects without bias when using the odds ratio scale (Appendix 1 Table 15 and 
Appendix 1 Table 16). 
3.7.3 Measurement error in the exposure or mediator 
These results show that in phenotypic approaches, with a continuous exposure and mediator, 




effect. This is consistent with previous methodological and applied work (275). Where non-
differential measurement error was simulated in the exposure, the mediated effect was over 
estimated (Appendix 1 Table 17).  
In Mendelian randomisation simulations, both MVMR and two-step MR estimated the 
mediated effects with little bias when non-differential measurement error was simulated 
either in the exposure or the mediator (Appendix 1 Table 18). This is consistent with the 
previous literature demonstrating that MR estimates are less prone to bias by non-differential 
measurement error than conventional phenotypic analyses (245, 279).  
3.7.4 Weak instrument bias 
In order to obtain valid causal inference for mediation, all standard MR assumptions must be 
met. This includes having strong instruments, typically determined through an F-statistic or 
conditional F-statistic of greater than 10. When the instruments in the simulation were weakly 
associated with the exposure both MVMR and two-step MR estimates of the indirect effect 
and proportion mediated were biased. The size of bias was greatest for a common binary 
outcome. When weak instruments were simulated for the mediator, estimates of the indirect 
effect and proportion mediated from both MVMR and two-step MR were biased (Figure 3.8). 
Bias due to weak instruments have been discussed extensively in the literature (244, 300, 301), 









Estimated proportion mediated 
Figure 3.8: Estimates of the proportion mediated and size of absolute bias when weak instrument bias is simulated in A) the exposure and B) the mediator for a true proportion mediated of 0.25 
(solid line) (simulated N = 5000) 




3.7.5 Small total effects 
In simulation studies with no true total effect the MR estimate of the proportion mediated is 
implausible (Appendix 1 Table 3). Where there is no evidence of a total effect, consideration 
should be given as to whether it is appropriate to continue with mediation analyses. Although 
an indirect effect can be estimated in the absence of a significant total effect, or absence of 
total effect when the indirect effect and direct effect act in opposing directions and cancel 
each other out, these estimates are prone to inflated type 1 errors (i.e. false positive results) 
(303).  
Where the total effect is weak or estimated imprecisely (with confidence intervals crossing the 
null) simulations show the indirect effect and the proportion mediated using MR can be 
estimated but have large standard deviations (Appendix 1 Table 19 to Appendix 1 Table 22). In 
this case, results should be interpreted with caution, especially considering the bounds of 
error. 
3.7.6 Analysis of multiple mediators 
The direct effect of an exposure controlling for multiple mediators in a single model can be 
assessed using MVMR, with no evidence of bias (Appendix 1 Table 23). Here, non-overlapping 
SNPs for all exposures and mediators are included in one set of instruments. The estimated 
direct effect attributable to multiple mediators is unbiased, even in the presence of mediator-
mediator relationships. In simulations presented here, this relationship was demonstrated by 
M2 causing M3 (Figure 3.4). 
Where there are no mediator-mediator relationships, estimates of the indirect effects and 
proportion mediated from both MVMR (mutually adjusting for all mediators) and two-step 
MR (considering each mediator individually and summing together) will coincide (Appendix 1 
Table 23). In simulations, both MR methods estimated the indirect effect of each mediator, 
and the three mediators jointly, with no bias (Appendix 1 Table 23). This is consistent with the 
existing literature on phenotypic multiple mediators (295).  
Where mediator-mediator relationships are present, the indirect effect estimated via two-step 
MR captures both the amount of the association explained by the mediator of interest, and the 
amount of the mediator-outcome association captured by related mediators. In the simulated 
example, this means that the effect of M3 is estimated twice, once directly and once via M2. As 
such, the estimate for the proportion mediated summing all three mediators together will 
likely be an overestimate of the combined proportion mediated, but the estimated direct effect 




by 6% (Appendix 1 Table 23), which is equivalent to the proportion explained by M2 through 
M3. The indirect effect of M2 therefore reflects both the direct effect of M2 on the outcome 
and the indirect effect via M3 (Figure 3.4). 
3.8 Applied results in context 
The results from the applied example demonstrate a causal total effect of education on systolic 
blood pressure, supporting results in the wider literature (304-306) and shows that BMI is a 
mediator of the association between education and systolic blood pressure. Given my analyses 
showing that systolic blood pressure is itself a mediator of the associations between education 
and CVD (Chapter 4), this work suggests systolic blood pressure is downstream of BMI on the 
causal pathway, although bi-directional associations were not explored in this analysis.  
Despite LDL-C being a major, modifiable risk factor for cardiovascular outcomes (50, 307), and 
there being some evidence from non-genetic instrumental variable analyses that levels of LDL-
C decrease with increased education (308), it does not appear to explain any of the of 
educational inequalities in these outcomes. Although the instrument for LDL-C only 
comprised of 9 SNPs which did not have pleiotropic effects on either high-density lipoprotein 
cholesterol or triglycerides, the F-statistics and conditional F-statistics for these analyses 
remained high, and results are unlikely to be biased due to weak instrument bias. 
Considering BMI and LDL-C jointly,  the proportion mediated between education and CVD 
increased by 9% compared with the BMI individually. However, for each of the individual 
estimates of the proportion mediated and the joint estimate the confidence intervals were 
wide. Considering systolic blood pressure and hypertension as the outcomes, the proportion 
mediated decreased. 
3.9 Limitations of Mendelian randomisation applied to mediation 
analysis 
3.9.1 Instrument selection 
Instruments associated with multiple exposures can be included in a MVMR analysis when 
MVMR is being used to test for potential pleiotropic pathways (22, 282, 309). However, when 
MVMR is used to test for mediation, these overlapping instruments should not be included. If 
overlapping instruments were included and an attenuation of the direct effect compared with 
the total effect was observed, it would not be possible to distinguish whether this were 
attributable to mediation or pleiotropy (i.e. an effect of the SNP on the outcome via the 




is considered as both an exposure (of the outcome) and as an outcome (of the exposure) and 
therefore any instruments for the exposure that are also instruments for the mediator are 
pleiotropic in the estimation of the effects of the exposure on the mediator and should be 
excluded. Where there are no independent SNPs, or the SNPs had a perfectly proportional 
effect on both the exposure and the mediator, then it would not be possible to use MR 
methods to estimate mediation. 
The exclusion restriction criteria assuming no pleiotropic pathway is an important assumption 
of standard univariable MR, which applies equally when MR is used for mediation analysis. 
Some methods are available to assess pleiotropy including for the use of MVMR (255, 256, 
297). 
3.9.2 Binary exposures and/or mediators 
Very few binary exposures will be truly binary and are likely a dichotomization of an 
underlying liability, changing the interpretation of an MR analysis (310). For example, smoking 
is often defined as ever versus never smokers, when the underlying exposure is a latent 
continuous variable reflecting smoking heaviness and duration. As a result, the exclusion 
restriction criteria are violated, where the genetic variant can influence the outcome via the 
latent continuous exposure, even if the binary exposure does not change (310). In a mediation 
setting, the same would apply to a binary mediator. In these scenarios, two-step MR could be 
used to test whether there is evidence of a causal pathway between the binary exposure and/or 
mediator. However, the estimates of mediation would likely be biased. 
3.9.3 Interactions between the exposure and mediators 
Within phenotypic analysis, exposure-mediator interactions can be accommodated when 
estimating mediation parameters. This is not possible in either MVMR or two-step MR. 
Methods are available for estimating interactions in an MR framework with individual level 
data, but these do not currently extend to estimating mediation in the presence of exposure-
mediator interactions (240, 251, 252). Estimates of mediation from MR mediation methods will 
require assuming effect homogeneity of both the exposure on the mediator and outcome, and 
mediator on the outcome. This means that the effects of the exposure and the mediator are 
the same for all individuals. Where interactions between the exposure and mediator are 
hypothesised this assumption may not hold true. Developing MR methods which can account 





Mendelian randomisation studies require very large sample sizes to achieve adequate 
statistical power. Conditional F-statistics in MVMR are typically weaker than standard F-
statistics, and indeed are likely to become weaker with each additional mediator included, 
further decreasing the power of complex analyses. Therefore, to achieve adequate statistical 
power, or precision, sample sizes for mediation analysis likely need to be even larger than 
those needed in a univariable MR analyses.  
In the absence of formal power calculators for complex MR scenarios, the power of these 
analyses can be considered by evaluating the precision of the confidence intervals for all of the 
total, direct and indirect effects, as well as assessing the conditional instrument strength.  
3.9.5 Confounding 
Although assumptions about unmeasured confounding in MR can be relaxed compared with 
traditional phenotypic analyses, confounding can be introduced through population 
stratification, assortative mating, and dynastic effects (186). Adjusting for genetic principal 
components and other explanatory variables that capture population structure or within 
family analyses can minimise bias. 
3.9.6 Mediation analysis with summary sample Mendelian randomisation 
Methods applied in this paper can be used with summary data MR (see Box 1). Similar 
considerations will apply for both individual level MR, as presented here, and summary data 
MR. Importantly, all sources of summary statistics for the exposure, mediator and outcome 
should be non-overlapping (289). As the mediator is considered an outcome in the exposure-
mediator model, sample overlap can introduce bias (289). As individual level data is not 
available in summary data MR, bootstrapping cannot be used to estimate the confidence 
intervals for the indirect effect or proportion mediated, but the delta method can be used to 
approximate these confidence intervals if samples are independent (287). Analyses will also be 
restricted to the scale reported by the GWAS used, so consideration will need to be given for 






Box 1: Summary of Mendelian randomisation 
Individual level data Mendelian randomisation 
Individual SNPs or polygenic risk scores are created for each individual in a study, where all study 
information and genetic information is provided for each individual.  
Both the gene-exposure and gene-outcome estimates are calculated in the same sample 
Analyses can be carried out on either a binary (log odds ratio) or continuous scale 
The F-statistic and Sanderson-Windmeijer F-statistic can be used to assess instrument strength in 
univariable and multivariable MR respectively.  
Summary data Mendelian randomisation 
Summary estimates of the gene-exposure and gene-outcome association are estimated in separate 
samples  
Analyses must be carried out on the scale reported by the outcome genome wide association study 
Provides an opportunity to maximise statistical power by using multiple data sources 
MR-Egger can be extended to investigate pleiotropy in MVMR (297) 
 
3.10 Which method and when 
Although MR is robust to many of the untestable causal assumptions in phenotypic mediation 
analysis, these are replaced with a set of MR specific causal assumptions (Figure 3.2), and 
careful consideration should be given to which assumptions are most plausible. Additionally, 
the data available, or research question of interest may not be suitable to test in an MR 
framework. For example, where the research question is primarily interested in time varying 
exposures or mediators, MR becomes increasingly complex (311). Mediation estimates from 
MR assume a time-fixed effect of the exposure and mediator, representing long-term 
relationships between the exposure and mediator (20). In some unique cases instruments may 
be available for an exposure at different time points (e.g. childhood and adulthood BMI), but 
using these instruments come with additional methodological challenges (312). 
Mendelian Randomisation has specific advantages compared with phenotypic methods where 
causal assumptions are required. The causal effect of the exposure on the outcome, the 
exposure on the mediator and the mediator on the outcome can all be tested. Additionally, bi-
directional MR could be used to determine which of two variables is the causal exposure and 
causal mediator, where this is not known. 
These results demonstrate that both MVMR (akin to the difference in coefficients method) 




effects for both continuous and binary outcomes, with little evidence of bias. However, 
caution is required in some instances, for example where total effects are weak. Where all 
exposures, mediators and outcomes are continuous, MVMR may confer an advantage of 
power, where the standard deviations for the simulated effects estimated in MVMR were 
smaller compared with the same effects estimated using two-step MR (313). 
If an analysis is interested in estimating the effects of multiple mediators, consideration 
should be given to the causal question of interest when deciding which method to use to 
analyse multiple mediators. Where the causal question specifically relates to identifying the 
combined effects of multiple mediators, MVMR is likely to be the most appropriate method. 
Where the causal question aims to estimate the effect of multiple mediators individually, and 
potentially any impact of intervening on a mediator, two-step MR is likely to be most 
appropriate. However, it is important to note, that as the number of mediators included in an 
MVMR model increases, the power of the analysis would likely decrease. Additionally, future 
research should be carried out to determine if including increasing numbers of exposures in 
an MVMR model further violates any of the MR assumptions. 
Although a range of simulation scenarios were included, including both continuous and 
binary outcomes, this is not an exhaustive range of scenarios and there may be further 
scenarios where MR methods are biased.  
The flow chart in Figure 3.9 aims to help with the decision-making process, based on practical 
limitations of MR. Key recommendations for these analyses are reviewed in Box 2.  However, 
best practice would always be to triangulate across phenotypic and genetic approaches, and 





Figure 3.9: Decision flow chart to determine most appropriate mediation method 




Box 2: Key recommendations when using Mendelian randomisation for mediation analysis 
• Ensure strong instruments are available for exposures and mediators and test 
instrument strength using the F-statistic. Test the conditional instrument strength for 
multivariable MR using the Sanderson-Windmeijer F-statistic (296) 
• Instruments for the exposure and mediator must be independent for both multivariable 
MR and two-step MR methods 
• The instruments must not have a pleiotropic effect on the mediator or outcome 
• Current MR methods are optimised for use with continuous exposures and mediators. 
Binary exposures or mediators which are a reflection of a true underlying continuous 
measure can lead to violation of the exclusion restriction criteria 
• Use univariable MR to test for evidence of causal association in each step of the 
mediation path, from the exposure to the outcome, exposure to the mediator and 
mediator to the outcome  
• Where individual-level data are being used and outcomes are binary, estimate effects 
on a linear scale to alleviate potential bias from non-collapsibility of odds ratios  
• If using summary level data with a binary outcome, estimate effects on the log odds 






Mendelian randomisation can be extended to estimate direct effects, indirect effects and 
proportions mediated. MR estimates are robust to violations of the often-untestable 
assumptions of phenotypic mediation analysis, including unmeasured confounding, reverse 
causality and measurement error. MR analysis makes its own strong, but distinct assumptions, 
especially relating to instrument validity. To estimate mediation using MR, large sample sizes 
are required, and strong instruments are needed for both the exposure and mediator.
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Studies have demonstrated causal effects of educational attainment on cardiovascular disease 
(CVD). We aimed to investigate the role of body mass index, systolic blood pressure and smoking 
in explaining the effect of education on risk of CVD outcomes triangulating across multivariable 
regression analysis of observational data and one- and two-sample Mendelian randomisation 
(MR) analysis; an instrumental variable approach more robust to bias from confounding and 
reverse causation. 
Methods: 
Individual level data from UK Biobank (N = 217 013) was used for multivariable analyses and 
individual level Mendelian randomisation. Summary statistics from genome-wide association 
studies were used in summary data MR.  
The total effect of education on risk of coronary heart disease, CVD (all subtypes), myocardial 
infarction and stroke (all measured in odds ratio, OR) was assessed using multivariable regression 
and univariable MR. 
The degree to which this effect is mediated through body mass index, systolic blood pressure and 
smoking respectively (the indirect effect and proportion mediated) was estimated using the 
product of coefficients method, where the effect of education on each mediator, and each 
mediator on each outcome was assessed using multivariable regression and two-step MR. The 
joint contribution of all three risk factors was assessed via the difference method, using 
multivariable regression or multivariable MR. 
Results: 
Each additional standard deviation of education associated with 13% lower risk of coronary heart 
disease (OR 0.87, 95% confidence interval [CI] 0.84 to 0.89) in observational analysis and 37% 
lower risk (OR 0.63, 95% CI 0.60 to 0.67) in MR analysis. As a proportion of the total risk 
reduction, body mass index mediated 15% (95% CI 13% to 17%) and 18% (95% CI 14% to 23%) in 
the observational and MR estimates respectively. Corresponding estimates for systolic blood 
pressure were 11% (95% CI 9% to 13%) and 21% (95% CI 15% to 27%), and for smoking, 19% (15% to 
22%) and 34% (95% CI 17% to 50%). All three risk factors combined mediated 42% (95% CI 36% to 
48%) and 36% (95 % CI 16% to 63%) of the effect of education on coronary heart disease in 
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observational and MR respectively. Similar results were obtained for risk of stroke, myocardial 
infarction and all-cause CVD. 
Conclusions:  
Body mass index, systolic blood pressure and smoking mediate a substantial proportion of the 
protective effect of education on risk of cardiovascular outcomes. Intervening on these would 
reduce cases of CVD attributable to lower education. However, more than half of the protective 




Cardiovascular disease (CVD) is the leading cause of mortality worldwide, accounting for over 17 
million deaths annually (1). Recent studies have suggested that socioeconomic risk factors such as 
education play a causal role in the aetiology of CVD (8, 9, 126). Tillmann and colleagues found 
that an additional 3.6 years of education reduced the risk of coronary heart disease by 
approximately one third (9). However, educational opportunities are not equitable throughout 
populations and education is inherently difficult to intervene on. Therefore, understanding the 
risk factors that may be driving the adverse later life outcomes associated with lower levels of 
education would provide the opportunity for interventions to reduce inequalities. 
Existing studies suggest that body mass index (BMI), systolic blood pressure and smoking 
behaviour at least partly explain differences in CVD risk related to educational attainment (12-14). 
However, these studies have relied on phenotypic mediation analyses, that may suffer from bias. 
Additionally, many phenotypic mediation methods use a single snapshot of a risk factor, which 
may incompletely capture a person’s lifetime exposure (275). For example, blood pressure 
measured at a single time point will suffer from measurement error due to day-to-day fluctuations 
and will not capture changes across the life course. This measurement error can lead to an 
underestimation of mediation (275). Furthermore, other biases such as unmeasured confounding 
cannot be addressed using phenotypic methods (229).  
Mendelian randomisation (MR) uses genetic variants as instrumental variables (IVs) to estimate 
the effect of an exposure on an outcome of interest (18). During meiosis, genetic variants are 
randomly allocated from parents to offspring, which remain fixed from the point of conception 
and are not altered during the life course. This random allocation of genetic variants can be 
exploited to infer causal effects that are potentially robust to non-differential measurement error 
and confounding of the exposure-outcome relationship (18). Two-step MR for mediation analysis, 
unlike phenotypic mediation analysis approaches, can be used to estimate the causal effects of the 
mediator, even if the phenotypes are measured with error (19). Recent genome-wide association 
study (GWAS) meta-analyses have identified a number of genetic variants for educational 
attainment and the other mediators of interest that may be used as IVs (17, 149).  
Mendelian randomisation has previously been used to demonstrate the causal effects of education 
on BMI, systolic blood pressure and smoking and also the effects of BMI and smoking on CVD 
(45, 59, 118, 119, 135, 268). While the results from these studies suggest that BMI, systolic blood 
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pressure and smoking are likely to explain some of the protective mechanisms of education on 
CVD, they alone do not quantify the mediated effect. In this study, I investigated the role of BMI, 
systolic blood pressure and lifetime smoking in mediating the causal effect of educational 
attainment on CVD risk using three complementary approaches: multivariable regression, 
individual level MR and summary data MR. BMI, systolic blood pressure and smoking were 
selected as intermediate risk factors based on previous literature implicating them as both being 
affected by education and as risk factors for CVD, with availability of data across all three 
complementary methods. I consider the three risk factors both individually and simultaneously. 
Understanding the mechanisms by which education affects cardiovascular health could have 
powerful applications, such as for public health policy. For this, it is important to understand the 
population-level implications of changes to BMI, smoking and systolic blood pressure on 
inequalities in CVD risk.  
4.6 Methods 
4.6.1 Overall study design 
This study used multivariable regression of phenotypic data, one-sample MR of individual level 
genetic data and two-sample MR of summary level genetic data to investigate whether lower BMI, 
systolic blood pressure and lifetime smoking explain the protective effect of education on risk 
coronary heart disease (CHD) myocardial infarction (MI), stroke risk and CVD (all subtypes).  
4.6.2 UK Biobank 
UK Biobank recruited 503,317 UK adults between 2006 and 2010. Participants attended assessment 
centres involving questionnaires, interviews, anthropometric, physical and genetic measurements 
(15, 16). In the phenotypic analysis, 217 013 White British individuals, with complete data on 
genotypes, age, sex, educational attainment, cardiovascular outcomes, BMI, smoking status, blood 
pressure, socioeconomic status (as measured by Townsend Deprivation Index at birth [TDI]) and 
place of birth were included.  
4.6.2.1 Exclusion criteria 
Individuals were excluded if their genetic sex differed to their gender reported at the assessment 
centre or for having aneuploidy of their sex chromosomes. Further individuals were excluded for 
being outliers for their heterozygosity and any missing genetic data. Related individuals were also 
excluded from analyses, and the remaining subset was a maximal set of unrelated individuals. 
 
 106 
This exclusion list was derived in-house using an algorithm applied to the list of all the related 
pairs provided by UK Biobank (3rd degree or closer). It preferentially removes the individuals 
related to the greatest number of other individuals until no related pairs remain (288). Individuals 
of White British descent were defined using both self-reported questionnaire data and similar 
genetic ancestry to the European ancestry principal components (PCs) computed from the 1000 
genomes project (288). Available follow-up data were used where baseline data were missing. For 
the sample used in mediation analyses, individuals were excluded if there were missing data at 
baseline and no available follow up data for education, BMI, systolic blood pressure, smoking, 
CVD status or for any of the variables considered as confounders. Figure 4.1 illustrates the 
exclusion criteria and number of individuals excluded at each stage for analyses in UK Biobank, 





Figure 4.1: Flow chart illustrating exclusions made in UK Biobank for the analysis sample for mediation analyses 
Note: At each stage the same participant could have missing data for multiple variables, therefore overlap is present between the 
variables. The total excluded may be less than the sum of individuals at each stage. 
CVD =  cardiovascular disease; BMI = body mass index 
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4.6.2.2 Educational Attainment 
Participants reported their highest qualification and age of leaving school if they did not have a 
degree. These were converted to the International Standard Classification for Education (ISCED) 
coding of educational attainment (Table 4.1)(149). 
 For the individual level MR analysis, instruments were selected from analysis of populations that 
did not overlap with those considered in the outcome estimates. Accordingly, 74 independent 
single-nucleotide polymorphisms (SNPs) that attained genome-wide significance (P<5x10-8) for 
education reported in main results from the 2016 SSGAC GWAS meta-analysis of 293,723 
individuals that did not include UK Biobank participants were used, to create a polygenic score 
(17). Five instruments for education were not available in UK Biobank and proxy synonymous 
SNPs in perfect LD (r2=1) were used (Table 4.2). The SNPs were clumped for linkage 
disequilibrium with an r2 threshold 0.001 and within a distance of 10 000kB.  
Table 4.1: International Standard for Classification of Education codes mapped to UK Biobank self-report highest 
qualification to estimate years of education 
 
Table 4.2: Proxy single nucleotide polymorphisms for educational attainment instrument used in individual level 
Mendelian Randomisation analyses 
GWAS SNP 
(Okbay) 








Qualification (As reported in UK Biobank) ISCED Years of education N 
College or University degree 5 20 69 935 
NVQ or HND or HNC or equivalent 5 19 14 017 
Other prof. qual. e.g.: nursing, teaching 4 15 10 986 
A levels/AS levels or equivalent 3 13 25 590 
O levels/GCSEs or equivalent 2 10 49 349 
CSEs or equivalent 2 10 12 288 
None of the above 1 7 34 849 
Prefer not to answer Excluded 
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4.6.2.3 Body mass index 
Measures of height and weight taken by UK Biobank study nurses at baseline assessment centres 
were used to calculate BMI (kg/m2). 
In individual level MR analysis, 77 SNPs which had attained genome-wide significance (P<5x10-8) 
for BMI in the Genetic Investigation of ANthropometric Traits (GIANT) Consortium genome-
wide association study (GWAS) analysis of individuals with European ancestry were used as 
instruments (290).The SNPs were clumped for linkage disequilibrium with an r2 threshold 0.001 
and within a distance of 10 000kB. Alleles were harmonised to all reflect BMI increasing SNPs and 
individual variants were recoded as 0, 1 or 2 according to the number of BMI increasing alleles. A 
genetic score for BMI was created by weighting each SNP by its relative effect size in the GWAS 
and summing all variants together in an additive model.  
4.6.2.4 Systolic blood pressure 
Systolic and diastolic blood pressure were recorded both automatically and manually at the 
baseline assessment centre for all participants. Each reading was taken twice, two minutes apart. 
This analysis uses the second reading of the automated blood pressure, where missing data were 
replaced with the first measure or any follow up assessment centre measures.  
Participants were required to take all medication they are currently using to the assessment 
centre, details of which were recorded by nurses. A variable for antihypertensive use was 
generated based on the treatments recorded and 10mmHg was added to systolic blood pressure 
measurements for these individuals, consistent with previous studies to account for treatment 
effects (314).  
Mendelian randomisation studies require the SNP-exposure and the SNP-outcome associations to 
be estimated in independent samples, otherwise estimates can be overestimated (244, 289). 
Existing systolic blood pressure and lifetime smoking GWASs have been estimated using UK 
Biobank data (315-317). To avoid participant overlap for exposure and outcome genetic estimates 
in the UK Biobank (289), a split sample GWASs of systolic blood pressure and smoking 
respectively were performed using the University of Bristol MRC Integrative Epidemiology Unit 
GWAS Pipeline (318). A total of 318,147 unrelated UK Biobank participants were eligible for 
inclusion in the GWAS ( 
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Figure 4.2). All the eligible participants were randomly allocated into one of two halves (sample 1 
and sample 2). A GWAS was performed on both samples 1 and 2 separately, adjusted for age, sex 
and the first 40 principle components in UK Biobank. BOLT-LMM method was used to account 
for population stratification. The top hit SNPs were determined using the ‘clump_data’ command 
in the Summary data MR R package (r2 > 0.001, distance >10,000kb) (default settings of the 
‘clump_data’ command) (319). This process was carried out for both systolic blood pressure and 
lifetime smoking phenotypes. 
The genetic score was created for each sample independently, by weighting each SNP by its 
relative effect size from the GWAS results of the opposing sample (i.e.  the genome-wide 
significant SNPs and betas identified in the GWAS of sample 1 were used to generate the genetic 





Figure 4.2: Flow chart for exclusions made in UK biobank for use in systolic blood pressure and smoking GWAS analyses 
4.6.2.5 Smoking 
A measure of lifetime smoking was constructed in the UK Biobank from self-reported age at 
initiation, age at cessation and cigarettes per day. From this information, smoking duration and 
time since cessation were calculated. The lifetime smoking measure further includes a simulated 
constant (half-life) which captures the exponentially decreasing effect of cigarettes on health over 
time. Aspects of smoking behaviour were combined into one score ranging from 0 (for non-
smokers) to 4.17. The mean lifetime smoking score was 0.35 (standard deviation = 0.69). Full 
details of score construction have been published previously (320). As described previously for 
systolic blood pressure, a split sample GWAS was carried out using the UK Biobank GWAS 
pipeline hosted by the MRC-IEU to identify suitable instruments from non-overlapping samples 




Variables considered as covariates were measured at the baseline assessment centres through 
interviews. Sex and ethnicity were confirmed according to genetic data. Place of Birth was 
adjusted for by the northing and easting birth location coordinates. Although the Townsend 
Deprivation Index (TDI) of historic birth locations are not recorded in UK Biobank, this has been 
estimated from the index of multiple deprivation indices using the current TDI of birth location 
as a proxy for historic birthplace TDI. Mendelian randomisation models were also adjusted for the 
same confounders. Although a core assumption of MR is that the genetic variants are unrelated to 
confounders, there is some evidence of small associations with place of birth for the educational 
attainment variants in UK Biobank (8, 185). MR models were additionally adjusted for the first 10 
genetic PCs, as derived by UK Biobank, to help control for population stratification. These were 
only considered in phenotypic and individual level MR analyses, where individual level data were 
available. 
4.6.2.7 Cardiovascular disease outcomes 
Cardiovascular diagnoses (including diagnoses of stroke, MI and CHD) and events were 
ascertained through linkage to mortality data and hospital inpatient records, with cases defined 
according to ICD-9 and ICD-10 codes (Table 4.3) (292). Individuals who had experienced a CVD 
event prior to the baseline assessment (prevalent cases) were excluded and only first event, 
incident cases following the assessment centre were considered). Hospital inpatient records were 
available from 1997 in England, 1998 in Wales and 1981 in Scotland (293), with the most recent 
entry recorded in this analysis in February 2016. 
 
Table 4.3: ICD 9 and ICD 10 codes used to identify incident cases of cardiovascular disease and cardiovascular subtypes 
from hospital inpatient records in UK Biobank 
Outcome ICD-9 code ICD-10 code 
CVD (all subtypes) 390-459 I, G45 
Stroke 434.91 I6, G45 
MI 410.9, 412.9 I21, I22 
CHD 410-414 I20-I25 
 
4.6.3  GWAS meta-analyses used for summary data Mendelian randomisation 
In the summary data MR analysis, summary genetic associations from GWAS data for each 
respective phenotype were obtained. For education, this was the Social Science Genetic 
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Association Consortium (SSGAC) GWAS meta-analysis of years of schooling in 1,131,881 
individuals of European ancestry (149), with summary data made available for 766,345 of these 
participants. Instruments were selected as the 1,271 independent genome-wide significant SNPs 
(pairwise r2<0.1) from the full discovery sample (149). Genetic estimates for BMI were obtained 
from the GIANT consortium’s 2018 GWAS meta-analysis of 681,275 individuals of European 
decent (61). Genetic association estimates for systolic blood pressure and smoking were estimated 
from a GWAS of 318,417 White British individuals in UK Biobank. Instruments for BMI, systolic 
blood pressure and smoking were identified as the lead SNPs in loci reaching genome-wide 
significance after clumping summary estimates from the largest available GWAS for linkage 
disequilibrium (LD) threshold r2<0.001 and distance >10,000kb, using a 1000 genomes European 
reference panel through the TwoSampleMR package (default settings of the ‘clump_data’ 
command) in the statistical software R (321). For CHD, publicly available genetic association 
estimates from the CARDIoGRAMplusC4D 1000 Genomes-based GWAS meta-analysis of 60,801 
cases and 123,504 controls were used (322). The definition for CHD was broad and inclusive, 
considering acute coronary syndrome, myocardial infarction, angina with one or angiographic 
stenoses of greater than 50%, and chronic stable angina. A summary of all phenotypes and GWAS 
data used are presented in Table 4.4.   
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to ISCED years of 
schooling 
Polygenic score, using 
genome-wide significance 
SNPs (NSNPs = 74) and 
beta weights from Okbay 
et al, 2016 (323) 
Individual SNPs from Lee 
et al, 2018 (149) 
(NSNPs = 1271) 
Body mass index 
Measured weight and 
height 
Polygenic score, using 
genome-wide significance 
SNPs (NSNPs = 77) and 
beta weights from Locke 
et al, 2015 (290) 
Individual SNPs from 
Yengo et al, 2018 (61) 
(NSNPs = 360) 
Systolic Blood 
pressure 




Polygenic score, using 
genome-wide significance 
SNPs (NSNPs = 65 and 55 
sample 1 and 2 
respectively) from a split 
sample GWAS in UK 
Biobank  
Individual SNPs from 
systolic blood pressure 
GWAS carried out as part 
of this work on full UK 
Biobank sample 
(NSNPs = 191) 
Smoking 
Estimate of lifetime 
smoking using self-
report data on 
smoking behaviours 
Polygenic score, using 
genome-wide significance 
SNPs (NSNPs = 18 and 15 
sample 1 and 2 
respectively) from a split 
sample GWAS in UK 
Biobank (317) 
Individual SNPs from 
Wootton et al, 2018 using 
full UK Biobank sample 
(317) 
(NSNPs = 126) 
 
4.6.4 Statistical Analysis 
4.6.4.1 Effect of education on cardiovascular disease  
In phenotypic analyses of UK Biobank data, multivariable logistic regression was used to estimate 
the association of education with CVD and its subtypes. All analyses using UK Biobank were 
adjusted for potential confounders; age, sex, place of birth, birth distance from London, and TDI 
at birth. These confounders were determined a priori, with place of birth and birth distance from 
London included to control for population structure in UK Biobank (8, 185).  
In the individual level MR of UK Biobank data, the total effect of education on cardiovascular 
outcomes was investigated using two-stage least squares regression. In the first regression, the 
effect of the education polygenic score on self-reported educational attainment was estimated. 
This estimate was used to generate a prediction of educational attainment. In the second stage, 
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the effect of predicted educational attainment on the CVD outcome using robust standard errors 
in a logistic model was estimated (324). Both regression stages were adjusted for adjusted for age, 
sex, place of birth, birth distance from London, and TDI as well as the first ten genetic PCs.  
In summary data MR analysis, the effects of education on CVD subtypes were investigated using 
ratio method MR with standard errors derived using the delta method (325). Fixed-effect inverse-
variance weighted (IVW) meta-analysis was used to pool MR estimates across individual SNPs 
(326).  
4.6.4.2 Mediation by body mass index, systolic blood pressure and smoking  
In multivariable phenotypic and individual level MR analyses, when investigating the degree to 
which the effects of education on CVD and its subtypes are mediated through each risk factor 
(BMI, systolic blood pressure and smoking) individually, the product of coefficients method was 
used to estimate the indirect effect (i.e. the effect of education on CVD that goes through the risk 
factor) (20).  
In the phenotypic analysis, multivariable linear regression was used to estimate the association of 
education with each risk factor after adjusting for confounders (as in the total effects models). 
The effect of each risk factor on the individual CVD subtypes was then estimated using 
multivariable logistic regression with the additional adjustment for self-reported educational 
attainment (241). The two estimates were multiplied together to estimate the indirect effect (of 
education, through the risk factor).  
In individual level MR analyses two-stage least squares regression using the Stata IVREG2 package 
was used to estimate the effect of education on each mediator individually.  
Two-stage least squares multivariable Mendelian randomisation (MVMR) was then used to 
estimate the effect of each mediator on each outcome, additionally controlling for the polygenic 
score for education. The second stage of this regression was estimated on the log odds ratio scale. 
This additionally provided an estimate of the direct effect of education on each outcome. All 
analyses were adjusted for covariates and PCs as above.  
These estimate of i) education on the mediator and ii) the mediator on the cardiovascular 
outcome controlling for education, were then multiplied to estimate the indirect effect, which is 




Where split sample GWAS estimates were used to create the allele score in systolic blood pressure 
and smoking the MR analyses were run separately for each 50% sample and meta-analysed to 
estimate an overall effect.  
For the summary data MR, the IVW MR approach was used to estimate the effect of education on 
each risk factor and regression-based multivariable MR was used to estimate the effect of each 
risk factor on risk of the considered CVD subtypes, adjusting for genetic effect of the instruments 
on education (255). The indirect effect of education on risk of each CVD subtype through the 
considered risk factor was estimated by multiplying results from these two MR analyses.  
4.6.4.3 Investigating all three risk factors combined 
When investigating the role of all three risk factors together on the association between 
education and CVD, the difference method of estimating the indirect effect was used (241). This 
involved estimating the total effect of education on each CVD subtype, as described in section 
4.6.4.2. The direct effect of education on each CVD subtype controlling for all three risk factors 
together was estimated, using either multivariable regression or multivariable MR, in phenotypic 
and MR analyses respectively. To estimate the total effect of education mediated indirectly 
through all three risk factors collectively using summary data MR, the direct effect of education 
after adjusting for the three risk factors together was estimated using MVMR, with this estimate 
divided by the total effect and then subtracted from one. In phenotypic analyses, a multivariable 
logistic model for the effect of education on CVD (and subtypes) adjusting for all three risk factors 
was used to estimate the direct effect of education independently of the risk factors. This was 
subtracted from the total effect to estimate the indirect effect of education through the three risk 
factors collectively. In individual level MR, the direct effect of education after adjusting for the 
three risk factors together was estimated using MVMR. This was subtracted from the total effect 
to estimate the indirect effect. The indirect effect was subsequently divided by the total effect to 
estimate the proportion mediated. Confidence intervals for the indirect effect and proportion 
mediated were estimated using bootstrapping. 
4.6.4.4 Sensitivity analyses  
A range of MR sensitivity analyses were carried out. Mendelian randomisation estimates are prone 
to bias if the underlying assumptions of the analysis are violated. Horizontal pleiotropy, where a 
genetic variant is associated to the outcome of interest via an alternative pathway, can potentially 
bias the MR estimates (254). MR-Egger allows for directional (unbalanced) horizontal pleiotropy 
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under the assumption that the size of the variants on the exposure are independent of the size of 
the direct effects on the outcome (i.e. there is no dose-response confounding) (253). The weighted 
median estimator is able to provide robust MR estimates when more than half of the information 
for the analysis comes from valid instruments (256). In the MR analysis of the total effect of 
education on CVD outcome risk, and the effect of education on each risk factor, we also 
performed these techniques to investigate the robustness of our findings when relaxing 
assumptions on horizontal pleiotropy. These pleiotropy robust techniques are not yet developed 
for application in MR mediation analysis. 
 For all analyses in UK Biobank, models were replicated on the risk difference scale using 
multivariable linear regression to assess whether the mediation estimates were biased by the non-
collapsibility of odds ratios. For the individual level MR analyses, the IVREG2 Stata package was 
used for this (327). Additionally, to test for sex differences and age differences, all analyses were 
replicated using unadjusted models, models adjusted for age and sex only, and models stratified 
by sex and age dichotomized at the median (39-57 years compared with 58-72 years). On a 
subsample of UK Biobank participants with dietary recall questionnaires (including protein, 
carbohydrate, total fat, saturated fat, polyunsaturated fat, total sugar and fibre consumption) and 
exercise (weekly duration of moderate and vigorous physical activity) measures (N = 20,298 with 
dietary recall measures), a phenotypic multivariable multiple mediator model was analysed. This 
could not be completed using MR analyses as there are not suitable instruments for diet and 
exercise phenotypes. This analysis, and those stratified by age and sex, were carried out for the 
association between education and CVD (all subtypes) only, due to limited outcome events. 
4.6.5 Statistical software and ethical approval 
Analysis was performed using Stata version 14 (StataCorp LP) and R version 3.4.3 (The R 
Foundation for Statistical Computing). The mrrobust package for Stata and the TwoSample MR 
package for R were used to facilitate MR analyses (321, 328). Ethical approval was not sought for 
publicly available data because all participating studies had already obtained relevant 
authorisation. Project approval was obtained from UK Biobank (study ID: 10953) and data will be 




4.6.6 Patient and public involvement 
Neither patients nor the public were involved in the initial design or implementation of this 
study. Feedback from a lay reviewer was incorporated in the revision stages. 
4.7 Results 
4.7.1 UK Biobank Cohort Description 
The UK Biobank sample used in the phenotypic and individual level MR analysis was comparable 
to the participants in UK Biobank as a whole, although UK Biobank is not representative of the 
wider UK population (participants are typically more educated and of a higher socioeconomic 
status as compared to the general population) (16). In the analysis sample, 32% of individuals had 
over 20 years of education, equivalent to a vocational qualification or degree. Comparatively, only 
16% of individuals left school with no formal qualifications after seven years (Table 4.1). The 
standard deviation (SD) of educational attainment was 3.6 years, BMI was 4.69 kg/m2 and systolic 
blood pressure was 18.68 mm Hg. For lifetime smoking, one SD increase is equivalent to, for 
example, an individual smoking 20 cigarettes a day for 15 years and stopping 17 years ago, or an 
individual smoking 60 cigarettes a day for 13 years and stopping 22 years ago (317). A total of 65 ( 
R2 = 0.0035)  and 55 ( R2 = 0.0027) genome-wide significant SNPs were identified for systolic blood 
pressure (with 10mm Hg added for antihypertensive use) for sample 1 and sample 2 respectively 
(Appendix 2 Table  1). In the split-sample GWAS for smoking, 18 ( R2 = 0.0012)  and 15 ( R2 = 
0.0014) genome-wide significant SNPs were identified in sample 1 and sample 2 respectively  




Table 4.5: Cohort Characteristics for the UK biobank analysis sample used in phenotypic analyses and individual level MR analyses and 
comparisons with the full UK Biobank cohort 
Variable Level 
N Analysis 




 N Full UKBB 
(N = 502 240) 
% Full UKBB 
Sex Female 119 198 54.93  273 076 54.37 
Age 
<40 2 260 1.04  5 424 1.08 
41-50 54 234 24.99  126 426 25.15 
51-60 77 071 35.51  177 264 35.27 
61-70 83 444 38.45  193 119 38.42 
71+ 4 <0.01  422 0.08 
Years of 
education 
7 years 34 637 15.96  84 895 17.23 
10 years 38 326 17.66  82 757 16.79 
13 years 11 865 5.47  27 008 5.48 
15 years 26 822 12.36  58 680 11.91 
19 years 34 934 16.10  32 725 6.65 





1 106 0.51  2 624 0.52 
Normal 73 037 33.66  162 261 32.28 
Overweight 92 742 42.74  212 071 42.19 
Obese 50 128 23.10  125 699 25.01 
Systolic blood 
pressure 
Mean (SD) 136.51 (18.68)   135.95 (18.72)  
Smoking 
initiation 
Never 86 999 40.20  200 747 40.2 




Control 200 787 92.52  418 126 92.38 
Case 16 225 7.48  34 513 7.62 
Stroke 
Control 200 787 99.18  418 126 99.09 




Control 200 787 99.37  418 126 99.32 
Case 1 343 0.66  2 860 0.68 
Coronary Heart 
Disease 
Control 200 787 97.82  418 126 97.74 
Case 4 582 2.23  9 677 2.26 
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4.7.2 Effect of education on risk of cardiovascular outcomes 
In phenotypic analyses, a 1-SD higher education was associated with a 14% lower risk of CHD 
with an odds ratio (OR) of 0.86 (95% CI 0.84 to 0.89). Individual level MR analysis indicated a 
stronger protective effect, with an OR of 0.38 (95% CI 0.24 to 0.59) (Figure 4.3).  
Similar protective associations were found for the effect of education on other CVD subtypes 
(Figure 4.3). In phenotypic analyses, a one SD higher education was associated with an 11% 
lower risk of stroke, with an OR of 0.89 (95% CI 0.85 to 0.93). In individual level MR analyses 
the protective effect was stronger, although estimated with less precision, with an OR of 0.53 
(0.26 to 1.07) (Figure 4.3). All three approaches (phenotypic, individual-level MR and 
summary-sample MR) provided consistent evidence for a protective effect of education with 
CVD risk and its subtypes. 
Figure 4.3: The effect of a 1-SD increase in education on the risk of cardiovascular disease and its subtypes. Phenotypic 
multivariable estimates are plotted in pink and individual level Mendelian randomisation (MR) estimates plotted in 
navy and summary data MR estimates in light blue. Multivariable analyses and individual level MR analyses adjusted 
for: age, sex, place of birth and Townsend deprivation index at birth. Body mass index  (BMI), systolic blood pressure 
(SBP) and smoking were measured in one SD units. Cardiovascular disease (CVD) (All subtypes) was not available for 
analysis in summary data MR analysis. 




4.7.3 Effect of education on BMI, systolic blood pressure and smoking 
In all methods, a longer time in education was associated with lower BMI, systolic blood 
pressure and smoking (Figure 4.4). 
Figure 4.4: Phenotypic and summary data MR estimates for the association between one SD higher education and 
body mass index (BMI), systolic blood pressure (SBP) and lifetime smoking respectively. All outcomes are in one SD 
units. Phenotypic multivariable results are plotted in pink, with individual level Mendelian randomisation (MR) 
estimates plotted in navy and summary data MR estimates in light blue. 
4.7.4 Effect of BMI, systolic blood pressure and smoking on risk of 
cardiovascular outcomes  
Both phenotypic and summary data MR analyses consistently found evidence to support an 
increased risk of CHD with higher BMI, systolic blood pressure and smoking, after adjusting 
for education (Figure 4.5). Although in some instances the point estimates from individual 
level MR indicated a protective effect of the risk factors, such as for BMI to MI, these estimates 




Figure 4.5: Phenotypic, individual level and summary data Mendelian randomisation (MR) associations of a one SD 
higher body mass index (BMI), systolic blood pressure (SBP)  and lifetime smoking on the risk of cardiovascular 
disease (CVD) and its subtypes. Phenotypic multivariable results are plotted in pink, with individual level MR 
estimates plotted in navy and summary data MR estimates in light blue. 





4.7.5 Mediation by BMI, systolic blood pressure and smoking 
In the phenotypic analysis, the proportion of the effect of education on CHD risk mediated by 
BMI was 15% (95% CI: 13% to 17%), 11% for systolic blood pressure (95% CI: 9% to 13%) and 
19% for smoking (95% CI: 15% to 22%) (Figure 4.6). In the individual level MR analysis, the 
proportion mediated by BMI was -4% (95% CI: -13% to 4.5%), 17% by systolic blood pressure 
(95% CI: -20% to 53%) and 17% by smoking (95% CI: -49% to 82%).  In the summary data MR 
analysis, the percentage mediated by BMI was 18% (95% CI: 14% to 23%), 21% by systolic blood 
pressure (95% CI: 15% to 26%) and 33% by smoking (95% CI: 17% to 49%) (Figure 4.6).  
In phenotypic analyses, combining all three risk factors together explained 42% (95% CI: 36% 
to 48%) of the effect of education on risk of CHD (Figure 4.6). In the individual level MR 
analyses, all three risk factors estimated 35% (95% CI: 15% to 56%) of the effect of BMI on 
CHD. In summary data MR the combined effect of all three risk factors on CHD as 36% (95% 
CI: 16% to 63%). 
Similar results were found for other CVD subtypes in multivariable phenotypic analyses. 
Smoking consistently mediated around 20% of the association. BMI explained between 10% 
and 17% of the association between education and CVD and its subtypes, whilst systolic blood 
pressure explained between 8% and 18%. In summary data MR analyses, smoking explained up 
to 34% of the association between education and CVD subtypes, whilst BMI estimated up to 
18% and systolic blood pressure up to 28% of the association. Individual level MR analyses 
were consistent with the main conclusions from phenotypic and summary data MR analyses, 
although estimates were more imprecise, and the confidence intervals spanned the null value 
for some risk factors (Figure 4.6). 
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Figure 4.6: Estimates for the effect of education on cardiovascular disease (CVD) and its subtypes explained by body 
mass index (BMI), systolic blood pressure (SBP) and smoking respectively estimated on the odds ratio scale. Results 
are provided for the multivariable phenotypic analysis (plotted in pink) and individual level Mendelian randomisation 
(MR) (plotted in navy) and summary data MR (plotted in light blue). Combined estimates refer to the effect of BMI, 
systolic blood pressure and smoking considered together in a single mode. Phenotypic and individual level MR 
analyses are adjusted for age, sex, place of birth and Townsend deprivation index at birth. BMI, systolic blood pressure 
and smoking were measured in 1-SD units. 
CHD = coronary heart disease; MI = myocardial infarction; CI = confidence interval  
 
 125 
4.7.6 Sensitivity analyses 
Results from MR-Egger sensitivity analyses were comparable to the main results but produced 
less precise estimates with wider confidence intervals, indicating results are unlikely to be 
biased by pleiotropy (Table 4.6 and Table 4.7). 
Unadjusted and age and sex adjusted models were also consistent with the main fully adjusted 
models for multivariable and individual level MR analyses (Table 4.8 and Table 4.9).  
Analyses stratified by age and separately by sex were consistent with the non-stratified main 
results, although confidence intervals were wide in MR (Figure 4.7 and Figure 4.8). 
The effects of each mediator individually, and combined, estimated on the risk difference scale 
and using the difference method in individual data were consistent with main analyses on the 
log odds ratio scale suggesting results are unlikely to be biased due to the non-collapsibility of 
the odds ratio (Figure 4.9). 
Including diet and exercise measures in addition to BMI, systolic blood pressure and smoking 
did not change the amount of the education to CVD (all subtypes) association explained 
(Figure 4.10). 
Table 4.6: Mendelian Randomisation sensitivity analyses for the association between education and mediators, using 
MR-Egger and Weighted median analyses, in standard deviation units.  
 Summary data MR Individual level MR 
 Estimate (95% CI) P Value Estimate (95% CI) P Value 
Education-body mass index 
IVW -0.22 (-0.24, -0.20) 1.10x10-123 -0.36 (-0.49, -0.23) 4.18x10-8 






Weighted median -0.27 (-0.30, -0.23) 5.33x10-53 -0.51 (-0.62, -0.39) 1.62x10-18 
Education-Systolic blood pressure 
IVW -0.15 (-0.17, -0.14) 3.59x10-105 -0.14 (-0.24, -0.04) 0.005 






Weighted median -0.18 (-0.21, -0.16) 1.14x10-52 -0.12 (-0.21, -0.03) 0.008 
Education-Smoking 
IVW -0.32 (-0.33, -0.31) <1x10-300 -0.37 (-0.47, -0.28) 1.243x10-14 
MR-Egger -0.29 (-0.36, -0.22) 1.43x10-16 -0.40 (-0.60, -0.20) 7.50x10-5 
MR-Egger intercept 
   
0.734 
Weighted median -0.35 (-0.37, -0.33) 4.05x10-236 -0.37 (-0.46, -0.29) 6.765x10-18 




Table 4.7: Mendelian Randomisation sensitivity analyses for the association between education and cardiovascular 
outcomes, using MR-Egger and Weighted median analyses, in OR units. In individual level analyses the weighted 
median was estimated on the risk difference scale and converted to OR using linear combinations. 
 
Summary data MR Individual level MR 
Estimate (95% CI) P Value Estimate (95% CI) P Value 
Education - Coronary heart disease 
IVW 0.63 (0.60, 0.67) 1.77-x10-59 0.51 (0.26, 1.00) 0.051 






Weighted median 0.62 (0.57, 0.67) 3.48x10-31 0.98 (0.96, 0.99) 0.33 
Education - Stroke 
IVW 0.71 (0.68, 0.75) 6.22x10-44 0.46 (0.30, 0.71) 3.58x10-4 
MR-Egger 0.72 (0.60, 0.87) 0.001 0.57 (0.22, 1.47) 0.245 
MR-Egger intercept  0.757  0.601 
Weighted median 0.71 (0.66, 0.76) 5.79x10-22 0.99 (0.98, 1.00) 0.002 
Education - myocardial infarction 
IVW 0.61 (0.58, 0.65) 5.63x10-55 0.18 (0.08, 0.38) 1.31x10-5 
MR-Egger 0.67 (0.52, 0.85) 0.001 0.20 (0.04, 1.03) 0.054 
MR-Egger intercept  0.384  0.883 
Weighted median 0.59 (0.54, 0.65) 2.09x10-28 0.99 (0.98, 1.00) 0.002 
Education - Cardiovascular disease (all subtypes) 
IVW   0.64 (0.51, 0.82) 1.98x10-4 
MR-Egger   0.57 (0.34, 0.95) 0.031 
MR-Egger intercept    0.591 
Weighted median   0.96 (0.94, 0.98) 1.05x10-4 





Table 4.8: Unadjusted estimates for the proportion mediated by body mass index (BMI), systolic blood pressure (SBP) 
and smoking on the association between education and cardiovascular outcomes using phenotypic logistic regression 
and  individual level Mendelian randomisation (MR) analyses in UK Biobank  





BMI 10.93 (9.52, 12.34) 
SBP 19.18 (16.96, 21.40) 
Smoking 12.66 (10.80, 14.52) 
Individual level MR 
BMI 9.47 (-8.18, 21.12) 
SBP 4.62 (-9.63, 18.88) 




BMI 5.76 (3.36, 8.16) 
SBP 21.68 (15.32, 28.05) 
Smoking 10.23 (6.71, 13.75) 
Individual level MR 
BMI 13.58 (-251.31, 278.47) 
SBP -4.88 (-66.78, 57.00) 





BMI 9.15 (6.03, 12.28) 
SBP 24.56 (17.42, 31.70) 
Smoking 18.35 (13.10, 23.59) 
Individual level MR 
BMI -4.93 (-18.47, 8.61) 
SBP 16.07 (-21.86, 54.00) 





BMI 10.64 (8.66, 12.62) 
SBP 23.68 (20.42, 26.95) 
Smoking 13.88 (11.60, 16.19) 
Individual level MR 
BMI -4.96 (-16.75, 6.84) 
SBP 13.76 (-15.49, 43.01) 




Table 4.9: Minimally adjusted (age and sex only)  estimates for the proportion mediated by body mass index (BMI), 
systolic blood pressure (SBP) and smoking on the association between education and cardiovascular outcomes using 
phenotypic logistic regression and individual level Mendelian randomisation (MR) analyses in UK Biobank 





BMI 16.75 (13.73, 19.77) 
SBP 8.10 (6.50, 9.69) 
Smoking 19.36 (15.67, 23.05) 
Individual level MR 
BMI 9.18 (-5.97, 24.34) 
SBP 5.95 (-10.04, 21.93) 




BMI 10.59 (3.05, 18.13) 
SBP 14.47 (5.77, 23.17) 
Smoking 19.83 (9.15, 30.51) 
Individual level MR 
BMI 12.43 (-233324.91, 23349.77) 
SBP -4.30 (-62.25, 53.66) 





BMI 9.85 (5.88, 13.83) 
SBP 10.78 (6.98, 14.58) 
Smoking 19.24 (12.99, 25.84) 
Individual level MR 
BMI -4.64 (-18.07, 8.79) 
SBP 20.23 (-26.15, 66.61) 





BMI 15.37 (11.55, 19.18) 
SBP 11.26 (8.92, 13.60) 
Smoking 18.50 (14.45, 22.56) 
Individual level MR 
BMI -4.24 (-15.23, 6.74) 
SBP 16.97 (-17.84, 51.79) 





Figure 4.7: Estimates of the proportion mediated between education and cardiovascular disease (all subtypes) by body mass index (BMI), 
systolic blood pressure (SBP) and smoking in phenotypic multivariable analyses and individual level Mendelian randomisation (MR) analyses 
stratified by below the median value for age (39-57 years in pink) and above the median value for age (58-72 years in Navy). Analyses are 
adjusted for age, sex, place of birth and Townsend deprivation index at birth. BMI, systolic blood pressure and smoking were measured in one 
SD units. 






Figure 4.8: Estimates of the proportion mediated between education and cardiovascular disease (CVD) by body mass index (BMI), systolic 
blood pressure (SBP) and smoking in phenotypic multivariable analyses and individual level Mendelian randomisation (MR) analyses 
stratified by sex. Analyses are adjusted for age, sex, place of birth and Townsend deprivation index at birth. BMI, systolic blood pressure and 
smoking were measured in one SD units. 




Figure 4.9: Estimates for the effect of education on cardiovascular disease (CVD) and its subtypes explained by body mass 
index (BMI), systolic blood pressure (SBP) and smoking respectively, estimated on the risk difference scale Results are 
provided for the multivariable phenotypic analysis (plotted in pink) and individual level Mendelian randomisation (MR) 
(plotted in navy). Combined estimates refer to the effect of BMI, SBP and smoking considered together in a single model 
Analyses are adjusted for age, sex, place of birth and Townsend deprivation index at birth. BMI, systolic blood pressure and 
smoking were measured in one SD units. 





Figure 4.10: Estimate of the additional proportion mediated by exercise and diet compared with body mass index (BMI), systolic blood 
pressure (SBP) and smoking in multivariable phenotypic multiple mediator models (N=20 298). Both models additionally adjusted for 
covariates, including age, sex, place of birth and Townsend deprivation index at birth. BMI, systolic blood pressure and smoking were 




In this chapter, I use phenotypic and genetic analyses to provide complementary evidence that 
the effect of education on risk of CVD is mediated by approximately up to one third through 
any of BMI, systolic blood pressure or smoking. When investigating all three risk factors 
together, around 40% of the association between education and CVD was explained by the 
three risk factors combined, both in phenotypic and MR analyses. It is important to note that 
over half of the effect of education remained unexplained in these analyses. The main analyses 
did not consider the contributions of exercise, diet, health system factors, lipid profile and 
glycaemic traits (329-335). However, these risk factors are likely to be inter-related with the 
three main risk factors considered in our analysis. For example, much of the effect of diet and 
activity on CVD is likely to act through BMI and systolic blood pressure, and therefore the 
cumulative effect of BMI, systolic blood pressure and smoking together is likely to be 
capturing some of their effects. Indeed, in a phenotypic sensitivity analysis including diet and 
exercise alongside BMI, systolic blood pressure and smoking, no more of the association 
between education and CVD was explained compared with just looking at BMI, systolic blood 
pressure and smoking.  
In this analysis, I have triangulated evidence across three distinct approaches. Although the 
point estimates vary, along with the mediation results, all three approaches indicate the same 
conclusions. The MR estimates are much larger in magnitude than the phenotypic results. In 
MR, the genetic instruments used to proxy the exposure and mediators estimate a lifetime 
effect, rather than a single snapshot, which may explain the larger estimates in MR. 
Additionally, this may be due to bias from negative confounding or measurement error in 
phenotypic analyses. Cases recruited to the case-control studies included in summary data 
analyses may represent a more extreme phenotype than in cohort studies such as UK Biobank. 
The summary data MR estimates are more precise than the individual level MR results from 
UK Biobank, likely related to the larger sample sizes and number of cases. 
4.8.1 Findings in context 
Mendelian randomisation studies have previously investigated the causal effects of education 
on CHD, BMI, systolic blood pressure and smoking (9, 118, 119, 268), with others further 
estimating the effects of BMI and smoking on CVD (45, 135). The current study makes a 
number of notable advances. The most recent GWAS of educational attainment was used to 
optimise the power of the summary data MR analysis. With the larger sample size, the 
instruments selected from this study explained approximately 12% of the variance in 
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education, as compared with the 3% accounted for in the previous studies of education and 
CVD (17, 149). Similarly, by leveraging the power of the UK Biobank and recent large-scale 
GWAS meta-analyses, it was possible to study additional cardiovascular outcomes, including 
stroke and MI. In addition to the overall effects of the considered risk factors on CVD, I have 
been able to estimate the proportion of the effect of education that they mediate using a 
recently developed method (19, 20). To date, genetic instruments for smoking have been 
limited and are typically related to binary measures that would introduce severe bias in MR 
(310). The development of a GWAS for the continuous measure of lifetime smoking allowed 
me to include this in a mediation model (317). 
A number of studies have used phenotypic multivariable regression methods to support 
mediating roles of BMI, systolic blood pressure and smoking in the pathway between 
education and CVD risk (13, 14, 114, 115), with consistent results obtained using various 
measures of education, including time spent in schooling and academic qualifications. In an 
analysis of Dutch individuals, Kershaw et al, attributed almost 27% of the association between 
education and CHD to be due to smoking, with 10% and 5% attributed to obesity and 
hypertension respectively (114). Similarly, Dégano et al found 7% and 14% of the association 
between education and CVD could be explained by BMI and hypertension respectively (14). 
However, they found little evidence that smoking mediated the association. Veronesi et al 
analysed their data stratified by sex, but consistently found that systolic blood pressure and 
smoking mediated the effects of education in both males and females (115). The findings in 
this study show that phenotypic estimates likely underestimate how much of the effect of 
education is mediated via smoking, BMI and systolic blood pressure compared to estimates 
from MR, likely due to measurement error in the mediators that bias phenotypic estimates 
towards the null, which is likely to have less impact on MR analyses (19). Given the 
importance of measurement error as a source of bias in mediation analysis (275), MR is 
potentially a useful tool for understanding mediation.   
4.8.2 Strengths and limitations 
The major strength of this work is that it allowed for assessment of the causal role of 
mediators using MR, an approach that is robust to non-differential measurement error in the 
mediator. I have used multiple data sources and approaches, each with different potential 
sources of biases, to thus improve the reliability of our findings through triangulation (259). 
Furthermore, the mediated effects estimated were consistent across the two MR approaches 
and in statistical sensitivity analyses. The imprecision in the individual level MR analysis 
demonstrates the need for very large sample sizes to achieve sufficient statistical power when 
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estimating mediation in an MR framework. The results were complemented by the summary 
data MR approach, which had greater statistical power, but may be susceptible to alternative 
sources of bias, including those related to participant overlap in the samples used to obtain 
genetic association estimates for the exposures and outcomes (289). Existing systolic blood 
pressure GWAS meta-analyses have adjusted for BMI as a covariate, which could introduce 
collider bias (315, 316), and for this reason I performed a GWAS of systolic blood pressure in 
UK Biobank to select instruments, without adjusting for BMI. I also applied a ‘split sample’ 
systolic blood pressure GWAS approach on unrelated individuals in UK Biobank for use in 
individual-level data MR to avoid overlapping populations in the genetic association estimates 
for the exposure and outcome (336), and any associated bias (244, 289). To this end, the 
individual level MR entirely avoided any population overlap when obtaining genetic estimates 
for the exposures and the outcomes. 
For all CVD subtypes and individual risk factors considered, the largest effects of education 
were consistently seen with the MR approaches, with smaller effects seen in the analysis of 
phenotypic data. Measurement error in a mediator leads to an underestimation of the 
proportion mediated, so the discrepancy between the phenotypic and MR analyses may in part 
be attributable to MR analyses suffering less bias from measurement error (275). BMI is 
accurately measured and has little daily variation – and correspondingly the estimates of the 
proportion of effect mediated by BMI in the phenotypic and MR analyses are similar (15% and 
18% respectively). In contrast, systolic blood pressure and lifetime smoking are difficult to 
measure accurately – and the estimated proportion mediated is smaller in the phenotypic 
analysis than the MR (11% vs. 21% for systolic blood pressure, and 19% vs. 33% for smoking). 
Measurement error could also be introduced by participants over-reporting traits perceived to 
be ‘desirable’ such as education and underreporting traits perceived to be ‘undesirable’ such as 
smoking (337). The estimates for all three risk factors together were more similar between 
phenotypic and MR estimates, although for all models, the confidence intervals were wide. It 
is important to note that while MR is more robust to measurement error, the instruments may 
not necessarily be capturing all aspects of the exposure phenotype under consideration. For 
example, the instruments for systolic blood pressure capture average systolic blood pressure 
but may not necessarily reflect variability in blood pressure. 
Estimates from MR analyses are robust to reverse causation bias, due to the random allocation 
of genetic instruments from parents at conception (and thus prior to development of the 
outcome under consideration). Tyrrell and colleagues have previously used MR to estimate 
the effects of BMI on education (265), and it is possible that education affects BMI. In these 
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analyses I only focused on one direction of effect – i.e. that from education to BMI. However, 
the results presented here are unlikely to be due to reverse causality. As the genetic variants 
used as instruments are set at conception, they are not influenced by later life exposures. 
Additionally, we used a large number of strong instruments for education.  
Another limitation of the MR approach is that estimates can be biased by pleiotropic pathways 
where the instrument is associated with the outcome via a phenotype independent of the 
exposure under consideration. To investigate this possibility, we additionally performed MR-
Egger and weighted median sensitivity analyses were performed that are more robust to such 
pleiotropy (255, 256, 338), which produced results consistent with those from the main MR 
analyses. If the assumption is made that the genetic variants have a monotonic effect on the 
exposure, MR estimates will reflect the local average effect of the exposure on the outcome for 
all individuals whose exposure was affected by the genetic instrument. Little evidence of 
heterogeneity in the effect of the exposures was found. This suggests the effects of the SNPs on 
the exposure may be similar across the population, in which case the MR estimate may 
provide a reliable estimate of the average effect in the population.  
Analyses in UK Biobank were carried out on white, European individuals, potentially limiting 
the generalisability of these results to other populations and ethnicities. However, summary 
data MR analyses were not exclusive to white European individuals (although proportions 
were low for other populations) and produced consistent results to individual level MR 
analyses. UK Biobank is not representative of the UK population as a whole and is subject to 
healthy volunteer bias. Therefore, these results may be biased by selection bias (339). 
When estimating the indirect effects of a mediator on a binary outcome, the product of 
coefficients method (two-step MR) results in the least amount of bias (241), and as such this 
approach was used to estimate the effects of education through each risk factor individually. 
However, this method cannot currently be used to consider multiple mediators 
simultaneously in an MR analyses. For this reason, the difference method (MVMR) was used 
to estimate the effect of education through the three considered risk factors collectively with 
MR. Although such an approach may introduce theoretical bias due to the non-collapsibility 
of an odds ratio when investigating a binary outcome, individual level data analyses in UK 
Biobank were also carried out on a linear risk difference scale to identify whether results on 
the odds ratio scale may be biased in this way. Estimates for the effect of education through 
the risk factors collectively were consistent between different scales in these analyses, and as 
such we would not expect any potential biases to alter the interpretation of our results. 
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4.8.3 Clinical and public health implications 
Past policies that increase the duration of compulsory education have improved health and 
such endeavours must continue (4). However, intervening directly on education is difficult to 
achieve without social and political reforms. The findings of this study have notable 
implications for policymakers as they identify potential strategies for reducing education 
inequalities in health. Furthermore, they also produce quantitative estimates of this, allowing 
specific consideration of potential public health impact. It is an important finding of this work 
that BMI, systolic blood pressure and smoking together explain less than half of the overall 
effect of education. Further research identifying the other related factors and the interplay 
between them will be key to reducing social inequalities in cardiovascular disease. 
Furthermore, work investigating more diverse populations will be necessary to support the 
extrapolation of these findings outside of the considered contexts. 
4.8.4 Conclusion 
Using distinct analytical methodologies, including genetic approaches that are able draw 
causal inference, these results suggest that interventions aimed at reducing BMI, systolic 
blood pressure and smoking in European populations would lead to reductions in cases of 
CVD attributable to lower levels of education. Importantly, over half of the effect of education 
on risk of cardiovascular disease is not mediated through these risk factors and further work is 
required towards investigating this. 
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Chapter 5. Educational inequalities in statin treatment 
for preventing cardiovascular disease: cross-sectional 
analysis of UK Biobank  
 
5.1 Author list and contributions 
Alice R Carter1,2*, Dipender Gill3-7, Richard Morris2,8, George Davey Smith1,2,9, Amy E Taylor2,9, 
Neil M Davies1,2,10†, Laura D Howe1,2† 
†NMD and LDH contributed equally 
 
ARC designed the study, cleaned and analysed the data, interpreted the results, wrote and 
revised the manuscript. DG advised on defining medications, interpreted the results and 
critically reviewed and revised the manuscript. RM advised on analyses, interpreted the results 
and critically reviewed and revised the manuscript. GDS, AET, NMD and LDH all designed the 
study, interpreted the results, critically reviewed and revised the manuscript and provided 
supervision for the project. NMD and LDH contributed equally and are joint senior authors on 
this manuscript. ARC and LDH serve as guarantors of the paper. The corresponding author 
attests that all listed authors meet authorship criteria and that no others meeting the criteria 
have been omitted.  
5.2 Summary of personal contributions 
In this chapter I triangulate data from UK Biobank baseline assessment centres, linked  
hospital inpatient records, linked primary care data and linked mediation records to 
investigate educational inequalities in statin prescribing.  
I was sole lead author for the work in this chapter. I was responsible for deriving QRISK3 
cardiovascular risk scores using data from baseline assessment centres. I carried out all 
analyses, following an analysis plan agreed upon by all co-authors, and created publication 
quality tables and figures. I was responsible for writing the manuscript and revising in 
accordance to co-authors advice.  
A version of this manuscript has been published on the MedRxiv preprint server and it is 
currently under review (doi: https://doi.org/10.1101/2020.06.11.20128116). In this thesis chapter I 
have incorporated supplementary figures with the main text.   





The most socioeconomically deprived individuals remain at the greatest risk of cardiovascular 
disease. Differences in risk adjusted use of statins between educational groups may contribute 
to these inequalities. I explore whether people with lower levels of educational attainment are 
less likely to take statins for a given level of cardiovascular risk. 
Methods:  
Using data from a large prospective cohort study, UK Biobank, I calculated a QRISK3 
cardiovascular risk score for 472 097 eligible participants with complete data on self-reported 
educational attainment and statin use (55% female; mean age, 56). I used logistic regression to 
explore the association between i) QRISK3 score and self-report statin use and ii) educational 
attainment and self-report statin use. I then stratified the association of QRISK3 score, and 
statin use by strata of educational attainment to test for an interaction.  
Results: 
There was evidence of an interaction between QRISK3 and education, such that for the same 
QRISK3 score, people with more education were more likely to report taking statins. For 
example, in women with 7 years of schooling, equivalent to leaving school with no formal 
qualifications, a one unit increase in QRISK3 score was associated with a 7% higher odds of 
statin use (odds ratio (OR) 1.07, 95% CI 1.07, 1.07). In contrast, in women with 20 years of 
schooling, equivalent to obtaining a degree, a one unit increase in QRISK3 score was 
associated with an 14% higher odds of statin use (OR 1.14, 95% CI 1.14, 1.15). Comparable ORs in 
men were 1.04 (95% CI 1.04, 1.05) for men with 7 years of schooling and 1.08 (95% CI 1.08, 1.08) 
for men with 20 years of schooling. Linkage between UK biobank and primary care data meant 
we were able to carry out a number of sensitivity analyses to test the robustness of our 
findings. However, a limitation of our study is that a number of assumptions were made when 
deriving QRISK3 scores which may overestimate the scores. 
Conclusions:  
For the same level of cardiovascular risk, individuals with lower educational attainment are 
less likely to receive statins, likely contributing to health inequalities.   




Despite reductions in cardiovascular morbidity and mortality in high income countries, the 
most socioeconomically deprived groups remain at the highest risk of cardiovascular disease 
(CVD) (3, 76). There is evidence that education is a causal risk factor for CVD (8, 9, 287). I 
have previously demonstrated that part of this association acts through three modifiable risk 
factors; body mass index (BMI), systolic blood pressure and lifetime smoking behaviour 
(Chapter 4) (287). However, as much as 60% of the effect of education on CVD remains 
unexplained.  
Previous studies have assessed the association of socioeconomic position (SEP) with primary 
(prescribed prior to a cardiovascular event) and secondary (prescribed as a result of a 
cardiovascular event) CVD preventative treatment rates; however, the direction of effect has 
been mixed (142, 143, 146, 147, 340). In an analysis of the Whitehall II cohort study (141), and in 
the British Regional Heart Study (341) there was no evidence of socioeconomic differences in 
statin prescribing. In other studies it has been reported that those with lower socioeconomic 
position are more likely to be prescribed statins (36, 142-144). Conversely, some studies have 
found that individuals of lower socioeconomic position are less likely to be prescribed statins 
(87, 145-147).  
One key challenge in trying to unpick the role of education in statin prescribing (or other 
primary or secondary prevention mechanisms) is that lower education is associated with 
higher levels of cardiovascular risk factors. For example, lower education is associated with 
higher BMI, smoking, higher blood pressure, and lower levels of physical activity (115, 117, 287). 
Therefore, individuals with low education likely have a greater underlying risk of CVD and 
therefore potentially have a greater need for statins. However, it is possible that educational 
differences in health-seeking behaviour or interactions between patients and healthcare 
professionals may result in those with higher educational levels being prescribed preventative 
medication at a lower level of clinical ‘need’ (342, 343). Consequently, it is more informative to 
test whether there are educational differences in statin use dependent upon cardiovascular 
risk, rather than to look at the crude association of education and statin use.  
Using the UK Biobank cohort, I investigated whether for a given level of cardiovascular risk, 
measured using the QRISK3 cardiovascular risk score, people with lower education were less 
likely to report taking statins as primary prevention than those with higher education (23, 344, 
345). In secondary analyses I identify whether there are inequalities in the type of statin 
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(Atorvastatin compared with Simvastatin) prescribed, given that Atorvastatin has greater 
efficacy than Simvastatin but is more costly (346-349). 
5.5 Methods 
5.5.1 UK Biobank 
The UK Biobank study recruited 503 317 UK adults between 2006 and 2010. Participants 
attended baseline assessment centres involving questionnaires, interviews, anthropometric, 
physical and genetic measurements (15, 16). All UK Biobank participants are linked to hospital 
episode statistics (HES) or Scottish morbidity records (SMR) (referred to jointly as hospital 
inpatient records), with data available from 1997 in England, 1998 in Wales and 1981 in 
Scotland (293), with the most recent entry recorded in this analysis in May 2017. Additionally, 
a subset of participants (approximately 230,000 participants) are linked with primary care data 
and prescribing data (350). In this chapter, I use data from baseline assessment centres, 
hospital inpatient records, and linked primary care data where available. 
5.5.2 QRISK risk score and included variables 
A CVD risk score was created using the QRISK3 algorithm (23). The QRISK3 score is currently 
used in primary care systems in England and Wales to define the treatment threshold for 
statin prescriptions. Current guidelines recommend prescribing statins to individuals with a 
10% or greater risk of having a cardiovascular event within 10 years (24, 25). QRISK3 scores 
were derived for all participants with complete data for educational attainment and reported 
statin use (N= 472 097) (Figure 5.1). For individuals with missing data in any of the QRISK3 
variables multiple imputation was used (see statistical analysis section). Scores were derived 
according to the publicly available QRISK3 algorithm https://qrisk.org/three/index.php.  
Where measures were recorded in baseline assessment centres, such as BMI, Townsend 
deprivation index (TDI) or systolic blood pressure, these values were used. With the exception 
of systolic blood pressure variability (standard deviation of repeated values) and coronary 
heart disease (CHD) in a first-degree relative under 60 years of age, all QRISK3 variables were 
available in UK Biobank. All variables used and assumptions made when deriving QRISK3 
scores are available in Table 5.1.  
5.5.2.1 Diagnoses of disease 
Diagnoses of disease including arthritis, diabetes (type I and type II), systemic lupus 
erythromatosus, atrial fibrillation, chronic kidney disease, migraine, HIV/AIDS, severe mental 
illness and erectile dysfunction were ascertained via linked hospital inpatient records or via 
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linked medication data. UK Biobank treatment codes used to identify cases and ICD-9 and 
ICD-10 codes are presented in Appendix 3 Table  1. 
5.5.2.2 Treatments 
Use of drugs at baseline (antihypertensives, corticosteroids and atypical antipsychotics) were 
defined by self-reported medication use to clinic nurses at baseline. Individuals were coded as 
using medication if they reported any medication included in the QRISK3 score. In the 
QRISK3 derivation cohort individuals were required to have at least two prescriptions 
representing long term use (23). It was not possible to ascertain the number of prescriptions in 
UK Biobank; however, UK Biobank participants were asked to record regular treatments, 
rather than short term medication or over the counter medication. All treatment codes used 
to define these variables in UK Biobank are available in Appendix 3 Table  2. 
5.5.2.3 Ethnicity 
Ethnicity was reported by participants to study nurses at UK baseline assessment centres. 
Ethnicity was categorised according to the categories used in the QRISK3 algorithm (23). 
5.5.2.4 Townsend deprivation index 
Townsend deprivation index of current location was recorded by UK Biobank at baseline . 
5.5.2.5 BMI 
Height (m) and weight (kg) were measured by UK Biobank study nurses ate baseline 
assessment centres which were used to calculate BMI (kg/m2). 
5.5.2.6 Smoking 
Smoking status (never, former or current) was determined by self-reported data at baseline 
assessment centres. The number of cigarettes smoked per day in current smokers was 
reported at baseline assessment centres and categorised according to QRISK3 categories of 
light (1-9/day), moderate (10-19/day) and heavy smokers (≥20/day) (23). 
5.5.2.7 Systolic blood pressure 
The mean from two resting automated measures of systolic blood pressure, measured using an 
Omron HEM-7105IT digital blood pressure monitor, was used in the QRISK3 score. 
5.5.2.8 Systolic blood pressure variability 
In the absence of longitudinal data on repeated measures of systolic blood pressure in UK 
Biobank a measure of systolic blood pressure variability was derived from the standard 
deviation of the two recorded measurements of systolic blood pressure at the baseline 
assessment centre. 
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5.5.2.9 Total cholesterol:HDL cholesterol ratio 
Non-fasting measures of total serum cholesterol and high-density lipoprotein (HDL)-
cholesterol were measured using enzymatic assays (Backman Coulter AU5800) and the ratio of 
the two values was calculated. UK Biobank corrected serum data for laboratory dilution effects 
and were excluded if they did not pass UK Biobank quality control (351).  
5.5.2.10 Coronary heart disease in a first degree relative under 60 years of age 
A measure of family history of CHD was proxied from reported CVD in mothers, fathers and 
siblings of UK Biobank participants, however age of diagnosis, nor type of CVD, could not be 
determined. 
5.5.2.11 Primary care QRISK score 
In a subset of individuals with linked primary care data, QRISK (read 2 code: 38DF.) (N=1 495) 
(344), or QRISK2 scores (read 2 code: 39DP.) (N = 10 633) (345) were recorded from 2007 
onwards. Where more than one QRISK score was recorded for an individual, the first recorded 
value was used in analysis. 
  
























Figure 5.1:Study flow chart identifying eligible participants for analysis 
Note: At each stage the same participant could have missing data for multiple variables, therefore overlap is present 
between the variables. The total excluded may be less than the sum of individuals at each stage. 
CVD = cardiovascular disease; BMI = body mass index; CHD = coronary heart disease 
  
Imputed QRISK3 variables 
Ethnicity N = 1 786 
Smoking N = 0 
Age N = 0 
BMI N =  2 314 
Cholesterol ratio N = 65 483 
Systolic blood pressure N = 40 636 
Systolic blood pressure variability N = 40 
636 
Townsend deprivation index N = 584 
Atrial fibrillation N = 0 
Atypical antipsychotics N = 0 
  
Corticosteroids N = 0 
Migraine N = 0 
Chronic kidney disease N = 0 
Severe mental illness N = 0 
Systemic lupus erythematosus N = 0  
Treated hypertension N = 0 
Type 1 diabetes N = 0 
Type 2 diabetes N = 0 
Family history of CHD N = 0 
Impotence (males only) N = 0 
UK Biobank full 
sample 
N = 503 317 
CVD at baseline 
N = 20  929 
Complete case 
analysis 
N = 368 721 
Complete data on 
education and no 
prevalent CVD* 
N = 472 097 
Withdrawn N = 790 
Pregnant N = 371 
  
Missing exposure or outcome data 
Education = 9 136 
Reported statins = 0 
  
Included in primary 
care sample 




primary care sample 
N = 12 128 
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Measured in UK 
Biobank by ICD Code 
UK Biobank 
Variable 
Assumptions/limitations to the UK 
Biobank variables 
Diagnoses 
Arthritis HES data and SMR M05   
Diabetes (Type I 
and II) HES data and SMR E10-E14   
Systemic lupus 
erythematosus HES data and SMR M32.9   
Atrial fibrillation HES data and SMR I48   
Chronic kidney 
disease HES data and SMR N18.3-N18.5   
Migraine HES data and SMR G43   
HIV/AIDS HES data and SMR B20   
Severe mental 
illness HES data and SMR 
F20, F23, F31, 
F32, F33   
Erectile dysfunction Nurses interview treatment data N52 n_20003_0  
Treatments 
Antihypertensives Nurses interview treatment data  n_20003_0 
Original QRISK3 derivation specifies 
that use of drugs at baseline was 
defined as at least two prescriptions, 
with the most recent one no more 
than 28 days before the date or cohort 
entry. This cannot be ascertained in 
UK Biobank baseline data, and 




treatment data  n_20003_0 
Lifestyle and biological factors 
Ethnicity Self-report/ Genetic confirmation  n_21000_0_0  
TDI Postcode at baseline  n_189_0_0  
BMI Baseline clinic  n_21001_0_0  
Smoking Self-report at baseline  n_20116_0_0 n_3456_0_0 
Calculated from derived variable for 
cigarettes per day 
Age Baseline clinic  n_21003_0_0  
Systolic blood 




pressure variability Baseline clinic  
n_4080_0_1n_4080_
0_0 
The QRISK3 algorithm uses the 
standard deviation of repeated values 
of blood pressure. This was not 
available in UK Biobank; therefore, 
systolic blood pressure variability was 
derived from the standard deviation 
between two baseline automated 
readings of systolic blood pressure 
Total cholesterol: 
HDL ratio 




CHD in first degree 




Includes all reported family history of 
CVD, not restricted to cases under 60 
or specific subtypes 
 
HES = hospital episode statistics; SMR = Scottish morbidity records; TDI = Townsend deprivation index; BMI = body 
mass index; HDL = high-density lipoprotein; CHD = coronary heart disease; CVD = cardiovascular disease 
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5.5.3 Measuring educational attainment 
UK Biobank participants reported their highest qualification achieved at baseline assessment 
centres, which was converted to the International Standard Classification for Education 
(ISCED) coding of years of education (Table 5.2) (323).  
Table 5.2: International Standard for Classification of Education codes mapped to UK Biobank self-report highest 
qualification to estimate years of education 
Qualification (As reported in UK Biobank) ISCED Years of education N 
College or University degree 5 20 157 109 
NVQ or HND or HNC or equivalent 5 19 30 919 
Other prof. qual. e.g.: nursing, teaching 4 15 24 550 
A levels/AS levels or equivalent 3 13 53 456 
O levels/GCSEs or equivalent 2 10 101 222 
CSEs or equivalent 2 10 25 999 
None of the above 1 7 78 422 
Prefer not to answer Excluded 
 
5.5.4 Measuring statin use 
Participants were asked about regular medication they were taking, details of which were 
recorded by UK Biobank study nurses. From this, a primary variable for any reported statin 
use was generated. The type of statin used (Atorvastatin, Simvastatin, Fluvastatin, Pravastatin 
and Rosuvastatin) was recorded by study nurses and was used to derive a variable for type of 
statin. 
In individuals with linked primary care data, statin prescriptions were recorded in prescription 
data. In these individuals, a measure of validated statin use was created, defined by a 
prescription in both the 3 months before and 3 months after baseline. For sensitivity analyses 
in individuals with a QRISK or QRISK2 score recorded in primary care data, statin use was 
defined as any statin prescription after a QRISK score was recorded. 
5.5.5 Exclusion criteria 
Individuals with prevalent CVD at baseline, which would result in a statin prescription 
according to NICE guidelines (24-26, 188), were excluded from analyses. These cardiovascular 
diagnoses and events were ascertained through linkage to hospital inpatient records, with 
cases defined according to ICD-9 and ICD-10 codes (Appendix 3 Table  1). Individuals were 
excluded if they had experienced at least one diagnosis of myocardial infarction, angina, 
stroke, transient ischaemic attack, peripheral arterial disease, type 1 diabetes, chronic kidney 
disease or familial hypercholesterolaemia (24, 26). The date for each diagnosis is provided in 
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the hospital inpatient records, which was linked with the date of assessment centre visit 
provided by UK Biobank. 
Complete case analyses were carried out on 368 721 individuals, with complete data on age, 
sex, educational attainment, self-reported statin (medication) use and all variables required 
for the QRISK3 score (Figure 5.1).  
5.5.6 Code and data availability 
The derived variables have been returned to UK Biobank for archiving. The code used to 
derive QRISK3 scores and carry out analyses is available at 
github.com/alicerosecarter/statin_inequalities. 
5.5.7 Patient and public involvement 
Ethical approval for this study was sought from the UK Biobank (project 10953). No patients or 
participants were involved in setting the research question or the outcome measures, nor were 
they involved in developing plans for design or implementation of the study. No patients were 
asked to advise on the interpretation or writing up of results. 
5.5.8 Statistical analyses 
To maximise power and potentially reduce bias, multivariable multiple imputation by chained 
equations (352) was used to impute variables included in the QRISK3 score with missing data, 
under the missing at random assumption. The sample for imputation was defined as all 
individuals with complete data on educational attainment and reported statin use. The 
proportion of missing data ranged from 0% to 15% (Table 5.3). In total, 77% of participants had 
no missing data, 13% of participants were missing data for one QRISK3 variable, 8% of 
participants were missing data for two QRISK3 variables and 2% of participants were missing 
data for three, four or five variables. A total of 25 imputed datasets were generated (353). 
Imputation was carried out separately within strata of years of education and sex to preserve 
interactions tested in the statistical analyses (354). The mean and standard deviation of 
continuous variables or proportion and standard error of categorical variables in the imputed 
data were compared with those from the complete data. All analyses were then carried out in 
each imputed dataset, with results combined according to Rubin’s rules.  
It was determined a priori to carry out all analyses stratified by sex given the known 
differences in cardiovascular risk profiles for males and females (355, 356), as well as the 
QRISK3 score being derived separately by sex (23).  
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To confirm the validity of the derived QRISK3 score, a univariable logistic regression model 
was used to assess the association of the risk score with i) self-reported statin use and ii) 
incident CVD.  
I estimated the associations of years of education with i) QRISK3 score (using linear 
regression) and ii) statin use (using logistic regression).  
 






Variable Female Male 
% missing 
QRISK 24% 22% 
   
Age 0% 0% 
   
BMI 0.5% 0.7% 


















   
Ethnicity 0.5% 0.7% 
   
Smoking 0% 0% 
   
Family history of 
CVD 
0% 0% 
   
Statin (reported) 0% 0% 
   
Statin type 0% 0% 
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5.5.8.1 Testing for interaction between QRISK3 score and educational attainment on 
statin use 
Logistic regression was used to estimate the association of QRISK3 score with self-reported 
statin use, stratified by years of education, providing an estimate of interaction on the 
multiplicative scale (Figure 5.2, Route 1). These analyses were not adjusted for any other 
covariates, assuming all relevant variables are incorporated into the QRISK3 score. Evidence of 
an interaction between QRISK3 score and years of education was evaluated in a linear model 
where the interaction term QRISK3*educational attainment was included in the regression 
model. 
 
Figure 5.2: Schematic of primary and secondary analyses carried out 
 
5.5.8.2 Secondary analyses 
To test the hypothesis that there may be educational inequalities in the type of statin 
prescribed, in individuals who reported using statins to baseline study nurses, I assessed i) 
whether there was an association of QRISK3 score and years of education independently with 
self-reported Atorvastatin, which has been suggested to have a greater efficacy, compared with 
self-reported Simvastatin (baseline) (346-348) and ii) whether there was any evidence of an 
interaction between QRISK3 score and years of education on type of statin prescribed (Figure 
5.2, Route 2). 
   
 
 150 
Analyses testing the association between QRISK3 and years of education on statin use and 
statin type independently, as well as for any interaction between QRISK3 score and 
educational attainment, on statin use were replicated on the additive interaction scale. 
Additionally main analyses for statin use and type of statin prescribed were replicated using 
complete case data (Figure 5.2, Route 3 and 4). 
To test whether the self-reported statin use data affected the results, I repeated analyses with 
statin use defined as a prescription both 3 months before and after baseline from linked 
primary care prescription data (Figure 5.2, Route 5), and also repeated main analyses with self-
reported statin use in the subset of participants with the linked prescription data (Figure 5.2, 
Route 6).  
In the subsample of primary care individuals with a QRISK or QRISK2 score recorded, 
analyses were replicated to test for evidence of an interaction between QRISK score and 
incident statin prescribing. This was defined as any prescription for a statin recorded in 
primary care data, excluding individuals who reported using statins to study nurses at the 
baseline assessment centre (Figure 5.2, Route 7). QRISK scores were included if they were 
recorded on or prior to the date of first statin prescription, but consideration was not given to 
the time between both events. 
Two further estimates of QRISK3 were derived excluding i) variability of systolic blood 
pressure and ii) family history of CVD from QRISK3 scores. The pairwise correlation between 
scores with and without these variables was tested. 
5.6 Results 
5.6.1 UK Biobank sample 
In the main analyses (N = 472 097) 55% of participants were female with a mean age of 56. In 
females, the QRISK3 score implied a mean 10-year risk of a cardiovascular event of 6.9% 
(standard deviation (SD) = 5.5). In males, the QRISK3 score implied mean a 10-year risk of a 
cardiovascular even of 13.1% (SD = 8.4). Participants were more likely to have completed 20 
years of education (female = 35%, male = 38%) than 7 years of education (female = 14%, male = 
14%). 10% of females and 17% of males reported using statins.  
The distribution of variables was similar between the multiply imputed dataset, complete case 
data, and in the subset of participants with linked primary care data (Table 5.4). 
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Table 5.4: Descriptive characteristics of UK Biobank participants in i) the full eligible sample analysed ii) the full eligible sample who also have linked primary care data and iii) participants with linked 
primary care data and a recorded QRISK score 
Variable 
Imputed analysis sample Primary care analysis sample (imputed) 
Primary care analysis sample 
with recorded QRISK Complete case analysis sample 
(N = 472 097) (N = 209 451) (N = 12 128) (N = 368 721) 
Female Males Female Males Female Male Female Male 
(N = 261 147) (N = 210 950) (N = 117 038) (N = 92 413) (N = 7 338) (N = 4 790) (N = 201 532) (N = 167 189) 
Continuous variables Mean (SD) 
QRISK* 
QRISK3 (baseline) 6.87 (5.54) 12.98 (8.34) 6.94 (5.57) 13.11 (8.35) 6.21 (4.68) 11.44 (7.1) 6.84 (5.5) 12.97 (8.32) 
QRISK3 excluding ‘non-
validated’ statin users 
NA NA 6.09 (4.98) 11.54 (7.82) NA NA NA NA 
Recorded value of QRISK 
in primary care NA NA NA NA 10.17 (6.94) 16.11 (9.2) NA NA 
Age  56.23 (7.98) 56.44 (8.2) 56.26 (7.94) 56.5 (8.15) 56.28 (7.98) 56.45 (8.2) 56.28 (7.98) 56.45 (8.2) 
BMI  27.02 (5.15) 27.75 (4.2) 27.14 (5.18) 27.86 (4.23) 26.96 (5.08) 27.74 (4.18) 26.96 (5.08) 27.74 (4.18) 
Systolic blood pressure  135.14 (19.18) 140.94 (17.35) 135.46 (19.17) 141.31 (17.39) 135.15 (19.15) 141 (17.31) 135.15 (19.15) 141 (17.31) 
TDI  -1.38 (3.2) -1.31 (3.12) -1.41 (2.95) -1.36 (3.05) -1.4 (2.99) -1.34 (3.09) -1.4 (2.99) -1.34 (3.09) 
Total cholesterol:HDL cholesterol  3.86 (1) 4.48 (1.15) 3.88 (1.01) 4.49 (1.15) 3.84 (1) 4.49 (1.15) 3.84 (1) 4.49 (1.15) 
 
Categorical variables  
Percent of Sample (SE) Frequency (%) 
Years of education 
7 years 14.21 (0.08) 13.83 (0.09) 15.29 (0.12) 14.67 (0.14) 1 034 (14) 601 (13) 32 785 (16) 26 874 (16) 
10 years 19.4 (0.09) 13.52 (0.09) 19.1 (0.13) 13.36 (0.13) 1 520 (21) 649 (14) 39 795 (20) 22 945 (14) 
13 years 6.06 (0.05) 5.27 (0.06) 5.81 (0.08) 5.05 (0.09) 436 (6) 285 (6) 11 729 (6) 8 449 (5) 
15 years 12.83 (0.07) 10.04 (0.08) 12.69 (0.11) 10.16 (0.12) 961 (13) 497 (10) 26 936 (13) 17 161 (10) 
19 years 12.88 (0.07) 19.67 (0.1) 13.13 (0.11) 20.17 (0.16) 911 (12) 944 (20) 25 653 (13) 32 940 (20) 
20 years 34.62 (0.11) 37.67 (0.12) 33.98 (0.16) 36.58 (0.19) 2 476 (34) 1 814 (38) 64 634 (32) 58 820 (35) 
Ethnicity 
White 94.96 (0.05) 94.7 (0.06) 95.75 (0.07) 95.33 (0.08) 7 026 (96) 4 600 (96) 190 903 (95) 158 386 (95) 
Indian 0.98 (0.02) 1.2 (0.03) 1.04 (0.03) 1.3 (0.04) 66 (1) 49 (1) 2 082 (1) 2 108 (1) 
Pakistani 0.23 (0.01) 0.42 (0.02) 26.52 (0.02) 0.46 (0.03) 21 (0) 11 (0) 462 (0) 717 (0) 
Other Asian 0.48 (0.02) 0.6 (0.02) 0.4 (0.02) 0.58 (0.03) 25 (0) 22 (0) 982 (0) 979 (1) 
Black Caribbean 10.73 (0.02) 0.81 (0.02) 0.77 (0.03) 0.64 (0.03) 55 (1) 18 (0) 2 464 (1) 1 408 (1) 
Black African 0.68 (0.02) 0.86 (0.02) 0.46 (0.02) 0.54 (0.03) 40 (1) 21 (0) 1 435 (1) 1 406 (1) 
Chinese 0.38 (0.01) 0.28 (0.01) 0.32 (0.02) 0.23 (0.02) 26 (0) 26 (0) 719 (0) 719 (0) 
Other 1.22 (0.02) 1.12 (0.03) 1.01 (0.03) 0.92 (0.04) 70 (1) 70 (1) 2 485 (1) 2 485 (1) 
 




Never 60.54 (0.11) 52.29 (0.13) 60.79 (0.16) 52.33 (0.19) 4 388 (60) 2 536 (53) 120 335 (60) 83 129 (50) 
Former 30.39 (0.1) 35.02 (0.12) 30.05 (0.15) 35.16 (0.19) 2 346 (32) 1 715 (36) 63 059 (31) 63 033 (38) 
Light (1-9/day) 1.66 (0.03) 1.29 (0.03) 1.59 (0.04) 1.24 (0.04) 128 (2) 57 (1) 3 287 (2) 2 056 (1) 
Moderate (10-19/day) 2.99 (0.04) 2.96 (0.04) 3.16 (0.06) 3.01 (0.07) 176 (2) 102 (2) 6 094 (3) 4 931 (3) 
Heavy (>20/day) 4.42 (4.42) 8.45 (0.07) 4.42 (0.07) 8.26 (0.11) 300 (4) 380 (8) 8 757 (4) 14 040 (8) 
Family history of CVD 
Control 72.37 (0.1) 78.22 (0.11) 71.5 (0.15) 77.57 (0.16) 5 242 (71) 3 749 (78) 142 641 (71) 128 314 (77) 
Case 27.63 (0.1) 21.78 (0.11) 28.5 (0.15) 22.43 (0.16) 2 096 (29) 1 041 (22) 58 891 (29) 38 875 (23) 
Statin (reported) 
Control 90.27 (0.06) 82.99 (0.08) 90.14 (0.09) 82.39 (0.13) NA NA 181 903 (90) 138 619 (83) 
Case 9.73 (0.06) 17.01 (0.08) 9.86 (0.09) 17.61 (0.13) NA NA 19 629 (10) 28 570 (17) 
Statin type 
No statin 90.27 (0.06) 82.99 (0.08) 90.14 (0.09) 82.39 (0.13) NA NA 181 903 (90) 138 619 (83) 
Atorvastatin 1.64 (0.02) 2.87 (0.04) 1.68 (0.04) 2.9 (0.06) NA NA 19 629 (10) 28 570 (17) 
Fluvastatin 0.02 (0) 0.06 (0.01) 0.03 (0) 0.06 (0.01) NA NA 181 903 (90) 138 619 (83) 
Pravastatin 0.3 (0.01) 0.47 (0.01) 0.29 (0.02) 0.44 (0.02) NA NA 3 281 (2) 4 750 (3) 
Rosuvastatin 0.39 (0.01) 0.61 (0.02) 0.38 (0.02) 0.65 (0.03) NA NA 49 (0) 96 (0) 
Simvastatin 7.37 (0.05) 13.01 (0.07) 7.49 (0.08) 13.56 (0.11) NA NA 617 (0) 787 (0) 
Statin (validated) 
Control NA NA 97.62 (0.05) 95.40 (0.08) 6 345 (86) 3 878 (81) NA NA 
Case NA NA 2.38 (0.05) 4.60 (0.08) 993 (14) 912 (19) NA NA 
Reported statin with no 
prescription* 
Control NA NA 92.90 (0.08) 86.01 (0.13) NA NA NA NA 
Case NA NA 7.10 (0.08) 13.99 (0.13) NA NA NA NA 
Incident CVD 
Control 79.63 (0.08) 0.08 (73.66) 79.85 (0.13) 0.13 (73.57) 5 379 (82) 3 439 (80) 140 753 (79) 106 032 (74) 
Case 20.37 (0.08) 0.08 (26.34) 20.15 (0.13) 0.13 (26.43) 1 179 (18) 885 (20) 36 401 (21) 38 171 (26) 
Derived QRISK3 variable from baseline measured in UK Biobank for the full analysis sample and primary care analysis sample, recorded QRISK or QRISK2 scores in primary care data for the primary 
care analysis sample with recorded QRISK. 
*Proportion of individuals excluding individuals with validated prescriptions 
BMI = body mass index; TDI = Townsend deprivation index; HDL = high-density lipoprotein cholesterol; SE = standard error; CVD = cardiovascular disease 
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5.6.2 Association of QRISK3 score with statins and cardiovascular disease  
For a one unit increase in QRISK3 score (i.e. a 1% increase in the 10-year risk of experiencing a 
cardiovascular event) in females, the odds ratio (OR) for reporting statin use to study nurses 
was 1.12 (95% confidence interval (CI): 1.12 to 1.13) and the OR for an incident cardiovascular 
event was 1.12 (95% CI: 1.12 to 1.12) (Figure 5.3 and Table 5.5). Females with a QRISK3 score of 
10 or greater were 1.34 (95% CI: 1.31 to 1.36) times more likely to report using statins than those 
with a QRISK score of less than 10. In males, the OR for statin use was 1.07 (95% CI: 1.07 to 
1.07) and for an incident cardiovascular event the OR was 1.08 (95% CI: 1.08 to 1.08) per unit 
higher QRISK3 score (Figure 5.3 and Table 5.5). Males with a QRISK3 score of 10 or greater 
were 1.49 (95% CI: 1.46 to 1.52) times more likely to report using statins than those with a 














Figure 5.3: Odds ratio of self-report statin use per unit increase in baseline QRISK3 score with no education 
interaction and stratified by years of education in females and males  
Analyses stratified by years of education provide an estimate of interaction on the multiplicative scale 
P value for interaction in females = 1.385x10
-85
 and males = 1.551x10
-48 
CI = confidence interval 
  
   
 
 154 
Table 5.5: Odds ratio of i) statin use and ii) incident cardiovascular disease per unit increase in QRISK3 score and unit 




Odds ratio (95% 
CI) 
(N = 201 532) 
Imputed sample 
Odds ratio (95% 
CI) 
(N = 261 147) 
Complete Case 
Odds ratio (95% 
CI) 
(N = 167 189) 
Imputed sample 
Odds ratio (95% 
CI) 
(N = 210 950) 
QRISK3 




1.14 (1.14, 1.15) 1.12 (1.12, 1.12) 1.09 (1.09, 1.09) 1.08 (1.08, 1.08) 
 
Education 




0.95 (0.95, 0.95) 0.95 (0.95, 0.95) 0.93 (0.93, 0.93) 0.96 (0.95, 0.96) 
 
5.6.3 Association of education with QRISK3 score and statin prescribing 
Per year increase in educational attainment was associated with a -0.30 (95% CI: -0.30 to -
0.29) reduction in mean QRISK3 score in females and a -0.35 (95% CI: -0.35 to -0.34) reduction 
in mean QRISK3 score in males (Table 5.6 and Figure 5.4).  
The prevalence of statin use was highest in those in the lowest strata of educational 
attainment (equivalent to leaving school after 7 years, with no formal qualifications). Not 
accounting for cardiovascular risk, each additional year of education was associated with a 
lower odds of being prescribed statins (all types), (OR in females: 0.93; 95% CI: 0.93 to 0.93, 
OR in males: 0.96; 95% CI: 0.96 to 0.96) (Table 5.5 and Figure 5.6).  
 


















(N = 210 950) 
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Figure 5.4: Mean value of QRISK3 score on those with complete data, by years of education for females and males 
Figure 5.5: Prevalence of statin prescribing by years of education in females and males in individuals with complete 
data 
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Figure 5.6: Odds ratio of statin use per year unit increase in educational attainment (all years) and per strata of 
educational attainment 
CI = confidence interval 
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5.6.4 Interaction between education and QRISK3 score in relation to statin 
prescribing 
In both females and males, there was evidence of an interaction between QRISK3 score and 
years of education on statin use, such that for the same increase in QRISK3 score, the 
likelihood of statin use increased more for those of high educational attainment. In females, 
per unit increase in QRISK3, the OR for reporting statin use in those with the greatest years of 
education (20 years, equivalent to obtaining a degree) was 1.14 (95% CI: 1.14 to 1.15) compared 
with an OR of 1.07 (95% CI: 1.07 to 1.07) for those with the least years of education (7 years, 
equivalent to leaving school with no formal qualifications) (Figure 5.3). In males, the OR for 
statin use per unit increase in QRISK3 score in those with 20 years of education was 1.08 (95% 
CI: 1.08 to 1.08) compared with an OR of 1.04 (95% CI: 1.04 to 1.05) for those with 7 years of 
education (Figure 5.3). The P value for interaction in females was 1.385x10-85 and in males the P 
value for interaction was 1.551x10-48. 
5.6.5 Secondary analyses 
Among individuals prescribed with either atorvastatin or simvastatin, those with higher 
QRISK3 scores were more likely to have been prescribed the more effective Atorvastatin. The 
OR for a one-unit higher QRISK3 and reporting Atorvastatin use was, 1.02 (95%CI: 1.02 to 1.03) 
(Table 5.7). This was similar in males; OR: 1.02 (95% CI: 1.01 to 1.02). Females, but not males, 
were less likely to have been prescribed Atorvastatin if they had more years of education; e.g. 
the OR for Atorvastatin prescription for 20 years of education versus 7 years of education was 
0.92 in females (95% CI 0.83 to 1.01) and 1.02 in males (95% CI 0.94 to 1.11). There was little 
evidence of an interaction between QRISK3 score and educational attainment on statin type in 
females and males (P value for interaction in females = 0.4; P value for interaction in males = 
0.9) (Figure 5.7).  
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Table 5.7: Odds ratio of Atorvastatin use compared with Simvastatin (baseline) use per unit increase in QRISK3 score 




Odds ratio (95% 
CI) 
(N = 18 180) 
Imputed 
sample 
Odds ratio (95% 
CI) 
(N = 23 538) 
Complete Case 
Odds ratio (95% 
CI) 
(N = 26 633) 
Imputed 
sample 
Odds ratio (95% 
CI) 
(N = 33 499) 




All years 1.00 (0.99, 1.00) 0.99 (0.99, 1.00) 1.00 (1.00, 1.01) 1.00 (1.00, 1.01) 
7 years Baseline Baseline 
10 years 1.02 (0.92, 1.14) 0.99 (0.90, 1.09) 1.02 (0.92, 1.14) 0.99 (0.90, 1.09) 
13 years 1.14 (0.95, 1.37) 1.08 (0.92, 1.26) 0.97 (0.83, 1.14) 1.00 (0.87, 1.15) 
15 years 1.14 (1.01, 1.28) 1.07 (0.97, 1.19) 1.00 (0.89, 1.12) 0.98 (0.89, 1.09) 
19 years 0.98 (0.85, 1.12) 0.93 (0.82, 1.05) 1.02 (0.93, 1.13) 0.99 (0.91, 1.08) 
20 years 0.92 (0.83, 1.03) 0.92 (0.83, 1.01) 1.06 (0.97, 1.15) 1.02 (0.95, 1.11) 
Note: Atorvastatin is generally regarded as more efficacious than Simvastatin. Simvastatin is available to purchase 
over the counter  
CI = confidence interval 
Figure 5.7: Odds ratio of Atorvastatin prescribing compared to Simvastatin, per unit increase in QRISK3 score with no 
education interaction and stratified by years of education in females and males to test for evidence of an interaction 
P value for interaction in females = 0.441 and males = 0.872 
CI = confidence interval  
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When interaction analyses were replicated using eligible participants with linked primary care 
data using i) baseline measures of QRISK3 and self-report statin use, ii) baseline measures of 
QRISK3 with statin use validated by a prescription and iii) QRISK or QRISK2 score recorded in 
primary care data with a statin prescription, the evidence for interaction between QRISK3 and 
educational attainment on statin use remained in females (Figure 5.8 and Figure 5.9). In 
males, the interaction between baseline QRISK3 scores and educational attainment on self-
report statin and validated prescription remained. However, there was less evidence of an 
interaction between the primary care recorded QRISK scores and educational attainment on 
statin prescriptions (P=0.09), although the direction of effect was similar where males with 20 
years of education were more likely to be prescribed statins (OR: 1.08; 95% CI: 1.07 to 1.10) than 
those with 7 years of education (OR: 1.05; 95% CI: 1.03 to 1.08) (Figure 5.8 and Figure 5.9). 
 
Figure 5.8: Odds ratio of self-report statin use per unit increase in baseline QRISK3 score with no education 
interaction and stratified by years of education to test for evidence of an interaction in females and males with linked 
primary care data 
P value for interaction in females = 4.76x10
-48
 and males = 4.25x10
-21 
CI = confidence interval 
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Figure 5.9: Odds ratio of statin use recorded in primary care prescription data per unit increase in A) baseline QRISK3 
score and B) QRISK or QRISK2 score recorded in primary care, in females and males. Analyses stratified by years of 
education provide an estimate of interaction on the multiplicative scale 
Baseline QRISK3: P value for interaction in females = 4.27x10
-10
 and males = 3.26x10
-7
 
QRISK score recorded in primary care: P value for interaction in females = 0.034 and males = 0.091 
CI = confidence interval 
  
   
 
 161 
In analyses on the additive scale, there was evidence of an interaction between QRISK3 score 
and education in both females and males, although the strength of the interaction was smaller 
compared with analyses on the multiplicative scale, particularly in females (Figure 5.10). 
In the complete case sample, there was evidence of an interaction between QRISK3 and 
education in both males and females considering reported statin use as the outcome, where 
the P value for interaction in females was 4.36x10-69 and in males it was 3.06x10-37. However, 
there was little evidence of an interaction between QRISK3 and education on statin type 
(Table 5.8). 
Pairwise correlation between the baseline derived QRISK3 score and QRISK3 scores derived 
excluding i) systolic blood pressure variability estimated from the difference between two 
baseline measures and ii) self-report of any CVD in a mother, father or sibling, were high (all 
>0.97) (Table 5.9). 
  
Figure 5.10: Odds ratio of self-report statin use per unit increase in baseline QRISK3 score with no education interaction and stratified by 
years of education to test for evidence of an interaction in females and males with linked primary care data 
P value for interaction in females = 0.064 and males = 9.41x10
-7 
CI = confidence interval 




Table 5.8: Odds ratio of i) statin use and ii) Atorvastatin use compared with Simvastatin (baseline) use per unit 
increase in QRISK3 score stratified by educational attainment in the complete case sample to test for evidence of an 
interaction 
Outcome Years of education 
Females Males 
Complete Case 
Odds ratio (95% 
CI) 
(N = 201 532) 
P Value for 
interaction 
Complete Case 
Odds ratio (95% 
CI) 
(N = 167 189) 




7 1.07 (1.06, 1.07) 
4.36x10-69 
1.04 (1.04, 1.05) 
3.06x10-37 
10 1.12 (1.12, 1.13) 1.08 (1.07, 1.08) 
13 1.13 (1.12, 1.14) 1.06 (1.06, 1.07) 
15 1.12 (1.11, 1.13) 1.06 (1.06, 1.07) 
19 1.14 (1.13, 1.15) 1.07 (1.07, 1.08) 
20 1.14 (1.14, 1.15) 1.08 (1.08, 1.08) 




7 1.02 (1.01, 1.03) 
0.707 
1.02 (1.01, 1.03) 
0.783 
10 1.03 (1.01, 1.04) 1.01 (1.00, 1.02) 
13 1.04 (1.01, 1.07) 1.01 (1.00, 1.03) 
15 1.02 (1.01, 1.04) 1.03 (1.02, 1.04) 
19 1.01 (1.00, 1.03) 1.02 (1.01, 1.03) 
20 1.01 (1.00, 1.02) 1.01 (1.00, 1.02) 
CI = confidence interval 
 
 
Table 5.9: Pairwise correlation for QRISK3 scores derived from baseline measures in UK Biobank including all 
variables and excluding i) family history of CVD and iii) systolic blood pressure variability 
QRISK3 score Pairwise correlation with complete score 
Female 
Excluding reported family history of any 
cardiovascular disease at any age 
0.9799 
Excluding systolic blood pressure from two 
baseline measures of systolic blood pressure 
0.9991 
Male 
Excluding reported family history of any 
cardiovascular disease at any age 
0.9736 
Excluding systolic blood pressure from two 








Despite there being a higher prevalence of statin prescribing overall in those with lower levels 
of education, at a given level of QRISK3 score as a measure of clinical assessment of 
cardiovascular risk, less educated individuals were less likely to receive statin treatment 
compared to more highly educated individuals. 
5.7.1 Results in context 
Lifestyle and behavioural factors, such as BMI, diet, smoking, risky drinking and exercise have 
previously been implicated as mediators of the association between education and CVD (12-14, 
112-117). Indeed, the higher overall prevalence of statin use in lower educated individuals is 
likely due to the greater prevalence of these intermediate risk factors, compared with those of 
greater education (114, 117, 287). However, much of the association between education and 
CVD remains unexplained. The results presented in this analysis suggest that access to 
preventative medication for CVD may be contributing to persisting socioeconomic 
inequalities. 
It has previously been reported that inequalities exist in favour of those with higher SEP when 
accessing preventative healthcare (357). In the UK, National Health Service (NHS) health 
checks are offered to all residents aged between 40 and 74 without pre-existing conditions 
every 5 years, with the aim of preventing a number of diseases including CVD (such as by 
calculating QRISK scores), kidney disease and dementia (358). In a recent systematic review 
by Bunten and colleagues, seven studies were identified that indicated uptake of these health 
checks is lower in more socioeconomically deprived groups (359). Additionally one study 
included in this systematic review identified a trend towards lower uptake in smokers; an 
important risk factor for CVD that is also socially patterned (359, 360). Similar findings were 
also reported by Wilson and colleagues (361). These reasons for non-uptake of health checks, 
in combination with the inequalities identified in this study, indicate that methods to improve 
engagement with NHS health checks and preventative screening methods may reduce 
inequalities in cardiovascular outcomes. 
Indeed, differences in health seeking behaviours may be driving some of the inequalities in 
statin use identified in this study. However, when interaction analyses were repeated using 
QRISK or QRISK2 scores recorded in primary care data and primary care records of 
prospective statin prescriptions, these inequalities remained. Therefore, attendance to primary 
care clinics cannot be the sole driver of these inequalities.  
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The literature is mixed in the direction to which inequalities in access to statins exist, where 
some studies suggest that individuals with lower SEP are less likely to be prescribed statins 
(87, 145-147) and other studies finding the opposite or no differences (36, 141-144). Of these 
previous studies, there was limited consideration for underlying cardiovascular risk in the 
analyses. Some studies adjusted for cardiovascular comorbidities (87, 143-145) such as 
cholesterol level, diabetes status or prevalent cardiovascular events. However, only one 
previous study was identified that comprehensively adjusted for cardiovascular risk (141). 
Forde and colleagues established risk status via 10-year absolute risk of coronary heart disease 
determined using the Framingham study (141, 362) and assessed SEP by British civil service 
grade of employment. In contrast to the results presented here using educational attainment 
as a measure of SEP, they did not find evidence of inequalities in statin use. The differences in 
my results compared with Forde and colleagues could be the different measure of SEP used 
(income vs education) or due to cohort differences, where Forde and colleagues used an 
occupational cohort study and here, this analysis uses a population-based cohort. 
Additionally, it has been demonstrated that the QRISK score has a greater predictive power 
compared with the Framingham score (363). Therefore, these analyses may better account for 
underlying differences in cardiovascular risk. 
Currently, the QRISK3 scores captures the prevalence of key risk factors in individuals, such as 
BMI, blood pressure and smoking, but these results show that accounting for these factors 
alone is not enough to address cardiovascular inequalities. Cardiovascular risk scores may 
need to be adapted to pay greater attention to SEP; something that has been described 
previously in the literature (364-366) These risk scores should be in principle, easy to use and 
clear for clinicians, where it has previously been reported that the use of risk scores in general 
practice is a source of confusion (367).  
Despite there being almost 30 000 first instances of statin prescriptions after 1st January 2008 
(where QRISK scores were first introduced in 2007), in the primary care data linked with UK 
Biobank, there were only around 14 000 individuals with a recorded QRISK or QRISK2 scores 
in the same data. This is higher than in previous research by Finnikin and colleagues, where 
they identified using primary care records, that only 27% of patients prescribed statins had a 
recorded QRISK2 score (368). However, the lack of recorded QRISK scores, suggests the 
decision to prescribe statin treatment may be independent of an objective measure of 
cardiovascular risk, and potentially prescribed based on more subjective measures by the 
clinician or the patient. 
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In individuals with linked primary care data, 14% of eligible participants reported using statins 
to study nurses, however only 3% of participants had a linked prescription in the three months 
before and after baseline. These individuals without a linked prescription are likely a 
combination of individuals who are purchasing statins over the counter, have received a 
prescription from a private clinician, or are no longer prescribed statins. The majority (91%) of 
those without a linked prescription reported taking Simvastatin (currently the only statin 
available as an over the counter medicine). Although the reason these individuals did not have 
a prescription cannot definitively be discerned, it is possible that accessing statins through 
non-NHS GPs (i.e. through private practices) or over the counter is further contributing to 
inequalities in cardiovascular outcomes. There is, to date, little freely available data on the 
prevalence of purchasing statins over the counter, rather than via attending a primary care 
clinic. However, data used here suggests it could indeed be highly prevalent in the population. 
5.7.2 Strengths and limitations 
The major strength of this work is the large sample size and array of data available. Given the 
age range of participants (45-76 years) reported statin use is highly prevalent (10% in females 
and 17% in males). Additionally, the linked primary care data for 44% of the eligible sample 
allowed us to i) validate self-reported statin use and ii) compare different mechanisms 
through which inequalities may be arising. Where inequalities are present in primary care 
recorded QRISK scores, inequalities are unlikely to be due to health seeking behaviour and 
more likely due to factors arising within clinic settings. Conversely, where data is used from 
UK Biobank baselines assessment, inequalities may be due to either differences in health 
seeking behaviour (i.e. attending NHS health checks) or factors that arise within the 
healthcare setting. 
Lifestyle and behavioural characteristics, which are incorporated in to the QRISK3 score, are 
likely to be captured much more accurately and completely in UK Biobank compared with a 
primary care setting. However, there may be some settings where UK Biobank variables may 
have been measured differently than they would in primary care (369), such as non-fasting 
blood biomarker measurements. However, the magnitude to which these measurements differ 
is unlikely to introduce much bias to estimates of the QRISK3 score. Additionally, selection 
bias is present in UK Biobank, where participants are generally of a higher SEP and healthier 
than the general population (16). Those who are of a lower SEP in the UK Biobank potentially 
differ to those of an equivalent SEP (or level of educational attainment) in the general 
population, where UK Biobank participants may be more health conscious and health aware. 
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Therefore, it is possible that the inequalities in the wider population are greater than the 
inequalities reported here.  
Despite the large sample size and wealth of data, a number of assumptions were made when 
generating the QRISK3 scores. For example, in the QRISK3 algorithm (23), the study authors 
specify medications should be considered if the individual has two or more prescriptions for 
each class of medication (e.g. corticosteroid or atypical antipsychotic). The number of 
prescriptions was not available at baseline and therefore relied on a single self-report measure 
of medication use. Therefore, medication use may be overestimated in this sample, which 
would result in an overestimate of the QRISK3 score. Additionally, some measures, such as 
systolic blood pressure variability and coronary heart disease in a first degree relative under 
the age of 60, are not available in the UK Biobank data. Although some proxy measures were 
included which would likely capture these risk factors, this may introduce bias to the QRISK3 
estimate in UK Biobank compared with a primary care setting. 
In this analysis, primary analyses have been carried out on the multiplicative scale for 
interaction. Where there is evidence of multiplicative interaction it means the effect of the 
combined association between education and QRISK3 score on statin use is greater than the 
product of the individual associations between education and QRISK3 separately on statin use 
(370). On the additive scale for interaction, the joint effect of the two risk factors is greater 
than the sum of the individual associations. This additive scale can be considered as more 
relevant for public health interventions, where . Here, I found evidence of an interaction 
between education and QRISK3 score on statin use on both the multiplicative and additive 
scale for an interaction. In practice, this means consideration should be given to both 
education and QRISK3 score when determining whether a statin prescription should be 
administered. 
The ISCED definitions of educational attainment (years in schooling) can differ with respect to 
other measures of socioeconomic position. For example, using ISCED definitions, individuals 
who left school with a vocational qualification are given a high number of years of schooling 
(19 years) but will typically go into manual labour jobs. This is likely to explain some of the 
non-linearities in effects stratified by educational attainment.  
5.7.3 Clinical implications 
The results presented here highlight inequalities in statin use by educational attainment. 
Given the persisting inequalities in CVD, addressing the contribution of differences in statin 
prescription provides a clear policy target. The two complimentary data sources used in this 
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analysis, UK Biobank baseline data and linked primary care data, indicate two potential 
mechanisms for these inequalities. Firstly, there are likely to be differences in health seeking 
behaviour such as in attending NHS health checks as previously evidenced in the literature. 
Secondly, the inequalities present in the primary care data suggest there are important 
interactions between the healthcare practitioner and patient that result in unequal prescribing 
of statins. 
Healthcare professionals should consider potential biases in prescribing preventative 
treatments, or in carrying out risk assessments, such as calculating a QRISK score. 
Additionally, patient preference for treatment may be socially patterned (371). However, 
addressing these inequalities requires systemic change and different interventions may be 
required to address the different mechanisms of inequalities. For example, policy makers and 
healthcare professionals should consider how they can improve the uptake of NHS health 
checks, where these risk assessments are carried out, in those who are socioeconomically 
disadvantaged. 
5.7.4 Conclusions  
These analyses demonstrate that at a given level of cardiovascular risk, people with lower 
levels of educational attainment are less likely to be prescribed statins than people with higher 
educational attainment, meaning differences in statin prescribing likely contribute to 
inequalities in cardiovascular disease. Policies should consider how these inequalities can be 
minimised.
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Chapter 6. Educational attainment as an effect modifier of 
polygenic scores for cardiovascular risk factors: cross-
sectional and prospective analysis of UK Biobank 
6.1 Author list and contributions 
Alice R Carter1,2*, Sean Harrison1,2, Dipender Gill3-6, Richard Morris2,7, George Davey Smith1,2,8, 
Amy E Taylor1,2,8, Laura D Howe1,2†, Neil M Davies1,2,9† 
†LDH and NMD contributed equally 
 
ARC designed the study, cleaned and analysed the data, interpreted the results, wrote and revised 
the manuscript. SH assisted with data analysis, interpreted the results and critically reviewed and 
revised the manuscript. DG advised on defining medications, interpreted the results and critically 
reviewed and revised the manuscript. RM advised on analyses, interpreted the results and 
critically reviewed and revised the manuscript. GDS, AET, NMD and LDH all designed the study, 
interpreted the results, critically reviewed and revised the manuscript and provided supervision 
for the project. NMD and LDH contributed equally and are joint senior authors on this 
manuscript. ARC and NMD serve as guarantors of the paper. The corresponding author attests 
that all listed authors meet authorship criteria and that no others meeting the criteria have been 
omitted.  
6.2 Summary of personal contributions 
In this chapter I use data from UK Biobank baseline assessment centres and linked hospital 
inpatient records to investigate how educational attainment acts as an effect modifier of polygenic 
scores for a number of cardiovascular risk factors and outcomes. 
I was the sole lead author for the work in this chapter. I carried out all analyses following an 
analysis plan agreed upon by all co-authors and created publication quality figures. I wrote and 
revised the manuscript in according to comments from co-authors. This manuscript has not yet 
been published, nor posted to a preprint server.  





The mechanisms relating socioeconomic position to cardiovascular disease is largely unknown. 
Understanding the interplay between socioeconomic position and genetic predictors of 
cardiovascular risk in this relationship may improve our understanding of underlying pathways. 
Methods:  
In 320 120 UK Biobank participants of White British ancestry (mean age = 57, female 54%), I 
created polygenic scores for nine cardiovascular risk factors or diseases; alcohol consumption, 
body mass index (BMI), low-density lipoprotein cholesterol (LDL-C), lifetime smoking behaviour, 
systolic blood pressure, atrial fibrillation, coronary heart disease, type 2 diabetes and stroke. I 
then estimated the extent to which educational attainment modified genetic susceptibility to 
these risk factors on the observed trait.  
Results: 
On the additive scale, higher educational attainment protected against genetic susceptibility to 
higher BMI, smoking, atrial fibrillation and type 2 diabetes. However, on the same scale, higher 
educational attainment increased genetic susceptibility to higher LDL-C and higher systolic blood 
pressure. 
On the multiplicative scale, there was evidence that higher educational attainment increased 
genetic susceptibility to atrial fibrillation and coronary heart disease, but no evidence of effect 
modification was found for other traits on the multiplicative scale. 
Conclusions:  
Educational attainment modifies the genetic susceptibility to some cardiovascular risk factors and 
diseases. The direction of this effect was mixed, suggesting modification of the effect of genetic 
susceptibility to cardiovascular risk factors or cardiovascular disease by education attainment are 
unlikely to contribute to the mechanisms driving inequalities in cardiovascular risk.  
  




Cardiovascular disease (CVD) remains the leading cause of death globally (27). Although rates of 
CVD have reduced in high income countries, individuals who are more socioeconomically 
deprived remain at the greatest risk of disease (92). Although some cardiovascular outcomes are 
monogenic in risk, such as familial hypercholesterolaemia (189), most cardiovascular outcomes 
are complex multifactorial diseases with both environmental and genetic aetiology (30, 158, 372). 
Therefore, it is plausible that socioeconomic position (SEP) may interact with, or modify, genetic 
susceptibility for CVD. 
Many previous studies have studied gene*environment interactions with single genetic variants, 
known as a candidate gene approach (203, 373-376). For example, using this approach , Schmidt 
and colleagues identified an interaction between income and a genetic polymorphisms in the 
CDKN2B-AS1 increasing the risk of experiencing coronary artery calcification (373). However, 
many of these studies have failed to replicate and results have been demonstrated to be spurious 
(204). Therefore, it is important to i) carry out gene*environment interaction studies in large 
sample sizes and, where possible, with replication in multiple independent studies, and ii) 
consider a polygenic approach to gene*environment interaction.  
Using a polygenic approach, Tyrrell and colleagues demonstrated in 120 000 UK Biobank 
participants, that individuals with a higher Townsend deprivation index have an accentuated risk 
of obesity in genetically susceptible adults (377). Rask-Anderson and colleagues replicated this 
association in the second release of genetic data for UK Biobank participants (175). However, in 
the same analysis, they did not find evidence that education modified the effect of genetic BMI 
risk on observed BMI (175). Amin and colleagues found similar results for the effect of education 
on BMI susceptibility in a study using data from the UK and Finland (378). 
Whilst educational attainment and has been shown to modify the association of cardiovascular 
risk factors on CVD (92, 379) it is unclear whether educational attainment modifies the effect of 
genetic susceptibility to a wide range of cardiovascular risk factors. Understanding the gene-
environment interplay in relation to education and cardiovascular risk factors may improve our 
understanding of the mechanisms underlying educational inequalities in cardiovascular disease 
(380). Here, I ask whether educational attainment modifies the effect of polygenic susceptibility 
to multiple cardiovascular risk factors. Previous research has often framed this as a 
gene*environment interaction. I will describe the interplay between education and polygenic 
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susceptibility to CVD as effect modification, where I hypothesise that education specifically 
changes the effect of the polygenic score on the phenotype. 
6.5 Methods 
6.5.1 UK Biobank 
The UK Biobank recruited 503 317 adults from around the UK between 2006 and 2010, aged 37 to 
73 (16). Participants attended baseline assessment centres involving questionnaires, interviews, 
anthropometric, physical and genetic measurements (15, 16). In this analysis, I use up to 320 120 





UK Biobank full 
sample 
N = 503 317 
CVD at baseline 
N = 13 697 
Complete data on 
education and 
polygenic scores with 
no prevalent CVD 
 
N = 320 120 
Withdrawn N = 790 
Pregnant N = 371 
Missing genetic data N = 14 358 
Highly related N = 9 
Non-white British N = 78 674 
Recommended withdrawals N = 1 812 
Minimally related N = 79 491 
Missing exposure or outcome data 
Education = 2 723 
Polygenic scores N = 28 
Reported statins = 0 
Complete genetic data 
passing quality control 
N = 336 838 
Figure 6.1: Study flow chart of eligible participants 
Note: At each stage the same participant could have missing data for multiple variables, therefore overlap is present between the 
variables. The total excluded may be less than the sum of individuals at each stage. 
CVD = cardiovascular disease 
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6.5.2 Educational attainment 
UK Biobank participants reported highest qualification achieved at baseline assessment centres, 
which was converted to the International Standard Classification for Education (ISCED) coding of 
educational attainment (Table 6.1) (17).  
Table 6.1: International Standard for Classification of Education definition of educational attainment 




College or University degree 5 20 104 037 
NVQ or HND or HNC or equivalent 5 19 20 892 
Other prof. qual. e.g.: nursing, teaching 4 15 16 481 
A levels/AS levels or equivalent 3 13 37 235 
O levels/GCSEs or equivalent 2 10 71 424 
CSEs or equivalent 2 10 17 551 
None of the above 1 7 52 500 
Prefer not to answer Excluded 
 
6.5.3 Cardiovascular risk factors and cardiovascular disease 
Cardiovascular risk factors were included in my study if there is causal evidence from either 
Mendelian randomisation studies or randomised controlled trials that they are a causal risk factor 
for CVD, and suitable genome wide association study (GWAS) summary statistics available. 
Additionally, I included a number of cardiovascular diseases for which PGS are available. In total, 
9 risk factors or diseases were included in my analyses; 6 risk factors (alcohol consumption (41), 
body mass index (BMI), diabetes (type 2) (381), low density lipoprotein cholesterol (LDL-C) (382), 
lifetime smoking behaviour (287, 383), systolic blood pressure (384)) and three diseases (atrial 
fibrillation, coronary heart disease (CHD) and stroke). Cardiovascular risk factors were measured 
at baseline assessment centres, whilst incident cases of cardiovascular diseases were determined 
by linked hospital episode statistics (HES) and Scottish Morbidity records (SMR) (referred to as 
hospital inpatient records) (see Table 6.2). 
Table 6.2: International Classification for Disease codes used in cardiovascular case definition 
Diagnosis ICD9 ICD10 
Atrial Fibrillation 42731 I48 
Coronary heart disease 4100 - 4149 I20-I25 
Stroke 4300 - 4389 I6, G45 
Type 2 diabetes 4359 G45 
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6.5.3.1 Alcohol consumption 
Alcohol consumption was defined as the number of drinks consumed per week. At baseline 
assessment centres, participants were asked to described current drinking status (current, former 
or never) and estimate their current alcohol intake. Of those reporting a current frequency of at 
least once or twice a week, they were asked to estimate their current average weekly intake of 
different alcohol beverages. These were summed together to estimate an average number of 
drinks per week. Never drinkers and individuals reporting a current intake of “one to three times 
a month” or less frequently, were assumed to have a weekly intake of 0. This variable has been 
described in detail previously (385). 
Summary statistics from the GWAS and Sequencing Consortium of Alcohol and Nicotine use 
(GSCAN) GWAS of drinks per week were used for the PGS (386). This GWAS included 
predominantly European participants, excluding participants from UK Biobank to avoid 
overlapping samples for the discovery and analysis dataset, which can lead to inflated effect 
estimates. 
6.5.3.2 BMI 
Baseline measures of height and weight were used to calculate BMI (kg/m2).  
Summary statistics for use in the PGS for BMI came from the Genetic Investigation of 
Anthropometric Traits (GIANT) Consortium GWAS analysis of 339 224 individuals with European 
ancestry (290). This is the most recent GWAS of BMI not including UK Biobank, to avoid sample 
overlap.  
6.5.3.3 Low density lipoprotein cholesterol 
Non-fasting measures of LDL-C were measured using enzymatic assays (Backman Coulter 
AU5800). UK Biobank corrected serum data for laboratory dilution effects and were excluded if 
they did not pass UK Biobank quality control (351). 
Summary statistics for use in the PGS came from the Global Lipids Genetics consortium, which 
included 188 577 males and females of predominantly European ancestry (291).  
6.5.3.4 Smoking 
A measure of lifetime smoking was constructed in the UK Biobank from self-reported age at 
initiation, age at cessation and cigarettes per day. From this information, smoking duration and 
time since cessation were calculated. The lifetime smoking measure further includes a simulated 
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constant (half-life) which captures the exponentially decreasing effect of cigarettes on health over 
time. Aspects of smoking behaviour were combined into one score ranging from 0 (for non-
smokers) to 4.00 (mean = 0.33, standard deviation = 0.67). Full details of score construction can 
be found elsewhere (320). The main advantage of using this measure of smoking is that it is a 
continuous measure, improving statistical power, and it considers all aspects of smoking which 
may affect health, e.g. duration of smoking and smoking heaviness. 
I carried out a split sample GWAS of lifetime smoking in UK Biobank to identify genetic variants 
associated with lifetime smoking to use in a PGS. I included 318 147 participants with White 
British ancestry, who were randomly assigned to one of two samples. In each half of the eligible 
participants, the GWAS was conducted, which was used to derive the PGS in the opposing sample 
so as to avoid sample overlap which can inflate genetic estimates. This split sample GWAS of 
lifetime smoking has previously been used in a PGS and described in detail (287). The estimates 
from each sample were meta-analysed using the metan command to create a single estimate 
(387). 
6.5.3.5 Systolic blood pressure 
The mean from two resting automated measures of systolic blood pressure, measured using an 
Omron HEM-7105IT digital blood pressure monitor at baseline assessment centres was used for 
phenotypic measurements.  
I carried out a split sample GWAS of systolic blood pressure in UK Biobank to identify genetic 
variants for use in the PGS. For individuals who reported taking antihypertensive medication to 
UK Biobank study nurses, I added 10mm Hg to the phenotypic measurement of systolic blood 
pressure (314). This GWAS was conducted as described previously for smoking and has been 
described in detail previously (287). The estimates from each sample were meta-analysed to 
create a single estimate of effect modification for systolic blood pressure. 
6.5.3.6 Atrial Fibrillation 
Atrial fibrillation events were ascertained through linkage to mortality data and hospital inpatient 
records, with cases defined according to ICD-9 and ICD-10 codes (see Table 6.2 for ICD codes 
used in case definition). Date of diagnoses are provided by hospital inpatient records, which was 
linked with the date of assessment centre provided by UK Biobank to identify incident and 
prevalent cases.  
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Summary statistics for use in the PGS were from a 2012 GWAS of 59 133 individuals (6 707 cases) 
of European ancestry (388). 
6.5.3.7 Coronary heart disease 
Coronary heart disease (CHD) events were ascertained through linkage to mortality data and 
hospital inpatient records, with cases defined according to ICD-9 and ICD-10 codes (see Table 6.2 
for ICD codes used in case definition) (292). Date of diagnoses are provided by hospital inpatient 
records, which was linked with the date of assessment centre provided by UK Biobank to identify 
incident and prevalent cases.  
Summary statistics from the most recent GWAS for CHD not including UK Biobank were used for 
deriving the PGS (322). A total of 184 305 individuals (60 801 cases) were included in this GWAS of 
predominantly European descent.  
6.5.3.8 Diabetes 
Type 2 diabetes was ascertained by linkage to hospital inpatient records (see Table 6.2), with date 
of diagnosis defined by hospital inpatient records. Additionally, individuals were defined as 
diabetic if they had reported to UK Biobank study nurses that they had ever had diabetes 
diagnosed by a doctor (variable 2443). This variable does not distinguish between type 1 and type 
2 diabetes, however individuals with a hospital inpatient recordsfor type 1 diabetes were excluded 
from analyses and in this adult population new diagnoses are more likely to be type 2 diabetes. 
Individuals were defined as a prevalent case if they reported a diagnosis at baseline assessment 
centres (variable n_2443_0_0). Incident cases were defined as those who reported a diagnosis at 
follow up clinics (variable n_2443_1_0 and variable n_2443_2_0), with no previous diagnosis 
reported (although only a subset of individuals have follow up measures).  
Summary statistics of 158 808 European individuals (26 276 Cases) from the DIAbetes Genetics 
Replication And Meta-analysis (DIAGRAM) Consortium GWAS of type 2 diabetes were used for 
the PGS (389). 
6.5.3.9 Stroke 
Stroke events (all subtypes) were ascertained through linkage to mortality data and hospital 
inpatient records, with cases defined according to ICD-9 and ICD-10 codes (see Table 6.2) (292). 
Date of diagnoses are provided by hospital inpatient records, which was linked with the date of 
assessment centre provided by UK Biobank to identify incident and prevalent cases.  
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For the PGS, summary statistics for all subtypes of stroke were obtained from the MEGASTROKE 
consortium, consisting of 521 612 males and females (67 162 cases) of predominantly European 
ancestry (390).  
6.5.4 Deriving polygenic scores 
Summary statistics for single nucleotide polymorphisms (SNPs) associated with each 
cardiovascular trait were downloaded from each of the relevant GWAS. Relevant GWAS were the 
most recent GWAS for each specified trait excluding UK Biobank participants to avoid bias by 
sample overlap. The 1000 genomes project was used to find proxy SNPs in LD with SNPs not 
found in UK Biobank. Pruning of SNPs was carried out using the clump command in PLINK using 
an r2 parameter of 0.25 and a physical distance threshold for clumping of 500kB. The pruned SNPs 
from each GWAS were harmonised with the SNPs from UK Biobank, aligning the effect estimates 
and alleles. Any SNPs that could not be harmonised, palindromic SNPs or triallelic SNPs were 
excluded from PGSs. The PGSs were created by multiplying the number of effect alleles for each 
participant in UK Biobank by the effect estimate of the SNP from summary statistics from each 
GWAS, then summing across all SNPs associated with each trait. For continuous traits, the PGSs 
represent a unit increase and for binary traits they represent a log odds ratio increase. All PGSs 
were standardized for use in analyses so that coefficients reflect a one standard deviation (SD) 
change. 
Polygenic scores were constructed using a range of p-value thresholds p≤5×10-8 (genome-wide 
significant), 0.05, and 0.5). As the p-value threshold increases, the variance explained by the PGS 
typically increases. However, increasing the numbers of SNPs increases the risk of pleiotropy and 
false positive effects. Main analyses are presented using PGSs derived at the genome-wide 
significance threshold with other PGSs presented in the supplement. See Appendix 4 Table 1 to 
Appendix 4 Table 11 for SNPs included in PGSs at the genome-wide significance level. 
6.5.5 Exclusion criteria 
As studies of effect modification can be biased by reverse causality, individuals who had 
experienced a cardiovascular event prior to baseline were excluded from analyses. These 
diagnoses and events were ascertained through linkage to mortality data and hospital inpatient 
records, with cases defined according to ICD-9 and ICD-10 codes (Table 6.3). Individuals were 
excluded if they had experienced at least one diagnosis of any of the outcomes considered in 
analyses (atrial fibrillation, CHD, stroke and type 2 diabetes) or any one of myocardial infarction, 
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angina, stroke, transient ischaemic attack, peripheral arterial disease or familial 
hypercholesterolaemia. Exclusions were also made for prevalent cases of type 1 diabetes and 
chronic kidney disease, which can result in statins being prescribed to prevent cardiovascular 
diseases (26) and therefore may affect behaviours and subsequently the observed effect 
modification. The date for each diagnosis is provided by hospital inpatient records, which was 
linked with the date of assessment centre visit provided by UK Biobank to determine prevalent 
cases of disease. 
Table 6.3: International classification for disease codes used for cardiovascular exclusions 
Cardiovascular event ICD9 ICD10 
Myocardial infarction 4100-4109, 4120-4129 I21, I22 
Angina 4139 I20 
Transient ischaemic attack 4359 G45 
Peripheral arterial disease 4439 I73.9 
Stroke 4349 I6, G45 
Type 1 diabetes 
2500- 25011, 25013, 2504-
25041, 25043, 2505-25051, 




Chronic kidney disease 5383, 5384, 5385 N183, N184, N185 
Familial 
hypercholesterolaemia 2720 I78.0 
 
Quality control of the genetic data was carried out according to the MRC Integrative 
Epidemiology Unit quality control pipeline, described in full previously (391). In brief, individuals 
were excluded if their genetic sex differed to their gender reported at the assessment centre or for 
having aneuploidy of their sex chromosomes (non-XX or -XY chromosomes). Further individuals 
were excluded for extreme heterozygosity or any missing genetic data. Related individuals were 
excluded based on an in-house algorithm removing those related (3rd degree or closer) to the 
greatest number of other participants, until no related pairs were left (391). This exclusion list was 
derived in-house using an algorithm applied to the list of all the related pairs provided by UK 
Biobank (3rd degree or closer) (Figure 6.1). In addition, individuals were excluded if they had 
withdrawn from UK Biobank or were, or may be, pregnant. 
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Additionally, individuals were excluded if there were any missing data for education, age and sex. 
Individuals were excluded from specific analyses if they were missing phenotypic measurements 
of the trait under consideration (see Figure 6.1).  
6.5.6 Statistical Analysis 
6.5.6.1 Association of educational attainment with outcomes 
Multivariable linear regression (adjusting for age and sex) was carried out to estimate the 
association between educational attainment and cardiovascular risk factors. 
6.5.6.2 Association between each polygenic score and observed phenotype 
For each of the cardiovascular risk factors or diseases, we estimated the association between each 
polygenic score and the phenotypic measure of the risk factor or outcome using multivariable 
linear regression. Analyses were adjusted for age, sex, educational attainment and 40 genetic 
principal components to control for population structure. For continuous cardiovascular risk 
factor, measures were standardised, so estimates reflect the mean difference in SD of the 
phenotype for a one SD higher polygenic score. For binary outcomes, estimates reflect the risk 
difference or log odds ratio of outcome for a one SD higher polygenic score. 
6.5.6.3 Effect modification by educational attainment on polygenic scores for 
cardiovascular risk 
To test for effect modification, the linear model was stratified by years of educational attainment. 
To estimate the magnitude and direction of the effect modification, an interaction term was 
included in the linear model (e.g, polygenic score*education [continuous]). Analyses were 
adjusted for age, sex and 40 genetic principal components. Continuous phenotypic measures were 
used to limit spurious results, where categorical variables can lead to inflations in the gene-
exposure estimates (377). Tests of effect modification were carried out on both the additive and 
multiplicative scale (370).  
6.5.7 Secondary Analyses 
All analyses were replicated for polygenic scores at P value thresholds of 0.05 and 0.5.   
6.5.8 Data and code availability 
The data used in this study has been archived with the UK Biobank study. The analysis code used 
is available at github.com/alicerosecarter/gxe_cv_riskfactors. 




6.6.1 UK Biobank cohort 
Eligible UK Biobank participants (55% female) had a mean age of 57 (standard deviation [SD] = 
8.00). A higher proportion of participants (33%) left school after 20 years (equivalent to obtaining 
a degree), compared with those who left school after 7 years (equivalent to no formal 
qualifications) (16%) (Table 6.4). 
For a P value of <5x10-8, the PGSs explained between 0.06% (atrial fibrillation) and 14% (systolic 
blood pressure) of variance in the phenotypes (Table 6.5). 
Table 6.4: Descriptive characteristics of the main analysis sample compared with all individuals in UK Biobank at baseline 
Variable 
Analysis sample Full UK Biobank* 
(N = 320 120) (N = 502 156) 
Continuous variables N Mean (SD) N Mean (SD) 
Age 320 120 56.66 (8.00) 502 156 56.54 (8.09) 
 
Drinks per week 318 300 8.17 (9.05) 497 917 7.79 (9.05) 
 
BMI 319 201 27.3 (4.72) 499 065 27.43 (4.8) 
 
LDL-C 304 700 3.61 (0.86) 468 390 3.56 (0.87) 
 
Systolic blood pressure 292 277 138.16 (18.58) 456 647 137.79 (18.62) 
 
Smoking (lifetime behaviour) 301 684 0.32 (0.66) 318 112 0.34 (0.67) 
 
Categorical variables N Frequency (%) N Frequency (%) 
Sex Female 320 120 175 108 (55) 502 156 273 025 (54) 
 






10 years 54899 (17) 82357 (17) 
13 years 17355 (5) 26857 (5) 
15 years 39144 (12) 58271 (12) 
19 years 51418 (16) 77668 (16) 
20 years 105292 (33) 163232 (33) 
 






Case 9560 (3) 15765 (3) 
 






Case 14481 (5) 22844 (5) 
 














Case 5929 (2) 10067 (2) 
*Excluding withdrawn participants; BMI = body mass index; LDL-C = low-density lipoprotein cholesterol  
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Table 6.5: Number of single nucleotide polymorphisms (SNPs) and variance explained (R
2
) by polygenic scores for 
cardiovascular risk factors and outcomes 
 
P=5x10-8 P=0.05 P=0.5 
NSNPs R2 NSNPs R2 NSNPs R2 
Alcohol (drinks per 
week) 14 0.0840 72 962 0.0857 449 080 0.0857 




398 0.0540 23 724 0.0144 13 337 0.0136 
Systolic blood 
pressure (sample 1 
GWAS) 
126 0.1407 77 709 0.1579 373 402 0.1574 
Systolic blood 
pressure (sample 2 
GWAS) 
112 0.1426 76 557 0.1633 372 715 0.1606 
Smoking (sample 1 
GWAS) 23 0.0097 67 741 0.0200 391 104 0.0206 
Smoking (sample 2 
GWAS) 21 0.0113 66 909 0.0222 390 557 0.0223 
Atrial fibrillation 3431 0.0061 60 738 0.0655 361 969 0.1064 
Coronary heart 
disease 75 0.0654 49 098 0.0661 345 040 0.0656 
Type 2 diabetes 18 0.0411 5 137 0.0366 134 673 0.0350 
Stroke 11 0.0474 63 025 0.0480 373 240 0.0472 
 
6.6.2 Association between educational attainment and cardiovascular risk factors 
use 
Educational attainment was associated with all cardiovascular risk factors, except for LDL-C 
(Table 6.6). For all risk factors, except for higher alcohol consumption, higher educational 
attainment led to a reduction in the mean difference of the trait (Table 6.6).  
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Table 6.6: Association between educational attainment and observed phenotypic trait adjusted for age and sex 
Trait 
Mean difference in SD of 
phenotypic trait per unit increase 
in education (95% CI) 
Alcohol 0.01 (0.01, 0.01) 
BMI -0.02 (-0.02, -0.02) 
Low density lipoprotein cholesterol 5.1x10-4 (-2.0x10-4, 1.2x10-3) 
Smoking (lifetime behaviour) -0.03 (-0.03, -0.03) 
Systolic blood pressure -0.01 (-0.01, -0.01) 
 
Risk difference of outcome per 
unit increase in education (95% 
CI) 
Atrial fibrillation -5.1x10-4 (-6.3x10-4, -3.9x10-4) 
Coronary artery disease -1.6x10-3 (-1.7x10-3, -1.5x10-3) 
Diabetes (type 2) -1.7x10-3 (-1.8x10-3, -1.6x10-3) 
Stroke -5.7x10-4 (-6.6x10-4, -4.7x10-4) 
 
6.6.3 Effect modification by educational attainment on genetic susceptibility to 
cardiovascular risk factors 
For most polygenic scores, there was evidence that educational attainment modified the effect of 
the polygenic score on either the additive or multiplicative scale. There was little evidence that 
educational attainment modified genetic susceptibility to alcohol consumption on either scale 
(Figure 6.1-Figure 6.4 and Table 6.7 and Table 6.8). 
On the additive scale, higher educational attainment protected against genetic susceptibility to 
higher BMI, smoking, atrial fibrillation and type 2 diabetes (Figure 6.2 and Figure 6.3 and Table 
6.7). For example, a one SD increase in polygenic score for smoking increased mean difference in 
lifetime smoking by 0.05 SD (95% CI: 0.04 to 0.06) for those with 7 years education and by 0.03 
SD (95% CI: 0.02 to 0.03) for 20 years of education (Figure 6.2 and Figure 6.3 and Table 6.7) (Peffect 
modification = 0.001).  
On the same scale, higher educational attainment increased genetic susceptibility to LDL-C and 
systolic blood pressure. For example, for those with 7 years of education an increase of one SD in 
the polygenic score for LDL-C increased mean phenotypic LDL-C by 0.19 SD (95% CI: 0.18 to 0.19). 
However, for those with 20 years of education, mean LDL-C increased by 0.22 SD (95% CI: 0.22 to 
0.23) (Peffect modification = 1.12x10
-4) per SD increase in polygenic score (Figure 6.3 and Table 6.7).  
   
 
 182 
On the multiplicative scale, there was evidence that higher educational attainment increased 
genetic susceptibility to atrial fibrillation and CHD. For example, for a one SD increase in atrial 
fibrillation polygenic score, the odds ratio for atrial fibrillation in individuals with 7 years of 
education was 1.59 (95% CI: 1.45 to 1.57) and for 20 years of educational attainment the odds ratio 
was 1.65 (95% CI: 1.59 to 1.71) (Peffect modification = 9.03x10
-8) (Figure 6.2 and Figure 6.4 and Table 6.8). 
There was little evidence of a effect modification by education on the multiplicative scale for all 
other PGSs.  
For all outcomes, the size of the coefficient for effect modification small. Where outcomes were 
binary, the coefficient was larger on the multiplicative scale, compared with the additive scale. 
However, for continuous outcomes, the coefficient was larger on the additive scale. For all 
outcomes, estimates on the multiplicative scale had greater uncertainty (Figure 6.2). 
Non-linear effects by strata of educational attainment were observed (Figure 6.3 and Figure 6.4). 
For example, considering the additive scale between BMI PGS and educational attainment, a one 
SD increase in PGS increased mean difference in BMI by 0.13 SD (95% CI: 0.12 to 0.14) for people 
with 7 years education, 0.13 SD (95% CI: 0.12 to 0.14) for 10 years education, 0.14 SD (95% CI: 0.13 
to 0.14) for 19 years education and by 0.12 SD (95% CI: 0.11 to 0.12) for 20 years of education 
(Figure 6.3 and Table 6.7) (Peffect modification = 0.036).   





Figure 6.2: Coefficient for educational attainment as an effect modifier of polygenic susceptibility to cardiovascular risk 
factors or diseases on the additive and multiplicative scale 
Analyses adjusted for age, sex and 40 genetic principal components 
Alcohol = drinks per weekly BMI = body mass index; LDL-C = Low density lipoprotein cholesterol; smoking = lifetime smoking 
behaviour; SBP = systolic blood pressure; AF = Atrial fibrillation; CHD = Coronary heart disease; T2D = Type 2 diabetes 
Note: coefficients for binary outcomes are on the log odds scale, rather than exponentiated odds ratio scale as in following 
figures to allow for direct comparisons in the direction of effect modification between the additive and multiplicative scales 




Figure 6.3: Association between polygenic scores for susceptibility to cardiovascular risk and phenotypic measure of each risk 
factor, stratified by educational attainment demonstrating effect modification on the additive scale 
Analyses adjusted for age, sex and 40 genetic principal components 
Alcohol (drinks per week) PEM = 0.384; body mass index (BMI) PEM = 0.036; low-density lipoprotein cholesterol (LDL-C) PEM = 
1.12x10
-4
; lifetime smoking behaviour PEM = 0.001; systolic blood pressure (SBP) PEM = 0.104 
Atrial fibrillation (AF) PEM = 9.03x10
-8
; coronary heart disease (CHD) PEM = 0.103; type 2 diabetes (T2D) PEM = 3.23x10
-10
; stroke 
PEM = 0.036 




Figure 6.4: Association between polygenic scores for susceptibility to cardiovascular risk and phenotypic measure of each risk 
factor, stratified by educational attainment demonstrating effect modification on the multiplicative scale 
Analyses adjusted for age, sex and 40 genetic principal components 
Alcohol (drinks per week) PEM = 0.976; body mass index (BMI) PEM = 0.330; low-density lipoprotein cholesterol (LDL-C) PEM = 
1.63x10
-6
; lifetime smoking behaviour PEM = 0.008; systolic blood pressure (SBP) PEM = 0.076 
Atrial fibrillation (AF) PEM = 0.008; coronary heart disease (CHD) PEM = 8.94x10
-4




   
 
 186 
Table 6.7:  Association between polygenic scores for susceptibility to continuous cardiovascular risk factors and phenotypic measure of each 
risk factor, stratified by educational attainment demonstrating effect modification 
Trait Years of education N 
Additive scale Multiplicative scale 
Mean difference in SD of 
phenotypic trait (95% CI) 
P value for 
effect 
modification 
Mean difference in SD of log 
phenotypic trait (95% CI) 




All 318 300 0.05 (0.04, 0.05)  0.05 (0.05, 0.05)  
Education 7 51 509 0.04 (0.03, 0.05) 
0.384 
0.04 (0.03, 0.05) 
0.976 
Education 10 54 567 0.05 (0.04, 0.06) 0.06 (0.05, 0.07) 
Education 13 17 267 0.04 (0.03, 0.06) 0.05 (0.04, 0.07) 
Education 15 38 974 0.05 (0.04, 0.06) 0.06 (0.05, 0.07) 
Education 19 51 095 0.05 (0.04, 0.06) 0.05 (0.04, 0.06) 
Education 20 104 888 0.04 (0.04, 0.05) 0.05 (0.04, 0.05) 
Effect modification beta 2.93x10-4 (-3.66x10-4, 9.51x10-4) 9.96x10-4 (-6.51x10-4, 6.71x10-4) 
BMI 
All 319 201 0.13 (0.12, 0.13)  0.13 (0.12, 0.13)  
Education 7 51 773 0.13 (0.12, 0.14) 
0.036 
0.13 (0.12, 0.14) 
0.330 
Education 10 54 739 0.13 (0.12, 0.14) 0.13 (0.12, 0.14) 
Education 13 17 319 0.13 (0.12, 0.15) 0.13 (0.12, 0.15) 
Education 15 39 041 0.13 (0.12, 0.14) 0.13 (0.12, 0.14) 
Education 19 51 309 0.14 (0.13, 0.14) 0.13 (0.13, 0.14) 
Education 20 105 020 0.12 (0.11, 0.12) 0.12 (0.11, 0.13) 




All 304 700 0.21 (0.21, 0.21)  0.21 (0.21, 0.21)  
Education 7 49 435 0.19 (0.18, 0.19) 
1.12x10-4 
0.18 (0.17, 0.19) 
1.63x10-6 
Education 10 52 311 0.22 (0.21, 0.23) 0.22 (0.21, 0.22) 
Education 13 16 521 0.22 (0.21, 0.24) 0.22 (0.21, 0.24) 
Education 15 37 257 0.21 (0.2, 0.22) 0.21 (0.2, 0.22) 
Education 19 48 942 0.21 (0.2, 0.21) 0.2 (0.2, 0.21) 
Education 20 100 234 0.22 (0.22, 0.23) 0.22 (0.21, 0.23) 




All 301 684 0.04 (0.04, 0.04)  0.04 (0.04, 0.04)  
Education 7 48 470 0.05 (0.04, 0.06) 
0.001 
0.05 (0.04, 0.06) 
0.008 
Education 10 52 292 0.03 (0.03, 0.04) 0.04 (0.03, 0.04) 
Education 13 16 261 0.03 (0.01, 0.04) 0.03 (0.01, 0.04) 
Education 15 37 149 0.05 (0.04, 0.06) 0.05 (0.04, 0.06) 
Education 19 48 639 0.04 (0.03, 0.05) 0.04 (0.03, 0.05) 
Education 20 98 873 0.03 (0.02, 0.03) 0.03 (0.02, 0.03) 




All 292 277 0.09 (0.09, 0.09)  0.07 (0.07, 0.07)  
Education 7 46 726 0.08 (0.07, 0.09) 
0.104 
0.06 (0.05, 0.07) 
0.076 
Education 10 50 789 0.09 (0.08, 0.1) 0.07 (0.06, 0.08) 
Education 13 15 772 0.09 (0.08, 0.11) 0.08 (0.06, 0.1) 
Education 15 36 033 0.1 (0.09, 0.11) 0.08 (0.07, 0.09) 
Education 19 47 177 0.09 (0.08, 0.1) 0.07 (0.06, 0.08) 
Education 20 95 780 0.09 (0.08, 0.1) 0.07 (0.07, 0.08) 
Effect modification beta 6.97x10-4 (1.03x10-5, 1.38x10-3) 6.74x10-4 (-7.03x10-5, 1.42x10-3) 
   
 
 187 
Table 6.8: Association between polygenic scores for susceptibility to cardiovascular risk factors and diseases and phenotypic measure of each 
risk factor or disease, stratified by educational attainment demonstrating effect modification 
Trait Years of education N 
N 
cases 
Additive scale Multiplicative scale 
Risk difference (95% 
CI) 
P value for 
effect 
modification 
OR (95% CI) 





All 316 912 9 560 0.0137 (0.0131, 0.0143)  1.59 (1.55, 1.62)  
Education 7 51 246 2 438 0.0188 (0.017, 0.0206) 
9.03x10-08 
1.51 (1.45, 1.57) 
0.008 
Education 10 54 460 1 466 0.0123 (0.0109, 0.0136) 1.59 (1.51, 1.67) 
Education 13 17 213 446 0.0126 (0.0102, 0.015) 1.66 (1.51, 1.82) 
Education 15 38 694 1 232 0.0147 (0.0129, 0.0164) 1.60 (1.51, 1.69) 
Education 19 50 942 1 396 0.0125 (0.0111, 0.0139) 1.58 (1.5, 1.67) 
Education 20 104 357 2 582 0.0123 (0.0113, 0.0132) 1.65 (1.59, 1.71) 
Effect modification beta 
-3.20x10-4 (-4.30x10-4, -
2.00x10-4) 





All 317 055 14 481 0.0085 (0.0077, 0.0092)  1.22 (1.2, 1.24)  
Education 7 51 061 3 989 0.0115 (0.0091, 0.0138) 
0.103 
1.18 (1.14, 1.21) 
0.001 
Education 10 54 483 2 292 0.0079 (0.0062, 0.0095) 1.22 (1.17, 1.28) 
Education 13 17 220 581 0.0053 (0.0027, 0.008) 1.18 (1.09, 1.28) 
Education 15 38 740 1 733 0.0073 (0.0053, 0.0094) 1.19 (1.14, 1.25) 
Education 19 50 912 2 477 0.0087 (0.0069, 0.0106) 1.22 (1.17, 1.27) 
Education 20 104 639 3 409 0.0082 (0.0071, 0.0092) 1.30 (1.26, 1.35) 
Effect modification beta 
-1.20x10-4 (-2.60x10-4,  
2.39x10-5) 




All 316 406 11 079 0.0081 (0.0074, 0.0087)  1.27 (1.24, 1.29)  
Education 7 50 904 3 175 0.0131 (0.011, 0.0152) 
3.23x10-10 
1.25 (1.2, 1.29) 
0.537 
Education 10 54 261 1 809 0.0088 (0.0073, 0.0103) 1.31 (1.25, 1.37) 
Education 13 17 190 512 0.0062 (0.0037, 0.0087) 1.23 (1.13, 1.35) 
Education 15 38 683 1 336 0.0074 (0.0056, 0.0092) 1.24 (1.18, 1.31) 
Education 19 50 814 1 914 0.0087 (0.007, 0.0103) 1.26 (1.21, 1.32) 
Education 20 104 554 2 333 0.0057 (0.0048, 0.0066) 1.29 (1.24, 1.35) 
Effect modification beta 
-4.00x10-4 (-5.30x10-4, -
2.80x10-4) 
1.00 (1.00, 1.00) 
 
Stroke 
NONE 320 120 5 929 0.0009 (0.0005, 0.0014)  1.05 (1.03, 1.08)  
Education 7 52 012 1 620 0.002 (0.0005, 0.0035) 
0.036 
1.07 (1.02, 1.12) 
0.292 
Education 10 54 899 948 0.0007 (-0.0004, 0.0018) 1.04 (0.98, 1.11) 
Education 13 17 355 311 0.0026 (0.0006, 0.0045) 1.16 (1.03, 1.29) 
Education 15 39 144 731 0.0009 (-0.0005, 0.0022) 1.05 (0.97, 1.13) 
Education 19 51 418 874 0.0016 (0.0005, 0.0027) 1.10 (1.03, 1.17) 
Education 20 105 292 1 445 
-4.83x10-5 (-0.0007, 
0.0007) 
1.00 (0.95, 1.05) 
Effect modification beta 
-9.80x10-5 (-1.90x10-4,  
-6.40x10-6) 
1.00 (0.99, 1.00) 
OR = odds ratio; SD = standard deviation; CI= confidence interval
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6.6.4 Secondary analyses 
Analyses using more liberal P-value thresholds to generate the PGS were broadly consistent with 
the main genome-wide results. Similar directions of effect and magnitudes of effect modification 
were observed, for example on the additive scale higher educational attainment protected against 
genetic susceptibility to BMI and lifetime smoking behaviour at the P-value threshold P=0.05. 
However, at the P=0.5 threshold, there was no longer evidence of an effect modification by 
education with BMI. Consistent with results using the genome-wide significant PGS, genetic 
susceptibility to LDL-C and systolic blood pressure were increased for PGSs derived using both 
the P-value threshold P=0.05 and P=0.5 (Table 6.9). Similar associations were observed for atrial 
fibrillation and coronary heart disease where a one unit increase in educational attainment 
increased susceptibility to these traits (Table 6.9). 
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Table 6.9: Education as an effect modifier of genetic susceptibility to cardiovascular risk factor on observed phenotypic cardiovascular risk factor for continuous traits (per SD), on the 
additive scale using polygenic scores at a range of P value thresholds 
Exposure Educational attainment N 
P=0.05 P=0.5 
Additive scale Multiplicative scale Additive scale Multiplicative scale 
Mean difference in SD 
of phenotypic trait 
(95%CI) 
P value 
Mean difference in 
SD of log phenotypic 
trait (95%CI) 
P value  
Mean difference in SD 
of phenotypic trait 
(95%CI) 
P value  
Mean difference in 
SD of log phenotypic 
trait (95%CI) 
P value  
Alcohol 
All years 318,300 0.08 (0.07, 0.08)  0.06 (0.06, 0.07)  0.08 (0.07, 0.08)  0.07 (0.06, 0.07)  
Education 7 51,509 0.08 (0.06, 0.09) 
0.694 
 
0.06 (0.05, 0.07) 
0.108  
0.06 (0.05, 0.07) 
0.669  
0.06 (0.06, 0.07) 
0.04 
 
Education 10 54,567 0.07 (0.06, 0.08) 0.07 (0.06, 0.08) 0.07 (0.06, 0.08) 0.07 (0.06, 0.08) 
Education 13 17,267 0.08 (0.06, 0.09) 0.08 (0.06, 0.09) 0.07 (0.06, 0.09) 0.07 (0.06, 0.09) 
Education 15 38,974 0.06 (0.05, 0.07) 0.06 (0.06, 0.07) 0.07 (0.06, 0.08) 0.07 (0.06, 0.08) 
Education 19 51,095 0.06 (0.05, 0.06) 0.06 (0.05, 0.07) 0.06 (0.05, 0.07) 0.06 (0.05, 0.07) 
Education 20 104,888 0.06 (0.06, 0.07) 0.06 (0.05, 0.07) 0.06 (0.06, 0.07) 0.06 (0.05, 0.06) 











All years 319,201 0.23 (0.23, 0.23)  0.23 (0.23, 0.23)  0.23 (0.23, 0.24)  0.24 (0.23, 0.24)  
Education 7 51,773 0.22 (0.22, 0.23) 
0.005 
 
0.22 (0.21, 0.23) 
0.453  
0.23 (0.22, 0.24) 
0.215  
0.22 (0.22, 0.23) 
0.396 
 
Education 10 54,739 0.24 (0.23, 0.25) 0.24 (0.23, 0.25) 0.24 (0.23, 0.25) 0.24 (0.23, 0.25) 
Education 13 17,319 0.24 (0.22, 0.25) 0.24 (0.22, 0.25) 0.25 (0.23, 0.26) 0.25 (0.23, 0.26) 
Education 15 39,041 0.23 (0.22, 0.24) 0.24 (0.23, 0.24) 0.23 (0.23, 0.24) 0.24 (0.23, 0.25) 
Education 19 51,309 0.23 (0.23, 0.24) 0.23 (0.22, 0.24) 0.24 (0.23, 0.25) 0.24 (0.23, 0.25) 
Education 20 105,020 0.21 (0.2, 0.22) 0.22 (0.21, 0.22) 0.22 (0.22, 0.23) 0.23 (0.22, 0.23) 
Effect modification beta 




-4.17x10-4 (-1.07x10-3,  
2.42x10-4) 






All years 304,700 0.07 (0.07, 0.07)  0.07 (0.07, 0.07)  0.07 (0.06, 0.07)  0.06 (0.06, 0.07)  
Education 7 49,435 0.06 (0.05, 0.07) 
0.148 
 
0.06 (0.05, 0.07) 
0.056  
0.05 (0.04, 0.06) 
0.072  
0.05 (0.04, 0.06) 
0.033 
 
Education 10 52,311 0.08 (0.07, 0.09) 0.08 (0.07, 0.09) 0.07 (0.06, 0.08) 0.07 (0.06, 0.08) 
Education 13 16,521 0.07 (0.05, 0.08) 0.07 (0.05, 0.08) 0.07 (0.05, 0.08) 0.06 (0.05, 0.08) 
Education 15 37,257 0.07 (0.06, 0.08) 0.07 (0.06, 0.08) 0.06 (0.05, 0.07) 0.05 (0.04, 0.06) 
Education 19 48,942 0.07 (0.06, 0.08) 0.07 (0.06, 0.08) 0.07 (0.06, 0.08) 0.06 (0.06, 0.07) 
Education 20 100,234 0.08 (0.07, 0.08) 0.07 (0.07, 0.08) 0.07 (0.06, 0.08) 0.07 (0.06, 0.07) 
















All years 301,684 0.13 (0.13, 0.14)  0.13 (0.13, 0.14)  0.15 (0.14, 0.15)  0.15 (0.15, 0.16)  
Education 7 48,470 0.18 (0.17, 0.2) 
2.16x10-52 
 
0.18 (0.16, 0.19) 
6.10x10-40  
0.2 (0.18, 0.21) 
8.85x10-
50  
0.19 (0.18, 0.21) 
9.83x10-38 
 
Education 10 52,292 0.14 (0.12, 0.15) 0.14 (0.13, 0.15) 0.16 (0.14, 0.17) 0.16 (0.14, 0.17) 
Education 13 16,261 0.11 (0.1, 0.13) 0.12 (0.1, 0.14) 0.13 (0.11, 0.15) 0.13 (0.11, 0.15) 
Education 15 37,149 0.12 (0.11, 0.13) 0.12 (0.11, 0.13) 0.14 (0.12, 0.15) 0.14 (0.12, 0.15) 
Education 19 48,639 0.14 (0.13, 0.15) 0.14 (0.13, 0.15) 0.16 (0.15, 0.18) 0.17 (0.15, 0.18) 
Education 20 98,873 0.09 (0.08, 0.1) 0.1 (0.09, 0.1) 0.10 (0.09, 0.11) 0.11 (0.1, 0.12) 
Effect modification beta 




-6.38x10-3 (-7.22x10-3,  
5.54x10-3) 






All years 292,277 0.19 (0.19, 0.2)  0.16 (0.15, 0.16)  0.2 (0.2, 0.21)  0.16 (0.16, 0.17)  
Education 7 46,726 0.18 (0.17, 0.19) 
0.160 
0.14 (0.13, 0.15) 
0.127 
 
0.19 (0.18, 0.2) 
0.124 
0.14 (0.13, 0.15) 
0.191 
Education 10 50,789 0.2 (0.19, 0.21) 0.17 (0.15, 0.18) 0.21 (0.2, 0.22) 0.18 (0.16, 0.19) 
Education 13 15,772 0.21 (0.19, 0.22) 0.17 (0.15, 0.19) 0.23 (0.21, 0.24) 0.18 (0.16, 0.2) 
Education 15 36,033 0.19 (0.18, 0.2) 0.15 (0.13, 0.16) 0.2 (0.19, 0.21) 0.15 (0.14, 0.17) 
Education 19 47,177 0.18 (0.17, 0.19) 0.14 (0.13, 0.15) 0.19 (0.18, 0.21) 0.15 (0.14, 0.16) 
Education 20 95,780 0.2 (0.19, 0.2) 0.16 (0.16, 0.17) 0.21 (0.2, 0.21) 0.17 (0.16, 0.18) 







6.45x10-4 (-3.24x10-4,  
1.61x10-3) 
 
P value = P value for effect modification; SD = standard deviation; CI = confidence interval   
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Table 6.10: Education as an effect modifier of genetic susceptibility to cardiovascular risk factor on observed phenotypic cardiovascular risk factor for binary traits , on the additive scale 
using polygenic scores at a range of P value thresholds 
Exposure Educational attainment N 
P=0.05 P=0.5 
Additive scale Multiplicative scale Additive scale Multiplicative scale 
Risk difference of 
phenotypic trait 
(95%CI) 
P value  
Odds ratio of 
phenotypic trait 
(95%CI) 
P value  
Risk difference of 
phenotypic trait 
(95%CI) 
P value  
Odds ratio of 
phenotypic trait 
(95%CI) 
P value  
Atrial 
fibrillation 
All years 316,912 0.05 (0.04, 0.05)  4.67 (4.56, 4.79)  0.06 (0.06, 0.06)  5.88 (5.73, 6.03)  
Education 7 51,246 0.07 (0.06, 0.07) 
4.52x10-
112 
4.44 (4.22, 4.67) 
0.004 
0.08 (0.08, 0.08) 
4.97x10-
167 
5.51 (5.23, 5.8) 
2.87x10-4 
Education 10 54,460 0.04 (0.04, 0.04) 4.5 (4.23, 4.79) 0.05 (0.05, 0.05) 5.58 (5.23, 5.95) 
Education 13 17,213 0.04 (0.04, 0.04) 4.88 (4.34, 5.48) 0.05 (0.05, 0.05) 6.49 (5.74, 7.35) 
Education 15 38,694 0.05 (0.05, 0.05) 4.71 (4.4, 5.05) 0.06 (0.06, 0.06) 5.77 (5.37, 6.2) 
Education 19 50,942 0.04 (0.04, 0.04) 4.92 (4.61, 5.26) 0.06 (0.05, 0.06) 6.4 (5.97, 6.86) 
Education 20 104,357 0.04 (0.04, 0.04) 4.83 (4.6, 5.06) 0.05 (0.05, 0.05) 6.15 (5.85, 6.46) 
Effect modification beta 
-1.31x10-3 (-1.42x10-3,  
-1.19x10-3) 
1.01 (1.00, 1.01) 
-1.57x10-3 (-1.69x10-3,  
-1.46x10-3) 





All years 317,055 0.01 (0.01, 0.01)  1.23 (1.21, 1.25)  0.01 (0.01, 0.01)  1.22 (1.2, 1.24)  
Education 7 51,061 0.01 (0.01, 0.02) 
8.79x10-
06 
1.2 (1.16, 1.24) 
0.372 
0.01 (0.01, 0.02) 
3.03x10-4 
1.21 (1.17, 1.25) 
0.140 
Education 10 54,483 0.01 (0.01, 0.01) 1.24 (1.19, 1.3) 0.01 (0.01, 0.01) 1.19 (1.14, 1.24) 
Education 13 17,220 0.01 (0.01, 0.01) 1.28 (1.18, 1.4) 0.01 (0, 0.01) 1.23 (1.13, 1.34) 
Education 15 38,740 0.01 (0.01, 0.01) 1.22 (1.16, 1.28) 0.01 (0.01, 0.01) 1.2 (1.14, 1.26) 
Education 19 50,912 0.01 (0.01, 0.01) 1.21 (1.16, 1.26) 0.01 (0.01, 0.01) 1.19 (1.14, 1.24) 
Education 20 104,639 0.01 (0.01, 0.01) 1.26 (1.21, 1.3) 0.01 (0.01, 0.01) 1.27 (1.23, 1.31) 
Effect modification beta 
-3.22x10-4 (-4.64x10-4,  
1.80x10-4) 
1.00 (1.00, 1.00) 
-2.61x10-4 (-4.03x10-4, 
1.19x10-4) 




All years 316,406 0.004 (0.004, 0.005)  1.14 (1.11, 1.16)  0.0016 (0.0009, 0.0022)  1.05 (1.03, 1.07)  
Education 7 50,904 0.006 (0.004, 0.008) 
 
0.011 
1.11 (1.07, 1.15) 
0.273 
0.0017 (-0.0004, 0.0037) 
0.317 
1.03 (0.99, 1.07) 
0.705 
Education 10 54,261 0.005 (0.003, 0.006) 1.15 (1.1, 1.21) 0.0024 (0.0009, 0.0039) 1.08 (1.03, 1.13) 
Education 13 17,190 0.003 (0, 0.005) 1.11 (1.01, 1.21) 0.0021 (-0.0004, 0.0047) 1.07 (0.98, 1.17) 
Education 15 38,683 0.004 (0.002, 0.006) 1.13 (1.07, 1.19) 0.0009 (-0.0009, 0.0027) 1.03 (0.97, 1.09) 
Education 19 50,814 0.006 (0.004, 0.008) 1.18 (1.13, 1.24) 0.0018 (0.0002, 0.0035) 1.05 (1.01, 1.1) 
Education 20 104,554 0.003 (0.002, 0.004) 1.14 (1.09, 1.18) 0.0011 (0.0002, 0.002) 1.05 (1.01, 1.1) 
Effect modification beta 
-1.64x10-4 (-2.90x10-4,  
-3.81x10-5) 
1.00 (1.00, 1.01) 
-6.41x10-5 (-1.90x10-4, 
6.15x10-5) 
1.00 (1.00, 1.00) 
 
  




All years 320,120 0.002 (0.002, 0.002)  1.1 (1.07, 1.13)  0.0003 (-0.0001, 0.0008)  1.02 (0.99, 1.05)  
Education 7 52,012 0.003 (0.003, 0.005) 
0.015 
1.12 (1.06, 1.17) 
0.538 
0.0007 (-0.0008, 0.0022) 
0.378 
1.02 (0.97, 1.08) 
0.666 
Education 10 54,899 0.001 (0.001, 0.002) 1.06 (0.99, 1.13) 0.0005 (-0.0006, 0.0016) 1.03 (0.97, 1.1) 
Education 13 17,355 0.001 (0.001, 0.003) 1.03 (0.92, 1.16) 0.0002 (-0.0018, 0.0022) 1.01 (0.9, 1.14) 
Education 15 39,144 0.002 (0.002, 0.004) 1.15 (1.06, 1.24) 0.0004 (-0.0009, 0.0018) 1.02 (0.95, 1.1) 
Education 19 51,418 0.001 (0.001, 0.002) 1.07 (1, 1.15) -0.0006 (-0.0017, 0.0005) 0.97 (0.9, 1.03) 





1.00 (0.99, 1.00) 
-4.13x10-5 (-1.33x10-4, 
5.05x10-5) 
1.00 (0.99, 1.00) 
 
P value = P value for effect modification; SD = standard deviation; CI = confidence interval




In this analysis of UK Biobank participants, I found evidence that educational attainment 
modified the risk of genetic susceptibility to a number of cardiovascular risk factors and 
outcomes. The direction of this effect was mixed the size of the coefficient for effect 
modification was small. For some risk factors such as BMI and smoking behaviours higher 
educational attainment mitigated genetic risk. However, for some risk factors and diseases, 
such as LDL-C, atrial fibrillation and CHD, higher educational attainment increased genetic 
susceptibility. These results suggest that modification of the effect of polygenic scores by 
educational attainment is unlikely to play a clinically meaningful role in the aetiology of 
cardiovascular inequalities. 
Where educational attainment increased genetic susceptibility to cardiovascular disease 
events and diagnoses it is possible these differences are observed due to differences in rates of 
diagnosis, which may independently contribute to cardiovascular inequalities. 
6.7.1.1 Results in context 
A number of studies have sought to identify the interplay between genetic susceptibility to 
cardiovascular risk factors with a range of lifestyle and environmental factors. For example, a 
number of studies have demonstrated interactions between genetic susceptibility to BMI and 
diet and with physical activity (392-395). Gene*environment interactions have been identified 
between the APOE genotype (increasing susceptibility to cardiovascular disease) and smoking 
(374, 375), the PPAR-g2 gene increasing susceptibility to type 2 diabetes risk with diet and 
exercise (376), polygenic score for type 2 diabetes and healthy lifestyle and between the 9p21 
genetic variant (increasingly susceptibility to CHD) and smoking (203). Most, although not all, 
of these previous studies have employed candidate gene approaches and few have considered 
the role of socioeconomic position interacting with genetic risk. 
Two recent studies using UK Biobank have demonstrated that a greater Townsend deprivation 
index accentuated the genetic risk of obesity (175, 377). However, the previous literature has 
not found evidence that education modifies the genetic risk of obesity (175, 378). We have 
expanded on this here by exploring the extent to which education modifies polygenic 
susceptibility to a wide range of cardiovascular risk factors, rather than focussing on one risk 
factor. In contrast to the previous literature, we found evidence that educational attainment 
modifies genetic susceptibility to BMI.  
One explanation as to why I found evidence of  education as an effect modifier of 
cardiovascular risk may be because of the education definition used. In my research I have 
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converted highest educational qualification to ISCED years of schooling, however previous 
research has used slightly different definitions of education. In one study using UK Biobank, 
age at which full time education was completed was used (175). In a study using the 
Understanding Society dataset, highest qualification was used to define education (378). My 
definition of education has previously been used to demonstrate causal effects of education on 
i) BMI and ii) CVD (287).  
A recent source of much debate in the genetic epidemiology literature is whether the addition 
of a polygenic risk score in clinical practice adds little predictive power over and above that of 
a phenotypic risk score (195-197). Whilst phenotypic cardiovascular risk would be known by a 
clinician, currently, genetic risk is typically unknown to both clinician and patient. My 
research demonstrates that at the individual level, understanding genetic susceptibility to 
cardiovascular risk factors or outcomes may help elucidate mechanisms in cardiovascular 
aetiology, but these are unlikely to explain a substantial proportion of socioeconomic 
inequalities. 
6.7.1.2 Strengths and weaknesses 
There are a number of strengths in this study. Much of the previous literature on gene 
*environment interactions in cardiovascular disease rely on candidate gene style studies (373, 
375, 376), which are often criticised for a failure to replicate (204). Here, I have created PGSs 
for nine phenotypic measures of cardiovascular risk factors or diseases. Whilst candidate gene 
studies typically focus on a (rare) single genetic variant, or small group of (common) genetic 
variants that individually explain a large(r) amount of the variance in the trait, PGSs include a 
large number of genetic variants which each explain a small amount of the variation, but 
cumulatively explain a large amount (170, 396). For most diseases, including CVD, polygenic 
inheritance of these common variants plays a greater role than rare monogenic mutations 
(170, 397). Therefore, the broad measure of genetic susceptibility used here is likely to 
represent a greater number of biological pathways for the aetiology of cardiovascular disease.  
Additionally, I created PGSs at a range of stringent and liberal P value thresholds. At a more 
stringent threshold (e.g. P=5x10-8) the genetic variants included are less likely to be pleiotropic 
(i.e. also associated with different phenotypes), but the variance explained by the PGS may be 
lower than with a more liberal threshold (e.g. P=0.5). 
Identifying whether the modifying effect of education acts in same direction for each risk 
factor (i.e. if. education decreased genetic susceptibility to all cardiovascular risk factors) 
would be of public health importance in identifying opportunities to mitigate cardiovascular 
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inequalities. With the exception of genetic susceptibility to alcohol consumption, educational 
attainment was found to modify the effect of all polygenic scores on at least one scale. 
However, the effect of education did not have the same direction of effect for all risk factors. 
In the case of BMI and smoking, higher education mitigated polygenic susceptibility to the 
phenotypes, however for LDL-C and systolic blood pressure, higher education resulted in 
higher phenotypic measures for a given value of the polygenic score. This means the results 
identified here are unlikely to explain persisting inequalities in CVD. 
The lack of effect modification for alcohol consumption could be due to insufficient power to 
detect an effect modification or because of the way the variable was defined. For example, 
alcohol consumption was defined as drinks per week, but type of alcohol consumed may be an 
important factor which was not accounted for. This work should be replicated in large 
independent samples to verify the validity of this effect modification.  
Studies of effect modification can be biased by reverse causality and confounding. Where 
possible, for example with genetic susceptibility to cardiovascular diseases, I restricted 
analyses to incident cases. As education is an early life measure of socioeconomic position 
many risk factors for disease would be acting as mediators (i.e. on the causal pathway between 
education and CVD) rather than as confounders (287). Similarly, genetic variants are 
determined at conception, and therefore not biased by unmeasured later life confounding. 
However, they can be confounded by population structure (185). In this analysis, I controlled 
for genetic principal components to minimise bias due to this.  
One limitation is the generalisability of these results to other populations. UK Biobank is not 
representative of the wider UK population, particularly with respect to SEP (16). UK Biobank 
participants are typically more highly educated and of a higher SEP. Therefore, the absence of 
effect modification in this sample may be due collider bias caused by non-random selection 
into the study (221).  
Although I have identified education modifies the effect of polygenic scores for some 
cardiovascular risk factors, these effects may differ (e.g. be larger in magnitude), should 
measures of adult socioeconomic position be considered. This may also explain some of the 
non-linearities observed when stratifying by years of educational attainment, as the ISCED 
definitions of educational attainment used here, assign a high number of years of education to 
those who attain a vocational qualification and likely enter manual labour. 
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I used the summary statistics from the largest available GWAS for each trait (not including UK 
Biobank), however the PGSs explain small amounts of the phenotypes. As GWAS become 
larger and explain more variance in phenotypic traits, it may be possible to detect smaller 
effect modification. 
6.7.1.3 Public health implications 
In this analysis I have demonstrated that educational attainment modifies genetic 
susceptibility to a number of cardiovascular risk factors and outcomes. However, the direction 
of these effects was not consistent. These results do not specifically say what it is about 
educational attainment that modified genetic susceptibility to cardiovascular risk factors and 
outcomes. Additionally, it is possible that differences in cardiovascular diseases are due to 
differences in rates of diagnosis. Although this works begins to allude to risk stratified 
interventions based on genetics, it will be important to understand more specifically what it is 
about education that leads to these more adverse consequences. For example, remaining in 
education may protect an individual from starting to smoke due to social pressure or 
increased knowledge of the harms, even if they have genetic variants increasing their 
susceptibility to heavier smoking. However, it will be important to identify what factors may 
explain the differences in the directions of effects.  
6.7.1.4 Conclusions 
In this study I have found that educational attainment modifies the genetic susceptibility to a 
number of cardiovascular risk factors. The direction of this effect was mixed, and the sizes of 
the effect modification coefficients were small, suggesting modification of the effect of genetic 
susceptibility to cardiovascular risk factors or cardiovascular disease by education attainment 
are unlikely to contribute to the mechanisms driving inequalities in cardiovascular risk. 
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Chapter 7. Discussion 
In Chapter 3 to Chapter 6 the main findings of each analysis were presented alongside a 
discussion of the strengths and limitations from each of the analyses, including the methods 
and data. In this chapter, I summarise the key findings of each analysis chapter. I consider the 
contribution this thesis makes to our understanding of cardiovascular inequalities and the 
causal inference literature. I discuss the strengths and limitations of the thesis as a whole. 
Finally, I examine the public health and policy implications of my thesis and make 
recommendations for future research.  
7.1 Summary of key findings 
Despite reductions in the rates of morbidity and mortality from cardiovascular disease (CVD) 
in high income countries (28, 30, 32), individuals who are the most socioeconomically 
deprived remain at the greatest risk of disease (3, 76). In this thesis, I aimed to understand 
what processes may be driving socioeconomic inequalities in CVD,  focussing on educational 
attainment as a measure of socioeconomic position (SEP) using causal inference methods.  
Multivariable Mendelian randomisation (MVMR) and two-step Mendelian randomisation 
(MR) methods were not new to this thesis (19-21, 283). Previous literature had used these 
methods to estimate direct effects (253, 398), including in the presence of pleiotropy (21, 282), 
and to infer causation (19, 399). However, they had not been used to decompose the direct 
effect indirect effect and proportion mediated. Additionally, there was no guidance in the 
literature about the two approaches to using MR for mediation, whether and when they 
differed, and whether there were situations in which one method was more appropriate than 
the other. In Chapter 3, using simulations and an applied example, I demonstrated how these 
two MR methods could be used in mediation analysis, to estimate direct effects, indirect 
effects and the proportion mediated. I presented a number of methodological considerations, 
including current limitations and sources of bias in these analyses. This work has been 
designed to reach different audiences, both applied and methodological researchers. In the 
motivating example for this chapter I demonstrated that body mass index (BMI) likely 
mediated the association between educational attainment and i) systolic blood pressure, ii) 
hypertension and iii) CVD (all subtypes combined). However, there was little evidence that 
low-density lipoprotein cholesterol (LDL-C) mediated these associations.  
In Chapter 4 I have identified that educational inequalities in CVD may occur via a number of 
mediating pathways. Individually, BMI explained up to 18% of the association between 
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education and coronary heart disease (CHD), smoking explained up to 21% and systolic blood 
pressure explained up to 33%. When considered together, BMI, smoking and systolic blood 
pressure were estimated to explain up to 36% of the effect of education on CHD. For the 
association between education and myocardial infarction the three risk factors explained up to 
41%. Considering stroke as the outcome up to 52% of the association was explained and for all 
CVD as the outcome up to 41% was explained. 
I have identified that educational differences in statin use for primary prevention are likely to 
contribute to educational inequalities in CVD. I identified an interaction between educational 
attainment and  cardiovascular risk (via QRISK3 score), such that for a given QRISK3 score 
individuals who leave education after 7 years (equivalent to compulsory education) are less 
likely to report using statin medication compared with those who leave education after 20 
years (equivalent to obtaining a degree) (Chapter 5).  
Finally, I have demonstrated that effect modification of cardiovascular risk by educational 
attainment is unlikely to substantially contribute to the development of inequalities in 
cardiovascular risk. My research showed that educational attainment mitigates genetic 
susceptibility to BMI and lifetime smoking, but accentuated genetic susceptibility to LDL-C, 
atrial fibrillation and CHD (Chapter 6). For example, for a given level of genetic risk of 
smoking, individuals with lower educational attainment, had a higher lifetime exposure to 
smoking compared with higher educated individuals with an equivalent genetic risk. However, 
for a given genetic risk of LDL-C, individuals with higher educational attainment were more 
likely to have higher observed levels of LDL-C, compared with lower educated individuals with 
an equivalent genetic risk. Where effect modification was observed, the size of the effect 
modification coefficients was typically small. 
7.2 Contributions to the literature 
Although each analysis chapter features a full discussion of the results in context, here I make 
a general discussion of the contributions made. My results indicate that BMI, smoking, 
systolic blood pressure and statin use contribute to the accumulation of CVD in individuals 
with low educational attainment, but not LDL-C or effect modification of polygenic scores by 
education on cardiovascular risk.  
Previous mediation analyses have implicated BMI, smoking and systolic blood pressure as 
mediators of education and CVD. For example, Kershaw and colleagues, identified that almost 
27% of the association between education and CHD was mediated by smoking, with 10% and 
5% attributed to obesity and hypertension respectively (114). My work in Chapter 4 builds on 
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the previous literature by using novel MR methods to investigate the causal role of BMI, 
smoking and systolic blood pressure as mediators. I demonstrated in Chapter 3 that MR could 
be used to overcome confounding and measurement error in mediation analyses, improving 
the causal inference that can be made. 
Whilst a number of studies have identified associations between SEP and statin use, the 
direction of this effect has been mixed (36, 87, 142, 143, 145-147, 340). Although some previous 
studies adjusted for some cardiovascular comorbidities, few previous studies have 
comprehensively accounted for underlying cardiovascular risk (87, 143, 145). As demonstrated 
in Chapter 4, individuals with lower educational attainment have a higher prevalence of 
cardiovascular risk factors. Therefore, it would be expected that individuals with lower 
educational attainment have a higher prevalence of statin use. One previous study was 
identified that accounted for underlying cardiovascular risk assessed by Framingham score; 
however, this study did not test for interaction between SEP and cardiovascular risk. Here, it 
was found that the use of statins was not associated with SEP (141). My research in Chapter 5 
builds on these previous studies by investigating interactions between educational attainment 
and underlying cardiovascular risk. Here, I found that for an equivalent cardiovascular risk 
(assessed via QRISK3 score) higher educated individuals were more likely to report using 
statins, compared with lower educated individuals.  
In Chapter 6, I investigated effect modification between educational attainment and polygenic 
scores (PGS) for a number of cardiovascular risk factors and diseases. Although some previous 
analyses had sought to study similar research questions, no previous analysis had examined 
multiple cardiovascular risk factors using a polygenic (as opposed to candidate gene) 
framework. For example, Tyrrell and Colleagues investigated gene*environment interactions 
between a BMI PGS and a number of indicators of the obesogenic environment (377). Here, an 
interaction between BMI PGS and Townsend deprivation index (TDI) (a population indicator 
of SEP) on observed BMI was found. Conversely, Amin and colleagues did not identify an 
interaction between BMI PGS and educational attainment in both Finnish and UK cohorts 
(378). I identified that educational attainment mitigated the risk of genetic susceptibility to 
BMI and smoking, but increased genetic susceptibility to LDL-C, atrial fibrillation and CHD. 
Although this work identified that educational attainment may be an important effect 
modifier for some cardiovascular risk factors, this is unlikely to strongly contribute to 
inequalities in CVD. 
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7.3 Strengths and limitations of this research 
There are a number of strengths and limitations of the work presented in this thesis. 
Understanding what these are and how they might affect the interpretation of the results 
presented is important for understanding the wider contribution of this work and the causal 
inference that can be made. 
7.3.1 UK Biobank 
UK Biobank is an incredibly rich data source, including phenotypic, genetic, metabolomic data 
and linked health outcomes in over 500 000 individuals. Few studies, if any, have the 
extensiveness of data like UK Biobank. The breadth of data collected has allowed for thorough 
and robust interrogation of the research aims addressed in this thesis. The adult population of 
UK Biobank (age range 36-75) makes this is an ideal cohort study for exploring cardiovascular 
outcomes, where CVD is most common in older individuals (28). Although it should be noted 
that as the length of follow up for participants is still relatively short (maximum follow up 11 
years) there are still relatively small numbers of some cardiovascular outcomes, and therefore 
MR mediation analyses in Chapter 4 were complemented with summary data MR analyses. 
Despite educational attainment being measured retrospectively in UK Biobank participants, 
individuals were asked to report their highest qualification achieved, which is unlikely to be 
subject to recall bias. The long latent period between educational attainment and CVD the 
study design of UK Biobank makes it a suitable cohort study for the research questions 
addressed here.  
There are a number of specific strengths and limitations of using these data within my thesis, 
which are discussed throughout this section. 
7.3.2 Statistical power 
The methods used in this thesis, such as individual level MR, mediation analysis and 
interaction analyses typically require very large sample sizes to achieve statistical power. 
Therefore, the number of participants in UK Biobank is important in going some way to 
achieve adequate power for analyses. Notably in individual level MR mediation results in 
Chapter 3 and Chapter 4 estimates are imprecise, suggesting power may not be sufficient to 
detect the effects of interest, particularly when estimating the proportion mediated.  
In Chapter 6, education as an effect modifier of PGSs for a number of cardiovascular risk 
factors or diseases was assessed. Risk factors were selected based on evidence of causal effects 
on CVD. Additionally, it has been demonstrated, including from my own research, that 
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education is a cause of CVD. Therefore, effect modification should be present for all risk 
factors on either the additive or multiplicative scale. For some risk factors, including alcohol 
consumption and stroke, there was no evidence of effect modification. It is possible this was 
due to there not being sufficient power to detect these associations. 
7.3.3 Reverse causality 
A key assumption throughout this work, is that the temporality between the exposures, 
mediators and outcomes have been correctly specified and the results are not biased by 
reverse causality. However, there is some evidence that high BMI is causally associated with 
lower SEP, including educational attainment (265, 400), as well as some evidence that 
smoking initiation and lifetime smoking are associated with lower educational attainment 
(401). 
Bias by reverse causality has been mitigated in two main ways in this thesis. Firstly, MR has 
been used where appropriate for mediation analyses. Due to the properties of genetic variants 
being i) randomly allocated at meiosis and ii) stable throughout the life course, MR estimates 
are robust to bias by reverse causality (see a full discussion of these methods in 7.3.4). These 
methods can also be used to identify the direction of causality and to test for evidence of bi-
directional effects (313). Secondly, wherever possible, the temporality of data has been 
maintained, particularly considering cardiovascular outcomes. For example, individuals with 
prevalent (at baseline) cases of CVD have been excluded from main analyses.  
Given the linkage to hospital inpatient records (hospital episode statistics in England and 
Wales and Scottish morbidity records), primary care data and prescription data, incident and 
prevalent cases of disease could be ascertained. This means the association between 
exposures, mediators (where applicable) and outcomes could be assessed prospectively. 
Although MR analyses (Chapter 3 and Chapter 4) are not biased by reverse causality, 
phenotypic analyses and studies of effect modification (Chapter 3 to Chapter 6) can be biased 
in this way. This temporality means bias due to reverse causality is unlikely to be present.  
In Chapter 5, the primary outcome considered was statin use. Due to the large sample sizes 
required to achieve statistical power in interaction analyses, primary analyses were carried out 
using cross sectional analyses, i.e. cardiovascular risk factors were assessed at the same time as 
statin use. These analyses were replicated using primary care and prescription data, available 
for about half of the eligible participants. Here, temporality could be maintained between 
assessing cardiovascular risk at baseline with prospective prescriptions for statins. These 
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prospective results were comparable to results using cross-sectional data, suggesting bias by 
reverse causality is not present in the main analyses. 
However, it should be noted that these linked sources of data (hospital inpatient records and 
prescription data for example) have their own limitations, particularly that of missing data 
both in terms of data collected in healthcare and because measurements are only available for 
individuals who present at a healthcare setting. (402).  
7.3.4 Assumptions of Mendelian randomisation 
In Chapter 3 and Chapter 4, MR methods were used to estimate the role of intermediate risk 
factors mediating the association between education and CVD. Mendelian randomisation 
studies have been described as natures Randomised controlled trial (RCT) (254, 403), where 
genetic variants are randomly allocated at conception and not influenced by later life factors 
(i.e. confounders) (18, 248). These properties mean estimates are unbiased by unmeasured 
confounding (with some exceptions, see section 7.3.6.1) and reverse causality. Additionally, 
non-differential measurement error is less of an issue (see section 7.3.7) in MR studies (248, 
279, 404).  
However, estimates from MR can be biased from a number of different sources (405). One 
important potential source of bias is through invalid instruments, which may have pleiotropic 
effects on pathways independent of the exposure of interest (254, 255). When carrying out MR 
mediation analysis, these pleiotropic pathways may also be present for the instrument for the 
mediator of interest. Limited methods are available for testing for pleiotropy in MR mediation 
(302) and indeed MVMR was introduced as a method for dealing with pleiotropy (282, 283). In 
the absence of specific tests, MR-Egger was used to test for evidence of pleiotropy by the 
instruments for the exposure and each of the mediators (255). The estimates from MR-Egger 
were consistent with those from the main IV regression analyses, suggesting that estimates are 
unlikely to be biased due to pleiotropy.  
Estimates from MR can also be biased by weak instrument bias (300). This was assessed by F-
statistics and conditional F-statistics in MR mediation analyses (296). For all exposures and 
mediators, the instruments had high F-statistics, indicating that the effect estimates were 
unlikely to be biased by weak instruments. As demonstrated in Chapter 3, weak instrument 
bias in the exposure and mediator introduced bias to the estimates of mediation, with the size 
of bias greatest when a common binary outcome was considered. 
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7.3.5 Lifetime exposure in Mendelian randomisation 
Estimates from MR are said to be estimating effects of lifetime exposure to a trait (18, 406). 
Whilst a trait such as educational attainment is likely to be stable across much of the life 
course, other traits, including BMI, smoking and systolic blood pressure are likely to be less 
stable. Indeed, systolic blood pressure is subject to daily, or even context dependent, variation 
(407). It may indeed be these variations that are more important to disease aetiology, rather 
than a lifetime exposure. Although methods for accounting for time-varying exposures in MR 
are emerging, they are not yet widespread and only available for a limited number of traits 
(311, 406, 408). It is important to consider the results presented in this thesis in the context of 
lifetime exposure to the traits considered. In Chapter 4 considering the mediating role of BMI, 
smoking and systolic blood pressure between education and a number of cardiovascular 
outcomes, estimates of the proportion mediated were typically larger in MR mediation 
analyses (in particular using summary data MR) compared with phenotypic analyses. For 
example, in phenotypic analyses systolic blood pressure mediated 19% of the association 
between education and CHD, in individual level MR the proportion mediated was 17% and in 
summary data MR the proportion mediated was 21%. 
7.3.6 Confounding 
Not all work in this thesis has used MR and therefore may be biased by unmeasured 
confounding (409). In Chapter 3 and  Chapter 4,phenotypic mediation analysis was also used. 
As educational attainment (the exposure considered) is an early life measure of SEP, many 
individual level risk factors for disease are more likely to be acting as mediators and not 
confounders of the association between educational attainment and CVD. However, based on 
the previous literature, some familial level factors may still be acting as confounders, such as 
parental SEP (8). If not appropriately controlled for, confounding can introduce bias by 
inducing an association between an exposure and an outcome that does not truly exist or 
over/under-estimate the effect of the exposure on the outcome. To control for this, a proxy 
measure for Townsend deprivation index (TDI) at birth was estimated based on birth location 
and current TDI for the location. Analyses were additionally adjusted for birth location. 
However, these proxy measures are poor measures of true family level SEP and therefore 
residual confounding may remain. It is important to note that mediators of an association 
should not be controlled for (if not in a specific mediation analysis) as this can underestimate 
the effect of the exposure on the outcome, therefore careful consideration was given in these 
analyses to not over-adjust (410). 
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The QRISK3 cardiovascular risk score estimated in Chapter 5 is a type of prediction model. 
The goal here is to estimate the 10 year risk of future cardiovascular disease, conditional on the 
values of multiple risk factors (411). These models represent a comprehensive assessment of 
cardiovascular risk, capturing risk factors that may be considered as either confounders or 
mediators of the association in addition to area level SEP measured by TDI of current location. 
Therefore, no further covariates were included in analyses in Chapter 5.  
7.3.6.1 Population stratification, assortative mating and dynastic effects 
Genetic associations are assumed to reflect direct genetic effects. However, family level effects 
including assortative mating (412, 413) and dynastic effects (414), or fine-scale population 
structure (185), are all potential sources of confounding in genetic studies of unrelated 
individuals (186, 415). Without accounting for, or controlling for these effects, confounding 
can be introduced. Indeed, even in non-genetic analyses dynastic effects, which occur when 
the parent phenotype directly influences the phenotype of their offspring, can lead to 
confounding due to family level SEP (186, 416).  
When considering social exposures, such as educational attainment, bias caused by these 
effects can be pertinent (185, 415). It has been demonstrated that after controlling for family 
effects, the heritability of educational attainment is reduced i.e. there is a strong indirect effect 
of parental education on offspring education (414). However, importantly for the work 
presented here, even after controlling for family level factors (in the form of twin-studies) 
causal effects of education on health remain (417).  
Methods are emerging for within-family MR analyses, and the results presented here would be 
an ideal candidate for replication with these analyses (see 7.5.1). Through this design, 
confounding by dynastic effects, assortative mating and population structure are controlled 
for. These designs can either account for family structure using sibling data or parent-
offspring trio data. In sibling studies, the difference between phenotype and genotype within 
siblings can be estimated or family level means can be estimated and controlled for (186, 418). 
In parent-offspring trio designs, parental genotype can simply be adjusted for, or MVMR 
methods can be used to estimate the direct and indirect effects of the parents genotypes (414, 
418). However, achieving adequate statistical power is challenging; particularly for analyses 
such as mediation and interactions. In UK Biobank, about 20 000 sibling pairs are available, 
but this sample size is unlikely to be large enough to provide adequate statistical power for the 
analyses carried out in this thesis. 
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In this thesis I adjusted genetic analyses for genetic principal components, as a method of 
controlling for wider population stratification. Although it should be noted that this often is 
not enough to account for population stratification (185, 419). In an effort to control for family 
level effects, TDI at birth and location of birth were adjusted for, which would capture some 
family level SEP. However, these family effects were not controlled for using genetic methods, 
e.g. within family genome-wide association studies (GWAS) (420).  
Despite these limitations, the results presented in this thesis remain important for considering 
potential opportunities to reduce inequalities in CVD. Understanding the role of family effects 
in the aetiology of cardiovascular inequalities will be important for improving the health of 
future generations. However, understanding the effect of educational attainment, without 
accounting for family effects, provides an opportunity to identify why and how inequalities 
exist in those (adults) most at risk of disease in the short term.  
7.3.7 Measurement error 
Throughout this work, careful consideration has been given to minimising measurement error 
in all risk factors (i.e. exposures and mediators) and outcomes considered. Although one of 
the main strengths of this thesis is the triangulation of different methods, where MR is robust 
to measurement error, phenotypic analyses analyses can still be biased by measurement error 
and indeed measurement error in GWAS can introduce bias to MR estimates. 
As previously discussed, (7.3.1), hospital inpatient records were used to identify cases of CVD. 
The end points considered in Chapter 3, Chapter 4 and Chapter 6 of this thesis, were all 
serious cardiac events that would likely result in a hospital admission. This is a more objective 
measurement of CVD, compared with self-report data for example, where misclassification of 
the outcome may occur due to misreporting or recall bias by an individual.  
UK Biobank baseline assessment centres followed clear protocols for all data collected. Risk 
factors considered in this thesis, such as BMI, systolic blood pressure and LDL-C (Chapter 3, 
Chapter 4 and Chapter 6) were measured objectively by trained study nurses using calibrated 
machinery, minimising risk of measurement error. Risk factors such as smoking and alcohol 
consumption (Chapter 4 and Chapter 6) may be subject to misclassification, or measurement 
error, due to self-reporting bias (421), possibly due to social desirability (422). As UK Biobank 
is typically healthier than the general population it can be difficult to compare with 
population estimates of smoking or alcohol consumption for example. 
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In Chapter 5 where a number of different disease diagnoses were included in QRISK3 scores. A 
combination of self-report disease status, assessment centre medication data and hospital 
inpatient records was used to code each disease. Typically, hospital inpatient records will only 
capture severe cases of disease, resulting in a hospital admission. Whilst this is highly likely to 
occur for a serious cardiac event (e.g. stroke or myocardial infarction) this is less likely to be 
the case for diabetes for example. Including self-report of a diabetes diagnosis therefore 
reduces the potential misclassification of a case as a control but does introduce potential recall 
bias. Similarly, for a diagnosis such as impotence (a variable included in the QRISK3 
cardiovascular risk score), a diagnostic ICD code is available, but cases are unlikely to attend a 
hospital for this condition. Therefore, cases could more reliably be ascertained via medication 
data. However, it should be acknowledged that for many conditions, including impotence, 
participants may choose not to present at a clinical setting for this reason and therefore would 
not have relevant medication data and nor would they self-report the condition to study 
nurses. The breadth of data available in UK Biobank therefore reduces potential bias by 
measurement error or misclassification as case status can be ascertained in a number of ways, 
although some small bias may still be present. 
One area where measurement error has been difficult to quantify is in reported statin use 
(Chapter 5). UK Biobank participants were asked to report to study nurses any regular 
medication they were taking, but not those purchased over the counter without a prescription, 
medications prescribed but not taken, or any supplements or vitamins the participants used. 
Participants were asked to take the packets of medication so study nurses could exactly record 
the medication and dosage. This is a clear strength; study nurses are likely to accurately record 
the medication and it is not reliant on participant recall. However, this method does rely on 
participant taking medication to assessment centres. Through triangulating with primary care 
prescription records there was a large amount of discrepancy between those reporting statin 
use to study nurses and those having a statin prescription (see 7.5.1 and 7.6). I was able to 
identify that a number of these individuals had a statin prescription prior to baseline, but no 
current prescription (defined as a prescriptions 3 months before and after baseline). Similarly, 
I was able to identify a number of participants who either never received a prescription, or 
only received a prescription after baseline. There were also individuals who had a prescription 
during the 3 months before and after baseline but did not report using them to study nurses. 
For this reason, care was taken to describe statins inequalities in terms of reporting, rather 
than prescriptions or use. Reassuringly, in analyses replicated with different definitions of 
statin use (e.g. self-report or prescription only) results were comparable.  
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Although MR estimates are robust to bias by non-differential measurement error, differential 
measurement error can induce bias in the GWAS used to identify instruments. This has been 
demonstrated using behavioural traits (alcohol consumption and smoking) in UK Biobank 
(423), where misreporting or longitudinal changes in a phenotype result in reduced power of a 
GWAS to detect true signals or the inducement of spurious signals. This would have 
implications for the validity of the instruments included in MR analyses.  
7.3.8 Selection bias and generalisability of results 
One of the key limitations of using UK Biobank, is that it is not representative of the general 
population (16). Participants are typically more highly educated, have a higher SEP and exhibit 
greater health seeking behaviours than the general population (16, 424). Despite the large 
sample size of UK Biobank, this sample represents a response rate of only 5.5% of the 9.2 
million individuals invited to take part (16, 425). Selection bias and unequal distributions of 
SEP is not unique to UK Biobank and indeed a number of studies report similar differences 
(426-430). This selection bias means the results presented here may not be generalisable to 
the general UK population (and indeed non-UK populations). This is particularly important 
when using these data to study health inequalities, as I have done in this thesis. It would be 
expected that the associations presented here are likely to be larger in the general population, 
where there are greater socioeconomic disparities (431). 
A number of studies have sought to identify predictors of this study participation and quantify 
the size and effect this selection bias may have on the generalisability of results, both in 
genetic and non-genetic analyses. Selection bias can occur if the exposure, outcome, or causes 
of the exposure and outcome are associated with participation (432). For this reason, Tyrrell 
and colleagues sought to identify causal factors that influenced participation into option UK 
Biobank follow-up assessments. Using summary data MR, it was found, that among other 
factors, higher educational attainment increased participation, whilst higher adiposity 
decreased participation. In phenotypic analyses lower deprivation and never smoking 
increased participation (433). Although these results are exploring participation for optional 
follow-up assessments in UK Biobank, not baseline participation, it is likely that similar factors 
will be involved in initial participation. Given that educational attainment, BMI and smoking 
have all been considered as exposures (or mediators) in analyses presented in this thesis and 
have previously been implicated as risk factors for cardiovascular outcomes, results presented 
here may be biased by selection bias. 
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It has often been said that selection bias should not have an effect on the observed 
associations between an exposure and outcome, but may lead to stronger biases in estimates 
of prevalence (434). This was recently assessed by Batty and colleagues comparing risk factor 
associations in UK Biobank with the more representative, general population based studies, 
Health Surveys for England and Scottish Health Surveys (HSE-SHS) (424). Both studies had 
similar age and sex distributions, although UK Biobank participants were more educated, 
more likely to be physically active and less likely to smoke compared with HSE-SHS 
participants. It was found that some, but not all, risk factor associations in UK Biobank were 
comparable to those from with HSE-SHS. For example, in UK Biobank the hazard ratio for the 
association of baseline biomedical characteristics (including among other characteristics  age, 
sex, total cholesterol and systolic blood pressure) on self-report CVD was 4.92 (95% CI: 4.50 to 
5.39), whilst the comparative hazard ratio in HSE-SHS was 2.61 (95% CI: 2.35 to 2.90). 
However, the association between baseline biomedical characteristics and obesity was more 
similar, where the hazard ratio in UK Biobank was 1.68 (95% CI: 1.55 to 1.83) and in HSE-SHS 
the hazard ratio was 1.47 (95% CI: 1.31 to 1.61). The study authors concluded that association 
estimates in UK Biobank were likely generalisable to the UK general population (424). 
However, this view that selection bias does not bias observed associations has been criticised 
for not considering the effect of selection bias on collider bias (221). Munafò and colleagues 
demonstrated in a simulation based on UK Biobank data, that analyses using PGSs are 
particularly vulnerable to collider bias caused by selection. Here, the association between the 
phenotypic of interest and participation will result in the PGS being more strongly related to 
participation, compared with individual genetic variants alone (221). Given the use of PGSs in 
this thesis there is potential that the results are affected by collider bias. 
Further to the issue of selection into the study, is selection out of a study, such as via non-
participation, loss to follow up or participant withdrawal (435, 436). There have been some 
selective follow up clinics of UK Biobank, however these have not sought to engage all 
participants. The primary source of follow up data used in this thesis is linked hospital 
inpatient records. Although participants are free to withdraw from the study, and indeed small 
numbers of participants have, this follow up process is automated through linkage processes. 
Therefore, in the context of these analyses, bias due to attrition (whereby those who remain in 
a study differ from those who remain in a study) should be limited (437). 
Further selection bias and limitations of generalisability may have been introduced when 
individuals were excluded from analyses based on missing data, previous CVD or due to 
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ancestry. Where genetic analyses have been carried out, analyses have been restricted to 
participants of White British ancestry (Chapter 3, Chapter 4 and Chapter 6). This restriction 
has been made due to i) the potential confounding that can be introduced by population 
stratification (185) and ii) because genome-wide association studies are typically carried out in 
European participants, where results are often not generalisable across different ancestries 
(438). Therefore, to ensure the validity of the instruments used, the analyses are carried out on 
a similarly restrictive sample of participants. Given known ethnic differences in CVD and SEP, 
it is likely that the association between education (or SEP more widely) and CVD differs in 
different ancestries. For example, different mediators may partly explain the association, or 
different interactions between the genes and observed environment may be important. 
Therefore, it may not be possible to generalise the results presented here to other populations 
(439). 
In Chapter 4, individual level MR estimates were triangulated to summary data MR estimates. 
Although the summary statistics for summary data MR largely came from GWAS of European 
participants, the populations considered represented greater population variation than in UK 
Biobank. Estimates from summary sample MR were comparable (albeit with greater precision) 
to the individual level MR analyses, suggesting despite this selection bias into UK Biobank the 
results were still largely generalisable to other (predominantly) European populations.  
Where exclusions to the UK Biobank sample were made, I compared the distribution of the 
characteristics between those included in analyses and those who were excluded either based 
on ancestry or other factors such as missing data. The characteristics were comparable across 
the participants included/excluded, suggesting this internal selection is unlikely to be a source 
of bias (with the exception of generalisability across ancestries).  
7.3.9 Missing data 
Although data from UK Biobank baseline assessment centres is largely complete, there is still 
some missing data. This is particularly pertinent for the biochemical assays, including 
measures of LDL-C and total cholesterol, as well as systolic blood pressure. To minimise bias 
due to missing data in Chapter 5 I carried out multivariate multiple imputation to impute data 
for any variable included in the QRISK3 cardiovascular risk score with missing data. This 
improved power to test for interactions by not reducing the sample size. Provided the 
assumption that data are missing not and random and that the regression model used to 
impute the data is correctly specified, analyses using multiple imputation are less prone to 
bias than complete case analyses (440). Importantly, for the analyses in Chapter 5, the 
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imputation model was specified to include interactions between i) sex and ii) educational 
attainment to preserve the interactions being tested in these analyses (354). Although there 
are no methods to directly test that the multiple imputation assumptions hold, when 
comparing the analyses using imputed data with the complete case data there was little 
difference between the observed effects, suggesting that missing data is not an important 
source of bias.  
7.3.10 Genome wide association study of educational attainment 
Educational attainment has long been described as a result of shared genetic and 
environmental influences (441). In Chapter 3 and Chapter 4 of this thesis I use GWAS 
summary statistics of educational attainment to instrument education in MR analyses (17, 
149). To avoid sample overlap between the discovery GWAS and analyses in UK Biobank, the 
2016 Okbay et al GWAS (17) was used in individual level MR analyses, and the Lee et al GWAS 
(149) which included UK Biobank participants in the complementary summary data MR 
analyses. As summary data MR analyses were carried out by co-authors, I will focus this 
discussion on the Okbay et al GWAS. 
As with most PGSs, individually, each of the 74 genome-wide significant single nucleotide 
polymorphisms (SNPs) explains a very small amount of the variance in education. For 
example, the single variant explaining the greatest amount of variation, only explained 0.035% 
of the variance in education. However, the combined 3.2% explained by all 74 SNPs in a PGS is 
large enough to be meaningfully useful for social science research. Indeed, in my MR analyses, 
I had large F statistics and conditional F statistics, indicative of instrument strength. 
Where PGSs for complex or behaviour traits are used, it is difficult to know what is being 
captured by the genetic variants. Of the 74 SNPs identified for educational attainment, 15 were 
found in genes and biological pathways involved in prenatal brain development (17). Some of 
the SNPs were also found to be associated with increased cognitive performance, increased 
risk of bipolar, decreased Alzheimer’s and lower neuroticism. These pathways could either 
reflect vertical pleiotropic pathways, where hypothetically the genetic variants affect cognitive 
performance which in turn affects educational attainment, or vice versa, where the genetic 
variants affect educational attainment, in turn affecting cognitive performance. This form of 
pleiotropy does not result in bias in MR estimates (254). Conversely, these pathways could 
reflect horizontal pleiotropy where the SNPs independently affect cognitive performance and 
education. This would result in bias in MR estimates (254). To evaluate potential pleiotropy, 
MR-Egger was carried out, which can detect violation of the exclusion restriction criteria 
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(255). My MR-Egger estimates indicated the MR results were not biased by horizontal 
pleiotropy.  
In this GWAS, educational attainment was defined in terms of the amount of formal education 
an individual had completed. Highest major educational qualification was converted to the 
International Standard Classification for Education (ISCED) definitions of years of education, 
allowing for comparisons between 64 heterogenous cohorts meta-analysed in the GWAS (17). 
This standard definition meant educational attainment in UK Biobank could be defined in the 
same way in analyses presented in this thesis. However, where analyses were stratified by 
years of education in non-genetic analyses for example in interaction analyses Chapter 5 and 
Chapter 6, typically non-linear associations were observed. Whilst this definition allows for a 
standard approach to measuring educational attainment in heterogenous studies, our results 
suggest this definition may not be suitable to the UK education system. In the UK context, the 
ISCED definitions allocate a high number of years of education (19 years) to those with a 
vocational qualification. However, these individuals are more likely to enter manual labour 
jobs. This will likely explain some of the non-linearities observed. 
Non-genetic instruments are available for educational attainment, such as the policy reform, 
the Raising of School Leaving Age (RoSLA). Most relevantly for social science research, in 1972 
in England and Wales the compulsory school leaving age was raised from 15 to 16. This means 
some individuals are forced to remain in education longer than they would have and increases 
the average education levels in the relevant cohorts (267). The validity of the RoSLA as an 
instrumental variable has previously been demonstrated and has widely been used in 
economics for causal inference (442). In the same way that genetic instrumental variables in 
an MR approach avoid bias by confounding and reverse causality, natural experiments cannot 
be biased by confounding or reverse causality and any effect must act through the change in 
education. Indeed, many of the MR methods have evolved from econometrics methods for 
instrumental variable analyses (443). However, a limitation of this approach is that the RoSLA 
instrument only estimates the effect of a 1-year increase in education, in those who leave 
school at 16 compared to 15, in a select cohort of individuals who were in education as the 
policy reform was enacted. Conversely, the genetic variants for educational attainment used in 
this thesis represent an average effect across the whole distribution of education i.e. is not 
restricted to a 1-year difference. 
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7.3.11 Triangulation of methods and data 
A strength of the work presented here is the triangulation of different methods and sources of 
data (259). For example, in Chapter 4 I triangulated mediation results from individual level 
MR and summary data MR to estimate the causal role BMI, smoking and systolic blood 
pressure play in mediating the association between educational attainment and CVD. In 
Chapter 5, I used multiple different data sources to answer my research aim, including data 
collected at baseline UK Biobank clinics, primary care data and prescription data to estimate 
interactions between educational attainment and cardiovascular risk on statin use (and 
prescriptions).  
Importantly, these different analytical designs and data sources have different sources of bias 
(259). For example, when comparing results from phenotypic and MR mediation methods in 
Chapter 4, phenotypic methods may be biased by unmeasured confounding or measurement 
error, whilst MR methods may be biased by pleiotropic pathways or in the presence of weak 
instrument bias. Similarly, when comparing estimates of interaction between QRISK scores 
and educational attainment on statin use in UK Biobank using data from baseline assessment 
centres and from primary care records in Chapter 5, the sources of bias in the data are 
different. For example, UK Biobank data is much more complete with little missing data, but 
the measurements of the data may not reflect those used in primary care and clinical practice. 
An example of this is cholesterol measures, where samples in UK Biobank were non-fasting, 
but typically would be fasting in clinical practice. Conversely, clinical data is not uniformly 
collected for all patients, and only clinically relevant information to the appointment is 
recorded.  
The triangulation in this thesis could be improved and strengthened further by triangulating 
with data from different countries, or different cohort studies with different sociodemographic 
characteristics to UK Biobank. 
7.4 Other potential mechanisms 
Although not exhaustive, a broad scope of mechanistic pathways has been considered in this 
work, ranging from behavioural and lifestyle factors, to biological pathways and preventative 
medication. All of these mechanistic pathways were found to be involved in the aetiology of 
inequalities in CVD.  
The risk factors considered as mediators in Chapter 3 and Chapter 4 were selected based on 
their known causal effects on CVD, the availability of genetic instruments and because they 
will be capturing a broad range of other risk factors. For example, BMI will also be capturing 
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related factors such as exercise and diet. Indeed, when these variables were included in a 
phenotypic mediation model (in the absence of genetic instruments) they explained no more 
of the effect of education on CVD than the three main mediators considered. However, there 
may be other mediators not captured, or only partially captured through these three 
mediators. For example, adverse mental health may be an important mediator, where lower 
educational attainment increases the risk of adverse mental health (444), which is suggested 
to be an independent risk factor for CVD (445). 
In Chapter 5 I have focused on statin use, however, other preventative medications, such as 
antihypertensives, may be important in the development of inequalities. Additionally, 
adherence to statins (and other preventative medication) may be important in determining 
inequalities.  
Interestingly in Chapter 6, the effect of education as an effect modifier for a numer of 
cardiovascular risk factors did not always act in the same direction. Whilst individuals with 
low educational attainment and higher genetic susceptibility were more likely to smoke, they 
were less likely to experience adverse levels of LDL-C. Understanding the mechanisms 
specifically involved in how educational attainment modifies genetic effects will be important. 
For example, these effects may be due to remaining in education leading to increased 
knowledge and, or because of, greater intelligence. However a number of studies have 
identified independent effects of education on CVD and cardiovascular risk factors after 
controlling for intelligence (272, 273, 398). Conversely, increased early SEP, would likely lead 
to higher adult SEP which may be more important for the aetiology of disease later in life.  
Throughout this thesis I have only considered educational attainment as an indicator of SEP. 
Socioeconomic position broadly covers a number of different indicators, including individual 
level SEP such as education and adulthood income, occupation or employment. At the family 
level, early life family SEP can be captured by parental education or parental income, and in 
adulthood, household income can be considered (71). At the population level, deprivation 
indices such as the TDI can be used to estimate SEP (446). These different indicators are 
often, incorrectly, used interchangeably (447). Across the life course, SEP is complex, where 
different indicators may remain more, or less, stable. For example, income will likely change 
during different life stages. During active professional life, income will likely fluctuate then 
change again at retirement (71). Conversely, education is determined during childhood and 
early adulthood and will likely remain stable through adulthood and to retirement. Indeed, 
there is evidence that these different indicators of SEP accumulate across the life course to 
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affect cardiovascular risk (448). By not considering these additional indicators across the life 
course it is likely that the analyses presented in this thesis are not capturing the full 
complexity of the association between SEP and CVD. However, the focus on educational 
attainment means causal inference methods such as MR can be used. Although a GWAS of 
income has been published during the duration of this thesis work (266), genetic association 
estimates are not available for other indicators of SEP. 
7.4.1 Individual and societal determinants of inequalities 
Socioeconomic inequalities in CVD are not a new phenomenon. The Whitehall I study of civil 
servants demonstrated an association between occupational social class and CHD in the 1970s, 
where men in the lowest grade of employment had 3.6 times the CHD mortality compared 
with those in the highest employment grade (94). Some 50 years later, I have demonstrated 
similar effects of education on CHD.  
In this thesis I have largely considered individual level factors in driving these inequalities. For 
example, by studying and demonstrating that BMI and smoking are mediators of educational 
inequalities, this shifts a focus and blame to individual behaviours. However, inequalities are 
not always an individual choice, rather the social and political structure of society dictates 
these inequalities exist (449). For example, the built environment around where an individual 
lives can result in an obesogenic environment (450). Although in the United Kingdom, we 
have a free at the point of use healthcare system, access to high quality healthcare is not 
universal (451). In analyses using primary care data in Chapter 5, I identify inequalities in 
statin prescriptions in individuals who attend primary care. Here, in individuals with a QRISK 
score recorded in primary care data, higher educated individuals are more likely to receive 
statin treatment compared to lower educated individuals with equivalent underlying 
cardiovascular risk. These results begin to elude to wider inequalities within healthcare 
settings which may be independent of individual health seeking behaviours.  
Not considering these wider societal determinants of inequalities places potentially unfair and 
unjust criticism on to individuals, rather than assigning criticism to the societal structure and 
interventions which result in these behaviours. However, these wider determinants are 
difficult to quantify and often not studied in social epidemiology. As a result of the Covid-19 
pandemic and the evidence of socioeconomic and racial inequalities in disease severity and 
mortality, these wider determinants have gained greater prominence in discussions of disease 
prevention (452). Whilst this pandemic may exacerbate health inequalities in the short term 
(453), both from Covid-19 and other conditions (454), it has been said that this could be the 
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turning point for inequalities (455). Any improvements implemented at a societal level to 
tackle Covid-19 inequalities will inevitably improve inequalities in other health outcomes, 
including CVD. Where the conversation shifts from blaming individuals for poor health to 
blaming society for poor health, we may begin to minimise health inequalities in a lasting 
manner. 
The wider context of the mechanisms identified in this thesis should be considered in future 
research and in the interpretation of the results of this thesis. Whilst in this thesis I have 
demonstrated a number of modifiable risk factors partly explaining educational inequalities in 
CVD, interventions to target these risk factors should consider the societal context in which 
these risk factors emerge, as well as the individual behaviours.  
7.5 Future work 
Important future work to this thesis would include replicating analyses in different 
populations or cohort studies. It would be important to carry this work out in studies with 
different sociodemographic characteristics, in different countries and including participants 
from a wide range of ancestries. However, UK Biobank is not unique in in its 
sociodemographic characteristic, where typically cohort studies have higher recruitment and 
retention on wealthier, more educated, less diverse participants (168, 169). Therefore, 
identifying suitable studies with appropriate data and a representative population will be 
important. Alternatively, methods such as inverse probability weighting could be used to 
account for this selection bias (456, 457).  
Future work would benefit from considering the role of different indicators of SEP. As more 
GWAS become available for SEP indicators, such as the GWAS of income (266), it may be 
possible to replicate analyses in this thesis. However, the more complex and difficult a 
phenotype is to define, the more likely it is that the exclusion-restriction criteria in MR will be 
violated. Similarly, future work should consider the most appropriate definition of educational 
attainment in a UK context. This applies mostly to future MR analyses where the GWAS 
define educational attainment according to ISCED definitions (17). 
As more genotypic data becomes available, particularly for related individuals, this work 
should be replicated to account for family population structure and dynastic effects through 
within-family analyses.  
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7.5.1 Extensions to each analysis 
In Chapter 3 I demonstrated how MR mediation methods, two-step MR and MVMR could be 
used to improve causal inference in mediation analysis. These methods have a number of clear 
advantages over phenotypic methods, such as not being biased by unmeasured confounding 
or mis-specified models resulting in reverse causality. However, there are a number of 
limitations to using these methods. These methods, and their usefulness, could be improved 
by carrying out future methodological research to be able to account for exposure-mediation 
interactions, such as by allowing for four-way decomposition analysis (458). Additionally, 
being able to account for time-varying mediators, such as childhood BMI and adulthood BMI 
would improve the breadth of applications possible (406, 408).  
These methods developments would be beneficial for more detailed analyses of Chapter 4. In 
MR mediation analyses in Chapter 4 the assumption of no exposure-mediator interaction was 
made. However, this may not be a valid assumption. Repeating these analyses being able to 
account for exposure-mediator interactions may provide a more reliable causal estimate of the 
role of the mediators. As previously discussed, the analyses in this chapter in particular would 
benefit from being replicated in a more diverse population. 
In Chapter 5 I demonstrated educational inequalities in statin prescribing given underlying 
cardiovascular risk. It would be interesting, and important for reducing disease, to identify 
whether these inequalities exist for other preventative medications, such as antihypertensive 
drugs. One challenge of this work is controlling for underlying risk. In England and Wales, 
QRISK3 scores are used to determine whether preventative statin treatment should be 
prescribed (25, 26), providing a suitable control measure. However, other preventative 
medications are often not prescribed on the basis of a risk score.  
Inequalities in statin use were present in a number of different data sources for the exposure 
(QRISK) and outcome (statin), including in self-reported statin use at baseline, in statin 
prescriptions 3 months prior to and after baseline, and in QRISK and QRISK2 scores recorded 
in primary care data with statin prescriptions. In the primary care data, there was a higher 
prevalence of statin prescriptions than there were QRISK scores recorded, suggesting statins 
are readily prescribed in the absence of risk assessment. To understand the context in which 
these inequalities arise, it would be important to identify why or when QRISK scores are (or 
are not) recorded. Inequalities have been identified in attendance to NHS health checks 
(where QRISK scores are routinely recorded) (359-361), where health seeking behaviours may 
partially explain some of these differences. However, given the inequalities in primary care 
   
 
 217 
data, differences must also arise at the clinical level. Engaging with clinicians and patients may 
help elucidate some of the decisions made when i) carrying out risk assessments and ii) when 
deciding whether to prescribe statins. As UK Biobank is a highly selected population, 
replicating these analyses of primary care data in the clinical practice research database for 
example will be important to understand how widespread these inequalities are. However, as 
educational attainment is not routinely recorded in primary care data, consideration should 
be given to which measures of SEP may be appropriate to explore interactions with. 
Further to inequalities in statin prescriptions (or preventative medications more widely) may 
be inequalities in adherence. Poor adherence to medication has been shown to increase the 
risk of i) stroke (459) and ii) atherosclerotic cardiovascular disease (460). Currently, it is not 
possible to examine medication adherence in UK Biobank. However, where register data with 
information on repeat prescription collected is available, for example in the Finnish Drug 
Prescription Register it is possible to estimate adherence (459). Future work may benefit from 
being expanded to additionally consider the role of adherence in educational inequalities. 
In Chapter 6 I identified effect modification by educational attainment on genetic 
susceptibility to a number of cardiovascular risk factors. These analyses can be biased by 
reverse causality and unmeasured confounding, unlike MR analyses. Instrumental variable 
analyses could be carried out to explore this effect modification in a causal framework. For 
example, the RoSLA could be used to instrument educational attainment (461). An avenue for 
future research would be to carry out MVMR to test for causal interactions between 
educational attainment and cardiovascular risk factors on CVD (251, 252). However, a 
challenge for both of these instrumental variable approaches would be having a large enough 
sample size to achieve adequate statistical power. In MVMR, issues of low power can often be 
mitigated by using summary data MR. However, MR interaction analyses currently require 
individual level data, and as for any interaction, require even larger sample sizes to achieve 
sufficient statistical power (252). As such, a continuous outcome is preferential for these 
analyses, but CVD is inherently a binary outcome. Therefore, identifying a suitable outcome 
for analyses, whilst maintaining adequate power will be important. 
7.6 Implications for public health and policy 
Narrowing inequalities requires large-scale interventions to address social and structural 
factors, including (among other factors) improved access to housing (462), improved 
opportunities for work and safe income (463), access to education (including higher 
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education) and limiting the obesogenic environment (377, 449). However, in the absence of 
these changes, some targeted interventions may help reduce inequalities.  
Through this work I have identified a number of opportunities for interventions. Firstly, I have 
identified three mediators that could be intervened on to reduce CVD, these are BMI, smoking 
and systolic blood pressure (Chapter 4). However, despite many attempts in recent years to 
reduce BMI in the population, rates of obesity keep increasing (464). Understanding barriers 
to reducing obesity, particularly in those of lower SEP, would be important to success (465). 
Although it is too soon to identify any meaningful reductions in obesity attributable to the 
sugar sweetened beverage tax, it has been estimated that this will work to reduce obesity 
equitably across strata of SEP (465, 466).  
The rates of smoking have successfully reduced in recent years, but in individuals with lower 
SEP these reductions have been smaller and are beginning to plateau (133). Some of the most 
successful stop smoking campaigns have involved population wide interventions, such as 
increasing taxation (467, 468) and banning smoking indoors in public places (469). Whilst 
further population wide interventions may be beneficial, such as the recently introduced plain 
packaging laws, there will be fewer opportunities to intervene on this scale as more policies 
are introduced and the effects of future interventions may be marginal. Lower educational 
attainment is associated both with greater uptake of smoking and lower cessation of smoking 
(129, 130). Therefore, targeted interventions to reduce smoking uptake in more 
socioeconomically deprived groups may improve health outcomes.  
Reducing systolic blood pressure may also reduce CVD in lower educated individuals. Given 
that high BMI increases systolic blood pressure, interventions to reduce BMI would likely also 
result in reductions to systolic blood pressure. Unlike BMI and smoking, systolic blood 
pressure is not an easily observable phenotype. Opportunistic, community blood pressure 
programmes may increase awareness of high blood pressure (470). Targeting these community 
interventions to areas of greater social deprivation may result in greater reductions of 
inequalities. Systolic blood pressure is also the only one of these mediators which is currently 
a target for medication, in the form of antihypertensives. Ensuring inequalities are not present 
in antihypertensive medication, which can be used to prevent CVD, will be important. Should 
these inequalities exit, interventions should consider how they can be reduced.  
In Chapter 5, I identified inequalities in self-report statin use and in statin prescribing. 
Although statins are the subject of considerable debate, a recent Cochrane review found 
statins resulted in reductions in all-cause mortality, major vascular events and 
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revascularisations without any excess of adverse events (139). Therefore, they represent a cost-
effective, safe method of reducing CVD. Understanding more about why and how these 
inequalities in statin use occur will be key to developing effective interventions to improve 
uptake in more socioeconomically deprived individuals. Reasons for non-uptake may include 
differences in health seeking behaviours, particularly for primary prevention, personal 
decision to not take them or implicit bias by clinicians not prescribing them.  
Currently, low-dose statins are available to purchase over the counter from pharmacies (471), 
and ongoing discussions are being had about opening this up to high-dose statins (472). This 
provides a useful opportunity to address some of these inequalities by removing barriers to 
healthcare e.g. by not needing to make an appointment for general practice. However, this 
also poses as an opportunity to widen inequalities. In our sample in UK Biobank, we found a 
high proportion of individuals who reported taking statins had no statin prescription in their 
primary care records. The majority of these individuals reported using Simvastatin (the only 
statin available over the counter) and a large proportion were under 60 (the age of free 
prescriptions in England and Wales); suggesting they were likely purchasing medication over 
the counter rather than via an NHS prescription. These medications are not available at all 
pharmacies; by ensuring pharmacies in more socially deprived areas are able to provide this 
service, and advertise this service, uptake of statins could be encouraged. However, this 
should not be at the detriment to primary care visits, where inequalities are not just present in 
cardiovascular outcomes, but a large number of health outcomes including dementia (108), 
mental health outcomes (473) and types of cancer (474). 
Although genetics cannot be modified, the identification of education as an effect modifier of 
genetic susceptibility to CVD in Chapter 6 provide implications for policy. A source of 
considerable debate has been the value added of genetic data; with mixed conclusions (170, 
195-197). The results presented in this chapter begin to suggest that although at the population 
level including genetic information may not add much over existing phenotypic data, at the 
individual level there may be some utility to considering genetically stratified risk. It will be 
important, before carrying out any stratified interventions, to understand more specifically 
what it is about educational attainment leads to these differences and why the direction of 
effects differs for some risk factors. This may be knowledge gained via remaining in education 
or later life income (and SEP) attributable to obtaining more education.   
Finally, a theme which applies to all of these mechanistic pathways is understanding when 
interventions may be most effective during the life course. Cardiovascular risk factors, 
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including those studied in this thesis, have distinct life course trajectories according to SEP 
(154, 475, 476). Given the long latent period between educational attainment and CVD, there 
is a large amount of time in which to intervene. However, different periods of the life course 
may lead to different outcomes. It has previously been demonstrated that even heavy smokers 
who quit in adulthood can improve their cardiovascular risk (477). This may equally apply to 
BMI, systolic blood pressure and medication.  
7.7 Conclusions 
In this final chapter I have summarised the key findings of my thesis. I have fully explored the 
strengths and limitations of all analyses presented here and how this influences the causal 
inference to be made from the results. I have considered potential mechanisms for the 
aetiology of inequalities in CVD which have not been explored in this thesis, along with 
making recommendations for future research. Finally, I have considered the implications of 
this work for public health and policy. 
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Appendix 1: Mendelian randomisation for mediation 
analysis: current methods and challenges for 
implementation 
Author affiliations 
1. MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK 
2. Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK 
3. Centre for Academic Mental Health, University of Bristol, Bristol, UK 
4. National Institute for Health Research Biomedical Research Centre at the University 
Hospitals Bristol NHS Foundation Trust and the University of Bristol, Bristol, UK 
5. K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, 
NTNU, Norwegian University of Science and Technology, Norway. 
 
Multiple mediator equations 
i. The difference method to estimate the direct effect and indirect effect using 
phenotypic observed data mutually adjusting for all mediators 
Total: 
Y = θ+0 + θ+1X + θ+5C 
Direct: 
Y = θ0 + θ1X + θ2M1 + θ3M2 + θ4M3 + θ5C 
Indirect: 
θ+1X - θ1X 
 
ii. The product of coefficients method to estimate the indirect effect using phenotypic 
observed data, considering each mediator individually 
Mediator 1: 
Exposure-Mediator: 
M1= β0 + β1X + β4C 
Direct:  






 M2= β0 + β2X + β4C 
Direct: 






M3= β0 + β3X + β4C 
Direct: 
Y= θ0 + θ1X + θ2M3M3 + θ4C 






β1θ2M1 + β2θ2M2 + β3θ2M3 
 
iii. Multivariable MR to estimate the direct effect and indirect effect using a single genetic 
instrumental variable for each of the exposure and mediator, using two-stage least 
squares regression 
Total: 
X = π0 + π1Gx + v1 
Y = β0 + βXTX + µ1 
 Direct: 
X = π0 + π1xGx + π2xGM1+ π3xGM2+ π4xGM3 + v1 
M1 = π1 + π1zGx + π2zGM1+ π3zGM2+ π4zGM3 + v2 
M2 = π2 + π1ΩGx + π2ΩGM1+ π3ΩGM2+ π4ΩGM3 + v3 
M3 = π3 + π3αGx + π2αGM1+ π2αGM2+ π4αGM3 + v4 
Y = β0 + βXX + βM1M1 + βM2M2 + βM3M3 + µ2 
Indirect: 
βXT - βX 
 
iv. Two-step MR to estimate the indirect effect using genetic instrumental variables for 
both the exposure and mediator, using two-stage least squares regression 
Mediator 1: 
Exposure-Mediator: 
X = π0 + π1Gx + vX 
M1 = β0 + βXM1X + µ1 
Direct: 
X = π0 + π1xGx + π2xGM1 + vX1 
M1= π01 + π11Gx + π21GM1 + vM1 






X = π0 + π1Gx + vX 
M2 = β0 + βxM2X + µ3 
Direct: 
X = π02 + π12Gx + π22GM2 + vX2 
M2 = π0M2 + π1M2Gx + π2M2GM2 + vM2 
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X = π0 + π1Gx + vX 
M3 = β0 + βXM3X + µ3 
Direct: 
X = π03 + π13Gx + π23GM3 + vX3 
M3 = π0M3 + π1M3Gx + π2M3GM2 + vM3 





βXM1βM1 + βXM2βM2+ βXM3βM3 
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Appendix 1 Table 1: Estimated effect sizes and size of bias for simulated effect of a phenotypically measured continuous mediator explaining the effect between a continuous exposure and continuous 









































Difference 0 0.5 1.1 (0.009) 0.60 1.20 0.833 (0.007) 0.33 0.67 0.267 (0.007) 0.27 NA 0.243 (0.006) 0.24 NA 
Product 0.267 (0.007) 0.27 NA 0.243 (0.006) 0.24 0.12 
Difference -0.5 0.5 1.1 (0.009) 0.60 1.20 1.5 (0.007) 0.75 1.50 -0.4 (0.008) -1.15 4.60 -0.364 (0.009) 0.14 -0.27 
Product -0.4 (0.008) -1.15 4.60 -0.364 (0.009) 0.14 0.07 
Difference 0.05 
 
0 0.6 (0.009) 0.60 NA 0.333 (0.007) 0.33 NA 0.267 (0.007) 0.27 NA 0.445 (0.009) 0.39 7.90 
Product 0.267 (0.007) 0.27 NA 0.445 (0.009) 0.39 0.20 
Difference 0.2 0.8 (0.009) 0.80 4.00 0.507 (0.007) 0.32 1.58 0.293 (0.007) 0.28 28.33 0.367 (0.007) 0.32 6.33 
Product 0.293 (0.007) 0.28 28.33 0.367 (0.007) 0.32 0.16 
Difference 0.5 1.1 (0.009) 0.90 1.80 0.767 (0.007) 0.29 0.58 0.333 (0.008) 0.31 12.32 0.303 (0.006) 0.25 5.05 
Product 0.333 (0.008) 0.31 12.32 0.303 (0.006) 0.25 0.13 
Difference 1 1.6 (0.009) 1.10 1.10 1.2 (0.007) 0.25 0.25 0.4 (0.008) 0.35 7.00 0.25 (0.004) 0.20 4.00 
Product 0.4 (0.008) 0.35 7.00 0.25 (0.004) 0.20 0.10 
Difference 0.25 
 
0 0.6 (0.008) 0.60 NA 0.334 (0.006) 0.33 NA 0.267 (0.007) 0.27 NA 0.444 (0.009) 0.19 0.78 
Product 0.267 (0.007) 0.27 NA 0.444 (0.009) 0.19 0.10 
Difference 0.2 0.8 (0.009) 0.80 4.00 0.4 (0.007) 0.25 1.25 0.399 (0.008) 0.35 6.99 0.499 (0.008) 0.25 1.00 
Product 0.399 (0.008) 0.35 6.99 0.499 (0.008) 0.25 0.12 
Difference 0.5 1.1 (0.009) 0.90 1.80 0.5 (0.01) 0.12 0.25 0.6 (0.01) 0.48 3.80 0.546 (0.008) 0.30 1.18 
Product 0.6 (0.01) 0.48 3.80 0.546 (0.008) 0.30 0.15 
Difference 1 1.6 (0.009) 1.10 1.10 0.667 (0.013) -0.08 -0.08 0.933 (0.014) 0.68 2.73 0.583 (0.008) 0.33 1.33 
Product 0.933 (0.014) 0.68 2.73 0.583 (0.008) 0.33 0.17 
Difference 0.75 
 
0 0.6 (0.009) 0.60 NA 0.333 (0.007) 0.33 NA 0.267 (0.007) 0.27 NA 0.445 (0.009) -0.31 -0.41 
Product 0.267 (0.007) 0.27 NA 0.445 (0.009) -0.31 -0.15 
Difference 0.2 0.8 (0.009) 0.80 4.00 0.134 (0.01) 0.08 0.42 0.666 (0.011) 0.52 3.44 0.833 (0.012) 0.08 0.11 
Product 0.666 (0.011) 0.52 3.44 0.833 (0.012) 0.08 0.04 
Difference 0.5 1.1 (0.008) 0.90 1.80 -0.166 (0.017) -0.29 -0.58 1.267 (0.017) 0.89 2.38 1.151 (0.016) 0.40 0.54 
Product 1.267 (0.017) 0.89 2.38 1.151 (0.016) 0.40 0.20 
Difference 1 1.6 (0.009) 1.10 1.10 -0.666 (0.03) -0.92 -0.92 2.266 (0.03) 1.52 2.02 1.416 (0.019) 0.67 0.89 
Product 2.266 (0.03) 1.52 2.02 1.416 (0.019) 0.67 0.33 
Difference = difference in coefficients; produce = product of coefficients; SD = standard deviation 
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Appendix 1 Table 2: Estimated effect sizes and size of bias for simulated effect of a phenotypically measured continuous mediator explaining the effect between a continuous exposure and continuous 
outcome (per unit increase in exposure), and a rare binary outcome and common binary outcome on the risk difference scale, with no residual covariance reflecting confounding (Simulated N=5000) 
























Size of bias 
(absolute) 







0.05 0 (0.01) 0.00 0 (0.01) 0.00 0 (0.01) 0.00 0 (0.01) 0.18 3.53 
Product 0 (0.003) 0.00 0.227 (10.342) 0.18 0.09 
Difference 
0.25 0 (0.01) 0.00 0 (0.01) 0.00 0 (0.01) 0.00 0 (0.01) -0.10 -0.39 
Product 0 (0.003) 0.00 0.152 (3.448) -0.10 -0.05 
Difference 
0.75 0 (0.01) 0.00 0 (0.01) 0.00 
0 (0.01) 0.00 0 (0.01) -1.18 -1.57 






0.05 0 (0.002) 0.00 0 (0.002) 0.00 
0 (0.002) 0.00 0 (0.002) -0.39 -7.83 
Product 0 (0) 0.00 -0.342 (13.323) -0.39 -7.83 
Difference 
0.25 0 (0.002) 0.00 0 (0.002) 0.00 0 (0.002) 0.00 0 (0.002) -0.18 -0.71 
Product 0 (0) 0.00 0.073 (3.212) -0.18 -0.71 
Difference 
0.75 0 (0.002) 0.00 0 (0.002) 0.00 0 (0.002) 0.00 0 (0.002) -0.48 -0.65 







0.05 0 (0.004) 0.00 0 (0.004) 0.00 0 (0.004) 0.00 0 (0.004) -0.01 -0.11 
Product 0 (0.001) 0.00 0.044 (3.642) -0.01 -0.11 
Difference 
0.25 0 (0.004) 0.00 0 (0.004) 0.00 0 (0.004) 0.00 0 (0.004) -0.13 -0.50 
Product 0 (0.001) 0.00 0.125 (4.933) -0.13 -0.50 
Difference 
0.75 0 (0.004) 0.00 0 (0.004) 0.00 0 (0.004) 0.00 0 (0.004) -0.64 -0.85 
Product 0 (0.001) 0.00 0.114 (9.155) -0.64 -0.85 
Note: Relative bias cannot be estimated for the total effect direct effect and indirect effect because there is no true total effect 
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Appendix 1 Table 3: Estimated effect sizes and size of bias for simulated effect of a continuous mediator explaining the effect between a continuous exposure and continuous outcome using Mendelian 
randomisation (Simulated N=5000) 
Total effect = estimated using univariate Mendelian randomisation; direct effect = estimated using multivariable Mendelian randomisation controlling for both exposure and mediator 












Size of bias 
(absolute) 

























0 0.5 0.499 (0.017) 0.00 0.00 0.5 (0.014) 0.00 0.00 0 (0.004) 0.00 NA 0 (0.008) 0.00 NA 
TSMR 0 (0.004) 0.00 NA 0.004 (0) 0.00 NA 
MVMR 
-0.5 0.5 0.499 (0.017) 0.00 0.00 0.75 (0.023) 0.00 0.00 
-0.25 (0.018) 0.00 0.00 -0.501 (0.043) 0.00 0.00 




0 0 (0.017) 0.00 NA 0 (0.014) 0.00 NA 
0 (0.004) 0.00 NA 0.164 (2.176) 0.11 2.28 
TSMR 0 (0.004) 0.00 NA 0.004 (0.164) 0.11 2.28 
MVMR 
0.2 0.2 (0.017) 0.00 0.00 0.19 (0.014) 0.00 0.00 
0.01 (0.004) 0.00 0.01 0.049 (0.017) 0.00 -0.01 
TSMR 0.01 (0.004) 0.00 0.01 0.004 (0.049) 0.00 -0.01 
MVMR 
0.5 0.5 (0.018) 0.00 0.00 0.475 (0.015) 0.00 0.00 
0.025 (0.004) 0.00 -0.01 0.05 (0.008) 0.00 -0.01 
TSMR 0.025 (0.004) 0.00 -0.01 0.004 (0.05) 0.00 -0.01 
MVMR 
1 1 (0.017) 0.00 0.00 0.95 (0.014) 0.00 0.00 
0.05 (0.005) 0.00 0.00 0.05 (0.005) 0.00 0.00 




0 0 (0.018) 0.00 NA 0 (0.014) 0.00 NA 
0 (0.004) 0.00 NA 0.111 (3.554) -0.14 -0.56 
TSMR 0 (0.004) 0.00 NA 0.004 (0.111) -0.14 -0.56 
MVMR 
0.2 0.199 (0.017) 0.00 -0.01 0.149 (0.014) 0.00 0.00 
0.049 (0.005) 0.00 -0.01 0.249 (0.022) 0.00 0.00 
TSMR 0.049 (0.005) 0.00 -0.01 0.005 (0.249) 0.00 0.00 
MVMR 
0.5 0.5 (0.017) 0.00 0.00 0.375 (0.017) 0.00 0.00 
0.125 (0.01) 0.00 0.00 0.25 (0.019) 0.00 0.00 
TSMR 0.125 (0.01) 0.00 0.00 0.01 (0.25) 0.00 0.00 
MVMR 
1 1.001 (0.017) 0.00 0.00 0.751 (0.023) 0.00 0.00 
0.249 (0.018) 0.00 0.00 0.249 (0.018) 0.00 0.00 
TSMR 0.249 (0.018) 0.00 0.00 0.018 (0.249) 0.00 0.00 
MVMR 
0.75 
0 0 (0.017) 0.00 NA 0 (0.014) 0.00 NA 
0 (0.004) 0.00 NA -0.046 
(4.949) -0.80 -1.06 





0.2 0.2 (0.018) 0.00 0.00 0.05 (0.018) 0.00 0.00 
0.15 (0.011) 0.00 0.00 0.754 (0.074) 0.00 0.01 
TSMR 0.15 (0.011) 0.00 0.00 0.011 (0.754) 0.00 0.01 
MVMR 
0.5 0.501 (0.017) 0.00 0.00 0.126 (0.029) 0.00 0.01 
0.374 (0.026) 0.00 0.00 0.748 (0.056) 0.00 0.00 
TSMR 0.374 (0.026) 0.00 0.00 0.026 (0.748) 0.00 0.00 
MVMR 
1 1 (0.017) 0.00 0.00 0.249 (0.057) 0.00 0.00 
0.751 (0.055) 0.00 0.00 0.751 (0.056) 0.00 0.00 
TSMR 0.751 (0.055) 0.00 0.00 0.055 (0.751) 0.00 0.00 
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Appendix 1 Table 4: Estimated effect sizes and size of bias for simulated effect of a continuous mediator explaining the effect between a continuous exposure and continuous outcome (per unit increase in 
exposure), and a rare binary outcome and common binary outcome on the risk difference scale using Mendelian randomisation, where no residual covariance is included reflecting confounding 
(Simulated N=5000) 
Total effect = estimated using univariate Mendelian randomisation; direct effect = estimated using multivariable Mendelian randomisation controlling for both exposure and mediator 


























Size of bias 
(absolute) 






0.05 0 (0.003) 0.00 0.227 (10.342) 0.00 
0 (0.015) 0.00 0.811 (24.209) 0.76 15.22 
TSMR 0 (0.004) 0.00 0.811 (24.209) 0.76 15.22 
MVMR 
0.25 0 (0.003) 0.00 0.152 (3.448) 0.00 
0 (0.015) 0.00 -0.672 (31.009) -0.92 -3.69 
TSMR 0 (0.004) 0.00 -0.672 (31.009) -0.92 -3.69 
MVMR 
0.75 0 (0.003) 0.00 -0.427 (24.509) 0.00 
0 (0.015) 0.00 -0.022 (5.39) -0.77 -1.03 





0.05 0 (0) 0.00 -0.342 (13.323) 0.00 
0 (0.003) 0.00 0 (0.003) 1.29 25.90 
TSMR 0 (0) 0.00 1.345 (43.052) 1.29 25.90 
MVMR 
0.25 0 (0) 0.00 0.073 (3.212) 0.00 
0 (0.003) 0.00 0 (0.003) -0.21 -0.85 
TSMR 0 (0) 0.00 0.039 (1.697) -0.21 -0.85 
MVMR 
0.75 0 (0) 0.00 0.266 (5.102) 0.00 
0 (0.003) 0.00 0 (0.003) -0.81 -1.08 






0.05 0 (0.001) 0.00 0.044 (3.642) 0.00 
0 (0.006) 0.00 0 (0.006) 0.78 15.57 
TSMR 0 (0.001) 0.00 0.829 (30.515) 0.78 15.57 
MVMR 
0.25 0 (0.001) 0.00 0.125 (4.933) 0.00 
0 (0.006) 0.00 0 (0.006) -0.24 -0.96 
TSMR 0 (0.001) 0.00 0.01 (4.135) -0.24 -0.96 
MVMR 
0.75 0 (0.001) 0.00 0.114 (9.155) 0.00 
0 (0.006) 0.00 0 (0.006) -0.19 -0.25 
TSMR 0 (0.001) 0.00 0.565 (59.327) -0.19 -0.25 
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Appendix 1 Table 5: Estimated effect sizes and size of bias for simulated effect of a phenotypically measured continuous mediator explaining the effect between a continuous exposure and rare binary 
outcome on the risk difference scale (Simulated N=5000) 











































0.064 (0.001) 0.04 1.54 0.048 (0.002) 0.02 0.92 
0.015 (0.001) 0.02 NA 0.244 (0.019) 0.24 NA 
Product 0.015 (0.001) 0.02 NA 0.244 (0.019) 0.24 NA 
Difference 
-0.5 0.064 (0.001) 0.04 1.54 0.087 (0.002) 0.05 1.31 
-0.023 (0.002) -0.06 4.86 -0.365 (0.029) 0.13 -0.27 




0 0.051 (0.002) 0.05 NA 0.028 (0.002) 0.03 NA 
0.023 (0.001) 0.02 NA 0.447 (0.029) 0.40 7.93 
Product 0.023 (0.001) 0.02 NA 0.447 (0.029) 0.40 7.93 
Difference 
0.1 0.058 (0.001) -0.04 -0.42 0.037 (0.002) -0.06 -0.61 
0.021 (0.001) 0.02 3.24 0.367 (0.025) 0.32 6.35 
Product 0.021 (0.001) 0.02 3.24 0.367 (0.025) 0.32 6.35 
Difference 
0.025 0.064 (0.001) 0.04 1.54 0.044 (0.002) 0.02 0.86 
0.019 (0.001) 0.02 14.43 0.304 (0.025) 0.25 5.07 
Product 0.019 (0.001) 0.02 14.43 0.304 (0.025) 0.25 5.07 
Difference 
0.05 0.068 (0.001) 0.02 0.36 0.051 (0.002) 0.00 0.07 
0.017 (0.002) 0.01 5.83 0.251 (0.026) 0.20 4.02 




0 0.051 (0.002) 0.05 NA 0.028 (0.002) 0.03 NA 
0.023 (0.001) 0.02 NA 0.445 (0.028) 0.19 0.78 
Product 0.023 (0.001) 0.02 NA 0.445 (0.028) 0.19 0.78 
Difference 
0.1 0.058 (0.001) -0.04 -0.21 0.029 (0.002) -0.05 -0.61 
0.029 (0.002) 0.00 0.16 0.5 (0.034) 0.25 1.00 
Product 0.029 (0.002) 0.00 0.16 0.5 (0.034) 0.25 1.00 
Difference 
0.025 0.064 (0.001) 0.04 1.55 0.029 (0.003) 0.01 0.55 
0.035 (0.002) 0.03 4.54 0.545 (0.043) 0.29 1.18 
Product 0.035 (0.002) 0.03 4.54 0.545 (0.043) 0.29 1.18 
Difference 
0.05 0.068 (0.001) 0.02 0.36 0.029 (0.004) -0.01 -0.24 
0.039 (0.004) 0.03 2.16 0.581 (0.061) 0.33 1.32 




0 0.051 (0.002) 0.05 NA 0.028 (0.002) 0.03 NA 
0.023 (0.001) 0.02 NA 0.447 (0.028) -0.30 -0.40 
Product 0.023 (0.001) 0.02 NA 0.447 (0.028) -0.30 -0.40 
Difference 
0.1 0.058 (0.001) -0.04 -0.21 0.01 (0.003) -0.02 -0.61 
0.048 (0.002) -0.03 -0.36 0.833 (0.054) 0.08 0.11 
Product 0.048 (0.002) -0.03 -0.36 0.833 (0.054) 0.08 0.11 
Difference 
0.025 0.064 (0.001) 0.04 1.54 -0.01 (0.006) -0.02 -2.55 
0.073 (0.005) 0.05 2.91 1.153 (0.091) 0.40 0.54 
Product 0.073 (0.005) 0.05 2.91 1.153 (0.091) 0.40 0.54 
Difference 
0.05 0.068 (0.001) 0.02 0.36 -0.028 (0.01) -0.04 -3.26 
0.096 (0.009) 0.06 1.57 1.416 (0.143) 0.67 0.89 
Product 0.096 (0.009) 0.06 1.57 1.416 (0.143) 0.67 0.89 
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Appendix 1 Table 6: Estimated effect sizes and size of bias for simulated effect of a phenotypically measured continuous mediator explaining the effect between a continuous exposure and common binary 
outcome on the risk difference scale (Simulated N=5000) 











































0 0.125 0.196 (0.002) 0.07 0.57 0.148 (0.003) 0.02 0.19 
0.048 (0.002) 0.05 NA 0.243 (0.011) 0.24 NA 
Product 0.048 (0.002) 0.05 NA 0.243 (0.011) 0.24 NA 
Difference 
-0.5 0.125 0.196 (0.002) 0.07 0.57 0.267 (0.003) 0.08 0.43 
-0.071 (0.003) -0.26 4.14 -0.364 (0.018) 0.14 -0.27 




0 0.157 (0.003) 0.16 NA 0.087 (0.004) 0.09 NA 
0.07 (0.002) 0.07 NA 0.445 (0.017) 0.40 7.91 
Product 0.07 (0.002) 0.07 NA 0.445 (0.017) 0.40 7.91 
Difference 
0.05 0.178 (0.003) 0.13 2.56 0.113 (0.004) 0.07 1.38 
0.065 (0.002) 0.06 25.09 0.366 (0.014) 0.32 6.33 
Product 0.065 (0.002) 0.06 25.09 0.366 (0.014) 0.32 6.33 
Difference 
0.125 0.196 (0.002) 0.07 0.57 0.137 (0.004) 0.02 0.15 
0.059 (0.002) 0.05 8.49 0.303 (0.014) 0.25 5.05 
Product 0.059 (0.002) 0.05 8.49 0.303 (0.014) 0.25 5.05 
Difference 
0.25 0.21 (0.002) -0.04 -0.16 0.157 (0.004) -0.08 -0.34 
0.052 (0.003) 0.04 3.19 0.25 (0.013) 0.20 4.00 




0 0.157 (0.003) 0.16 NA 0.087 (0.004) 0.09 NA 
0.07 (0.002) 0.07 NA 0.444 (0.017) 0.19 0.78 
Product 0.07 (0.002) 0.07 NA 0.444 (0.017) 0.19 0.78 
Difference 
0.05 0.178 (0.003) 0.13 2.56 0.089 (0.004) 0.05 1.37 
0.089 (0.003) 0.08 6.12 0.5 (0.018) 0.25 1.00 
Product 0.089 (0.003) 0.08 6.12 0.5 (0.018) 0.25 1.00 
Difference 
0.125 0.196 (0.002) 0.07 0.57 0.089 (0.005) 0.00 -0.05 
0.107 (0.004) 0.08 2.42 0.545 (0.023) 0.29 1.18 
Product 0.107 (0.004) 0.08 2.42 0.545 (0.023) 0.29 1.18 
Difference 
0.25 0.21 (0.002) -0.04 -0.16 0.087 (0.007) -0.10 -0.53 
0.122 (0.006) 0.06 0.96 0.583 (0.03) 0.33 1.33 




0 0.157 (0.003) 0.16 NA 0.087 (0.004) 0.09 NA 
0.07 (0.002) 0.07 NA 0.444 (0.016) -0.31 -0.41 
Product 0.07 (0.002) 0.07 NA 0.444 (0.016) -0.31 -0.41 
Difference 
0.05 0.178 (0.003) 0.13 2.56 0.03 (0.006) 0.02 1.36 
0.148 (0.004) 0.11 2.96 0.834 (0.03) 0.08 0.11 
Product 0.148 (0.004) 0.11 2.96 0.834 (0.03) 0.08 0.11 
Difference 
0.125 0.196 (0.002) 0.07 0.57 -0.029 (0.009) -0.06 -1.94 
0.225 (0.008) 0.13 1.40 1.149 (0.047) 0.40 0.53 
Product 0.225 (0.008) 0.13 1.40 1.149 (0.047) 0.40 0.53 
Difference 
0.25 0.21 (0.002) -0.04 -0.16 -0.087 (0.015) -0.15 -2.39 
0.297 (0.014) 0.11 0.58 1.415 (0.073) 0.66 0.89 
Product 0.297 (0.014) 0.11 0.58 1.415 (0.073) 0.66 0.89 
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Appendix 1 Table 7: Estimated effect sizes and size of bias for simulated effect of a phenotypically measured continuous mediator explaining the effect between a continuous exposure and rare binary 
outcome on the risk difference scale, where simulated total effects are small (Simulated N=5000) 














































0.0005 0.051 (0.002) 0.05 101.47 0.029 (0.002) 0.03 59.32 
0.023 (0.001) 0.02 884.28 0.441 (0.029) 0.39 7.83 
Product 0.023 (0.001) 0.02 884.28 0.441 (0.029) 0.39 7.83 
Difference 
0.0025 0.053 (0.002) 0.05 20.17 0.031 (0.002) 0.03 11.90 
0.022 (0.001) 0.02 159.28 0.422 (0.027) 0.37 7.43 
Product 0.022 (0.001) 0.02 159.28 0.422 (0.027) 0.37 7.43 
Difference 
0.005 0.055 (0.002) 0.05 9.93 0.033 (0.002) 0.03 6.80 
0.022 (0.001) 0.02 85.70 0.401 (0.028) 0.35 7.02 




0.0005 0.051 (0.002) 0.05 101.63 0.028 (0.002) 0.03 74.49 
0.023 (0.001) 0.02 181.05 0.449 (0.029) 0.20 0.80 
Product 0.023 (0.001) 0.02 181.05 0.449 (0.029) 0.20 0.80 
Difference 
0.0025 0.053 (0.002) 0.05 20.17 0.028 (0.002) 0.03 14.19 
0.024 (0.001) 0.02 36.10 0.462 (0.03) 0.21 0.85 
Product 0.024 (0.001) 0.02 36.10 0.462 (0.03) 0.21 0.85 
Difference 
0.005 0.055 (0.001) 0.05 9.94 0.029 (0.002) 0.03 7.54 
0.026 (0.001) 0.03 20.56 0.477 (0.031) 0.23 0.91 




0.0005 0.051 (0.002) 0.05 101.74 0.027 (0.002) 0.03 217.47 
0.024 (0.001) 0.02 63.83 0.469 (0.031) -0.28 -0.37 
Product 0.024 (0.001) 0.02 63.83 0.469 (0.031) -0.28 -0.37 
Difference 
0.0025 0.053 (0.002) 0.05 20.14 0.023 (0.003) 0.02 35.87 
0.03 (0.002) 0.03 15.57 0.565 (0.038) -0.19 -0.25 
Product 0.03 (0.002) 0.03 15.57 0.565 (0.038) -0.19 -0.25 
Difference 
0.005 0.055 (0.001) 0.05 9.93 0.018 (0.003) 0.02 14.37 
0.037 (0.002) 0.04 9.71 0.67 (0.042) -0.08 -0.11 
Product 0.037 (0.002) 0.04 9.71 0.67 (0.042) -0.08 -0.11 
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Appendix 1 Table 8: Estimated effect sizes and size of bias for simulated effect of a phenotypically measured continuous mediator explaining the effect between a continuous exposure and common binary 













































0.0025 0.158 (0.003) 0.16 62.22 0.089 (0.004) 0.09 36.27 
0.07 (0.002) 0.07 537.24 0.44 (0.017) 0.39 7.80 
Product 0.07 (0.002) 0.07 537.24 0.44 (0.017) 0.39 7.80 
Difference 
0.0125 0.163 (0.003) 0.15 12.05 0.095 (0.004) 0.08 6.96 
0.069 (0.002) 0.06 90.70 0.42 (0.016) 0.37 7.41 
Product 0.069 (0.002) 0.06 90.70 0.42 (0.016) 0.37 7.41 
Difference 
0.025 0.169 (0.003) 0.14 5.74 0.101 (0.004) 0.08 3.26 
0.067 (0.002) 0.04 34.97 0.4 (0.015) 0.35 7.01 
Product 0.067 (0.002) 0.04 34.97 0.4 (0.015) 0.35 7.01 
Difference 
0.25 
0.0025 0.158 (0.003) 0.16 62.22 0.087 (0.004) 0.09 45.56 
0.071 (0.002) 0.07 110.19 0.448 (0.016) 0.20 0.79 
Product 0.071 (0.002) 0.07 110.19 0.448 (0.016) 0.20 0.79 
Difference 
0.0125 0.163 (0.003) 0.15 12.06 0.088 (0.004) 0.08 8.38 
0.075 (0.002) 0.07 21.08 0.461 (0.017) 0.21 0.85 
Product 0.075 (0.002) 0.07 21.08 0.461 (0.017) 0.21 0.85 
Difference 
0.025 0.169 (0.003) 0.14 5.75 0.088 (0.004) 0.07 3.72 
0.08 (0.002) 0.06 9.84 0.476 (0.017) 0.23 0.90 
Product 0.08 (0.002) 0.06 9.84 0.476 (0.017) 0.23 0.90 
Difference 
0.75 
0.0025 0.158 (0.003) 0.16 62.22 0.084 (0.004) 0.08 133.04 
0.074 (0.002) 0.07 39.28 0.47 (0.017) -0.28 -0.37 
Product 0.074 (0.002) 0.07 39.28 0.47 (0.017) -0.28 -0.37 
Difference 
0.0125 0.163 (0.003) 0.15 12.05 0.071 (0.004) 0.07 21.75 
0.092 (0.003) 0.09 9.48 0.564 (0.02) -0.19 -0.25 
Product 0.092 (0.003) 0.09 9.48 0.564 (0.02) -0.19 -0.25 
Difference 
0.025 0.169 (0.003) 0.14 5.75 0.056 (0.005) 0.05 8.01 
0.112 (0.003) 0.11 5.66 0.666 (0.023) -0.08 -0.11 
Product 0.112 (0.003) 0.11 5.66 0.666 (0.023) -0.08 -0.11 
Difference = difference in coefficients; produce = product of coefficients; SD = standard deviation 
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Appendix 1 Table 9: Estimated effect sizes and size of bias for simulated effect of a continuous mediator explaining the effect between a continuous exposure and a rare binary outcome on the risk 
difference scale using Mendelian randomisation (Simulated N=5000) 
Total effect = estimated using univariate Mendelian randomisation; direct effect = estimated using multivariable Mendelian randomisation controlling for both exposure and mediator 












Size of bias 
(absolute) 





Size of bias 
(absolute) 












Size of bias 
(absolute) 
Size of bias 
(relative) 
MVMR 
0 0.025 0.029 (0.003) 0.00 0.15 
0.029 
(0.003) 0.00 0.15 
0 (0) 0.00 NA -0.001 (0.008) 0.00 NA 
TSMR 0 (0) 0.00 NA 0 (-0.001) 0.00 NA 
MVMR 
-0.5 0.025 0.029 (0.003) 0.00 0.15 
0.043 
(0.004) 0.01 0.15 
-0.014 (0.003) 0.00 0.16 -0.509 (0.133) -0.01 0.02 
TSMR -0.014 (0.003) 0.00 0.16 -0.509 (0.133) -0.01 0.02 
MVMR 
0.05 
0 0 (0.003) 0.00 NA 0 (0.003) 0.00 NA 
0 (0) 0.00 NA -0.038 (2.344) -0.09 -1.77 
TSMR 0 (0) 0.00 NA 0 (-0.038) -0.09 -1.77 
MVMR 
0.1 0.014 (0.003) -0.09 -0.86 
0.014 
(0.003) -0.08 -0.86 
0.001 (0) 0.00 -0.85 0.051 (0.023) 0.00 0.02 
TSMR 0.001 (0) 0.00 -0.85 0 (0.051) 0.00 0.02 
MVMR 
0.025 0.029 (0.003) 0.00 0.15 
0.027 
(0.003) 0.00 0.15 
0.001 (0) 0.00 0.15 0.05 (0.015) 0.00 0.01 
TSMR 0.001 (0) 0.00 0.15 0 (0.05) 0.00 0.01 
MVMR 
0.05 0.043 (0.003) -0.01 -0.15 
0.04 
(0.003) -0.01 -0.15 
0.002 (0.001) 0.00 -0.14 0.051 (0.017) 0.00 0.02 
TSMR 0.002 (0.001) 0.00 -0.14 0.001 (0.051) 0.00 0.02 
MVMR 
0.25 
0 0 (0.003) 0.00 NA 0 (0.003) 0.00 NA 
0 (0) 0.00 NA -0.08 (3.313) -0.33 -1.32 
TSMR 0 (0) 0.00 NA 0 (-0.08) -0.33 -1.32 
MVMR 
0.1 0.014 (0.003) -0.09 -0.43 
0.011 
(0.003) -0.06 -0.86 
0.004 (0.001) -0.02 -0.86 0.26 (0.078) 0.01 0.04 
TSMR 0.004 (0.001) -0.02 -0.86 0.001 (0.26) 0.01 0.04 
MVMR 
0.025 0.029 (0.003) 0.00 0.16 
0.022 
(0.003) 0.00 0.17 
0.007 (0.002) 0.00 0.15 0.25 (0.066) 0.00 0.00 
TSMR 0.007 (0.002) 0.00 0.15 0.002 (0.25) 0.00 0.00 
MVMR 
0.05 0.043 (0.003) -0.01 -0.15 
0.032 
(0.004) -0.01 -0.14 
0.011 (0.004) 0.00 -0.16 0.248 (0.085) 0.00 -0.01 
TSMR 0.011 (0.004) 0.00 -0.16 0.004 (0.248) 0.00 -0.01 
MVMR 
0.75 
0 0 (0.003) 0.00 NA 0 (0.003) 0.00 NA 
0 (0) 0.00  0.027 (2.198) -0.72 -0.96 
TSMR 0 (0) 0.00  0 (0.027) -0.72 -0.96 
MVMR 
0.1 0.014 (0.003) -0.09 -0.43 
0.004 
(0.004) -0.02 -0.85 
0.011 (0.002) -0.06 -0.86 0.782 (0.237) 0.03 0.04 
TSMR 0.011 (0.002) -0.06 -0.86 0.002 (0.782) 0.03 0.04 
MVMR 
0.025 0.029 (0.003) 0.00 0.16 
0.007 
(0.006) 0.00 0.16 
0.022 (0.005) 0.00 0.16 0.757 (0.202) 0.01 0.01 
TSMR 0.022 (0.005) 0.00 0.16 0.005 (0.757) 0.01 0.01 
MVMR 
0.05 0.043 (0.003) -0.01 -0.15 
0.011 
(0.011) 0.00 -0.15 
0.032 (0.01) -0.01 -0.15 0.753 (0.247) 0.00 0.00 
TSMR 0.032 (0.01) -0.01 -0.15 0.01 (0.753) 0.00 0.00 
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Appendix 1 Table 10: Estimated effect sizes and size of bias for simulated effect of a continuous mediator explaining the effect between a continuous exposure and a common binary outcome on the risk 







































Size of bias 
(relative) 
MVMR 
0 0.125 0.089 (0.005) -0.04 -0.29 
0.089 
(0.005) -0.04 -0.29 
0 (0.001) 0.00 NA -0.001 (0.008) 0.00 NA 
TSMR 0 (0.001) 0.00 NA -0.001 (0.008) 0.00 NA 
MVMR 
-0.5 0.125 0.089 (0.005) -0.04 -0.29 
0.133 
(0.007) -0.05 -0.29 
-0.045 (0.006) 0.02 -0.29 -0.503 (0.079) 0.00 0.01 
TSMR -0.045 (0.006) 0.02 -0.29 -0.503 (0.079) 0.00 0.01 
MVMR 
0.05 
0 0 (0.006) 0.00 NA 0 (0.006) 0.00 NA 
0 (0.001) 0.00 NA -1.207 (38.778) -1.26 -25.14 
TSMR 0 (0.001) 0.00 NA -1.207 (38.778) -1.26 -25.14 
MVMR 
0.05 0.045 (0.006) -0.01 -0.10 
0.043 
(0.005) 0.00 -0.10 
0.002 (0.001) 0.00 -0.10 0.05 (0.019) 0.00 -0.01 
TSMR 0.002 (0.001) 0.00 -0.10 0.05 (0.019) 0.00 -0.01 
MVMR 
0.125 0.089 (0.005) -0.04 -0.29 
0.085 
(0.005) -0.03 -0.29 
0.004 (0.001) 0.00 -0.29 0.05 (0.01) 0.00 -0.01 
TSMR 0.004 (0.001) 0.00 -0.29 0.05 (0.01) 0.00 -0.01 
MVMR 
0.25 0.131 (0.004) -0.12 -0.48 
0.125 
(0.004) -0.11 -0.48 
0.007 (0.001) -0.01 -0.48 0.05 (0.009) 0.00 0.00 
TSMR 0.007 (0.001) -0.01 -0.48 0.05 (0.009) 0.00 0.00 
MVMR 
0.25 
0 0 (0.006) 0.00 NA 0 (0.006) 0.00 NA 
0 (0.001) 0.00 NA 1.384 (49.314) 1.13 4.54 
TSMR 0 (0.001) 0.00 NA 1.384 (49.314) 1.13 4.54 
MVMR 
0.05 0.044 (0.005) -0.01 -0.12 
0.033 
(0.005) 0.00 -0.12 
0.011 (0.002) 0.00 -0.12 0.252 (0.04) 0.00 0.01 
TSMR 0.011 (0.002) 0.00 -0.12 0.252 (0.04) 0.00 0.01 
MVMR 
0.125 0.089 (0.005) -0.04 -0.29 
0.067 
(0.006) -0.03 -0.28 
0.022 (0.003) -0.01 -0.29 0.248 (0.037) 0.00 -0.01 
TSMR 0.022 (0.003) -0.01 -0.29 0.248 (0.037) 0.00 -0.01 
MVMR 
0.25 0.131 (0.004) -0.12 -0.48 
0.098 
(0.007) -0.09 -0.48 
0.033 (0.006) -0.03 -0.47 0.25 (0.044) 0.00 0.00 
TSMR 0.033 (0.006) -0.03 -0.47 0.25 (0.044) 0.00 0.00 
MVMR 
0.75 
0 0 (0.006) 0.00 NA 0 (0.005) 0.00 NA 
0 (0.001) 0.00 NA -0.065 (9.881) -0.81 -1.09 
TSMR 0 (0.001) 0.00 NA -0.065 (9.881) -0.81 -1.09 
MVMR 
0.05 0.044 (0.006) -0.01 -0.11 
0.011 
(0.006) 0.00 -0.12 
0.033 (0.004) 0.00 -0.11 0.764 (0.13) 0.01 0.02 
TSMR 0.033 (0.004) 0.00 -0.11 0.764 (0.13) 0.01 0.02 
MVMR 
0.125 0.089 (0.005) -0.04 -0.29 
0.023 
(0.01) -0.01 -0.26 
0.066 (0.009) -0.03 -0.29 0.744 (0.109) -0.01 -0.01 
TSMR 0.066 (0.009) -0.03 -0.29 0.744 (0.109) -0.01 -0.01 
MVMR 
0.25 0.131 (0.004) -0.12 -0.48 
0.033 
(0.017) -0.03 -0.47 
0.098 (0.017) -0.09 -0.48 0.748 (0.131) 0.00 0.00 
TSMR 0.098 (0.017) -0.09 -0.48 0.748 (0.131) 0.00 0.00 
Total effect = estimated using univariate Mendelian randomisation; direct effect = estimated using multivariable Mendelian randomisation controlling for both exposure and mediator 
MVMR = multivariable Mendelian randomisation; two-step = TSMR Mendelian randomisation; SD = standard deviation   
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Total effect = estimated using univariate Mendelian randomisation; direct effect = estimated using multivariable Mendelian randomisation controlling for both exposure and mediator 
MVMR = multivariable Mendelian randomisation; two-step = TSMR Mendelian randomisation; SD = standard deviation 
 
  
Appendix 1 Table 11: Estimated effect sizes and size of bias for simulated effect of a continuous mediator explaining the effect between a continuous exposure and rare binary outcome on the risk 









































0.0005 0.001 (0.003) 0.00 0.39 
0.001 
(0.003) 0.00 0.38 
0 (0) 0.00 0.56 -0.021 (5.936) -0.07 -1.42 
TSMR 0 (0) 0.00 0.56 -0.021 (5.936) -0.07 -1.42 
MVMR 
0.0025 0.004 (0.003) 0.00 0.64 
0.004 
(0.003) 0.00 0.64 
0 (0) 0.00 0.71 0.05 (0.682) 0.00 -0.01 
TSMR 0 (0) 0.00 0.71 0.05 (0.682) 0.00 -0.01 
MVMR 
0.005 0.008 (0.003) 0.01 1.45 
0.007 
(0.003) 0.01 1.45 
0 (0) 0.00 1.45 0.05 (0.169) 0.00 -0.01 




0.0005 0.001 (0.003) 0.00 0.70 
0.001 
(0.003) 0.00 0.71 
0 (0) 0.00 0.65 0.055 (1.544) -0.20 -0.78 
TSMR 0 (0) 0.00 0.65 0.055 (1.544) -0.20 -0.78 
MVMR 
0.0025 0.004 (0.003) 0.00 0.61 
0.003 
(0.003) 0.00 0.61 
0.001 (0) 0.00 0.62 1.169 (30.416) 0.92 3.68 
TSMR 0.001 (0) 0.00 0.62 1.169 (30.416) 0.92 3.68 
MVMR 
0.005 0.008 (0.003) 0.01 1.44 
0.006 
(0.003) 0.01 1.43 
0.002 (0) 0.00 1.45 0.275 (0.864) 0.02 0.10 




0.0005 0.001 (0.003) 0.00 0.96 0 (0.003) 0.00 1.86 
0.001 (0) 0.00 0.66 -0.061 (7.019) -0.81 -1.08 
TSMR 0.001 (0) 0.00 0.66 -0.061 (7.019) -0.81 -1.08 
MVMR 
0.0025 0.004 (0.003) 0.00 0.64 
0.001 
(0.003) 0.00 0.67 
0.003 
(0.001) 0.00 0.63 
0.492 
(18.682) -0.26 -0.34 
TSMR 
0.003 
(0.001) 0.00 0.63 
0.492 
(18.682) -0.26 -0.34 
MVMR 
0.005 0.008 (0.003) 0.01 1.43 
0.002 
(0.003) 0.00 1.33 
0.006 
(0.001) 0.01 1.47 1.047 (2.14) 0.30 0.40 
TSMR 
0.006 
(0.001) 0.01 1.47 1.047 (2.14) 0.30 0.40 
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Total effect = estimated using univariate Mendelian randomisation; direct effect = estimated using multivariable Mendelian randomisation controlling for both exposure and mediator 





Appendix 1 Table 12: Estimated effect sizes and size of bias for simulated effect of a continuous mediator explaining the effect between a continuous exposure and common binary outcome on the risk 












































0.0025 0.002 (0.006) 0.00 -0.02 0.002 (0.006) 0.00 -0.02 
0 (0.001) 0.00 -0.05 0.115 (2.813) 0.07 1.31 
TSMR 0 (0.001) 0.00 -0.05 0.115 (2.813) 0.07 1.31 
MVMR 
0.0125 0.013 (0.006) 0.00 0.02 0.012 (0.006) 0.00 0.02 
0.001 (0.001) 0.00 0.04 0.047 (0.533) 0.00 -0.06 
TSMR 0.001 (0.001) 0.00 0.04 0.047 (0.533) 0.00 -0.06 
MVMR 
0.025 0.024 (0.006) 0.00 -0.04 0.023 (0.005) 0.00 -0.04 
0.001 (0.001) 0.00 -0.05 0.046 (0.044) 0.00 -0.08 




0.0025 0.003 (0.006) 0.00 0.04 0.002 (0.005) 0.00 0.05 
0.001 (0.001) 0.00 0.01 0.243 (5.842) -0.01 -0.03 
TSMR 0.001 (0.001) 0.00 0.01 0.243 (5.842) -0.01 -0.03 
MVMR 
0.0125 0.013 (0.006) 0.00 0.02 0.01 (0.006) 0.00 0.02 
0.003 (0.001) 0.00 0.00 0.287 (1.014) 0.04 0.15 
TSMR 0.003 (0.001) 0.00 0.00 0.287 (1.014) 0.04 0.15 
MVMR 
0.025 0.024 (0.006) 0.00 -0.04 0.018 (0.005) 0.00 -0.04 
0.006 (0.001) 0.00 -0.05 0.26 (0.075) 0.01 0.04 




0.0025 0.003 (0.006) 0.00 0.01 0.001 (0.006) 0.00 -0.03 
0.002 (0.001) 0.00 0.02 1.458 (28.614) 0.71 0.94 
TSMR 0.002 (0.001) 0.00 0.02 1.458 (28.614) 0.71 0.94 
MVMR 
0.0125 0.013 (0.006) 0.00 0.02 0.003 (0.006) 0.00 0.06 
0.009 (0.001) 0.00 0.01 0.877 (4.495) 0.13 0.17 
TSMR 0.009 (0.001) 0.00 0.01 0.877 (4.495) 0.13 0.17 
MVMR 
0.025 0.024 (0.006) 0.00 -0.04 0.006 (0.006) 0.00 -0.02 
0.018 (0.002) 0.00 -0.04 0.792 (0.231) 0.04 0.06 
TSMR 0.018 (0.002) 0.00 -0.04 0.792 (0.231) 0.04 0.06 
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Appendix 1 Table 13: Estimated effect sizes and size of bias for simulated effect of a continuous mediator explaining the effect between a continuous exposure and a rare binary outcome on the log odds 
ratio scale using Mendelian randomisation (Simulated N=5000) 
Total effect = estimated using univariate Mendelian randomisation; direct effect = estimated using multivariable Mendelian randomisation controlling for both exposure and mediator 










































0 0.5 0.617 (0.063) 0.12 0.23 0.62 (0.062) 0.12 0.24 
-0.003 (0.006) 0.00 NA -0.004 (0.01) 0.00 NA 
TSMR 0 (0.005) 0.00 NA -0.001 (0.008) 0.00 NA 
MVMR 
0.05 
0 -0.003 (0.063) 0.00 NA -0.003 (0.062) 0.00 NA 
0 (0.007) 0.00 NA -0.049 (2.294) -0.10 -1.99 
TSMR 0 (0.007) 0.00 NA -0.039 (2.356) -0.09 -1.78 
MVMR 
0.2 0.306 (0.061) 0.11 0.53 0.292 (0.06) 0.10 0.54 
0.014 (0.007) 0.00 0.39 0.046 (0.024) 0.00 -0.08 
TSMR 0.016 (0.007) 0.01 0.56 0.051 (0.023) 0.00 0.03 
MVMR 
0.5 0.621 (0.065) 0.12 0.24 0.592 (0.064) 0.12 0.25 
0.028 (0.009) 0.00 0.14 0.046 (0.014) 0.00 -0.08 
TSMR 0.031 (0.01) 0.01 0.25 0.051 (0.016) 0.00 0.01 
MVMR 
1 0.946 (0.065) -0.05 -0.05 0.901 (0.066) -0.05 -0.05 
0.045 (0.015) -0.01 -0.10 0.048 (0.016) 0.00 -0.05 




0 0 (0.063) 0.00 NA 0 (0.061) 0.00 NA 
0 (0.007) 0.00 NA -0.048 (3.005) -0.30 -1.19 
TSMR 0 (0.007) 0.00 NA -0.08 (3.316) -0.33 -1.32 
MVMR 
0.2 0.305 (0.062) 0.10 0.52 0.23 (0.062) 0.08 0.53 
0.075 (0.016) 0.02 0.50 0.256 (0.078) 0.01 0.02 
TSMR 0.077 (0.017) 0.03 0.53 0.261 (0.079) 0.01 0.05 
MVMR 
0.5 0.625 (0.065) 0.12 0.25 0.472 (0.073) 0.10 0.26 
0.153 (0.037) 0.03 0.22 0.247 (0.065) 0.00 -0.01 
TSMR 0.156 (0.038) 0.03 0.25 0.251 (0.067) 0.00 0.01 
MVMR 
1 0.947 (0.067) -0.05 -0.05 0.715 (0.102) -0.04 -0.05 
0.232 (0.077) -0.02 -0.07 0.246 (0.083) 0.00 -0.02 




0 -0.003 (0.065) 0.00 NA -0.003 (0.063) 0.00 NA 
0 (0.007) 0.00 NA 0.042 (2.245) -0.71 -0.94 
TSMR 0 (0.007) 0.00 NA 0.028 (2.217) -0.72 -0.96 
MVMR 
0.2 0.304 (0.063) 0.10 0.52 0.077 (0.075) 0.03 0.55 
0.227 (0.045) 0.08 0.51 0.781 (0.237) 0.03 0.04 
TSMR 0.229 (0.046) 0.08 0.52 0.786 (0.239) 0.04 0.05 
MVMR 
0.5 0.622 (0.061) 0.12 0.24 0.156 (0.13) 0.03 0.25 
0.465 (0.115) 0.09 0.24 0.756 (0.202) 0.01 0.01 
TSMR 0.468 (0.116) 0.09 0.25 0.761 (0.204) 0.01 0.01 
MVMR 
1 0.945 (0.064) -0.05 -0.05 0.234 (0.235) -0.02 -0.06 
0.711 (0.227) -0.04 -0.05 0.756 (0.248) 0.01 0.01 
TSMR 0.714 (0.229) -0.04 -0.05 0.759 (0.25) 0.01 0.01 
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Appendix 1 Table 14: Estimated effect sizes and size of bias for simulated effect of a continuous mediator explaining the effect between a continuous exposure and a common binary outcome on the log 
odds ratio scale using Mendelian randomisation (Simulated N=5000) 
Total effect = estimated using univariate Mendelian randomisation; direct effect = estimated using multivariable Mendelian randomisation controlling for both exposure and mediator 









































0 0.5 0.496 (0.032) 0.00 -0.01 0.5 (0.03) 0.00 0.00 
-0.004 (0.004) 0.00 NA -0.008 (0.009) -0.01 -0.02 




0 -0.001 (0.033) 0.00 NA -0.001 (0.03) 0.00 NA 
0 (0.005) 0.00 NA -1.244 (38.267) -1.29 NA 
TSMR 0 (0.006) 0.00 NA -1.226 (39.475) -1.28 NA 
MVMR 
0.2 0.242 (0.031) 0.04 0.21 0.232 (0.029) 0.04 0.22 
0.01 (0.005) 0.00 -0.05 0.039 (0.019) -0.01 -0.06 
TSMR 0.012 (0.005) 0.00 0.23 0.05 (0.019) 0.00 0.00 
MVMR 
0.5 0.497 (0.03) 0.00 -0.01 0.476 (0.029) 0.00 0.00 
0.021 (0.005) 0.00 -0.16 0.042 (0.009) -0.01 -0.02 
TSMR 0.025 (0.006) 0.00 0.00 0.05 (0.01) 0.00 0.00 
MVMR 
1 0.775 (0.032) -0.23 -0.23 0.74 (0.032) -0.21 -0.22 
0.035 (0.006) -0.01 -0.30 0.045 (0.008) 0.00 0.00 




0 0.001 (0.034) 0.00 NA 0.001 (0.031) 0.00 NA 
0 (0.006) 0.00 NA 1.345 (48.216) 1.10 NA 
TSMR 0 (0.006) 0.00 NA 1.423 (50.673) 1.17 NA 
MVMR 
0.2 0.238 (0.03) 0.04 0.19 0.181 (0.029) 0.03 0.21 
0.058 (0.008) 0.01 0.15 0.244 (0.039) -0.01 -0.04 
TSMR 0.06 (0.008) 0.01 0.20 0.255 (0.041) 0.01 0.04 
MVMR 
0.5 0.498 (0.031) 0.00 0.00 0.377 (0.034) 0.00 0.01 
0.12 (0.017) 0.00 -0.04 0.243 (0.036) -0.01 -0.02 
TSMR 0.124 (0.018) 0.00 -0.01 0.25 (0.038) 0.00 0.00 
MVMR 
1 0.775 (0.032) -0.22 -0.22 0.584 (0.044) -0.17 -0.22 
0.191 (0.033) -0.06 -0.23 0.247 (0.043) 0.00 0.00 




0 0.001 (0.032) 0.00 NA 0.001 (0.03) 0.00 NA 
0 (0.005) 0.00 NA -0.048 (9.389) -0.80 NA 
TSMR 0 (0.005) 0.00 NA -0.066 (10.008) -0.82 NA 
MVMR 
0.2 0.239 (0.031) 0.04 0.19 0.06 (0.035) 0.01 0.19 
0.179 (0.021) 0.03 0.19 0.762 (0.131) 0.01 0.24 
TSMR 0.182 (0.022) 0.03 0.21 0.773 (0.133) 0.02 0.46 
MVMR 
0.5 0.497 (0.031) 0.00 -0.01 0.129 (0.057) 0.00 0.03 
0.368 (0.05) -0.01 -0.02 0.743 (0.109) -0.01 -0.06 
TSMR 0.372 (0.051) 0.00 -0.01 0.75 (0.111) 0.00 0.00 
MVMR 
1 0.774 (0.031) -0.23 -0.23 0.196 (0.103) -0.05 -0.22 
0.579 (0.099) -0.17 -0.23 0.748 (0.131) 0.00 -0.01 
TSMR 0.582 (0.101) -0.17 -0.22 0.753 (0.133) 0.00 0.01 
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Appendix 1 Table 15: Estimated effect sizes and size of bias for simulated effect of a continuous mediator explaining the effect between a continuous exposure and a rare binary outcome on the odds ratio 










































0 1.65 1.857 (0.116) 0.21 0.13 1.862 (0.115) 0.21 0.13 
-0.005 (0.011) 0.00 NA -0.003 (0.006) 0.00 NA 




1.00 0.999 (0.063) 0.00 0.00 0.999 (0.062) 0.05 0.05 
0 (0.007) -0.05 -1.00 0 (0.007) -0.05 -1.00 
TSMR 0 (0.029) -0.05 -1.01 0.029 (-0.001) -0.05 -1.02 
MVMR 
1.22 1.361 (0.084) 0.14 0.11 1.342 (0.081) 0.18 0.16 
0.019 (0.01) -0.04 -0.69 0.014 (0.007) -0.04 -0.72 
TSMR 0.069 (0.028) 0.01 0.13 0.028 (0.05) 0.00 0.01 
MVMR 
1.65 1.864 (0.121) 0.22 0.13 1.812 (0.117) 0.25 0.16 
0.052 (0.017) -0.03 -0.36 0.028 (0.009) -0.02 -0.44 
TSMR 0.161 (0.029) 0.08 0.95 0.029 (0.086) 0.04 0.72 
MVMR 
2.72 2.58 (0.168) -0.14 -0.05 2.467 (0.163) -0.12 -0.04 
0.113 (0.037) -0.02 -0.17 0.044 (0.014) -0.01 -0.12 




1.00 1.002 (0.063) 0.00 0.00 1.002 (0.061) 0.25 0.34 
0 (0.007) -0.25 -1.00 0 (0.007) -0.25 -1.00 
TSMR -0.001 (0.029) -0.25 -1.00 0.029 (-0.002) -0.25 -1.01 
MVMR 
1.22 1.359 (0.084) 0.14 0.11 1.261 (0.078) 0.34 0.38 
0.098 (0.022) -0.21 -0.68 0.072 (0.015) -0.18 -0.71 
TSMR 0.339 (0.034) 0.03 0.11 0.034 (0.25) 0.00 0.00 
MVMR 
1.65 1.872 (0.122) 0.22 0.14 1.607 (0.117) 0.37 0.30 
0.265 (0.063) -0.15 -0.36 0.141 (0.032) -0.11 -0.43 
TSMR 0.803 (0.055) 0.39 0.95 0.055 (0.431) 0.18 0.72 
MVMR 
2.72 2.583 (0.173) -0.14 -0.05 2.055 (0.209) 0.02 0.01 
0.528 (0.162) -0.15 -0.22 0.205 (0.061) -0.05 -0.18 




1.00 0.999 (0.065) 0.00 0.00 0.999 (0.063) 0.75 3.00 
0 (0.007) -0.75 -1.00 0 (0.007) -0.75 -1.00 
TSMR 0 (0.028) -0.75 -1.00 0.028 (0) -0.75 -1.00 
MVMR 
1.22 1.359 (0.086) 0.14 0.11 1.083 (0.081) 0.78 2.55 
0.275 (0.053) -0.64 -0.70 0.202 (0.036) -0.55 -0.73 
TSMR 1.019 (0.067) 0.10 0.11 0.067 (0.752) 0.00 0.00 
MVMR 
1.65 1.865 (0.113) 0.22 0.13 1.179 (0.156) 0.77 1.86 
0.686 (0.143) -0.55 -0.44 0.368 (0.073) -0.38 -0.51 
TSMR 2.412 (0.151) 1.18 0.95 0.151 (1.298) 0.55 0.73 
MVMR 
2.72 2.578 (0.165) -0.14 -0.05 1.299 (0.304) 0.62 0.91 
1.28 (0.308) -0.76 -0.37 0.496 (0.115) -0.25 -0.34 
TSMR 4.545 (0.279) 2.51 1.23 0.279 (1.77) 1.02 1.36 
Total effect = estimated using univariate Mendelian randomisation; direct effect = estimated using multivariable Mendelian randomisation controlling for both exposure and mediator 
MVMR = multivariable Mendelian randomisation; two-step = TSMR Mendelian randomisation; SD = standard deviation   
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Appendix 1 Table 16: Estimated effect sizes and size of bias for simulated effect of a continuous mediator explaining the effect between a continuous exposure and a common binary outcome on the odds 








































0 1.65 1.643 (0.052) -0.01 0.00 1.65 (0.05) 0.00 0.00 
-0.006 (0.007) -0.01 NA -0.004 (0.004) 0.00 NA 




1.00 1 (0.033) 0.00 0.00 1 (0.03) 0.05 0.05 
0 (0.005) -0.05 -1.00 0 (0.005) -0.05 -1.00 
TSMR 0 (0.027) -0.05 -1.01 -0.001 (0.027) -0.05 -1.02 
MVMR 
1.22 1.274 (0.039) 0.05 0.05 1.262 (0.036) 0.10 0.09 
0.012 (0.006) -0.05 -0.80 0.009 (0.005) -0.04 -0.81 
TSMR 0.064 (0.025) 0.00 0.05 0.05 (0.019) 0.00 0.01 
MVMR 
1.65 1.645 (0.049) 0.00 0.00 1.611 (0.046) 0.04 0.03 
0.034 (0.008) -0.05 -0.58 0.021 (0.005) -0.03 -0.58 
TSMR 0.152 (0.026) 0.07 0.85 0.093 (0.015) 0.04 0.85 
MVMR 
2.72 2.171 (0.07) -0.55 -0.55 2.096 (0.067) -0.49 -0.19 
0.075 (0.013) -0.06 -0.45 0.034 (0.006) -0.02 -0.31 




1.00 1.001 (0.034) 0.00 0.00 1.001 (0.031) 0.25 0.33 
0 (0.006) -0.25 -1.00 0 (0.006) -0.25 -1.00 
TSMR -0.001 (0.027) -0.25 -1.00 -0.001 (0.027) -0.25 -1.01 
MVMR 
1.22 1.27 (0.038) 0.05 0.05 1.199 (0.035) 0.28 0.31 
0.071 (0.01) -0.23 -0.77 0.056 (0.007) -0.19 -0.78 
TSMR 0.317 (0.027) 0.01 0.04 0.249 (0.019) 0.00 0.00 
MVMR 
1.65 1.646 (0.051) 0.00 0.00 1.459 (0.05) 0.69 0.18 
0.187 (0.025) -0.07 -0.55 0.113 (0.015) -0.14 -0.55 
TSMR 0.763 (0.032) 0.51 0.85 0.464 (0.02) 0.21 0.85 
MVMR 
2.72 2.173 (0.069) -0.55 -0.55 1.795 (0.08) 1.01 -0.12 
0.377 (0.06) 0.11 -0.44 0.174 (0.027) -0.08 -0.31 




1.00 1.001 (0.032) 0.00 0.00 1.001 (0.03) 0.75 3.01 
0 (0.005) -0.75 -1.00 0 (0.005) -0.75 -1.00 
TSMR 0 (0.026) -0.75 -1.00 0 (0.026) -0.75 -1.00 
MVMR 
1.22 1.27 (0.039) 0.05 0.05 1.062 (0.038) 0.76 2.48 
0.208 (0.024) -0.71 -0.77 0.164 (0.018) -0.59 -0.78 
TSMR 0.956 (0.037) 0.04 0.04 0.753 (0.029) 0.00 0.00 
MVMR 
1.65 1.645 (0.051) 0.00 0.00 1.14 (0.066) 0.88 1.77 
0.505 (0.059) -0.26 -0.59 0.307 (0.035) -0.44 -0.59 
TSMR 2.288 (0.067) 1.52 0.85 1.392 (0.053) 0.64 0.86 
MVMR 
2.72 2.170 (0.068) -0.55 -0.55 1.222 (0.126) 0.96 0.80 
0.948 (0.126) 0.16 -0.54 0.437 (0.056) -0.31 -0.42 
TSMR 4.382 (0.12) 3.59 1.15 2.021 (0.08) 1.27 1.69 
Total effect = estimated using univariate Mendelian randomisation; direct effect = estimated using multivariable Mendelian randomisation controlling for both exposure and mediator 
MVMR = multivariable Mendelian randomisation; two-step = TSMR Mendelian randomisation; SD = standard deviation   
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Appendix 1 Table 17: Estimated effect sizes and size of bias for simulated effect of a phenotypically measured continuous mediator explaining the effect between a continuous exposure and continuous 
outcome (per unit increase in exposure), and a rare binary outcome and common binary outcome on the risk difference scale, where measurement error is introduced in either the exposure or mediator 
(Simulated N=5000)  
Product = product in coefficients; difference = difference in coefficients; SD = standard deviation   

















































0.5 0.366 (0.009) 0.17 0.33 
0.078 
(0.004) -0.30 -0.59 
0.288 
(0.008) 0.16 1.30 
0.786 
(0.011) 0.54 2.14 
Product 
0.288 
(0.008) 0.16 1.30 
0.786 
(0.011) 0.54 0.27 
Rare binary 
Difference 
0.025 0.021 (0.001) 0.00 -0.15 
0.005 
(0.001) -0.01 -0.76 
0.017 
(0.001) 0.01 1.66 
0.787 
(0.049) 0.54 2.15 
Product 
0.017 
(0.001) 0.01 1.66 
0.787 




0.125 0.065 (0.002) -0.06 -0.48 
0.014 
(0.002) -0.08 -0.85 
0.051 
(0.001) 0.02 0.64 
0.785 
(0.027) 0.54 2.14 
Product 
0.051 
(0.001) 0.02 0.64 
0.785 
(0.027) 0.54 2.14 
Measurement 






0.5 1.10 (0.009) 0.60 1.20 
0.936 
(0.01) 0.56 1.12 
0.164 
(0.006) 0.04 0.31 
0.149 
(0.006) -0.10 -0.40 
Product 
0.164 
(0.006) 0.04 0.31 
0.149 
(0.006) -0.10 -0.05 
Rare binary 
Difference 
0.025 0.064 (0.001) 0.04 1.54 
0.054 
(0.002) 0.04 1.89 
0.009 
(0.001) 0.00 0.51 
0.148 
(0.021) -0.10 -0.41 
Product 
0.009 
(0.001) 0.00 0.51 
0.148 




0.125 0.196 (0.002) 0.07 0.57 
0.167 
(0.004) 0.07 0.78 
0.029 
(0.002) 0.00 -0.07 
0.148 
(0.012) -0.10 -0.41 
Product 
0.029 
(0.002) 0.00 -0.07 
0.148 
(0.012) -0.10 -0.41 
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Appendix 1 Table 18: Estimated effect sizes and size of bias for simulated effect of a phenotypically measured continuous mediator explaining the effect between a continuous exposure and continuous 
outcome (per unit increase in exposure), and a rare binary outcome and common binary outcome on the risk difference scale using Mendelian randomization, where measurement error is introduced in 
either the exposure or mediator (Simulated N=5000) 
Total effect = estimated using univariate Mendelian randomisation; direct effect = estimated using multivariable Mendelian randomisation controlling for both exposure and mediator 
MVMR = multivariable Mendelian randomisation; two-step = TSMR Mendelian randomisation; SD = standard deviation   


















































0.5 0.499 (0.022) 0.00 0.00 
0.375 
(0.021) 0.00 0.00 
0.124 
(0.013) 0.00 -0.01 
0.249 
(0.024) 0.00 0.00 
TSMR 
0.124 
(0.013) 0.00 -0.01 
0.013 
(0.249) 0.00 0.00 
Rare binary 
MVMR 
0.025 0.029 (0.003) 0.00 0.16 
0.022 
(0.003) 0.00 0.16 
0.007 
(0.002) 0.00 0.15 
0.252 
(0.067) 0.00 0.01 
TSMR 
0.007 
(0.002) 0.00 0.15 
0.002 




0.125 0.089 (0.006) -0.04 -0.29 
0.067 
(0.006) -0.03 -0.29 
0.022 
(0.003) -0.01 -0.29 
0.248 
(0.039) 0.00 -0.01 
TSMR 
0.022 
(0.003) -0.01 -0.29 
0.248 
(0.039) 0.00 -0.01 
Measurement 






0.5 0.499 (0.017) 0.00 0.00 
0.374 
(0.018) 0.00 0.00 
0.125 
(0.012) 0.00 0.00 
0.251 
(0.022) 0.00 0.00 
TSMR 
0.125 
(0.012) 0.00 0.00 
0.012 
(0.251) 0.00 0.00 
Rare binary 
MVMR 
0.025 0.029 (0.003) 0.00 0.15 
0.022 
(0.003) 0.00 0.15 
0.007 
(0.002) 0.00 0.16 
0.255 
(0.068) 0.00 0.02 
TSMR 
0.007 
(0.002) 0.00 0.16 
0.002 




0.125 0.089 (0.005) -0.04 -0.29 
0.067 
(0.006) -0.03 -0.29 
0.022 
(0.003) -0.01 -0.29 
0.249 
(0.04) 0.00 0.00 
TSMR 
0.022 
(0.003) -0.01 -0.29 
0.249 
(0.04) 0.00 0.00 
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Appendix 1 Table 19: Estimated effect sizes and size of bias for simulated effect of a continuous mediator explaining the effect a continuous exposure and continuous outcome (per unit increase in 
















































0.05 0.319 (0.058) 0.00 0.00 
0.334 
(0.066) 0.00 0.00 
0.2 (0.144) 0.00 -0.07 -0.137 (14.419) -0.19 -3.73 
TSMR 0.009 (0.015) 0.00 -0.07 -0.137 (14.419) -0.19 -3.73 
MVMR 
0.25 0.419 (0.076) -0.01 -0.03 
0.439 
(0.088) -0.01 -0.05 
0.194 (0.147) 0.00 0.02 0.228 (3.527) -0.02 -0.09 
TSMR 0.051 (0.03) 0.00 0.02 0.228 (3.527) -0.02 -0.09 
MVMR 
0.75 0.648 (0.113) 0.00 0.00 
0.679 
(0.131) 0.00 0.03 
0.2 (0.144) 0.00 -0.01 0.849 (9.156) 0.10 0.13 





0.05 0.01 (0.004) 0.00 -0.39 
0.352 
(0.154) 0.00 -0.39 
0.006 
(0.009) 0.00 -0.38 
0.006 
(0.009) -0.13 -2.56 
TSMR 0 (0.001) 0.00 -0.38 -0.078 (2.288) -0.13 -2.56 
MVMR 
0.25 0.013 (0.005) 0.00 -0.43 
0.456 
(0.216) 0.00 -0.46 
0.006 (0.01) 0.00 -0.36 0.004 (0.01) -0.14 -0.55 
TSMR 
0.002 
(0.002) 0.00 -0.36 0.113 (2.935) -0.14 -0.55 
MVMR 
0.75 0.02 (0.008) 0.00 -0.39 
0.702 
(0.314) 0.00 -0.38 
0.006 (0.01) 0.00 -0.39 0.002 (0.011) -1.48 -1.97 
TSMR 
0.005 
(0.005) 0.00 -0.39 
-0.731 





0.05 0.03 (0.008) -0.03 -0.62 
0.334 
(0.098) -0.03 -0.62 
0.019 (0.019) 0.00 -0.65 0.018 (0.019) 0.00 -0.05 
TSMR 0.001 (0.002) 0.00 -0.65 0.047 (2.153) 0.00 -0.05 
MVMR 
0.25 0.04 (0.01) -0.03 -0.63 
0.44 
(0.124) -0.02 -0.64 
0.018 (0.019) -0.01 -0.62 0.013 (0.019) -1.68 -6.72 
TSMR 
0.005 
(0.004) -0.01 -0.62 -1.431 (48.68) -1.68 -6.72 
MVMR 
0.75 0.062 (0.015) -0.03 -0.61 
0.682 
(0.191) -0.01 -0.57 
0.019 (0.019) -0.02 -0.62 0.005 (0.021) -0.02 -0.02 
TSMR 0.014 (0.01) -0.02 -0.62 0.731 (16.786) -0.02 -0.02 
Total effect = estimated using univariate Mendelian randomisation; direct effect = estimated using multivariable Mendelian randomisation controlling for both exposure and mediator 
MVMR = multivariable Mendelian randomisation; two-step = TSMR Mendelian randomisation; SD = standard deviation 
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Appendix 1 Table 20: Estimated effect sizes and size of bias for simulated effect of a continuous mediator explaining the effect between a continuous exposure and continuous outcome using Mendelian 










































0.01 0.01 (0.017) 0.00 -0.03 
0.009 
(0.014) 0.00 -0.02 
0.00 (0.004) 0.00 -0.09 -0.448 (15.516) -0.50 -9.97 
TSMR 0.00 (0.004) 0.00 -0.09 -0.448 (15.516) -0.50 -9.97 
MVMR 
0.05 0.05 (0.017) 0.00 0.01 
0.048 
(0.014) 0.00 0.01 
0.003 (0.004) 0.00 0.04 0.027 (0.113) -0.02 -0.46 
TSMR 0.003 (0.004) 0.00 0.04 0.027 (0.113) -0.02 -0.46 
MVMR 
0.1 0.1 (0.018) 0.00 0.00 
0.095 
(0.015) 0.00 0.00 
0.005 (0.004) 0.00 -0.02 0.044 (0.039) -0.01 -0.11 




0.01 0.01 (0.017) 0.00 -0.04 
0.007 
(0.014) 0.00 -0.05 
0.002 (0.004) 0.00 -0.02 0.198 (5.108) -0.05 -0.21 
TSMR 0.002 (0.004) 0.00 -0.02 0.198 (5.108) -0.05 -0.21 
MVMR 
0.05 0.05 (0.018) 0.00 -0.01 
0.037 
(0.014) 0.00 -0.01 
0.012 (0.004) 0.00 -0.01 0.257 (0.124) 0.01 0.03 
TSMR 0.012 (0.004) 0.00 -0.01 0.257 (0.124) 0.01 0.03 
MVMR 
0.1 0.099 (0.017) 0.00 -0.01 
0.074 
(0.014) 0.00 -0.01 
0.025 (0.004) 0.00 -0.02 0.251 (0.033) 0.00 0.00 




0.01 0.01 (0.017) 0.00 -0.02 
0.002 
(0.014) 0.00 -0.04 
0.007 (0.004) 0.00 -0.01 2.062 (68.799) 1.31 1.75 
TSMR 0.007 (0.004) 0.00 -0.01 2.062 (68.799) 1.31 1.75 
MVMR 
0.05 0.051 (0.017) 0.00 0.02 
0.013 
(0.014) 0.00 0.06 
0.038 (0.005) 0.00 0.00 0.901 (1.63) 0.15 0.20 
TSMR 0.038 (0.005) 0.00 0.00 0.901 (1.63) 0.15 0.20 
MVMR 
0.1 0.1 (0.017) 0.00 0.00 
0.025 
(0.015) 0.00 0.00 
0.075 (0.007) 0.00 0.00 0.767 (0.117) 0.02 0.02 
TSMR 0.075 (0.007) 0.00 0.00 0.767 (0.117) 0.02 0.02 
Total effect = estimated using univariate Mendelian randomisation; direct effect = estimated using multivariable Mendelian randomisation controlling for both exposure and mediator 
MVMR = multivariable Mendelian randomisation; two-step = TSMR Mendelian randomisation; SD = standard deviation 
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Appendix 1 Table 21: Estimated effect sizes and size of bias for simulated effect of a phenotypically measured continuous mediator explaining the effect between a continuous exposure and continuous 
outcome (per unit increase in exposure), and a rare binary outcome and common binary outcome on the risk difference scale, where simulated total effects are imprecise (Simulated N=1000) 















































0.05 0.961 (0.076) 0.76 3.80 
0.642 
(0.095) 0.45 2.26 
0.961 
(0.076) 0.13 12.86 
0.642 
(0.095) 0.28 5.67 
Product 
0.319 
(0.058) 0.13 12.86 
0.334 
(0.066) 0.28 0.14 
Difference 
0.25 0.962 (0.079) 0.76 3.81 
0.542 
(0.109) 0.39 1.96 
0.962 
(0.079) 0.27 5.38 
0.542 
(0.109) 0.19 0.76 
Product 
0.419 
(0.076) 0.27 5.38 
0.439 
(0.088) 0.19 0.09 
Difference 
0.75 0.961 (0.079) 0.76 3.81 
0.313 
(0.137) 0.26 1.31 
0.961 
(0.079) 0.60 3.99 
0.313 
(0.137) -0.07 -0.09 
Product 
0.648 
(0.113) 0.60 3.99 
0.679 





0.05 0.03 (0.005) 0.02 1.98 
0.02 
(0.006) 0.01 1.07 
0.03 
(0.005) 0.00 1.31 
0.02 
(0.006) 0.30 6.04 
Product 
0.01 
(0.004) 0.00 1.31 
0.352 
(0.154) 0.30 6.04 
Difference 
0.25 0.03 (0.005) 0.02 1.97 
0.017 
(0.008) 0.01 1.22 
0.03 
(0.005) 0.01 2.22 
0.017 
(0.008) 0.21 0.82 
Product 
0.013 
(0.005) 0.01 2.22 
0.456 
(0.216) 0.21 0.82 
Difference 
0.75 0.03 (0.005) 0.02 2.00 
0.01 
(0.01) 0.01 2.88 
0.03 
(0.005) 0.02 2.37 0.01 (0.01) -0.05 -0.06 
Product 
0.02 
(0.008) 0.02 2.37 
0.702 






0.05 0.092 (0.01) 0.04 0.84 
0.062 
(0.013) 0.01 0.30 
0.092 
(0.01) -0.02 -6.86 
0.062 
(0.013) 0.28 5.69 
Product 
0.03 
(0.008) -0.02 -6.86 
0.334 
(0.098) 0.28 5.69 
Difference 
0.25 0.092 (0.009) 0.04 0.84 
0.052 
(0.014) 0.01 0.39 
0.092 
(0.009) 0.00 0.20 
0.052 
(0.014) 0.19 0.76 
Product 
0.04 
(0.01) 0.00 0.20 0.44 (0.124) 0.19 0.76 
Difference 
0.75 0.092 (0.01) 0.04 0.84 
0.03 
(0.019) 0.02 1.41 
0.092 
(0.01) 0.05 1.31 0.03 (0.019) -0.07 -0.09 
Product 
0.062 
(0.015) 0.05 1.31 
0.682 
(0.191) -0.07 -0.09 
Difference = difference in coefficients; product = product of coefficients; SD = standard deviation   
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Appendix 1 Table 22: Estimated effect sizes and size of bias for simulated effect of a phenotypically measured continuous mediator explaining the effect between a continuous exposure and continuous 










































0.01 0.61 (0.009) 0.60 60.05 
0.342 
(0.007) 0.33 33.25 
0.268 (0.007) 0.26 517.96 0.44 (0.009) 0.39 7.80 
Product 0.268 (0.007) 0.26 517.96 0.44 (0.009) 0.39 0.19 
Difference 
0.05 0.65 (0.009) 0.60 12.00 
0.377 
(0.007) 0.33 6.58 
0.273 (0.007) 0.23 90.32 0.42 (0.009) 0.37 7.41 
Product 0.273 (0.007) 0.23 90.32 0.42 (0.009) 0.37 0.19 
Difference 
0.1 0.7 (0.009) 0.60 6.00 0.42 (0.007) 0.33 3.25 
0.28 (0.008) 0.18 36.95 0.4 (0.008) 0.35 6.99 




0.01 0.61 (0.009) 0.60 59.95 
0.336 
(0.006) 0.33 32.87 
0.273 (0.007) 0.27 106.31 0.448 (0.009) 0.20 0.79 
Product 0.273 (0.007) 0.27 106.31 0.448 (0.009) 0.20 0.10 
Difference 
0.05 0.65 (0.008) 0.60 12.01 
0.35 
(0.007) 0.31 6.26 
0.3 (0.007) 0.26 21.01 0.461 (0.009) 0.21 0.85 
Product 0.3 (0.007) 0.26 21.01 0.461 (0.009) 0.21 0.11 
Difference 
0.1 0.7 (0.009) 0.60 6.00 0.367 (0.007) 0.29 2.92 
0.333 (0.008) 0.26 10.31 0.476 (0.008) 0.23 0.90 




0.01 0.61 (0.009) 0.60 59.99 
0.323 
(0.007) 0.32 32.07 
0.287 (0.008) 0.28 37.90 0.47 (0.009) -0.28 -0.37 
Product 0.287 (0.008) 0.28 37.90 0.47 (0.009) -0.28 -0.14 
Difference 
0.05 0.65 (0.009) 0.60 12.00 
0.284 
(0.007) 0.27 5.42 
0.366 (0.008) 0.35 9.44 0.564 (0.01) -0.19 -0.25 
Product 0.366 (0.008) 0.35 9.44 0.564 (0.01) -0.19 -0.09 
Difference 
0.1 0.7 (0.009) 0.60 6.00 0.233 (0.008) 0.21 2.08 
0.467 (0.009) 0.44 5.89 0.667 (0.01) -0.08 -0.11 
Product 0.467 (0.009) 0.44 5.89 0.667 (0.01) -0.08 -0.04 
Difference = difference in coefficients; product = product of coefficients; SD = standard deviation   
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Appendix 1 Table 23: Estimated indirect effect and proportion mediated by multiple continuous mediators explaining the association between a continuous exposure and continuous outcome in 














Mutually adjusting for all mediators 
(Difference in coefficients/MVMR) 
Considering each mediator independently 
(Product of coefficients/TSMR) 



































































































































































True indirect effect of independent mediators: M1 = 0.05; M2 = 0.08; M3 = 0.12 
True indirect effect of related mediators: M1 = 0.05; M2 = 0.05; M3 = 0.12; M2 via M3; 0.03 
MVMR = multivariable Mendelian randomisation; TSMR = two-step Mendelian randomisation; MR = Mendelian randomisation; SD = standard deviation
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Appendix 2: Understanding the consequences of education 
inequality on cardiovascular disease: mendelian 
randomisation study. 
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Appendix 2 Table  1: Genome-wide significant SNPs for SBP from split sample GWAS analysis in UK Biobank 
Chromosome RSID Position Beta SE Other Allele P Value Sample 
1 rs5068 11905974 1.3283 0.1374 A 4.10E-22 1 
1 rs448385 25395133 -0.3464 0.0630 G 3.80E-08 1 
1 rs3790604 113046879 -0.8724 0.1204 C 4.30E-13 1 
1 rs2765524 89417695 0.3965 0.0641 C 6.00E-10 1 
2 rs953246 146335486 -0.3924 0.0685 T 1.00E-08 1 
2 rs1344653 19730845 -0.3481 0.0626 A 2.70E-08 1 
2 rs1009358 65276452 0.3693 0.0645 T 1.00E-08 1 
2 rs268263 164954174 -0.5652 0.0735 T 1.50E-14 1 
2 rs35021474 26916844 0.4639 0.0645 C 6.30E-13 1 
2 rs2867114 651380 0.6149 0.1073 C 1.00E-08 1 
3 rs3821843 53558012 -0.4129 0.0681 G 1.40E-09 1 
3 rs1343040 169186293 -0.4317 0.0637 G 1.20E-11 1 
3 rs2643826 27562988 -0.3780 0.0631 C 2.20E-09 1 
3 rs263016 183502559 0.3475 0.0631 T 3.60E-08 1 
4 rs10857147 81181072 -0.8157 0.0690 A 3.00E-32 1 
4 rs6825268 26783453 -0.3573 0.0631 A 1.50E-08 1 
4 rs13107325 103188709 0.7689 0.1190 C 1.00E-10 1 
4 rs1842896 156511459 -0.4014 0.0626 G 1.40E-10 1 
5 rs13436194 157803588 0.4570 0.0632 A 4.80E-13 1 
5 rs12656497 32831939 -0.7161 0.0638 T 3.00E-29 1 
6 rs2607015 31762843 -0.4232 0.0636 G 2.90E-11 1 
6 rs2499801 96854594 0.4442 0.0806 G 3.60E-08 1 
6 rs13219548 127165290 -0.4051 0.0630 C 1.30E-10 1 
7 rs62481856 106412082 -0.8444 0.0789 G 9.30E-27 1 
7 rs2854747 45959917 0.4198 0.0637 G 4.40E-11 1 
7 rs10241964 19042114 -0.5983 0.1056 G 1.40E-08 1 
7 rs10269774 92253972 0.3854 0.0669 G 8.40E-09 1 
7 rs891511 150704843 0.3765 0.0681 G 3.20E-08 1 
7 rs2023843 27243221 -0.8627 0.1198 C 6.00E-13 1 
7 rs3823483 131010943 -0.3546 0.0634 T 2.30E-08 1 
8 rs877116 10712945 0.4697 0.0636 G 1.50E-13 1 
8 rs7463212 143991858 0.3776 0.0629 T 2.00E-09 1 
8 rs73563812 25900405 0.4215 0.0737 G 1.10E-08 1 
10 rs56137952 134376691 -0.5494 0.0985 G 2.40E-08 1 
10 rs10883543 102552752 -0.6995 0.0996 G 2.20E-12 1 
10 rs10995311 64564934 0.3941 0.0634 C 5.00E-10 1 
10 rs11191580 104906211 1.0970 0.1180 T 1.50E-20 1 
10 rs7076938 115789375 -0.4606 0.0711 C 9.30E-11 1 
10 rs12258967 18727959 0.6582 0.0686 C 8.00E-22 1 
10 rs7922049 63462365 0.5533 0.0869 G 1.90E-10 1 
10 rs10786156 96014622 0.3767 0.0632 C 2.50E-09 1 
11 rs55925664 10192809 -0.6415 0.0805 T 1.60E-15 1 
11 rs7120737 47702395 0.6316 0.0891 A 1.30E-12 1 
11 rs10750766 65473798 -0.3930 0.0691 C 1.30E-08 1 
11 rs633185 100593538 -0.6945 0.0698 G 2.60E-23 1 
11 rs12418543 1894163 0.5668 0.0645 A 1.50E-18 1 
11 rs747249 130271647 0.3747 0.0656 A 1.10E-08 1 
12 rs73437338 90054619 0.7678 0.0843 T 8.80E-20 1 
12 rs4766578 111904371 0.4066 0.0626 T 8.60E-11 1 
12 rs35444 115552437 0.3909 0.0643 A 1.20E-09 1 
12 rs73073676 20351276 0.3773 0.0670 A 1.80E-08 1 
15 rs8039305 91422543 -0.5943 0.0630 T 4.00E-21 1 
15 rs1717200 41368334 -0.3912 0.0628 A 4.70E-10 1 
15 rs1543927 75063573 0.4218 0.0712 T 3.10E-09 1 
15 rs11634851 81028965 -0.4216 0.0628 C 1.90E-11 1 
16 rs77870048 69965021 -0.9117 0.1399 C 7.20E-11 1 
16 rs2188717 24730230 -0.5361 0.0792 T 1.30E-11 1 
17 rs9907379 59489893 -0.4257 0.0769 T 3.20E-08 1 
17 rs60289499 43218677 -0.4564 0.0708 G 1.10E-10 1 
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17 rs34710835 45146717 0.5223 0.0643 C 4.40E-16 1 
17 rs11650511 1337960 -0.4085 0.0634 C 1.20E-10 1 
19 rs73046792 49605705 0.4714 0.0843 G 2.30E-08 1 
19 rs12978472 7257990 0.8468 0.0941 C 2.20E-19 1 
20 rs74729242 57718690 -0.5901 0.1013 T 5.80E-09 1 
20 rs2423514 10693337 0.3709 0.0628 A 3.50E-09 1 
1 rs55857306 11895795 0.7687 0.0850 G 1.60E-19 2 
1 rs4648815 1687152 0.3807 0.0638 G 2.40E-09 2 
1 rs6541328 230833262 -0.5551 0.1010 A 3.80E-08 2 
1 rs778121 56620268 -0.3887 0.0659 T 3.60E-09 2 
1 rs6657049 115825531 -0.3665 0.0658 G 2.50E-08 2 
2 rs268263 164954174 -0.5602 0.0738 T 3.20E-14 2 
2 rs4666493 19765225 -0.3641 0.0639 G 1.20E-08 2 
2 rs1275988 26914364 0.4835 0.0650 C 9.90E-14 2 
2 rs6724607 191466532 0.3656 0.0630 A 6.40E-09 2 
3 rs2307032 27432995 0.3879 0.0664 T 5.20E-09 2 
3 rs6442260 11590751 0.3595 0.0659 G 4.90E-08 2 
4 rs10024506 89764197 0.4173 0.0745 G 2.10E-08 2 
4 rs11099097 81167309 -0.6371 0.0696 C 5.40E-20 2 
4 rs4690974 156393641 -0.3741 0.0631 T 3.10E-09 2 
4 rs17010961 86723103 -0.5775 0.0913 T 2.50E-10 2 
5 rs10059884 32832474 -0.5859 0.0643 C 7.80E-20 2 
5 rs12652819 121244520 0.3775 0.0677 A 2.50E-08 2 
5 rs17715065 158261163 -0.3662 0.0631 C 6.60E-09 2 
5 rs11241959 127787964 -0.3715 0.0631 A 4.00E-09 2 
5 rs2964330 157743781 -0.3645 0.0641 G 1.30E-08 2 
6 rs17080069 150989698 0.7199 0.1218 A 3.40E-09 2 
6 rs6923947 127098553 -0.4974 0.0635 G 5.00E-15 2 
6 rs7889 31605448 -0.3792 0.0657 C 7.80E-09 2 
7 rs891511 150704843 0.4141 0.0683 G 1.30E-09 2 
7 rs2392929 106414069 -0.7165 0.0790 T 1.20E-19 2 
7 rs42032 92237426 0.3967 0.0720 G 3.60E-08 2 
7 rs57301765 19052733 -0.5059 0.0866 G 5.20E-09 2 
9 rs2780072 9340831 -0.5035 0.0902 A 2.40E-08 2 
10 rs76443711 75449789 -0.5442 0.0915 G 2.70E-09 2 
10 rs7070797 63551773 0.6290 0.0905 G 3.60E-12 2 
10 rs11187838 96038686 0.5615 0.0637 G 1.20E-18 2 
10 rs732998 104897901 0.8365 0.1184 T 1.60E-12 2 
10 rs12258967 18727959 0.5893 0.0691 C 1.50E-17 2 
11 rs4980379 1888614 -0.5896 0.0657 C 2.70E-19 2 
11 rs12807950 107057190 -0.3790 0.0631 T 1.90E-09 2 
11 rs7107356 47676170 -0.4793 0.0630 A 2.90E-14 2 
11 rs1216743 100573120 -0.5662 0.0705 G 9.60E-16 2 
12 rs2681492 90013089 0.6765 0.0840 T 8.00E-16 2 
12 rs4767328 115929396 -0.3575 0.0640 G 2.30E-08 2 
12 rs35427 115556307 0.4110 0.0664 T 6.00E-10 2 
12 rs4883481 50574311 0.4218 0.0652 T 1.00E-10 2 
12 rs597808 111973358 0.4310 0.0634 A 1.00E-11 2 
15 rs7176022 75107880 0.4365 0.0713 A 9.10E-10 2 
15 rs4932373 91429287 -0.5144 0.0672 A 2.00E-14 2 
15 rs117539635 69682916 1.3387 0.2009 A 2.70E-11 2 
16 rs77870048 69965021 -0.9216 0.1415 C 7.40E-11 2 
16 rs11646987 24832408 0.3922 0.0709 G 3.20E-08 2 
17 rs1436138 75316880 0.3615 0.0661 A 4.40E-08 2 
17 rs7217916 76769434 0.3944 0.0650 A 1.30E-09 2 
17 rs2301597 43173273 0.5081 0.0640 T 2.00E-15 2 
17 rs11874 45017193 -0.5820 0.0917 G 2.20E-10 2 
17 rs4480845 1958609 0.4024 0.0662 T 1.20E-09 2 
19 rs167479 11526765 0.5743 0.0630 G 8.20E-20 2 
20 rs75777337 57702450 -0.6125 0.1033 T 3.10E-09 2 
20 rs913220 10966476 -0.4389 0.0649 C 1.40E-11 2 
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Appendix 2 Table  2: Genome-wide significant SNPs for lifetime smoking from split sample GWAS analysis in UK Biobank 
Chromosome RSID Position Beta SE Other Allele P Value Sample 
1 rs71673396 107507403 .0159243 .0029062 T 4.30e-08 1 
1 rs499257 44078384 .0146849 .0024706 T 2.80e-09 1 
2 rs2890772 146175106 -.0140201 .0023608 G 2.90e-09 1 
3 rs4856463 83638568 .0156642 .0028286 C 3.10e-08 1 
3 rs326341 107811142 .013281 .0023333 G 1.30e-08 1 
4 rs6852351 28064697 .0132797 .00241 C 3.60e-08 1 
5 rs17159727 106632458 .0241372 .0040898 T 3.60e-09 1 
5 rs986391 166993972 .0151657 .0024028 G 2.80e-10 1 
6 rs16879271 16822974 -.0325007 .0059395 A 4.50e-08 1 
7 rs10226228 32315613 -.0141999 .0024083 A 3.70e-09 1 
7 rs10233018 117523709 -.0129883 .0023226 A 2.20e-08 1 
8 rs10093628 9393379 -.0165694 .0027221 T 1.20e-09 1 
9 rs113382419 136463019 -.0242553 .0036827 C 4.50e-11 1 
11 rs10750016 112837740 -.0160683 .0023918 T 1.80e-11 1 
11 rs11030088 27646247 -.0157839 .002668 G 3.30e-09 1 
11 rs6590701 133315869 -.0144894 .0026473 G 4.40e-08 1 
12 rs4763463 10355901 .0132272 .0023863 G 3.00e-08 1 
15 rs7173514 78849918 .0224245 .0027791 C 7.10e-16 1 
1 rs10922907 91193049 .0134411 .0023251 A 7.40e-09 2 
2 rs1863161 60139524 -.0127982 .0023263 G 3.80e-08 2 
2 rs16824949 146168208 -.0145352 .0023181 G 3.60e-10 2 
2 rs7559547 615627 -.0219576 .0030462 C 5.70e-13 2 
2 rs263771 185921692 -.0151079 .0027443 C 3.70e-08 2 
3 rs62261249 49594060 -.0158442 .0026313 T 1.70e-09 2 
7 rs17657924 96625589 .0132644 .0023312 C 1.30e-08 2 
9 rs12553882 128195044 -.014292 .0024004 G 2.60e-09 2 
9 rs56116178 136460224 -.0306714 .0038063 A 7.70e-16 2 
11 rs7948789 112839532 -.0164578 .0023768 A 4.40e-12 2 
14 rs12897150 104319530 -.0136766 .0023459 A 5.50e-09 2 
15 rs28669908 78910267 .0237801 .0028216 C 3.50e-17 2 
15 rs34794623 47680801 -.0195197 .0028221 C 4.60e-12 2 
20 rs45577732 61983934 -.0386369 .0042941 C 2.30e-19 2 
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Appendix 3: Educational inequalities in statin treatment for 
preventing cardiovascular disease: cross-sectional analysis of 
UK Biobank 
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Campus, Imperial College London, London, UK. 
4) Novo Nordisk Research Centre Oxford, Old Road Campus, Oxford, UK 
5) Clinical Pharmacology and Therapeutics Section, Institute of Medical and Biomedical 
Education and Institute for Infection and Immunity, St George’s, University of London, 
London, UK 
6) Clinical Pharmacology Group, Pharmacy and Medicines Directorate, St George’s 
University Hospitals NHS Foundation Trust, London, UK 
7) Centre for Academic Primary Care, University of Bristol  
8) NIHR Bristol Biomedical Research Centre, University of Bristol  
9) K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, 
NTNU, Norwegian University of Science and Technology, Norway. 
Appendix 3 Table  1: ICD codes used to define incident and prevalent cases of cardiovascular disease 
 
Cardiovascular event ICD9 ICD10 
Incident cardiovascular 
disease (all subtypes 
combined) 
3900-4599 I* G45 
Myocardial infarction 4100-4109, 4120-4129 I21, I22 
Angina 4139 I20 
Stroke 43- 4389 I6, G45 
Transient ischaemic attack 4359 G45 
Peripheral arterial disease 4439 I73.9 
Type 1 diabetes 
2500- 25011, 25013, 2504-25041, 
25043, 2505-25051, 25053, 
2506-25061, 25063, 2507-25071, 
25073, 2509-25091, 25093 
E10 





   
 
 278 
Appendix 3 Table  2: Treatment codes in UK Biobank to define medications 
Medication UK Biobank treatment code  
Statins 1141146234 1140888594 1140888648 1141192410 1140861958 
Erectile 
dysfunction 
1140869100 1140883010 1141168936 1141168944 1141168946 1141168948 1141187810 1141187814 1141187818 
1141192248 1141192256 1141192258 1141192260 
Antihypertensives 
 1140860332 1140860334 1140860336 1140860338 1140860340 1140860342 1140860348 1140860352 
1140860356 1140860358 1140860362 1140860380 1140860382 1140860386 1140860390 1140860394 
1140860396 1140860398 1140860402 1140860404 1140860406 1140860410 1140860418 1140860422 
1140860426 1140860434 1140860454 1140860470 1140860478 1140860492 1140860498 1140860520 
1140860532 1140860534 1140860544 1140860552 1140860558 1140860562 1140860564 1140860580 
1140860590 1140860610 1140860628 1140860632 1140860638 1140860654 1140860658 1140860690 
1140860696 1140860706 1140860714 1140860728 1140860736 1140860738 1140860750 1140860752 
1140860758 1140860764 1140860776 1140860784 1140860790 1140860802 1140860806 1140860828 
1140860830 1140860834 1140860836 1140860838 1140860840 1140860842 1140860846 1140860848 
1140860862 1140860878 1140860882 1140860892 1140860904 1140860912 1140860918 1140860938 
1140860942 1140860952 1140860954 1140860966 1140860972 1140860976 1140860982 1140860988 
1140860994 1140861000 1140861002 1140861008 1140861010 1140861016 1140861022 1140861024 1140861034 
1140861046 1140861068 1140861070 1140861088 1140861090 1140861106 1140861110 1140861114 1140861120 
1140861128 1140861130 1140861136 1140861138 1140861166 1140861176 1140861190 1140861194 1140861202 
1140861266 1140861268 1140861276 1140861282 1140861326 1140861384 1140864950 1140864952 1140866072 
1140866074 1140866078 1140866084 1140866086 1140866090 1140866092 1140866094 1140866096 
1140866102 1140866104 1140866108 1140866110 1140866116 1140866122 1140866128 1140866132 1140866136 
1140866138 1140866140 1140866144 1140866146 1140866156 1140866158 1140866162 1140866164 1140866168 
1140866182 1140866192 1140866194 1140866200 1140866202 1140866206 1140866210 1140866212 
1140866220 1140866222 1140866226 1140866230 1140866232 1140866236 1140866244 1140866248 
1140866262 1140866280 1140866282 1140866306 1140866308 1140866312 1140866318 1140866324 
1140866328 1140866330 1140866332 1140866334 1140866340 1140866352 1140866354 1140866356 
1140866360 1140866388 1140866390 1140866396 1140866400 1140866402 1140866404 1140866406 
1140866408 1140866410 1140866412 1140866416 1140866418 1140866420 1140866422 1140866426 
1140866438 1140866440 1140866442 1140866444 1140866446 1140866448 1140866450 1140866460 
1140866466 1140866484 1140866506 1140866546 1140866554 1140866692 1140866704 1140866712 
1140866724 1140866726 1140866738 1140866756 1140866758 1140866764 1140866766 1140866778 
1140866782 1140866784 1140866798 1140866800 1140866802 1140866804 1140875808 1140879758 
1140879760 1140879762 1140879778 1140879782 1140879786 1140879794 1140879798 1140879802 
1140879806 1140879810 1140879818 1140879822 1140879824 1140879826 1140879830 1140879834 
1140879842 1140879854 1140879866 1140888510 1140888512 1140888552 1140888556 1140888560 
1140888578 1140888582 1140888586 1140888646 1140888686 1140888760 1140888762 1140909368 
1140911698 1140916356 1140916362 1140917428 1140923572 1140923712 1140923718 1140926778 1140926780 
1141145658 1141145660 1141145668 1141151016 1141151018 1141151382 1141152600 1141152998 1141153006 
1141153026 1141153032 1141153328 1141156754 1141156808 1141156836 1141156846 1141157252 1141157254 
1141164148 1141164154 1141164276 1141164280 1141165470 1141165476 1141166006 1141167822 1141167832 
1141171152 1141171336 1141171344 1141172682 1141172686 1141172698 1141173888 1141180592 1141180598 
1141187788 1141187790 1141190160 1141192064 1141193282 1141193346 1141194794 1141194800 1141194804 
1141194808 1141194810 1141201038 1141201040 




1140853854 1140854694 1140854700 1140854784 1140854788 1140854816 1140854834 1140854888 
1140854916 1140854990 1140857672 1140857678 1140862572 1140868364 1140868370 1140873620 
1140874790 1140874792 1140874794 1140874810 1140874814 1140874816 1140874822 1140874896 
1140874930 1140874936 1140874940 1140874944 1140874950 1140874954 1140874956 1140874976 
1140874978 1140875668 1140875684 1140876032 1140876036 1140876044 1140876046 1140876052 
1140876058 1140876076 1140876104 1140876456 1140878562 1140879922 1140879934 1140881938 
1140882152 1140882622 1140882624 1140882626 1140882630 1140882694 1140882708 1140882718 
1140882722 1140882724 1140882728 1140882730 1140882732 1140882740 1140882742 1140882756 
1140882758 1140882764 1140882766 1140882768 1140882774 1140882776 1140882778 1140882780 
1140882782 1140882794 1140882800 1140882806 1140882808 1140882816 1140882818 1140882820 
1140882822 1140882824 1140882826 1140882830 1140882832 1140882836 1140882840 1140882842 
1140882844 1140882846 1140882848 1140882850 1140882852 1140882864 1140882888 1140882892 
1140882894 1140882896 1140882898 1140882902 1140882904 1140882906 1140882908 1140882910 
1140882914 1140882916 1140882918 1140882920 1140882926 1140882928 1140882932 1140882934 
1140882938 1140883022 1140883026 1140883028 1140883030 1140883034 1140883038 1140883040 
1140883044 1140883048 1140883052 1140883054 1140883056 1140883058 1140883060 1140883062 
1140883064 1140884636 1140884640 1140884642 1140884646 1140884654 1140884660 1140884664 
1140884672 1140884676 1140884696 1140884700 1140884704 1140884716 1140888074 1140888092 
1140888098 1140888124 1140888130 1140888134 1140888142 1140888150 1140888166 1140888168 1140888172 
1140888176 1140888178 1140888184 1140888194 1140909786 1140909894 1140910424 1140910634 1141151424 
1141157294 1141157402 1141157418 1141162532 1141164086 1141167174 1141169844 1141173346 1141174512 
1141174520 1141174548 1141174552 1141179072 1141179982 1141180342 1141181062 1141181554 1141181610 
1141189464 1141191748 1141194840 1141195232 1141195280 
Second generation 
atypical Psychotics 
1140867420 1140867432 1140867444 1140927956 1140927970 1140928916 1141152848 1141152860 1141153490 
1141167976 1141177762 1141195974 1141202024 
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Tables: List of single nucleotide polymorphisms (SNPs) included in polygenic scores 
Appendix 4 Table 1: List of SNPs used in polygenic score for alcohol consumption, measured as drinks per week, at the 
genome-wide significance level with a clumping threshold of 500kb and an R
2
 threshold of 0.25 
 
 SNP (RSID) Effect allele Other allele Beta Standard error P value 
1 rs11940694 G A 0.0229 0.00308 4.82E-14 
2 rs1229978 C T 0.0208 0.00301 3.04E-12 
3 rs1229984 C T 0.186 0.0105 1.12E-65 
4 rs145441283 G A -0.197 0.0196 5.07E-24 
5 rs151180 T G -0.0229 0.00415 3.84E-08 
6 rs1789889 A G 0.022 0.0038 6.33E-09 
7 rs181163639 C A -0.0708 0.0115 8.33E-10 
8 rs1919208 T C 0.137 0.0212 4.30E-08 
9 rs3114045 C T 0.0336 0.00461 2.08E-13 
10 rs4699680 A G 0.0428 0.00762 1.97E-08 
11 rs55872084 T G 0.0203 0.00359 2.20E-08 
12 rs676388 C T 0.0183 0.00307 2.31E-09 
13 rs71612659 A G -0.0398 0.00719 1.26E-08 
14 rs7187575 T C 0.02 0.00338 5.23E-09 
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Appendix 4 Table 2: List of SNPs used in polygenic score for body mass index at the genome-wide significance level with a clumping threshold 
of 500kb and an R
2
 threshold of 0.25 
 SNP (RSID) Effect allele Other allele Beta Standard error P value 
1 rs1000940 G A 0.0192 0.0034 1.28E-08 
2 rs10132280 A C -0.023 0.0034 1.14E-11 
3 rs1016287 C T -0.0229 0.0034 2.25E-11 
4 rs10176391 G C -0.0793 0.0133 2.64E-09 
5 rs10182181 G A 0.0307 0.0031 8.78E-24 
6 rs10484664 A G 0.0185 0.0031 3.76E-09 
7 rs10493499 C T -0.0263 0.0037 1.48E-12 
8 rs10733682 G A -0.0174 0.0031 1.83E-08 
9 rs10798580 A G -0.0177 0.0031 1.16E-08 
10 rs10938397 G A 0.0402 0.0031 3.21E-38 
11 rs10968576 G A 0.0249 0.0033 6.61E-14 
12 rs11030066 T C 0.0282 0.0047 2.14E-09 
13 rs11030104 G A -0.0414 0.0038 5.56E-28 
14 rs11057405 A G -0.0307 0.0055 2.02E-08 
15 rs11074422 T A 0.0188 0.0034 3.34E-08 
16 rs11074446 C T -0.0256 0.0045 1.31E-08 
17 rs11075986 G C -0.0423 0.006 1.23E-12 
18 rs11126666 A G 0.0207 0.0034 1.33E-09 
19 rs11165643 T C 0.0218 0.0031 2.07E-12 
20 rs11191560 C T 0.0308 0.0053 8.45E-09 
21 rs11583200 T C -0.0177 0.0031 1.48E-08 
22 rs1167827 G A 0.0202 0.0033 6.33E-10 
23 rs11688816 A G -0.0172 0.0031 1.89E-08 
24 rs11727676 C T -0.0358 0.0064 2.55E-08 
25 rs11847697 T C 0.0492 0.0084 3.99E-09 
26 rs12286929 G A 0.0217 0.0031 1.31E-12 
27 rs12354124 T A -0.0224 0.0031 2.18E-13 
28 rs12361415 G T -0.0234 0.0034 1.09E-11 
29 rs12401738 A G 0.0211 0.0033 1.15E-10 
30 rs12429545 A G 0.0334 0.0047 1.09E-12 
31 rs12446632 A G -0.0403 0.0046 1.48E-18 
32 rs12566985 A G -0.0242 0.0031 3.28E-15 
33 rs12607795 C T -0.0287 0.0037 1.47E-14 
34 rs12885454 A C -0.0207 0.0033 1.94E-10 
35 rs1292637 G C -0.0196 0.0033 2.88E-09 
36 rs12940622 A G -0.0182 0.0031 2.49E-09 
37 rs12996547 T C 0.0246 0.0033 3.67E-14 
38 rs12999373 A G -0.0199 0.0036 4.10E-08 
39 rs13021737 G A 0.0601 0.004 1.11E-50 
40 rs13078960 G T 0.0297 0.0039 1.74E-14 
41 rs13107325 T C 0.0477 0.0068 1.83E-12 
42 rs1317006 C T 0.0214 0.0034 4.97E-10 
43 rs13191362 G A -0.0277 0.0048 7.34E-09 
44 rs13411762 T C -0.0325 0.0057 1.08E-08 
45 rs1344840 A G -0.0206 0.0035 2.88E-09 
46 rs1477199 G A 0.0242 0.0044 4.56E-08 
47 rs1516725 C T 0.0451 0.0046 1.89E-22 
48 rs1519480 T C -0.0306 0.0033 9.58E-21 
49 rs1528435 T C 0.0178 0.0031 1.20E-08 
50 rs1558902 A T 0.0818 0.0031 7.51E-153 
51 rs1620977 G A -0.0241 0.0035 5.28E-12 
52 rs16851483 T G 0.0483 0.0077 3.55E-10 
53 rs16951275 C T -0.0311 0.0037 1.91E-17 
54 rs17001654 G C 0.0306 0.0053 7.76E-09 
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55 rs17024393 C T 0.0658 0.0088 7.03E-14 
56 rs17066842 A G -0.0626 0.0083 6.40E-14 
57 rs17094222 C T 0.0249 0.0038 5.94E-11 
58 rs17115529 C A 0.0233 0.0042 2.90E-08 
59 rs17391694 T C 0.0299 0.0052 1.03E-08 
60 rs17405819 C T -0.0224 0.0033 2.07E-11 
61 rs17724992 G A -0.0194 0.0035 3.42E-08 
62 rs1808579 T C -0.0167 0.0031 4.17E-08 
63 rs1927850 A C -0.0187 0.0031 1.69E-09 
64 rs1928295 C T -0.0188 0.0031 7.91E-10 
65 rs1943229 T G 0.0274 0.0039 2.80E-12 
66 rs2033529 G A 0.019 0.0033 1.39E-08 
67 rs2033732 C T 0.0192 0.0035 4.89E-08 
68 rs205262 G A 0.0221 0.0035 1.75E-10 
69 rs2058908 C T 0.0637 0.0039 5.87E-60 
70 rs2075650 G A -0.0258 0.0045 1.25E-08 
71 rs2112347 G T -0.0261 0.0031 6.19E-17 
72 rs2121279 T C 0.0245 0.0044 2.31E-08 
73 rs2176598 C T -0.0198 0.0036 2.97E-08 
74 rs2207139 G A 0.0447 0.004 4.13E-29 
75 rs2245368 T C -0.0317 0.0057 3.19E-08 
76 rs2287019 T C -0.036 0.0042 4.59E-18 
77 rs2365389 T C -0.02 0.0031 1.63E-10 
78 rs2650492 A G 0.0207 0.0035 1.92E-09 
79 rs2744489 A G -0.0171 0.0031 1.94E-08 
80 rs2817419 A G 0.0275 0.0035 3.66E-15 
81 rs2820292 C A 0.0195 0.0031 1.83E-10 
82 rs2821236 C T -0.0282 0.0038 6.30E-14 
83 rs29941 G A 0.0182 0.0033 2.41E-08 
84 rs3101336 C T 0.0334 0.0031 2.66E-26 
85 rs3736485 G A -0.0176 0.0031 7.41E-09 
86 rs3810291 A G 0.0283 0.0036 4.81E-15 
87 rs3817334 T C 0.0262 0.0031 5.15E-17 
88 rs3849570 A C 0.0188 0.0034 2.60E-08 
89 rs3888190 A C 0.0309 0.0031 3.14E-23 
90 rs423934 C T 0.0226 0.0035 5.59E-11 
91 rs4256980 G C 0.0209 0.0031 2.90E-11 
92 rs4280233 T G -0.0374 0.0067 3.00E-08 
93 rs4514364 T C -0.0195 0.0033 4.46E-09 
94 rs4611674 G A -0.0218 0.0031 4.54E-12 
95 rs4671328 G T -0.0215 0.0037 6.22E-09 
96 rs4740619 C T -0.0179 0.0031 4.56E-09 
97 rs4788115 A T -0.0285 0.0048 3.28E-09 
98 rs4940929 G C 0.0274 0.0042 6.85E-11 
99 rs543874 G A 0.0482 0.0039 2.62E-35 
100 rs561634 T A 0.0195 0.0031 2.32E-10 
101 rs6477694 T C -0.0174 0.0031 2.67E-08 
102 rs6499653 C T -0.0269 0.0037 2.32E-13 
103 rs6567160 C T 0.0556 0.0036 3.93E-53 
104 rs657452 G A -0.0227 0.0031 5.48E-13 
105 rs6749646 T A 0.027 0.0047 9.21E-09 
106 rs6804842 G A 0.0185 0.0031 2.48E-09 
107 rs6845132 T C 0.0182 0.0031 2.50E-09 
108 rs7138803 A G 0.0315 0.0031 8.15E-24 
109 rs7141420 T C 0.0235 0.0031 1.23E-14 
110 rs7144011 T G 0.0289 0.0038 1.38E-14 
111 rs7186521 G A 0.0279 0.0031 1.50E-19 
112 rs7203521 A G 0.0326 0.0032 3.46E-24 
113 rs7243357 G T -0.0217 0.004 3.86E-08 
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114 rs758747 T C 0.0225 0.0037 7.47E-10 
115 rs7599312 A G -0.022 0.0034 1.17E-10 
116 rs7629375 A C -0.021 0.0031 1.85E-11 
117 rs7899106 G A 0.0395 0.0071 2.96E-08 
118 rs7903146 T C -0.0234 0.0034 1.11E-11 
119 rs8097783 A G -0.0398 0.006 4.20E-11 
120 rs879620 T C 0.0244 0.004 1.06E-09 
121 rs9400239 C T 0.0188 0.0033 1.61E-08 
122 rs9579083 C G 0.0295 0.0047 3.46E-10 
123 rs9829032 G A 0.0194 0.0032 1.86E-09 
124 rs9925964 G A -0.0192 0.0031 8.11E-10 
125 rs9945063 T C 0.0217 0.0038 1.35E-08 
126 rs9947301 T C -0.0377 0.0057 3.70E-11 
127 rs9956279 T C 0.0348 0.0033 2.62E-25 
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Appendix 4 Table 3:List of SNPs used in polygenic score for Low-density lipoprotein cholesterol at the genome-wide significance level with a 
clumping threshold of 500kb and an R
2 
threshold of 0.25 
 SNP (RSID) Effect allele Other allele Beta Standard error P value 
1 rs1010167 G C 0.0208 0.0038 4.41E-08 
2 rs10102164 A G 0.0301 0.0043 2.56E-12 
3 rs10102352 G A 0.0399 0.005 1.46E-15 
4 rs10178381 T A 0.0557 0.0064 3.23E-18 
5 rs10184004 T C -0.0205 0.0037 3.02E-08 
6 rs10208987 G T -0.0439 0.0065 1.44E-11 
7 rs10209020 T C 0.0295 0.0039 3.91E-14 
8 rs1025447 C T 0.0344 0.0046 7.53E-14 
9 rs103294 T C 0.0314 0.0045 3.00E-12 
10 rs10401969 C T -0.1369 0.007 3.59E-85 
11 rs10402271 G T 0.0702 0.0037 2.85E-80 
12 rs10403668 A G -0.0392 0.005 4.51E-15 
13 rs10455872 G A 0.1238 0.014 9.33E-19 
14 rs10468017 T C 0.0617 0.004 1.11E-53 
15 rs1048699 T C 0.0315 0.0056 1.86E-08 
16 rs10489488 A G -0.0906 0.0165 4.00E-08 
17 rs10490626 A G -0.0415 0.0066 3.22E-10 
18 rs10493329 G A -0.0452 0.0048 4.66E-21 
19 rs10515214 G A 0.0456 0.0048 2.10E-21 
20 rs10757056 T C 0.0265 0.0047 1.72E-08 
21 rs10773003 A G 0.0369 0.0058 1.99E-10 
22 rs1077514 T C 0.0301 0.0052 7.10E-09 
23 rs1077834 C T 0.0652 0.0043 6.24E-52 
24 rs10832962 T C 0.0315 0.0039 6.64E-16 
25 rs10838738 G A -0.0208 0.0038 4.41E-08 
26 rs10903129 G A 0.029 0.0035 1.17E-16 
27 rs10904908 G A 0.025 0.0036 3.80E-12 
28 rs10910490 A G 0.0398 0.0049 4.57E-16 
29 rs1107851 C T -0.0243 0.0035 3.84E-12 
30 rs11096689 T C -0.0667 0.0039 1.42E-65 
31 rs11102964 C T -0.0405 0.0047 6.87E-18 
32 rs111826230 G A 0.0615 0.0094 6.05E-11 
33 rs11206510 C T -0.069 0.0048 7.43E-47 
34 rs11206514 A C 0.0355 0.0039 8.82E-20 
35 rs11208004 A G -0.0758 0.0037 2.84E-93 
36 rs11216137 A G -0.0742 0.0077 5.61E-22 
37 rs11220462 A G 0.0474 0.0058 3.02E-16 
38 rs11230815 C G -0.0361 0.0061 3.26E-09 
39 rs1129555 G A -0.0317 0.0039 4.36E-16 
40 rs11563251 T C 0.0368 0.0059 4.45E-10 
41 rs11591147 T G -0.3341 0.0173 4.25E-83 
42 rs11603023 C T -0.0216 0.0036 1.97E-09 
43 rs11659960 C G 0.0267 0.0041 7.41E-11 
44 rs11668536 T C -0.0388 0.0044 1.16E-18 
45 rs11672862 T C -0.0537 0.0078 5.79E-12 
46 rs11679386 C T 0.0393 0.0059 2.72E-11 
47 rs11685356 T C 0.0474 0.0041 6.50E-31 
48 rs11694172 G A 0.0277 0.0041 1.42E-11 
49 rs11699690 A G -0.0362 0.0062 5.26E-09 
50 rs11709504 C T -0.0322 0.0045 8.33E-13 
51 rs11742194 T C 0.056 0.0058 4.67E-22 
52 rs1174604 C T 0.021 0.0038 3.27E-08 
53 rs11753995 A G 0.0489 0.0048 2.25E-24 
54 rs117733303 G A 0.1303 0.0213 9.51E-10 
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55 rs11789603 T C 0.0427 0.0062 5.69E-12 
56 rs11820504 C T 0.0266 0.0045 3.40E-09 
57 rs11858279 C T 0.0431 0.0044 1.18E-22 
58 rs11875600 G A 0.0533 0.0076 2.33E-12 
59 rs11881156 T C -0.0689 0.0048 1.00E-46 
60 rs12052201 T G -0.0613 0.0042 3.01E-48 
61 rs12122434 G A -0.0666 0.0098 1.08E-11 
62 rs12123703 G A -0.0567 0.01 1.43E-08 
63 rs12208357 T C 0.0576 0.0098 4.16E-09 
64 rs12270837 C A -0.056 0.0074 3.80E-14 
65 rs12285095 G T 0.1024 0.0072 6.67E-46 
66 rs12309 T C 0.0258 0.0047 4.03E-08 
67 rs12321904 T G 0.0222 0.0036 6.97E-10 
68 rs12448528 G A 0.0461 0.005 2.97E-20 
69 rs1264344 T C 0.0218 0.0038 9.65E-09 
70 rs12660382 T C 0.0266 0.0046 7.36E-09 
71 rs12670798 C T 0.0364 0.0041 6.80E-19 
72 rs12691202 T C -0.1031 0.0109 3.12E-21 
73 rs12708454 C A 0.0366 0.0057 1.35E-10 
74 rs12710745 G A -0.0405 0.0037 6.95E-28 
75 rs12720796 C A 0.0821 0.0133 6.70E-10 
76 rs12720842 C T 0.0892 0.0111 9.28E-16 
77 rs12721109 A G -0.3234 0.0179 5.79E-73 
78 rs12749263 C T 0.0357 0.0041 3.11E-18 
79 rs12916 C T 0.0684 0.0036 1.71E-80 
80 rs12920974 T G -0.029 0.0053 4.46E-08 
81 rs12924285 A G 0.0371 0.006 6.28E-10 
82 rs12931964 G T 0.0356 0.0049 3.72E-13 
83 rs12983316 G A 0.0402 0.005 8.98E-16 
85 rs13277646 G A -0.0217 0.0039 2.64E-08 
86 rs13292582 G A -0.0572 0.0052 3.82E-28 
87 rs13315871 A G -0.0355 0.0061 5.90E-09 
88 rs13344893 T C -0.0352 0.0045 5.19E-15 
89 rs13375691 T C -0.06 0.0062 3.76E-22 
90 rs13396400 G A 0.0294 0.0036 3.17E-16 
91 rs13465 G A 0.084 0.0082 1.26E-24 
92 rs1367117 A G 0.0995 0.0038 4.02E-151 
93 rs138764 C T -0.0214 0.0037 7.30E-09 
94 rs1475701 C T 0.0652 0.0089 2.37E-13 
95 rs1475961 G A 0.0206 0.0037 2.58E-08 
96 rs1494369 G A -0.0292 0.0053 3.60E-08 
97 rs1501909 T G 0.0347 0.0038 6.75E-20 
98 rs1525764 A T 0.0237 0.004 3.12E-09 
99 rs1529711 T C 0.0315 0.0049 1.29E-10 
100 rs1534842 G A -0.0416 0.0076 4.41E-08 
101 rs1535 G A -0.0497 0.0037 3.90E-41 
102 rs157580 A G 0.0969 0.0043 1.89E-112 
103 rs1594895 C T -0.0259 0.0045 8.64E-09 
104 rs1604144 T C 0.0215 0.0039 3.53E-08 
105 rs16831243 T C 0.0378 0.0053 9.89E-13 
106 rs16872670 A G 0.0525 0.0081 9.08E-11 
107 rs16941759 A G 0.0264 0.0048 3.80E-08 
108 rs16942887 A G 0.031 0.0052 2.50E-09 
109 rs16970670 T A 0.0529 0.0092 8.92E-09 
110 rs16979372 G T -0.1057 0.0094 2.46E-29 
111 rs16979595 A G 0.0296 0.005 3.22E-09 
112 rs17035630 A G 0.0402 0.0058 4.18E-12 
113 rs17035665 T C -0.0594 0.0057 1.99E-25 
114 rs17035949 G T -0.0944 0.0133 1.27E-12 
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115 rs17248748 T C -0.1062 0.0176 1.60E-09 
116 rs17301746 T C 0.0798 0.0146 4.61E-08 
117 rs17398765 G A 0.0734 0.0073 8.75E-24 
118 rs17405319 T C 0.0429 0.0049 2.04E-18 
119 rs17424122 A T 0.0653 0.0087 6.11E-14 
120 rs174468 A G 0.0232 0.0038 1.03E-09 
121 rs174532 A G 0.0331 0.0041 6.85E-16 
122 rs174602 C T -0.0334 0.0056 2.46E-09 
123 rs174634 C G -0.0267 0.0042 2.06E-10 
124 rs17584208 A G -0.0803 0.0064 4.14E-36 
125 rs17630235 A G -0.0298 0.0036 1.25E-16 
126 rs17649913 C T -0.0243 0.0044 3.34E-08 
127 rs17651629 T C -0.0324 0.0059 3.98E-08 
128 rs17661330 G T -0.0261 0.0042 5.16E-10 
129 rs17800819 T C -0.033 0.0053 4.77E-10 
130 rs17819328 G T 0.0277 0.0037 7.07E-14 
131 rs17821316 C A -0.0535 0.0067 1.40E-15 
132 rs1787328 C T 0.0268 0.0038 1.76E-12 
133 rs1800562 A G -0.0565 0.0077 2.17E-13 
134 rs1800961 T C -0.1062 0.0101 7.38E-26 
135 rs1801701 T C 0.0497 0.0062 1.09E-15 
136 rs180326 T G -0.0443 0.0039 6.69E-30 
137 rs181360 G T -0.0278 0.0043 1.01E-10 
138 rs1825955 A C 0.0438 0.0058 4.30E-14 
139 rs1874776 C T 0.0339 0.0042 6.95E-16 
140 rs1883025 T C -0.0671 0.0042 1.87E-57 
141 rs1943681 T A -0.0295 0.0037 1.55E-15 
142 rs1943979 A G 0.0298 0.0036 1.25E-16 
143 rs1997243 G A 0.0332 0.005 3.14E-11 
144 rs2000813 T C 0.0226 0.004 1.60E-08 
145 rs2000999 A G 0.0617 0.0044 1.13E-44 
146 rs2006760 G C 0.0534 0.0074 5.35E-13 
147 rs2023472 G A 0.0214 0.0039 4.08E-08 
148 rs2035191 C T 0.0556 0.0045 4.55E-35 
149 rs207145 T C 0.042 0.0055 2.23E-14 
150 rs2071593 A G 0.0389 0.0063 6.63E-10 
151 rs2073048 A G 0.0298 0.0048 5.35E-10 
152 rs2073547 G A 0.0456 0.0047 2.95E-22 
153 rs2075650 G A 0.1432 0.0052 6.08E-167 
154 rs2148489 C T -0.028 0.0042 2.62E-11 
155 rs2149116 A G 0.0407 0.0052 5.00E-15 
156 rs2155216 T C 0.0895 0.0146 8.78E-10 
157 rs2156499 A G -0.0262 0.0039 1.84E-11 
158 rs2156552 T A -0.057 0.0047 7.54E-34 
159 rs217181 T C -0.0572 0.0047 4.48E-34 
160 rs217386 A G -0.0338 0.0036 6.06E-21 
161 rs217420 C A 0.023 0.0042 4.35E-08 
162 rs2178198 T C 0.0393 0.0053 1.22E-13 
163 rs2194562 A G 0.0419 0.0059 1.23E-12 
164 rs2199403 T C -0.0221 0.0036 8.31E-10 
165 rs2230365 T C 0.0307 0.0049 3.72E-10 
166 rs2230808 C T 0.031 0.0042 1.57E-13 
167 rs2235367 G A 0.0357 0.0035 1.98E-24 
168 rs2244608 G A 0.0313 0.0037 2.69E-17 
169 rs2247056 C T 0.0391 0.0041 1.48E-21 
170 rs2248372 A G 0.0257 0.0037 3.76E-12 
171 rs2266788 A G -0.1138 0.0071 8.12E-58 
173 rs2287019 T C -0.0292 0.0046 2.18E-10 
174 rs2287623 A G -0.0273 0.0036 3.37E-14 
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175 rs2288904 G A 0.0409 0.0045 1.00E-19 
176 rs2294261 C A -0.0245 0.0036 1.01E-11 
177 rs2297374 T C -0.0311 0.0036 5.68E-18 
178 rs2305929 G A 0.0277 0.0046 1.73E-09 
179 rs2326077 T C -0.0388 0.0036 4.38E-27 
180 rs2336438 C T 0.0613 0.0111 3.34E-08 
181 rs2390536 A G 0.0221 0.0037 2.33E-09 
182 rs2394427 A G 0.0388 0.005 8.49E-15 
183 rs2395471 A G 0.0334 0.0039 1.09E-17 
184 rs2479394 A G -0.0359 0.0039 3.41E-20 
185 rs2479409 A G -0.054 0.004 1.56E-41 
186 rs2495477 G A -0.0452 0.0052 3.55E-18 
187 rs2516440 A G 0.028 0.0041 8.53E-12 
188 rs2517546 T C -0.0407 0.0056 3.65E-13 
189 rs2521567 A G -0.0205 0.0035 4.71E-09 
190 rs2523864 T C -0.0236 0.004 3.64E-09 
191 rs2596501 T C 0.0233 0.0036 9.66E-11 
192 rs2621321 G A 0.0242 0.004 1.45E-09 
193 rs2642438 G A 0.037 0.004 2.24E-20 
194 rs2737252 A G -0.0331 0.0039 2.12E-17 
195 rs2738464 C G -0.0364 0.0059 6.85E-10 
196 rs2758886 A G 0.0232 0.0039 2.70E-09 
197 rs2770 A G 0.0327 0.0055 2.76E-09 
199 rs2814982 T C -0.0441 0.0057 1.02E-14 
200 rs283813 A T 0.1104 0.009 1.37E-34 
201 rs2845573 G A -0.051 0.0059 5.42E-18 
202 rs2857595 A G -0.0369 0.0048 1.50E-14 
203 rs2858331 G A 0.0279 0.0037 4.68E-14 
204 rs28718232 G A 0.0383 0.0062 6.52E-10 
205 rs2886232 C T -0.0358 0.0062 7.73E-09 
206 rs2894254 G T -0.0466 0.0059 2.83E-15 
207 rs289741 A G -0.0296 0.004 1.36E-13 
208 rs2899624 G A -0.0382 0.0051 6.88E-14 
209 rs2902940 G A -0.0241 0.0039 6.43E-10 
210 rs2920500 A G 0.0243 0.0036 1.48E-11 
212 rs2960420 G C 0.024 0.0039 7.56E-10 
213 rs2965101 C T -0.0499 0.0038 2.17E-39 
214 rs2965156 C G -0.0353 0.0057 5.90E-10 
215 rs2965157 C T -0.1222 0.0107 3.30E-30 
216 rs2965185 C T -0.042 0.0039 4.81E-27 
217 rs2972564 G A 0.0474 0.0065 3.05E-13 
218 rs2980885 A G -0.0337 0.0044 1.87E-14 
219 rs312046 T C 0.0406 0.0038 1.21E-26 
220 rs3124785 A G 0.0374 0.0057 5.33E-11 
221 rs3125055 A T 0.0467 0.0053 1.24E-18 
222 rs3132454 G A 0.0234 0.0037 2.54E-10 
223 rs314253 C T -0.0233 0.0037 3.03E-10 
224 rs3184504 C T 0.0318 0.0037 8.36E-18 
225 rs3208856 T C -0.2034 0.0188 2.79E-27 
226 rs3213422 C A -0.0277 0.0037 7.07E-14 
227 rs3745157 C T -0.0252 0.0038 3.32E-11 
228 rs3757354 T C -0.0348 0.0042 1.17E-16 
229 rs3764261 A C 0.0503 0.004 2.90E-36 
230 rs3780181 G A -0.0442 0.0071 4.80E-10 
232 rs3786721 C T -0.0366 0.0037 4.51E-23 
233 rs379309 T C -0.0266 0.0038 2.56E-12 
234 rs3798180 G A -0.0254 0.0036 1.72E-12 
235 rs3798221 T G -0.0317 0.0043 1.68E-13 
236 rs3800406 G A -0.0437 0.006 3.26E-13 
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237 rs3810444 A T 0.0648 0.0081 1.24E-15 
238 rs3817588 C T -0.0438 0.0044 2.41E-23 
239 rs3823151 C A 0.0554 0.01 3.02E-08 
240 rs3873380 T C 0.0243 0.0038 1.61E-10 
241 rs387976 C A -0.0697 0.0056 1.46E-35 
242 rs3891175 T C -0.0302 0.0047 1.31E-10 
243 rs389883 T G 0.0346 0.0043 8.52E-16 
244 rs3935470 G A 0.0389 0.0038 1.36E-24 
245 rs4148177 A G -0.0364 0.0049 1.10E-13 
246 rs4148218 A G -0.0385 0.0045 1.17E-17 
247 rs4149311 T C 0.0456 0.0055 1.12E-16 
248 rs4245791 T C -0.078 0.004 1.10E-84 
249 rs4253772 T C 0.0322 0.0058 2.83E-08 
250 rs4360309 T C 0.0387 0.0036 5.93E-27 
251 rs4382144 A G 0.0285 0.0035 3.86E-16 
252 rs4530754 A G 0.0228 0.0035 7.30E-11 
253 rs461473 A G -0.0384 0.0062 5.88E-10 
254 rs4622454 T C 0.0234 0.0036 8.03E-11 
255 rs4635554 G T 0.0691 0.004 7.26E-67 
256 rs4666366 C T -0.0219 0.004 4.38E-08 
257 rs4704810 A G 0.0219 0.0036 1.18E-09 
258 rs4711268 T C 0.0335 0.0041 3.07E-16 
259 rs4722551 C T 0.029 0.0047 6.82E-10 
260 rs4752805 G A 0.0251 0.0041 9.24E-10 
261 rs4783962 C T 0.0242 0.0043 1.82E-08 
262 rs4788589 A T -0.0296 0.0043 5.83E-12 
263 rs4803750 G A -0.1485 0.0075 2.98E-87 
264 rs4803760 C T 0.0837 0.0048 4.28E-68 
265 rs4803767 T C 0.0417 0.0058 6.50E-13 
266 rs4803770 G C 0.0431 0.0042 1.05E-24 
267 rs4804158 C T 0.0243 0.0038 1.61E-10 
268 rs4808802 C G 0.0251 0.0044 1.17E-08 
269 rs486394 C A 0.0307 0.004 1.65E-14 
270 rs488191 G A 0.0358 0.0062 7.73E-09 
271 rs4921914 T C -0.0332 0.0042 2.68E-15 
272 rs4926670 T C -0.0636 0.0058 5.60E-28 
273 rs4938303 T C -0.0414 0.0039 2.53E-26 
274 rs4953023 A G -0.1249 0.0072 2.07E-67 
275 rs4968255 T C 0.0275 0.0048 1.01E-08 
276 rs4988235 A G -0.0308 0.004 1.36E-14 
277 rs505000 T C 0.0253 0.0045 1.89E-08 
278 rs5110 A C 0.0857 0.0138 5.29E-10 
279 rs511676 G T -0.0523 0.0054 3.49E-22 
280 rs516246 T C 0.0315 0.0037 1.69E-17 
282 rs533556 C A -0.0433 0.0037 1.23E-31 
283 rs533617 C T -0.1111 0.0095 1.36E-31 
284 rs541041 A G 0.1245 0.0046 2.53E-161 
285 rs548638 G T -0.0253 0.0045 1.89E-08 
286 rs558971 G A 0.0398 0.0036 2.06E-28 
287 rs570877 G T 0.0864 0.0063 8.34E-43 
288 rs572512 T C 0.0361 0.0045 1.04E-15 
289 rs5742911 G A -0.0468 0.0055 1.75E-17 
290 rs5763662 T C 0.0692 0.0117 3.33E-09 
291 rs579459 C T 0.062 0.0044 4.32E-45 
292 rs581080 C G -0.0377 0.0047 1.05E-15 
293 rs584626 T C 0.0437 0.0047 1.43E-20 
294 rs585362 T C 0.0703 0.0053 3.74E-40 
295 rs5880 C G 0.0622 0.0092 1.37E-11 
296 rs599839 A G 0.1281 0.0042 2.61E-204 
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297 rs6016381 C T -0.0328 0.0036 8.15E-20 
298 rs6124309 G A 0.0286 0.0046 5.05E-10 
299 rs629001 T C 0.0847 0.0076 7.60E-29 
300 rs630014 G A 0.0295 0.0036 2.52E-16 
301 rs633862 T C 0.0244 0.0036 1.22E-11 
302 rs6413458 A G -0.0802 0.0134 2.16E-09 
303 rs6435161 G T -0.0243 0.0039 4.64E-10 
304 rs648673 G C -0.0411 0.0055 7.85E-14 
305 rs6504872 T C 0.025 0.0035 9.14E-13 
306 rs6511720 T G -0.1851 0.0059 4.74E-216 
307 rs655246 G A 0.0439 0.0036 3.33E-34 
308 rs6587970 A G -0.0286 0.0046 5.05E-10 
309 rs6603981 T C 0.0351 0.0043 3.27E-16 
310 rs6662286 C T 0.0691 0.007 5.54E-23 
311 rs6664692 T C 0.0289 0.0044 5.09E-11 
312 rs6689614 A G 0.0507 0.0036 4.81E-45 
313 rs6725189 T G -0.0548 0.0043 3.36E-37 
314 rs6728178 A G -0.0499 0.004 1.02E-35 
315 rs6729410 G A -0.036 0.0038 2.70E-21 
316 rs6730157 G A 0.0298 0.0039 2.15E-14 
317 rs6739502 G A -0.0315 0.0035 2.26E-19 
318 rs6756743 T C 0.0551 0.0089 5.98E-10 
319 rs676385 G A 0.0254 0.0042 1.47E-09 
320 rs6818397 G T -0.0254 0.0039 7.38E-11 
321 rs6831256 G A 0.023 0.0037 5.09E-10 
322 rs6859 G A -0.0636 0.0037 3.20E-66 
323 rs6873053 G A 0.0396 0.0063 3.26E-10 
324 rs688 T C 0.0416 0.0036 6.92E-31 
325 rs6882076 C T 0.0508 0.0037 6.74E-43 
326 rs6917747 A G 0.0324 0.0052 4.64E-10 
327 rs6935921 T C 0.0254 0.0041 5.82E-10 
328 rs709167 T G -0.0227 0.0037 8.51E-10 
329 rs7117842 C T 0.0294 0.0036 3.17E-16 
330 rs714948 A C 0.0364 0.006 1.31E-09 
331 rs7164909 T C -0.0397 0.0068 5.28E-09 
332 rs7188 C A 0.0426 0.0042 3.57E-24 
333 rs7193549 C T 0.0332 0.0048 4.62E-12 
334 rs7229377 T C 0.0362 0.0046 3.56E-15 
335 rs7235005 A G 0.0244 0.0036 1.22E-11 
336 rs7241596 T C 0.0274 0.0037 1.31E-13 
337 rs7255743 A G -0.1066 0.015 1.19E-12 
338 rs7259004 C G 0.1247 0.0088 1.40E-45 
339 rs7264396 T C -0.0313 0.0043 3.36E-13 
340 rs72703204 A G -0.1193 0.0136 1.75E-18 
341 rs73015030 A G -0.1319 0.0142 1.56E-20 
342 rs732839 A G 0.0269 0.0043 3.95E-10 
343 rs7349418 T C -0.0201 0.0036 2.36E-08 
344 rs739468 G T -0.0378 0.0061 5.77E-10 
345 rs73959582 C T 0.0437 0.0076 8.92E-09 
346 rs74019428 T C -0.0805 0.0135 2.48E-09 
347 rs7412 T C -0.3736 0.0096 0 
348 rs742748 C T -0.022 0.0037 2.75E-09 
349 rs7499892 T C -0.0513 0.005 1.07E-24 
350 rs7512480 T C 0.0339 0.0036 4.66E-21 
351 rs7515901 T C -0.0407 0.005 3.95E-16 
352 rs7544735 A G 0.0273 0.0039 2.56E-12 
353 rs7550711 T C -0.0566 0.0101 2.10E-08 
354 rs7551981 T G 0.0358 0.0037 3.83E-22 
355 rs7567653 A G -0.1009 0.0107 4.10E-21 
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356 rs7578637 A G -0.1124 0.0181 5.30E-10 
357 rs7616006 G A -0.0315 0.0036 2.13E-18 
358 rs7640978 T C -0.0376 0.0066 1.22E-08 
359 rs7715806 T C 0.0355 0.0037 8.42E-22 
360 rs7742144 C T -0.0238 0.004 2.68E-09 
361 rs7770628 T C -0.0245 0.0036 1.01E-11 
362 rs7774197 C A 0.0507 0.007 4.39E-13 
363 rs780093 C T -0.0515 0.0036 2.02E-46 
364 rs7832643 T G 0.0289 0.0037 5.68E-15 
365 rs8017377 A G 0.0251 0.0037 1.17E-11 
366 rs8044335 C A 0.0288 0.0035 1.89E-16 
367 rs8044476 G A 0.0317 0.0051 5.11E-10 
368 rs8060878 G A 0.0287 0.0035 2.40E-16 
369 rs8069974 C G 0.0244 0.0041 2.66E-09 
370 rs8103315 A C 0.0422 0.0055 1.68E-14 
371 rs8176720 C T -0.0257 0.0037 3.76E-12 
372 rs8180991 G C 0.0483 0.0043 2.82E-29 
373 rs865774 T C -0.0328 0.0053 6.07E-10 
374 rs868943 A G -0.0292 0.0036 5.02E-16 
375 rs873870 A G -0.0216 0.0038 1.31E-08 
376 rs887829 T C -0.0228 0.0037 7.18E-10 
377 rs888246 T C 0.0617 0.0061 4.75E-24 
378 rs889545 A G -0.0581 0.0091 1.72E-10 
379 rs892114 G A -0.0294 0.0045 6.43E-11 
380 rs904743 G A 0.0611 0.0052 7.06E-32 
381 rs914547 T C -0.0269 0.0046 4.98E-09 
382 rs926054 G T -0.0334 0.0057 4.64E-09 
383 rs9273363 A C -0.0232 0.004 6.63E-09 
384 rs9275406 T G 0.0328 0.0043 2.39E-14 
385 rs9282575 A G -0.1076 0.0128 4.23E-17 
386 rs9302635 C T -0.0366 0.0047 6.85E-15 
387 rs934287 G A 0.0278 0.0046 1.51E-09 
388 rs936960 G T -0.0376 0.0066 1.22E-08 
389 rs9376090 C T -0.0254 0.004 2.15E-10 
390 rs9378212 T C 0.0355 0.0052 8.68E-12 
391 rs9391858 G A 0.0495 0.005 4.16E-23 
392 rs940434 T C -0.021 0.0038 3.27E-08 
393 rs9457843 T C -0.0297 0.0054 3.80E-08 
394 rs9501587 A G 0.0292 0.0046 2.18E-10 
395 rs970548 C A 0.025 0.004 4.10E-10 
396 rs9951669 G A 0.027 0.0043 3.41E-10 
397 rs9972882 C A 0.0243 0.004 1.24E-09 
398 rs9987289 G A 0.0842 0.0063 9.67E-41 
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Appendix 4 Table 4: List of SNPs used in polygenic score for lifetime smoking behaviour in the sample 1 GWAS at the genome-wide 
significance level with a clumping threshold of 500kb and an R
2
 threshold of 0.25 
 
 SNP (RSID) Effect allele Other allele Beta Standard error P value 
1 rs10093628 C T 0.0165694 0.00272207 1.20E-09 
2 rs10187072 T C -0.0130905 0.00235359 2.70E-08 
3 rs10226228 G A 0.0141999 0.0024083 3.70E-09 
4 rs10233018 G A 0.0129883 0.00232256 2.20E-08 
5 rs10750016 A T 0.0160683 0.00239178 1.80E-11 
6 rs11030088 A G 0.0157839 0.00266804 3.30E-09 
7 rs112151537 T C 0.0289527 0.00500391 7.20E-09 
8 rs113382419 A C 0.0242553 0.00368267 4.50E-11 
9 rs16879271 C A 0.0325007 0.00593948 4.50E-08 
10 rs17159727 C T -0.0241372 0.0040898 3.60E-09 
11 rs2890772 T G 0.0140201 0.00236079 2.90E-09 
12 rs326341 A G -0.013281 0.00233329 1.30E-08 
13 rs4763463 A G -0.0132272 0.00238627 3.00E-08 
14 rs4841235 G A -0.0130052 0.00234148 2.80E-08 
15 rs4856463 T C -0.0156642 0.00282864 3.10E-08 
16 rs4957528 C A 0.0160705 0.00287694 2.30E-08 
17 rs499257 C T -0.0146849 0.0024706 2.80E-09 
18 rs6590701 T G 0.0144894 0.00264731 4.40E-08 
19 rs6852351 T C -0.0132797 0.00240999 3.60E-08 
20 rs71673396 C T -0.0159243 0.00290616 4.30E-08 
21 rs7173514 T C -0.0224245 0.00277906 7.10E-16 
22 rs8042849 T C -0.0175789 0.00244843 7.00E-13 
23 rs986391 A G -0.0151657 0.00240275 2.80E-10 
 
Appendix 4 Table 5: List of SNPs used in polygenic score for lifetime smoking behaviour in the sample 2 GWAS at the genome-wide 
significance level with a clumping threshold of 500kb and an R
2
 threshold of 0.25 
 
 SNP (RSID) Effect allele Other allele Beta Standard error P value 
1 rs10922907 T A -0.0134411 0.00232508 7.40E-09 
2 rs112151537 T C 0.0294478 0.00497115 3.10E-09 
3 rs12897150 T A 0.0136766 0.00234592 5.50E-09 
4 rs12900091 G A -0.0131482 0.00231911 1.40E-08 
5 rs12914385 T C 0.0189068 0.00237702 1.80E-15 
6 rs13292239 A G 0.0152012 0.00248573 9.60E-10 
7 rs159058 C A 0.0142308 0.0025321 1.90E-08 
8 rs16824949 T G 0.0145352 0.00231811 3.60E-10 
9 rs17657924 A C -0.0132644 0.00233124 1.30E-08 
10 rs1863161 A G 0.0127982 0.00232631 3.80E-08 
11 rs263771 A C 0.0151079 0.00274433 3.70E-08 
12 rs28669908 A C -0.0237801 0.00282163 3.50E-17 
13 rs3025354 T C 0.0150973 0.00237188 2.00E-10 
14 rs34794623 A C 0.0195197 0.00282212 4.60E-12 
15 rs45568238 G C 0.0225856 0.00308616 2.50E-13 
16 rs45577732 G C 0.0386369 0.00429408 2.30E-19 
17 rs56116178 G A 0.0306714 0.00380628 7.70E-16 
18 rs62261249 C T 0.0158442 0.00263127 1.70E-09 
19 rs7559547 T C 0.0219576 0.00304622 5.70E-13 
20 rs7948789 G A 0.0164578 0.00237675 4.40E-12 
21 rs8043105 T C -0.0287382 0.0052151 3.60E-08 
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Appendix 4 Table 6: List of SNPs used in polygenic score for systolic blood pressure in the sample 1 GWAS at the genome-wide significance 
level with a clumping threshold of 500kb and an R2 threshold of 0.25 
 SNP (RSID) Effect allele Other allele Beta Standard error P value 
1 rs1009358 C T -0.369257 0.0644871 1.00E-08 
2 rs10171080 C G 0.462857 0.0647265 8.60E-13 
3 rs10269774 A G -0.385427 0.0669084 8.40E-09 
4 rs1032777 C T -0.475747 0.0649262 2.30E-13 
5 rs1053924 C T 0.388981 0.0675514 8.50E-09 
6 rs10750766 A C 0.393005 0.0691166 1.30E-08 
7 rs10764329 C G 0.3665 0.0636834 8.70E-09 
8 rs10769602 T A -0.556702 0.0890515 4.10E-10 
9 rs1077394 T C 0.373884 0.0668653 2.20E-08 
10 rs10786156 G C -0.376662 0.0631706 2.50E-09 
11 rs10838873 C T -0.562113 0.0859116 6.00E-11 
12 rs10857147 T A 0.815677 0.0690015 3.00E-32 
13 rs10883543 T G 0.699532 0.0996261 2.20E-12 
14 rs10995311 G C -0.394142 0.0633664 5.00E-10 
15 rs11105429 C T 0.487352 0.0710168 6.80E-12 
16 rs11187837 C T -0.556212 0.100308 2.90E-08 
17 rs11191580 C T -1.09699 0.118001 1.50E-20 
18 rs1121450 T C -0.575418 0.0903921 1.90E-10 
19 rs11246486 T C -0.5443 0.0920554 3.40E-09 
20 rs11634851 G C 0.421599 0.062824 1.90E-11 
21 rs11646677 C T 0.360837 0.063622 1.40E-08 
22 rs11650511 T C 0.408482 0.0633763 1.20E-10 
23 rs1173690 G A -0.417164 0.0645566 1.00E-10 
24 rs1175651 T C 0.420797 0.0769911 4.60E-08 
25 rs11853441 G T 0.357549 0.0626497 1.10E-08 
26 rs12136566 G A 0.410475 0.0670484 9.20E-10 
27 rs12221645 C T -0.551699 0.0895822 7.30E-10 
28 rs12258967 G C -0.658175 0.0685584 8.00E-22 
29 rs12418543 G A -0.566817 0.0644978 1.50E-18 
30 rs12656497 C T 0.716061 0.0637776 3.00E-29 
31 rs12677146 G C 0.42607 0.065947 1.00E-10 
32 rs12978472 G C -0.84682 0.0940538 2.20E-19 
33 rs13107325 T C -0.768905 0.119024 1.00E-10 
34 rs1320340 T G 0.824129 0.148358 2.80E-08 
35 rs13219548 T C 0.405146 0.0630438 1.30E-10 
36 rs13328893 T C -0.558092 0.088806 3.30E-10 
37 rs1343040 A G 0.431735 0.063705 1.20E-11 
38 rs13436194 G A -0.457014 0.0632129 4.80E-13 
39 rs1344653 G A 0.348057 0.0625861 2.70E-08 
40 rs147045545 G A -0.544935 0.0932389 5.10E-09 
41 rs1543927 C T -0.4218 0.0711512 3.10E-09 
42 rs1548391 G A -0.417502 0.0660732 2.60E-10 
43 rs167479 T G -0.470301 0.0628261 7.10E-14 
44 rs16952009 T C -0.365616 0.0658472 2.80E-08 
45 rs1703982 T A -0.447104 0.0629233 1.20E-12 
46 rs1717200 G A 0.391185 0.0627883 4.70E-10 
47 rs17713163 G C -0.957472 0.172387 2.80E-08 
48 rs1801131 G T -0.555138 0.0674219 1.80E-16 
49 rs1842896 T G 0.401431 0.062567 1.40E-10 
50 rs1864587 A G 0.39065 0.0658407 3.00E-09 
51 rs1939309 T C -0.36633 0.0637749 9.20E-09 
52 rs1939310 A G 0.379368 0.0628021 1.50E-09 
53 rs1945211 T A 0.545985 0.0955267 1.10E-08 
54 rs1989803 G C 0.399848 0.0667533 2.10E-09 
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55 rs2023843 T C 0.862691 0.119811 6.00E-13 
56 rs204883 A G 0.360713 0.0644452 2.20E-08 
57 rs2082450 G A 0.582839 0.105292 3.10E-08 
58 rs2107595 A G 0.536691 0.0876715 9.30E-10 
59 rs2188717 C T 0.536128 0.0791637 1.30E-11 
60 rs2423514 G A -0.370939 0.0628149 3.50E-09 
61 rs2499801 A G -0.44416 0.0806357 3.60E-08 
62 rs2524099 A G 0.36444 0.0640551 1.30E-08 
63 rs2607015 C G 0.423217 0.0636473 2.90E-11 
64 rs2610989 C T 0.393514 0.0712999 3.40E-08 
65 rs263016 C T -0.34751 0.0630696 3.60E-08 
66 rs2643826 T C 0.377984 0.0631442 2.20E-09 
67 rs268263 A T 0.565244 0.0734925 1.50E-14 
68 rs2765524 T C -0.396517 0.0640623 6.00E-10 
69 rs2854747 A G -0.419782 0.0636961 4.40E-11 
70 rs2867114 T C -0.614906 0.10733 1.00E-08 
71 rs3131007 T A 0.367603 0.0634629 6.90E-09 
72 rs34071855 G C 0.370798 0.0663072 2.20E-08 
73 rs34406901 G A 0.74674 0.135852 3.90E-08 
74 rs34710835 T C -0.52234 0.0642725 4.40E-16 
75 rs34742161 T C 0.453475 0.0823403 3.60E-08 
76 rs35021474 G C -0.463939 0.0644971 6.30E-13 
77 rs35444 G A -0.390865 0.0642817 1.20E-09 
78 rs35726503 T A -0.449535 0.0634517 1.40E-12 
79 rs360153 C T 0.389126 0.0632899 7.80E-10 
80 rs3790604 A C 0.872402 0.120391 4.30E-13 
81 rs3821843 A G 0.412853 0.0681401 1.40E-09 
82 rs3823483 C T 0.354643 0.0634247 2.30E-08 
83 rs3828591 C G -0.521162 0.0642105 4.80E-16 
84 rs4480845 C T -0.406496 0.0656129 5.80E-10 
85 rs448385 A G 0.34644 0.0629656 3.80E-08 
86 rs4753981 C G 0.365393 0.0636624 9.50E-09 
87 rs4766578 A T -0.406594 0.0626484 8.60E-11 
88 rs5068 G A -1.32827 0.137364 4.10E-22 
89 rs55840650 T C 0.422052 0.0671703 3.30E-10 
90 rs55925664 A T 0.641451 0.0805291 1.60E-15 
91 rs56137952 A G 0.549446 0.0984794 2.40E-08 
92 rs60289499 A G 0.456364 0.070768 1.10E-10 
93 rs620315 A G 0.478634 0.0651849 2.10E-13 
94 rs62481856 A G 0.844443 0.078857 9.30E-27 
95 rs633185 C G 0.694507 0.0698276 2.60E-23 
96 rs6825268 G A 0.357322 0.0631452 1.50E-08 
97 rs6982308 G C -0.422162 0.0627861 1.80E-11 
98 rs7076938 T C 0.460615 0.0711061 9.30E-11 
99 rs7107356 G A 0.386324 0.0625051 6.40E-10 
100 rs7120737 G A -0.63164 0.0890932 1.30E-12 
101 rs7136259 C T 0.523423 0.0634848 1.70E-16 
102 rs71373532 T C 0.707799 0.11879 2.50E-09 
103 rs72843938 A G -0.511856 0.0766282 2.40E-11 
104 rs73007683 T A -0.448092 0.0800131 2.10E-08 
105 rs73046792 A G -0.471445 0.0843393 2.30E-08 
106 rs73073676 T A -0.377265 0.0670153 1.80E-08 
107 rs73437338 C T -0.767786 0.0843419 8.80E-20 
108 rs73563812 T G -0.421515 0.0737441 1.10E-08 
109 rs7463212 A T -0.377575 0.0629451 2.00E-09 
110 rs747249 G A -0.374676 0.065604 1.10E-08 
111 rs74729242 C T 0.59008 0.101342 5.80E-09 
112 rs75230966 A G 0.565429 0.0950299 2.70E-09 
113 rs753012 C T -0.408732 0.0659309 5.70E-10 
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114 rs77870048 T C 0.911699 0.139917 7.20E-11 
115 rs7822500 C T -0.367521 0.0654572 2.00E-08 
116 rs7835002 C G 0.40281 0.0652194 6.60E-10 
117 rs7909027 C T 0.422909 0.0658512 1.30E-10 
118 rs7922049 A G -0.553349 0.0869331 1.90E-10 
119 rs7930107 G A -0.523191 0.0935296 2.20E-08 
120 rs79780963 T C -1.06814 0.118415 1.90E-19 
121 rs8039305 C T 0.594252 0.0630046 4.00E-21 
122 rs877116 T G -0.46967 0.0636099 1.50E-13 
123 rs890431 C T 0.616178 0.108373 1.30E-08 
124 rs891511 A G -0.376501 0.0680582 3.20E-08 
125 rs953246 A T 0.392405 0.0685268 1.00E-08 
126 rs9907379 C T 0.425715 0.0769493 3.20E-08 
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Appendix 4 Table 7: List of SNPs used in polygenic score for systolic blood pressure in the sample 2 GWAS at the genome-wide significance 
level with a clumping threshold of 500kb and an R2 threshold of 0.25 
 SNP (RSID) Effect allele Other allele Beta Standard error P value 
1 rs10059884 A C 0.585862 0.0642636 7.80E-20 
2 rs1051006 A G -0.505227 0.0826819 9.90E-10 
3 rs10783339 G A -0.389187 0.0714149 5.00E-08 
4 rs10839472 C T -0.405148 0.0737475 3.90E-08 
5 rs10849937 G A -0.529839 0.0781559 1.20E-11 
6 rs10882412 C T -0.387459 0.0654848 3.30E-09 
7 rs11014012 T G -0.387608 0.0640686 1.40E-09 
8 rs11099097 T C 0.637052 0.0695747 5.40E-20 
9 rs11105358 G C 0.442412 0.0644037 6.40E-12 
10 rs11187793 A G 0.429409 0.063869 1.80E-11 
11 rs11187838 A G -0.561505 0.0637082 1.20E-18 
12 rs11188220 T C 0.473499 0.0863154 4.10E-08 
13 rs11224417 C A 0.365772 0.0633882 7.90E-09 
14 rs11241959 G A 0.371451 0.0631332 4.00E-09 
15 rs11246667 A G 0.482296 0.087972 4.20E-08 
16 rs112873218 T C -0.636788 0.105091 1.40E-09 
17 rs11646987 T G -0.392246 0.0709123 3.20E-08 
18 rs11671314 C G 0.581767 0.0973419 2.30E-09 
19 rs117539635 G A -1.33873 0.200873 2.70E-11 
20 rs117574138 G C 0.58339 0.106127 3.90E-08 
21 rs117754181 A G 0.848858 0.13851 8.90E-10 
22 rs11894064 T A -0.358367 0.0633502 1.50E-08 
23 rs12046278 C T 0.438565 0.0660808 3.20E-11 
24 rs12053529 A G -0.47616 0.085436 2.50E-08 
25 rs12130314 T G -0.414228 0.070268 3.70E-09 
26 rs1216743 A G 0.566196 0.0704896 9.60E-16 
27 rs12229946 T G 0.409993 0.0706661 6.60E-09 
28 rs12258967 G C -0.589339 0.0690826 1.50E-17 
29 rs12575654 A G 0.473968 0.0729086 8.00E-11 
30 rs12652819 G A -0.377534 0.0677462 2.50E-08 
31 rs1275988 T C -0.483465 0.0649665 9.90E-14 
32 rs12788272 A C 0.930086 0.163013 1.20E-08 
33 rs12946454 T A 0.459599 0.0712814 1.10E-10 
34 rs12951057 G C 0.530415 0.0855947 5.80E-10 
35 rs12978472 G C -0.70494 0.0947152 9.90E-14 
36 rs142289341 A T 0.737241 0.121777 1.40E-09 
37 rs1436138 G A -0.361529 0.0660546 4.40E-08 
38 rs167479 T G -0.574313 0.0630398 8.20E-20 
39 rs17010961 A T 0.577535 0.0912832 2.50E-10 
40 rs17080069 G A -0.719939 0.121839 3.40E-09 
41 rs17715065 T C 0.366183 0.0631246 6.60E-09 
42 rs2031323 T C 0.418446 0.0652904 1.50E-10 
43 rs2301597 C T -0.508119 0.0639747 2.00E-15 
44 rs2307032 C T -0.387941 0.0664115 5.20E-09 
45 rs2392929 G T 0.716545 0.0789963 1.20E-19 
46 rs2472299 G A -0.458136 0.0709387 1.10E-10 
47 rs2681492 C T -0.676486 0.0839838 8.00E-16 
48 rs268263 A T 0.560215 0.0738018 3.20E-14 
49 rs2760748 A T 0.639762 0.105431 1.30E-09 
50 rs2780072 T A 0.503507 0.0902206 2.40E-08 
51 rs2964330 T G 0.364522 0.0641049 1.30E-08 
52 rs3020644 G A 0.359631 0.0655733 4.10E-08 
53 rs34040136 A G 1.08492 0.17975 1.60E-09 
54 rs34477350 T G 1.03609 0.172755 2.00E-09 
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55 rs35312823 T C 1.13407 0.205392 3.40E-08 
56 rs35427 G T -0.411027 0.0663981 6.00E-10 
57 rs35838379 G A 0.464904 0.0831492 2.30E-08 
58 rs3740360 C A -0.700725 0.100635 3.30E-12 
59 rs3792765 G A -0.553424 0.064696 1.20E-17 
60 rs42032 A G -0.396654 0.0719921 3.60E-08 
61 rs4425336 G A -0.453477 0.0770397 3.90E-09 
62 rs4468343 T C 0.589876 0.094465 4.30E-10 
63 rs4480845 C T -0.402416 0.066164 1.20E-09 
64 rs448798 G A 0.371658 0.0636445 5.20E-09 
65 rs4648815 A G -0.380689 0.0637656 2.40E-09 
66 rs4690974 C T 0.374146 0.0631476 3.10E-09 
67 rs4767328 A G 0.357508 0.0639895 2.30E-08 
68 rs4883481 C T -0.421841 0.0652497 1.00E-10 
69 rs4932373 C A 0.514421 0.0672123 2.00E-14 
70 rs4980379 T C 0.58963 0.0656634 2.70E-19 
71 rs5066 A C -0.707267 0.128245 3.50E-08 
72 rs55714388 C A -0.676772 0.110871 1.00E-09 
73 rs55857306 A G -0.76866 0.0850282 1.60E-19 
74 rs57301765 A G 0.505862 0.0865903 5.20E-09 
75 rs59652089 T C -0.496269 0.0910536 5.00E-08 
76 rs597808 G A -0.430999 0.0633734 1.00E-11 
77 rs61572747 G A -0.403188 0.0720379 2.20E-08 
78 rs61867141 A G 0.553681 0.0807567 7.10E-12 
79 rs61868776 T C -0.488816 0.0710773 6.10E-12 
80 rs62049035 A G 0.736701 0.128326 9.40E-09 
81 rs6442260 A G -0.359497 0.0658933 4.90E-08 
82 rs6504591 T G -0.352197 0.0641313 4.00E-08 
83 rs6541328 G A 0.555125 0.100955 3.80E-08 
84 rs6657049 A G 0.366463 0.0657613 2.50E-08 
85 rs6668659 G T -0.49247 0.066692 1.50E-13 
86 rs6724607 G A -0.365573 0.0629604 6.40E-09 
87 rs6923947 A G 0.49736 0.0635489 5.00E-15 
88 rs7070797 A G -0.628952 0.0904607 3.60E-12 
89 rs7102374 A G -0.372813 0.0674884 3.30E-08 
90 rs7107356 G A 0.479333 0.0630371 2.90E-14 
91 rs7129056 A G 0.403445 0.0631572 1.70E-10 
92 rs7217916 G A -0.39437 0.0650295 1.30E-09 
93 rs73143584 A G -0.561522 0.100825 2.60E-08 
94 rs732998 C T -0.836528 0.118393 1.60E-12 
95 rs74679637 A G 0.929741 0.15789 3.90E-09 
96 rs75615848 A G -0.757813 0.130765 6.80E-09 
97 rs75777337 A T 0.612514 0.103339 3.10E-09 
98 rs7588932 T C -0.471728 0.0741433 2.00E-10 
99 rs7600124 T A 0.418679 0.0644378 8.20E-11 
100 rs76443711 C G 0.544241 0.0915247 2.70E-09 
101 rs778121 C T 0.388712 0.0658549 3.60E-09 
102 rs77870048 T C 0.921644 0.141505 7.40E-11 
103 rs7889 G C 0.379228 0.065705 7.80E-09 
104 rs7908334 T C 0.540497 0.0779396 4.10E-12 
105 rs7918142 G T -0.359412 0.0639049 1.90E-08 
106 rs7953257 T A -0.370313 0.0653828 1.50E-08 
107 rs79553110 G A 0.893733 0.155023 8.20E-09 
108 rs79780963 T C -0.831243 0.118335 2.10E-12 
109 rs80335285 G A 0.598781 0.091777 6.80E-11 
110 rs891511 A G -0.414076 0.0682559 1.30E-09 
111 rs913220 G C 0.43889 0.064947 1.40E-11 
112 rs9898793 T C 0.414299 0.0719183 8.40E-09 
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Appendix 4 Table 8: List of SNPs used in polygenic score for atrial fibrillation at the genome-wide significance level with a clumping threshold 
of 500kb and an R
2
 threshold of 0.25 
 SNP (RSID) Effect allele Other allele Beta Standard error P value 
1 rs10005432 A G 0.1432 0.0111 4.76E-38 
2 rs10109521 A G -0.0471 0.0071 3.35E-11 
3 rs1011441 G A 0.0939 0.0082 4.66E-30 
4 rs1015864 C T 0.0763 0.0122 4.19E-10 
5 rs10165883 T C -0.0642 0.0072 5.83E-19 
6 rs10213171 G C 0.1041 0.0139 6.09E-14 
7 rs10222783 T C -0.1406 0.0131 4.99E-27 
8 rs1044258 C T -0.0463 0.0076 1.07E-09 
9 rs10466138 C T -0.0534 0.0073 1.97E-13 
10 rs10516564 G A 0.0548 0.0079 4.74E-12 
11 rs10520260 G A -0.0539 0.0079 8.98E-12 
12 rs10753933 G T -0.0743 0.0072 5.83E-25 
13 rs10760361 T G -0.0434 0.0075 7.03E-09 
14 rs10786662 C G -0.0403 0.0072 1.99E-08 
15 rs10800507 G C -0.0814 0.0072 7.01E-30 
16 rs10800898 G A -0.0404 0.0073 2.67E-08 
17 rs10822152 G A 0.0565 0.0098 8.90E-09 
18 rs10842383 T C -0.1088 0.0104 1.02E-25 
19 rs10873299 G A -0.0483 0.0075 9.62E-11 
20 rs10883913 T C -0.0626 0.0073 7.27E-18 
21 rs10919364 C T -0.0587 0.0102 7.70E-09 
22 rs11001667 G A 0.0619 0.0091 1.06E-11 
23 rs11075959 G A 0.1397 0.0216 1.03E-10 
24 rs111233078 A G -0.0426 0.0074 8.12E-09 
25 rs111621680 T C 0.0754 0.011 6.15E-12 
26 rs11180703 A G -0.0457 0.0073 3.58E-10 
27 rs11191801 C A 0.0533 0.0077 4.89E-12 
28 rs112156684 C T 0.2125 0.0241 1.07E-18 
29 rs112453500 A G 0.228 0.0384 2.82E-09 
30 rs112515238 T C 0.1065 0.0172 5.77E-10 
31 rs112599895 G A 0.643 0.0361 6.57E-71 
32 rs11264280 T C 0.127 0.0078 4.60E-59 
33 rs113378881 A G 0.1314 0.0135 2.75E-22 
34 rs113535611 A T 0.1512 0.0274 3.49E-08 
35 rs113640213 A G -0.2895 0.0467 5.72E-10 
36 rs113654447 T C -0.0564 0.0078 6.40E-13 
37 rs113819537 G C -0.049 0.0082 2.23E-09 
38 rs113832645 A G -0.2785 0.02 3.58E-44 
39 rs114014056 C T -0.1957 0.0303 1.02E-10 
40 rs114691030 C G 0.2167 0.0227 1.39E-21 
41 rs11598047 G A 0.1533 0.0095 4.83E-58 
42 rs116202356 A G 0.1971 0.0323 1.01E-09 
43 rs11641227 A G 0.0449 0.0074 1.16E-09 
44 rs116455344 A G -0.1153 0.0187 6.59E-10 
45 rs11717092 G A 0.0465 0.0073 2.33E-10 
46 rs11768850 T C 0.0392 0.0072 4.96E-08 
47 rs11773845 A C 0.1162 0.0072 4.61E-58 
48 rs117984853 T G 0.1132 0.0136 8.38E-17 
49 rs1180286 C T -0.0682 0.008 2.29E-17 
50 rs11814244 T G 0.0432 0.0072 2.57E-09 
51 rs11835327 G A 0.0681 0.0122 2.14E-08 
52 rs11848040 T G 0.047 0.0086 4.76E-08 
53 rs12044963 T G 0.0795 0.0113 1.61E-12 
54 rs12046897 G A -0.0676 0.0102 3.32E-11 
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55 rs12121494 A G 0.2056 0.0367 2.11E-08 
56 rs12122060 A T 0.1373 0.0112 2.73E-34 
57 rs12131638 G A 0.1082 0.0178 1.27E-09 
58 rs12142379 C T 0.1058 0.0156 1.32E-11 
59 rs1218574 G A 0.0718 0.0109 5.18E-11 
60 rs1218577 C T 0.0522 0.0075 3.60E-12 
61 rs1218578 G A -0.0406 0.0072 1.83E-08 
62 rs1218598 A G -0.0591 0.0088 1.78E-11 
63 rs12189392 T A 0.0581 0.0095 9.54E-10 
64 rs12208899 A G 0.049 0.0087 1.95E-08 
65 rs1229741 A G 0.0459 0.0076 1.71E-09 
66 rs12298484 T C -0.0455 0.0076 2.05E-09 
67 rs12325558 C A 0.0583 0.0071 2.90E-16 
68 rs12360357 T C -0.1093 0.0088 1.04E-35 
69 rs12589834 G A 0.0639 0.0089 7.66E-13 
70 rs12591736 A G -0.0606 0.0102 2.47E-09 
71 rs12647973 T G -0.0732 0.0093 3.62E-15 
72 rs12649917 A G 0.0926 0.0119 6.11E-15 
73 rs12730906 T C 0.0743 0.0104 1.06E-12 
74 rs12809354 C T 0.081 0.01 5.48E-16 
75 rs12810346 T C 0.0658 0.011 2.34E-09 
76 rs12812948 G A -0.0509 0.0084 1.20E-09 
77 rs12908004 G A 0.0753 0.0098 1.95E-14 
78 rs12908437 C T -0.0468 0.0073 1.25E-10 
79 rs12992412 T A 0.0406 0.0073 2.30E-08 
80 rs13061421 A G 0.0476 0.0081 4.48E-09 
81 rs1307274 G T -0.0741 0.0135 3.85E-08 
82 rs13105878 A C -0.1787 0.0136 1.47E-39 
83 rs13121747 A G -0.0626 0.0087 5.61E-13 
84 rs13126426 C T 0.1875 0.0186 6.56E-24 
85 rs13191450 C A -0.0704 0.0075 8.92E-21 
86 rs13242816 T C -0.1213 0.0126 8.53E-22 
87 rs13334473 C A 0.0561 0.0089 2.83E-10 
88 rs139811148 A G -0.0627 0.0108 6.01E-09 
89 rs140185678 A G 0.1813 0.0241 5.57E-14 
90 rs141221125 A G 0.2181 0.0289 4.55E-14 
91 rs141752220 A G 0.4067 0.0291 1.86E-44 
92 rs142822330 C T 0.12 0.0215 2.29E-08 
93 rs1443926 G A -0.0482 0.008 1.94E-09 
94 rs1448813 C T -0.0471 0.0076 4.63E-10 
95 rs145538762 C T 0.1041 0.0179 5.84E-09 
96 rs146269981 A G 0.3064 0.0398 1.44E-14 
97 rs146518726 A G 0.1617 0.0254 2.05E-10 
98 rs1470618 T C 0.1357 0.0094 7.12E-47 
99 rs147352248 C T -0.3097 0.0429 5.53E-13 
100 rs151107921 A G -0.083 0.0129 1.32E-10 
101 rs1538575 T A -0.0473 0.0071 2.86E-11 
102 rs1562641 G A -0.0604 0.0094 1.17E-10 
103 rs168367 C T -0.1108 0.018 7.38E-10 
104 rs17041835 G A -0.1209 0.0212 1.29E-08 
105 rs17042059 A G 0.4252 0.0097 0 
106 rs17079881 G A 0.0851 0.0105 4.23E-16 
107 rs17341992 C T -0.0502 0.0083 1.51E-09 
108 rs174048 C T 0.0665 0.0098 1.05E-11 
109 rs17490701 A G -0.07 0.0107 5.43E-11 
110 rs17507821 C T 0.0459 0.0078 4.67E-09 
111 rs17513625 A G 0.464 0.0249 9.55E-78 
112 rs17513772 A T -0.1568 0.0171 4.96E-20 
113 rs17513814 T C 0.1905 0.0242 3.55E-15 
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114 rs17552555 C T 0.18 0.0218 1.45E-16 
115 rs17662087 G A -0.1039 0.0132 2.90E-15 
116 rs17746631 G A -0.1718 0.0183 4.98E-21 
117 rs1822273 A G -0.0683 0.0082 8.99E-17 
118 rs1866961 C T 0.0572 0.0074 9.80E-15 
119 rs187311 G A -0.1388 0.0191 3.35E-13 
120 rs1896002 C A 0.0582 0.0071 2.69E-16 
121 rs192667187 C T 0.3073 0.0466 4.08E-11 
122 rs1963560 T C 0.0599 0.0106 1.36E-08 
123 rs2047036 T C -0.0549 0.0075 2.80E-13 
124 rs2072412 G C 0.0515 0.0084 7.43E-10 
125 rs2073341 A G -0.0421 0.0073 9.60E-09 
126 rs2145274 C A -0.1015 0.0141 6.97E-13 
127 rs2145587 A G 0.0754 0.0079 2.32E-21 
128 rs214575 T C -0.0539 0.0073 2.23E-13 
129 rs2216553 T C -0.0489 0.0076 1.14E-10 
130 rs2240331 A C 0.0499 0.0072 4.87E-12 
131 rs2286466 G A 0.0718 0.0095 3.53E-14 
132 rs2291437 G T 0.0786 0.0105 7.53E-14 
133 rs2306272 C T 0.0512 0.0078 4.54E-11 
134 rs2359171 A T 0.1884 0.0089 2.94E-100 
135 rs242557 A G -0.0439 0.0075 4.35E-09 
136 rs2500549 T C 0.0498 0.0081 7.50E-10 
137 rs2540949 T A -0.0752 0.0073 8.17E-25 
138 rs2595110 G A -0.0725 0.0083 3.77E-18 
139 rs2604195 T C -0.0581 0.0082 1.39E-12 
140 rs2660824 T C 0.0403 0.0071 1.47E-08 
141 rs2723307 T A -0.1577 0.0075 3.33E-99 
142 rs2738413 G A -0.0807 0.0072 1.81E-29 
143 rs2739200 C G -0.1711 0.0076 4.24E-112 
144 rs2810915 T G -0.0536 0.0078 7.33E-12 
145 rs2834618 G T -0.1096 0.0126 2.93E-18 
146 rs28436726 A G 0.0977 0.0157 4.48E-10 
147 rs28488916 A G -0.0488 0.0089 4.23E-08 
148 rs28587043 A G -0.0929 0.0076 8.77E-35 
149 rs28601812 C A -0.0901 0.0083 1.24E-27 
150 rs28631169 T C 0.07 0.0093 3.80E-14 
151 rs2894040 C A 0.0452 0.0074 8.62E-10 
152 rs295114 T C -0.0676 0.0073 1.76E-20 
153 rs2984131 T C -0.1023 0.012 1.59E-17 
154 rs2986036 C T 0.0419 0.0072 5.36E-09 
155 rs3014204 A C 0.0571 0.01 1.33E-08 
156 rs3112133 G A -0.0442 0.0077 8.52E-09 
157 rs3176326 A G -0.0599 0.0092 7.95E-11 
158 rs34195153 G C 0.2303 0.0393 4.62E-09 
159 rs34515871 T C 0.1253 0.008 1.19E-55 
160 rs34750263 T C 0.0873 0.0076 2.89E-30 
161 rs34969716 A G 0.0875 0.0084 2.91E-25 
162 rs35006907 A C 0.0454 0.0076 2.76E-09 
163 rs35056927 A G -0.0826 0.0131 3.18E-10 
164 rs35176054 A T 0.1458 0.0109 8.47E-41 
165 rs35349325 C T -0.0524 0.0073 9.04E-13 
166 rs35504893 T C 0.09 0.0087 6.89E-25 
167 rs361834 A G -0.047 0.0075 3.49E-10 
168 rs369081 C T 0.0414 0.0075 4.16E-08 
169 rs3731640 A G -0.0667 0.0115 6.32E-09 
170 rs374582 A G -0.0938 0.0076 9.66E-35 
171 rs3781339 T C -0.0834 0.009 2.56E-20 
172 rs3784193 A T 0.0678 0.0082 1.64E-16 
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173 rs3796097 C T -0.0404 0.0073 3.01E-08 
174 rs3796903 C T 0.0911 0.0132 4.79E-12 
175 rs3822259 T G 0.0463 0.0077 1.93E-09 
176 rs3849045 C T -0.0393 0.0072 4.34E-08 
177 rs3853444 C T -0.0706 0.0086 1.99E-16 
178 rs3855819 G C -0.141 0.0098 3.07E-47 
179 rs3922844 C T -0.0478 0.0078 6.84E-10 
180 rs3925798 T C -0.0461 0.0073 2.80E-10 
181 rs3951016 A T 0.0543 0.0072 4.62E-14 
182 rs396024 G C 0.0662 0.0118 1.85E-08 
183 rs3960788 C T 0.0507 0.0072 2.09E-12 
184 rs3968564 A G -0.05 0.0091 3.58E-08 
185 rs4115273 A C 0.1766 0.0082 1.42E-103 
186 rs4124174 T G 0.1048 0.0081 6.01E-38 
187 rs41264253 A G 0.1138 0.0125 8.17E-20 
188 rs412768 G A 0.0467 0.0078 2.56E-09 
189 rs41298968 T C -0.0603 0.0096 3.18E-10 
190 rs41312411 G C -0.0605 0.0105 8.32E-09 
191 rs4146379 C T 0.0505 0.0072 2.39E-12 
192 rs42874 C T -0.0485 0.0074 4.81E-11 
193 rs438258 T A -0.053 0.0081 5.88E-11 
194 rs4385527 A G 0.092 0.0073 2.26E-36 
195 rs4401702 A G -0.0522 0.0091 1.14E-08 
196 rs4414093 A C -0.0466 0.0074 3.05E-10 
197 rs4484922 C G -0.063 0.0078 4.57E-16 
198 rs449333 G C -0.0716 0.0077 1.38E-20 
199 rs4607376 G A 0.0397 0.0073 4.64E-08 
200 rs4656215 T C 0.0656 0.0084 4.45E-15 
201 rs4656754 A G 0.1603 0.028 1.04E-08 
202 rs4656794 A G -0.0795 0.0075 2.20E-26 
203 rs4673891 G C 0.0543 0.0079 7.45E-12 
204 rs4743034 A G 0.049 0.0083 3.98E-09 
205 rs4744374 A G -0.0539 0.008 1.70E-11 
206 rs478454 C T -0.0633 0.0072 1.96E-18 
207 rs4788489 G T 0.0413 0.0071 6.50E-09 
208 rs4788490 C G 0.1002 0.0079 4.13E-37 
209 rs4788697 A G 0.0785 0.0078 3.96E-24 
210 rs480667 A C -0.051 0.0081 2.51E-10 
211 rs4845703 T C -0.0447 0.008 2.02E-08 
212 rs4855075 T C 0.0604 0.0103 4.00E-09 
213 rs4871397 C G -0.1018 0.0145 1.95E-12 
214 rs4951261 C A 0.0441 0.0072 1.17E-09 
215 rs4977397 G A -0.0432 0.0075 8.60E-09 
216 rs4981979 T C 0.0459 0.0078 3.16E-09 
217 rs4986938 T C -0.0516 0.0075 6.25E-12 
218 rs4999127 A G 0.0891 0.011 4.77E-16 
219 rs514739 G A 0.1231 0.0217 1.35E-08 
220 rs524788 C T -0.1592 0.0193 1.59E-16 
221 rs532748 A T -0.0589 0.0094 4.11E-10 
222 rs55734480 A G 0.0504 0.0082 7.34E-10 
223 rs55754224 T C 0.0477 0.0083 9.25E-09 
224 rs55947985 T C 0.0728 0.0107 9.76E-12 
225 rs55985730 G T 0.0957 0.017 1.81E-08 
226 rs56103503 T C -0.0823 0.0078 6.31E-26 
227 rs56181519 T C -0.0778 0.0086 1.52E-19 
228 rs56305400 T C 0.0539 0.0083 8.37E-11 
229 rs56308529 G C 0.1198 0.018 3.01E-11 
230 rs58847541 A G 0.054 0.0099 4.63E-08 
231 rs591715 A G -0.076 0.0089 1.26E-17 
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232 rs60029182 T G -0.0671 0.0104 1.07E-10 
233 rs60050852 A G -0.0543 0.0094 6.66E-09 
234 rs60212594 C G -0.1097 0.0102 6.48E-27 
235 rs608930 T G -0.0968 0.0071 1.94E-42 
236 rs61150523 G A 0.072 0.0117 6.90E-10 
237 rs61826205 G T -0.081 0.0141 8.70E-09 
238 rs62011291 G A 0.0519 0.0089 6.14E-09 
239 rs62055086 T C -0.0657 0.0088 6.92E-14 
240 rs62059797 G A -0.0529 0.0086 8.72E-10 
241 rs62337205 G A -0.2505 0.0211 2.13E-32 
242 rs62337249 G A -0.1193 0.0107 8.25E-29 
243 rs62380877 A G -0.0565 0.0096 4.14E-09 
244 rs62483627 A G 0.0489 0.0084 5.17E-09 
245 rs62521286 G A 0.1224 0.0148 1.24E-16 
246 rs634851 T C 0.0636 0.0096 3.28E-11 
247 rs6427245 T C 0.0531 0.0072 2.20E-13 
248 rs6462078 A C 0.058 0.0086 1.35E-11 
249 rs6499606 C T 0.0781 0.0074 4.13E-26 
250 rs6546620 C T 0.0708 0.0093 2.96E-14 
251 rs6553712 A T -0.14 0.0225 5.25E-10 
252 rs6661079 C T -0.053 0.0071 9.75E-14 
253 rs6680785 T C 0.0505 0.0073 4.51E-12 
254 rs6701640 C A -0.0733 0.0095 9.36E-15 
255 rs6708345 C A 0.0456 0.0072 2.20E-10 
256 rs6742276 A G 0.0485 0.0073 2.42E-11 
257 rs6790396 G C 0.0636 0.0073 4.13E-18 
258 rs6793245 A G -0.0413 0.0076 4.57E-08 
259 rs6810325 C T 0.0747 0.0076 5.24E-23 
260 rs6823804 A G -0.0817 0.0099 1.48E-16 
261 rs6838973 T C -0.1842 0.0072 1.35E-142 
262 rs6882776 A G -0.06 0.0079 3.18E-14 
263 rs6907805 T G -0.0405 0.0071 1.10E-08 
264 rs6907980 G A 0.0402 0.0072 2.41E-08 
265 rs6931433 G C 0.0523 0.009 7.53E-09 
266 rs6993266 A G 0.0443 0.0072 9.73E-10 
267 rs700607 C T -0.0631 0.0088 7.70E-13 
268 rs700613 C A -0.0462 0.0082 1.65E-08 
269 rs7067666 T C 0.0955 0.0071 2.57E-41 
270 rs710768 A T -0.043 0.0079 4.71E-08 
271 rs71419908 A C -0.0469 0.0072 7.22E-11 
272 rs71424150 C T -0.0792 0.0137 6.73E-09 
273 rs71628635 C A 0.1615 0.015 7.27E-27 
274 rs716845 A G 0.0594 0.008 1.16E-13 
275 rs7219869 G C 0.046 0.0072 1.49E-10 
276 rs721994 G A 0.0724 0.008 9.65E-20 
277 rs723363 C T -0.2414 0.0075 2.89E-229 
278 rs723840 T C 0.0444 0.0073 1.23E-09 
279 rs72666200 C T 0.0854 0.0104 2.47E-16 
280 rs72667931 T C 0.1546 0.0147 5.61E-26 
281 rs72674110 T G 0.088 0.0105 5.03E-17 
282 rs72690464 G T 0.1375 0.0226 1.12E-09 
283 rs7269123 T C -0.0443 0.0076 5.59E-09 
284 rs72700114 C G 0.2026 0.0139 7.32E-48 
285 rs72702041 T C 0.0608 0.0109 2.30E-08 
286 rs72712048 A G 0.1288 0.0209 7.52E-10 
287 rs72715944 A G 0.1463 0.0193 3.91E-14 
288 rs72802815 G A 0.0495 0.0085 6.48E-09 
289 rs72811294 C G -0.0667 0.0115 6.87E-09 
290 rs728713 G A -0.0969 0.0137 1.42E-12 
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291 rs72926475 A G -0.0708 0.0113 3.49E-10 
292 rs73032363 G A -0.0432 0.0078 3.59E-08 
293 rs73241997 T C 0.072 0.0097 1.10E-13 
294 rs73366713 A G -0.1052 0.0112 5.80E-21 
295 rs7349311 A G -0.0758 0.0097 4.80E-15 
296 rs73666807 T C 0.1083 0.019 1.29E-08 
297 rs7373065 C T -0.2151 0.0287 6.50E-14 
298 rs74022964 T C 0.1059 0.0097 1.27E-27 
299 rs7460121 A G 0.0708 0.0125 1.65E-08 
300 rs74910854 G A 0.0942 0.0159 3.36E-09 
301 rs7502669 G A -0.0417 0.0075 3.21E-08 
302 rs7508 A G 0.072 0.008 2.22E-19 
303 rs7514023 T C 0.1654 0.0293 1.74E-08 
304 rs7526113 A G -0.0718 0.0116 7.15E-10 
305 rs7549338 G C -0.0454 0.0071 1.71E-10 
306 rs75577686 G T 0.1239 0.0203 9.52E-10 
307 rs76097649 A G 0.1264 0.0137 2.19E-20 
308 rs76306191 G C 0.058 0.0094 6.19E-10 
309 rs7632427 C T -0.0425 0.0074 1.10E-08 
310 rs76774446 A C 0.0633 0.0111 1.13E-08 
311 rs76872986 T C -0.1651 0.027 9.94E-10 
312 rs77316573 T C 0.0528 0.0093 1.48E-08 
313 rs7755375 T C 0.0406 0.0071 1.03E-08 
314 rs77668866 T C -0.1314 0.0146 2.82E-19 
315 rs7789146 A G -0.0571 0.0092 6.51E-10 
316 rs77953709 T C 0.1728 0.0201 9.49E-18 
317 rs77955149 G C 0.0822 0.0093 1.05E-18 
318 rs78053786 A G 0.1085 0.0148 2.44E-13 
319 rs7835298 A G 0.0392 0.0072 4.49E-08 
320 rs7846485 A C -0.0872 0.0111 3.71E-15 
321 rs78710246 T A -0.0875 0.0143 1.07E-09 
322 rs79187193 A G -0.1116 0.0182 8.07E-10 
323 rs7919685 T G -0.0579 0.0071 5.00E-16 
324 rs7953024 G C 0.0626 0.0091 6.12E-12 
325 rs7966951 G A 0.044 0.008 3.31E-08 
326 rs7978685 C T -0.0547 0.0079 5.99E-12 
327 rs8005490 C T -0.0465 0.0073 1.94E-10 
328 rs80141833 G A 0.2211 0.013 1.71E-64 
329 rs8073937 A G -0.0504 0.0074 1.02E-11 
330 rs876727 G T -0.0905 0.0089 4.69E-24 
331 rs880315 C T 0.0437 0.0075 5.04E-09 
332 rs883079 T C 0.1196 0.0079 1.26E-51 
333 rs926198 T C 0.0533 0.0079 1.20E-11 
334 rs9414802 C T -0.0534 0.009 3.18E-09 
335 rs9428207 G A 0.0474 0.0078 1.01E-09 
336 rs9481825 A G 0.0639 0.0092 4.54E-12 
337 rs949078 T C -0.0534 0.0081 4.77E-11 
338 rs9580438 C T 0.0568 0.0076 1.01E-13 
339 rs9669457 G A 0.0472 0.0085 2.52E-08 
340 rs9920 C T -0.1075 0.0128 3.99E-17 
341 rs9953366 C T 0.0504 0.0078 9.03E-11 
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Appendix 4 Table 9: List of SNPs used in polygenic score for coronary heart disease at the genome-wide significance level with a clumping 
threshold of 500kb and an R
2
 threshold of 0.25 
 SNP (RSID) Effect allele Other allele Beta Standard error P value 
1 rs10139550 G C 0.05538 0.0097569 1.38E-08 
2 rs10174652 G A 0.079086 0.0144747 4.66E-08 
3 rs10840293 A G 0.054714 0.009619 1.28E-08 
4 rs11065979 T C 0.068556 0.0107672 1.93E-10 
5 rs11066188 A G 0.063162 0.0108943 6.72E-09 
6 rs11191416 G T -0.079249 0.0135252 4.65E-09 
7 rs11206510 C T -0.074519 0.0133438 2.34E-08 
8 rs11556924 T C -0.072569 0.0110605 5.34E-11 
9 rs115654617 A C 0.137846 0.0158314 3.12E-18 
10 rs11617955 A T -0.088766 0.0161041 3.55E-08 
11 rs11790231 A G 0.118907 0.0163887 4.00E-13 
12 rs11838776 A G 0.068566 0.0107552 1.83E-10 
13 rs12202017 G A -0.066813 0.0099612 1.98E-11 
14 rs12202891 T C 0.076537 0.0133417 9.65E-09 
15 rs13209002 T C 0.105577 0.0161942 7.06E-11 
16 rs1333050 T C 0.140772 0.010438 1.88E-41 
17 rs1412444 T C 0.066812 0.0096809 5.15E-12 
18 rs16986953 A G 0.08516 0.0150265 1.45E-08 
19 rs17087335 T G 0.060764 0.0111159 4.59E-08 
20 rs1746050 A C -0.092397 0.0128431 6.28E-13 
21 rs17678683 G T 0.098786 0.0166548 3.00E-09 
22 rs180803 T G -0.180923 0.0283062 1.64E-10 
23 rs1833024 A G 0.08283 0.0149787 3.20E-08 
24 rs1855185 G T 0.13824 0.0248682 2.71E-08 
25 rs186696265 T C 0.550351 0.0481949 3.35E-30 
26 rs1870634 G T 0.075878 0.0097113 5.55E-15 
27 rs2107595 A G 0.073415 0.0112951 8.05E-11 
28 rs2128739 C A -0.065565 0.0100568 7.05E-11 
29 rs2487928 A G 0.062633 0.0095049 4.41E-11 
30 rs2519093 T C 0.079704 0.0117524 1.19E-11 
31 rs2681472 G A 0.074114 0.0113331 6.17E-11 
32 rs28451064 A G 0.127571 0.015952 1.33E-15 
33 rs2891168 G A 0.193401 0.0091877 2.29E-98 
34 rs3120147 T C 0.077862 0.0136132 1.07E-08 
35 rs36049381 A G -0.083549 0.0140684 2.87E-09 
36 rs3731249 T C 0.171038 0.0301757 1.44E-08 
37 rs3743058 T C 0.06925 0.0101317 8.20E-12 
38 rs3918226 T C 0.133315 0.0221275 1.69E-09 
39 rs4420638 G A 0.091906 0.0140977 7.07E-11 
40 rs4468572 C T 0.077234 0.0095277 4.44E-16 
41 rs4593108 G C -0.07083 0.0115558 8.82E-10 
42 rs4773141 G C 0.069732 0.0116482 2.14E-09 
43 rs515135 C T 0.067499 0.0121924 3.09E-08 
44 rs55730499 T C 0.316641 0.0242403 5.39E-39 
45 rs56031815 A G 0.075204 0.0127681 3.86E-09 
46 rs56062135 T C -0.069743 0.0118937 4.52E-09 
47 rs56289821 A G -0.13361 0.0170415 4.44E-15 
48 rs56336142 C T -0.066813 0.0118763 1.85E-08 
49 rs61271866 A T -0.112191 0.0107857 2.43E-25 
50 rs624249 A C -0.061265 0.0105717 6.82E-09 
51 rs6511721 A G -0.061674 0.0111409 3.10E-08 
52 rs663129 A G 0.058163 0.0105173 3.20E-08 
53 rs66478960 A G -0.124511 0.0129191 5.54E-22 
54 rs6689306 G A -0.056012 0.0094061 2.60E-09 
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55 rs67180937 G T 0.078807 0.0110551 1.01E-12 
56 rs6905073 T G -0.058185 0.0096896 1.91E-09 
57 rs7041637 A C 0.099171 0.0103044 6.33E-22 
58 rs7212798 C T 0.079961 0.0142216 1.88E-08 
59 rs72652411 T G 0.131271 0.0239959 4.49E-08 
60 rs72652478 G C 0.202956 0.0354724 1.06E-08 
61 rs72689147 T G -0.068558 0.0117905 6.07E-09 
62 rs73013166 C T -0.131384 0.0234973 2.25E-08 
63 rs73015007 A G -0.08328 0.0116884 1.04E-12 
64 rs7412 T C -0.137045 0.0210923 8.17E-11 
65 rs74923585 G A 0.167726 0.0277262 1.45E-09 
66 rs7528419 G A -0.11453 0.011482 1.97E-23 
67 rs7568458 A T 0.059618 0.0095093 3.62E-10 
68 rs762158 G C 0.078 0.0114591 9.98E-12 
69 rs8042271 A G -0.096711 0.0175662 3.68E-08 
70 rs9349379 G A 0.131836 0.0096527 1.81E-42 
71 rs9457861 T C 0.097078 0.0177867 4.82E-08 
72 rs9457995 G A 0.068647 0.0101947 1.66E-11 
73 rs9515203 C T -0.071146 0.0116243 9.33E-10 
74 rs9804352 G A 0.058132 0.0092898 3.91E-10 
75 rs9970807 T C -0.12575 0.016695 5.00E-14 
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Appendix 4 Table 10: List of SNPs used in polygenic score for Type 2 diabetes at the genome-wide significance level with a clumping threshold 
of 500kb and an R
2
 threshold of 0.25 
 SNP (RSID) Effect allele Other allele Beta Standard error P value 
1 rs10954284 A T -0.0953102 0.01616572 1.20E-08 
2 rs11196175 C T 0.26236426 0.02543351 4.80E-24 
3 rs11196212 C T 0.10436002 0.01602064 1.90E-10 
4 rs11709077 A G -0.1570037 0.02618728 1.10E-09 
5 rs12110493 G A 0.23111172 0.04025689 2.20E-08 
6 rs12266632 G C 0.25464222 0.03932415 8.50E-11 
7 rs1801214 T C 0.11332869 0.01822933 1.30E-08 
8 rs2383208 G A -0.1655144 0.02369738 6.00E-14 
9 rs3802177 A G -0.14842 0.02410481 2.10E-11 
10 rs3915932 C G -0.0953102 0.01856106 4.70E-08 
11 rs4506565 T A 0.31481074 0.01862886 4.90E-68 
12 rs5015480 T C -0.1397619 0.01775339 2.20E-16 
13 rs7651090 G A 0.12221763 0.01806787 2.00E-11 
14 rs7901275 C A 0.14842001 0.01760022 3.90E-18 
15 rs7933855 A G 0.11332869 0.02041906 1.30E-09 
16 rs864745 C T -0.1133287 0.01602064 7.30E-11 
17 rs9368222 A C 0.19062036 0.01906213 4.80E-23 
18 rs9936385 C T 0.12221763 0.02023896 4.70E-11 
 
 
Appendix 4 Table 11:  List of SNPs used in polygenic score for stroke at the genome-wide significance level with a clumping threshold of 500kb 
and an R
2
 threshold of 0.25 
 
 SNP (RSID) Effect allele Other allele Beta Standard error P value 
1 rs1052053 G A -0.0675 0.0096 2.25E-12 
2 rs10774624 A G -0.0654 0.0094 4.04E-12 
3 rs11066283 G A 0.0692 0.0104 2.36E-11 
4 rs11242678 T C 0.0643 0.0105 8.71E-10 
5 rs1537375 C T 0.0519 0.0091 1.24E-08 
6 rs2107595 A G 0.0803 0.0121 3.59E-11 
7 rs2634074 A T -0.084 0.0112 6.56E-14 
8 rs475937 C A -0.0757 0.0137 2.92E-08 
9 rs4942561 T G 0.064 0.0107 2.05E-09 
10 rs76110445 C T 0.0814 0.0147 2.94E-08 
11 rs847892 A G -0.054 0.0098 3.28E-08 
 
 
 
